

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



#5 attachment

09/899532

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : C07H 21/04, C07K 14/705, C12N 15/09, 15/63, C12Q 1/68		A1	(11) International Publication Number: WO 00/11015																								
			(43) International Publication Date: 2 March 2000 (02.03.00)																								
(21) International Application Number: PCT/US99/19351		(74) Agent: SPRUNGER, Suzanne, A.; American Home Products Corporation, Patent & Trademark Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US).																									
(22) International Filing Date: 24 August 1999 (24.08.99)																											
(30) Priority Data: <table border="0"><tr><td>60/097,638</td><td>24 August 1998 (24.08.98)</td><td>US</td></tr><tr><td>60/097,659</td><td>24 August 1998 (24.08.98)</td><td>US</td></tr><tr><td>60/099,618</td><td>9 September 1998 (09.09.98)</td><td>US</td></tr><tr><td>60/102,092</td><td>28 September 1998 (28.09.98)</td><td>US</td></tr><tr><td>60/109,978</td><td>25 November 1998 (25.11.98)</td><td>US</td></tr><tr><td>60/113,645</td><td>23 December 1998 (23.12.98)</td><td>US</td></tr><tr><td>60/113,646</td><td>23 December 1998 (23.12.98)</td><td>US</td></tr><tr><td>09/379,246</td><td>23 August 1999 (23.08.99)</td><td>US</td></tr></table>		60/097,638	24 August 1998 (24.08.98)	US	60/097,659	24 August 1998 (24.08.98)	US	60/099,618	9 September 1998 (09.09.98)	US	60/102,092	28 September 1998 (28.09.98)	US	60/109,978	25 November 1998 (25.11.98)	US	60/113,645	23 December 1998 (23.12.98)	US	60/113,646	23 December 1998 (23.12.98)	US	09/379,246	23 August 1999 (23.08.99)	US	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
60/097,638	24 August 1998 (24.08.98)	US																									
60/097,659	24 August 1998 (24.08.98)	US																									
60/099,618	9 September 1998 (09.09.98)	US																									
60/102,092	28 September 1998 (28.09.98)	US																									
60/109,978	25 November 1998 (25.11.98)	US																									
60/113,645	23 December 1998 (23.12.98)	US																									
60/113,646	23 December 1998 (23.12.98)	US																									
09/379,246	23 August 1999 (23.08.99)	US																									
(71) Applicant: ALPHAGENE, INC. [US/US]; 260 West Cummings Park, Woburn, MA 01801 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>																									
(72) Inventors: VALENZUELA, Dario; 260 West Cummings Park, Woburn, MA 01801 (US). YUAN, Olive; 260 West Cummings Park, Woburn, MA 01801 (US). HOFFMAN, Heidi; 260 West Cummings Park, Woburn, MA 01801 (US). HALL, Jeff; 260 West Cummings Park, Woburn, MA 01801 (US). RAPIEJKO, Peter; 260 West Cummings Park, Woburn, MA 01801 (US).																											
(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM																											
(57) Abstract Novel polynucleotides and the proteins encoded thereby are disclosed.																											

302-185-2222

617-210-6830

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

5

This application is a continuation-in-part of the following applications:

- (1) provisional application Ser. No. 60/097,638 (GI 6908), filed August 24, 1998;
 - (2) provisional application Ser. No. 60/097,659 (GI 6909), filed August 24, 1998;
 - (3) provisional application Ser. No. 60/099,618 (GI 6910), filed September 9, 1998;
 - 10 (4) provisional application Ser. No. 60/102,022 (GI 6912), filed September 28, 1998;
 - (5) provisional application Ser. No. 60/109,978 (GI 6914), filed November 25, 1998;
 - (6) provisional application Ser. No. 60/113,645 (GI 6916), filed December 23, 1998; and
 - (7) provisional application Ser. No. 60/113,646 (GI 6917), filed December 23, 1998;
- all of which are incorporated by reference herein.

15

FIELD OF THE INVENTION

The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

20

BACKGROUND OF THE INVENTION

Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques
25 clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader
30 sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the
35 polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb11_1 deposited with the ATCC under
10 accession number 98846;
- (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846;
- (e) a polynucleotide comprising the nucleotide sequence of a mature
15 protein coding sequence of clone vb11_1 deposited with the ATCC under accession number 98846;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846;
- (g) a polynucleotide encoding a protein comprising the amino acid
20 sequence of SEQ ID NO:2;
- (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of
25 (a)-(f) above;
- (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- 30 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:1.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934; the nucleotide sequence of the full-length

protein coding sequence of clone vb11_1 deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vb11_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846.

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:1.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and

(ab) the nucleotide sequence of the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (ba) SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1; and
- (bb) the nucleotide sequence of the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846;
- 5 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a
10 nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1, but excluding the poly(A) tail at the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the
15 cDNA sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934.

20 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) a fragment of the amino acid sequence of SEQ ID NO:2, the
25 fragment comprising eight contiguous amino acids of SEQ ID NO:2; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred
30 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 37 to amino acid 46 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
10 NO:3 from nucleotide 201 to nucleotide 482;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb12_1 deposited with the ATCC under accession number 98846;
- (e) a polynucleotide encoding the full-length protein encoded by the
15 cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb12_1 deposited with the ATCC under accession number 98846;
- 20 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
- (i) a polynucleotide encoding a protein comprising a fragment of the
25 amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein
30 of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
5 NO:3 from nucleotide 63 to nucleotide 482; the nucleotide sequence of SEQ ID NO:3 from
nucleotide 201 to nucleotide 482; the nucleotide sequence of the full-length protein coding
sequence of clone vb12_1 deposited with the ATCC under accession number 98846; or the
nucleotide sequence of a mature protein coding sequence of clone vb12_1 deposited with
the ATCC under accession number 98846. In other preferred embodiments, the
10 polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert
of clone vb12_1 deposited with the ATCC under accession number 98846. In further
preferred embodiments, the present invention provides a polynucleotide encoding a
protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having
biological activity, the fragment preferably comprising eight (more preferably twenty,
15 most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide
encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4
having biological activity, the fragment comprising the amino acid sequence from amino
acid 65 to amino acid 74 of SEQ ID NO:4.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
20 ID NO:3.

Further embodiments of the invention provide isolated polynucleotides produced
according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize
25 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
consisting of:
 - (aa) SEQ ID NO:3, but excluding the poly(A) tail at the
3' end of SEQ ID NO:3; and
 - (ab) the nucleotide sequence of the cDNA insert of clone
30 vb12_1 deposited with the ATCC under accession number 98846;
 - (ii) hybridizing said probe(s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the
probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

(bb) the nucleotide sequence of the cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 201 to nucleotide 482, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 201 to nucleotide 482, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 201 to nucleotide 482.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

- (b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;
- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
- 10 of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:4.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 1195 to nucleotide 1527;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
- 20 NO:5 from nucleotide 1468 to nucleotide 1527;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb14_1 deposited with the ATCC under accession number 98846;
- (e) a polynucleotide encoding the full-length protein encoded by the
- 25 cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb14_1 deposited with the ATCC under accession number 98846;
- 30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:5.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 1195 to nucleotide 1527; the nucleotide sequence of SEQ ID NO:5 from nucleotide 1468 to nucleotide 1527; the nucleotide sequence of the full-length protein coding sequence of clone vb14_1 deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vb14_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846.

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:5.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(ab) the nucleotide sequence of the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(bb) the nucleotide sequence of the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 1195 to nucleotide 1527, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 1195 to nucleotide 1527, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 1195 to

nucleotide 1527. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 1468 to nucleotide 1527, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from
5 nucleotide 1468 to nucleotide 1527, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 1468 to nucleotide 1527.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:6;
- (b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
- 20 of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 50 to amino acid 59 of SEQ ID NO:6.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
- 30 NO:7 from nucleotide 109 to nucleotide 294;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ve11_1 deposited with the ATCC under accession number 98846;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;
- 5 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ve11_1 deposited with the ATCC under accession number 98846;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;
- 10 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- 15 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:7.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294; the nucleotide sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294; the nucleotide sequence of the full-length protein coding sequence of clone ve11_1 deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone ve11_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide

25

30

encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 30 to amino acid 39 of SEQ ID NO:8.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
5 ID NO:7.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

10 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

15 (ab) the nucleotide sequence of the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

20 and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

25 (ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

(bb) the nucleotide sequence of the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;

30 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending

contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the

5 cDNA sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294. Also preferably the polynucleotide isolated according to the above

10 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294

15 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
- (b) a fragment of the amino acid sequence of SEQ ID NO:8, the
- 20 fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
- (c) the amino acid sequence encoded by the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8. In further preferred

25 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from

30 amino acid 30 to amino acid 39 of SEQ ID NO:8.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 22 to nucleotide 468;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 10 98846;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA 15 insert of clone vf2_1 deposited with the ATCC under accession number 98846;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment 20 comprising eight contiguous amino acids of SEQ ID NO:10;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:9.
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 22 to nucleotide 468; the nucleotide sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468; the nucleotide sequence of the full-length protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vf2_1 deposited with

the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 69 to amino acid 78 of SEQ ID NO:10.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 15 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 20 (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 25 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - 30 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and

- (bb) the nucleotide sequence of the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to

10 a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 22 to nucleotide 468, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of

15 SEQ ID NO:9 from nucleotide 22 to nucleotide 468, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 22 to nucleotide 468. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468, and extending contiguously from a

20 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group

25 consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vf2_1
- 30 deposited with the ATCC under accession number 98846;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 69 to amino acid 78 of SEQ ID NO:10.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- 10 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 262 to nucleotide 1641;
- 15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
- 20 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
- 25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;
- 30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:11.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641; the nucleotide sequence of SEQ ID NO:11 from nucleotide 262 to nucleotide 1641; the nucleotide sequence of the full-length protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 248 to amino acid 257 of SEQ ID NO:12.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(bb) the nucleotide sequence of the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 262 to nucleotide 1641, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 262 to nucleotide 1641, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 262 to nucleotide 1641.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:12;

- (b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
- 10 of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 248 to amino acid 257 of SEQ ID NO:12.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:13 from nucleotide 380 to nucleotide 892;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
- 20 NO:13 from nucleotide 416 to nucleotide 892;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vj1_1 deposited with the ATCC under accession number 98846;
- (e) a polynucleotide encoding the full-length protein encoded by the
- 25 cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vj1_1 deposited with the ATCC under accession number 98846;
- 30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;

5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

10 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:13.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:13 from nucleotide 380 to nucleotide 892; the nucleotide sequence of SEQ ID NO:13
15 from nucleotide 416 to nucleotide 892; the nucleotide sequence of the full-length protein coding sequence of clone vj1_1 deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vj1_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert
20 of clone vj1_1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a polynucleotide
25 encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 80 to amino acid 89 of SEQ ID NO:14.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.

30 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:13; and

5 (ab) the nucleotide sequence of the cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

10 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

15

(ba) SEQ ID NO:13; and

(bb) the nucleotide sequence of the cDNA insert of clone

vj1_1 deposited with the ATCC under accession number 98846;

20 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and
25 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 380 to nucleotide 892, and extending contiguously from a nucleotide sequence
30 corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 380 to nucleotide 892, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 380 to nucleotide 892. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 116 to nucleotide 892, and

extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 416 to nucleotide 892, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 416 to nucleotide 892.

5 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:14;
- (b) a fragment of the amino acid sequence of SEQ ID NO:14, the
10 fragment comprising eight contiguous amino acids of SEQ ID NO:14; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:14. In further preferred
15 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the amino acid sequence
20 from amino acid 80 to amino acid 89 of SEQ ID NO:14.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15;
- 25 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 62 to nucleotide 1057;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:15 from nucleotide 659 to nucleotide 1057;
- (d) a polynucleotide comprising the nucleotide sequence of the full-
30 length protein coding sequence of clone v11_1 deposited with the ATCC under accession number 98846;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone v11_1 deposited with the ATCC under accession number 98846;

- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vl1_1 deposited with the ATCC under accession number 98846;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vl1_1 deposited with the ATCC under accession number 98846;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:15.
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 62 to nucleotide 1057; the nucleotide sequence of SEQ ID NO:15 from nucleotide 659 to nucleotide 1057; the nucleotide sequence of the full-length protein coding sequence of clone vl1_1 deposited with the ATCC under accession number 98846; or the nucleotide sequence of a mature protein coding sequence of clone vl1_1 deposited with the ATCC under accession number 98846. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vl1_1 deposited with the ATCC under accession number 98846. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 161 to amino acid 170 of SEQ ID NO:16.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 5 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 10 (aa) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vl1_1 deposited with the ATCC under accession number 98846;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 15 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that
 - 20 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15; and
 - (bb) the nucleotide sequence of the cDNA insert of clone
 - 25 vl1_1 deposited with the ATCC under accession number 98846;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).
- 30 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15, but excluding the poly(A) tail at the 3' end of SEQ ID NO:15. Also preferably the

polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 62 to nucleotide 1057, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 62 to nucleotide 1057, to a nucleotide
5 sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 62 to nucleotide 1057. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:15 from nucleotide 659 to nucleotide 1057, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from
10 nucleotide 659 to nucleotide 1057, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 659 to nucleotide 1057.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 15 (a) the amino acid sequence of SEQ ID NO:16;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vl1_1 deposited with the ATCC under accession number 38846;
- 20 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:16. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
25 of SEQ ID NO:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising the amino acid sequence from amino acid 161 to amino acid 170 of SEQ ID NO:16.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 30 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 74 to nucleotide 529;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:17 from nucleotide 140 to nucleotide 529;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838;
- 5 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838;
- 10 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- 15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- 20 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 25 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:17.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:17 from nucleotide 74 to nucleotide 529; the nucleotide sequence of SEQ ID NO:17 from nucleotide 140 to nucleotide 529; the nucleotide sequence of the full-length protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838; or the nucleotide sequence of a mature protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert

30

of clone vk2_1 deposited with the ATCC under accession number 98838. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, 5 most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:18.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ 10 ID NO:17.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize 15 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and
 - (ab) the nucleotide sequence of the cDNA insert of clone 20 vk2_1 deposited with the ATCC under accession number 98838;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- 25 and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 30 (ba) SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17; and
 - (bb) the nucleotide sequence of the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

- 5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17, but excluding the poly(A) tail at the 3' end of SEQ ID NO:17. Also preferably the
- 10 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 74 to nucleotide 529, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 74 to nucleotide 529, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide
- 15 74 to nucleotide 529. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 140 to nucleotide 529, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 140 to nucleotide 529, to a nucleotide sequence corresponding to the 3' end of
- 20 said sequence of SEQ ID NO:17 from nucleotide 140 to nucleotide 529.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- 25 (b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;

- the protein being substantially free from other mammalian proteins. Preferably such
- 30 protein comprises the amino acid sequence of SEQ ID NO:18. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a protein comprising a fragment of the amino acid sequence of SEQ

ID NO:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:18.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19 from nucleotide 174 to nucleotide 3170;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
10 NO:19 from nucleotide 1098 to nucleotide 3170;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb21_1 deposited with the ATCC under accession number 98862;
- (e) a polynucleotide encoding the full-length protein encoded by the
15 cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb21_1 deposited with the ATCC under accession number 98862;
- 20 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
- (i) a polynucleotide encoding a protein comprising a fragment of the
25 amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein
30 of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:19.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 174 to nucleotide 3170; the nucleotide sequence of SEQ ID NO:19 from nucleotide 1098 to nucleotide 3170; the nucleotide sequence of the full-length protein coding sequence of clone vb21_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vb21_1 deposited with the ATCC under accession number 98862. In other preferred
5
10
embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862.

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably
15
twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 494 to amino acid 503 of SEQ ID NO:20.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:19.
20

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize
25 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and
 - (ab) the nucleotide sequence of the cDNA insert of clone
30 vb21_1 deposited with the ATCC under accession number 98862;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19; and

(bb) the nucleotide sequence of the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19, but excluding the poly(A) tail at the 3' end of SEQ ID NO:19. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 174 to nucleotide 3170, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 174 to nucleotide 3170, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 174 to nucleotide 3170. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 1098 to nucleotide 3170, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 1098 to nucleotide 3170, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 1098 to nucleotide 3170.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:20;

(b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;

- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:20. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
- 10 of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 494 to amino acid 503 of SEQ ID NO:20.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21 from nucleotide 74 to nucleotide 1453;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
- 20 NO:21 from nucleotide 224 to nucleotide 1453;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862;

- (e) a polynucleotide encoding the full-length protein encoded by the
- 25 cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862;

- (g) a polynucleotide encoding a mature protein encoded by the cDNA
- 30 insert of clone vc35_1 deposited with the ATCC under accession number 98862;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:22;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:22;

5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

10 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:21.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:21 from nucleotide 74 to nucleotide 1453; the nucleotide sequence of SEQ ID NO:21 from nucleotide 224 to nucleotide 1453; the nucleotide sequence of the full-length protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 225 to amino acid 234 of SEQ ID NO:22.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:21.

30 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:21, but excluding the poly(A) tail at the 3' end of SEQ ID NO:21; and

(ab) the nucleotide sequence of the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:21, but excluding the poly(A) tail at the 3' end of SEQ ID NO:21; and

(bb) the nucleotide sequence of the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:21, but excluding the poly(A) tail at the 3' end of SEQ ID NO:21. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 74 to nucleotide 1453, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 74 to nucleotide 1453, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide

74 to nucleotide 1453. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 224 to nucleotide 1453, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from
5 nucleotide 224 to nucleotide 1453, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 224 to nucleotide 1453.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:22;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:22. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
20 of SEQ ID NO:22, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 225 to amino acid 234 of SEQ ID NO:22.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:23 from nucleotide 243 to nucleotide 368;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
- 5 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
- 10 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:24;
- 15 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:23.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368; the nucleotide sequence of SEQ ID NO:23 from nucleotide 243 to nucleotide 368; the nucleotide sequence of the full-length protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a polynucleotide

encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 34 to amino acid 43 of SEQ ID NO:24.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
5 ID NO:23.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize
10 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:23, but excluding the poly(A) tail at the 3' end of SEQ ID NO:23; and
 - (ab) the nucleotide sequence of the cDNA insert of clone
15 vc36_1 deposited with the ATCC under accession number 98862;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
20 and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
25
 - (ba) SEQ ID NO:23, but excluding the poly(A) tail at the 3' end of SEQ ID NO:23; and
 - (bb) the nucleotide sequence of the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
 - (ii) hybridizing said primer(s) to human genomic DNA in
30 conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23, and

extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:23, but excluding the poly(A) tail at the 3' end of SEQ ID NO:23. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence
5 corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368. Also preferably the polynucleotide isolated according to the above
10 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 243 to nucleotide 368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 243 to nucleotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 243 to nucleotide 368.

15 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:24;
- (b) a fragment of the amino acid sequence of SEQ ID NO:24, the
20 fragment comprising eight contiguous amino acids of SEQ ID NO:24; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:24. In further preferred
25 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence
30 from amino acid 34 to amino acid 43 of SEQ ID NO:24.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:25 from nucleotide 370 to nucleotide 1662;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc38_1 deposited with the ATCC under accession number 98862;
- 5 (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc38_1 deposited with the ATCC under accession number 98862;
- 10 (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:26;
- 15 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 20 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:25.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 370 to nucleotide 1662; the nucleotide sequence of the full-length protein coding sequence of clone vc38_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc38_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862.

30

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a
5 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 210 to amino acid 219 of SEQ ID NO:26.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:25.

10 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group
15 consisting of:

(aa) SEQ ID NO:25, but excluding the poly(A) tail at the 3' end of SEQ ID NO:25; and

(ab) the nucleotide sequence of the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;

20 (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

25 (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

30 (ba) SEQ ID NO:25, but excluding the poly(A) tail at the 3' end of SEQ ID NO:25; and

(bb) the nucleotide sequence of the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25, and
5 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:25, but excluding the poly(A) tail at the 3' end of SEQ ID NO:25. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide
10 1662, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from nucleotide 370 to nucleotide 1662, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide 370 to nucleotide 1662.

In other embodiments, the present invention provides a composition comprising
15 a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:26;
- (b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and
- 20 (c) the amino acid sequence encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:26. In further preferred
25 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 210 to amino acid 219 of SEQ ID NO:26.

30 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 105 to nucleotide 365;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:27 from nucleotide 147 to nucleotide 365;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;
- 10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;
- 15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:28;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:27.
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:27 from nucleotide 105 to nucleotide 365; the nucleotide sequence of SEQ ID NO:27 from nucleotide 147 to nucleotide 365; the nucleotide sequence of the full-length protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc39_1 deposited

with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:28.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:27.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 15 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 25 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27; and

- (bb) the nucleotide sequence of the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
10 ID NO:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:27, but excluding the poly(A) tail at the 3' end of SEQ ID NO:27. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 105 to nucleotide 365, and extending contiguously from a nucleotide sequence corresponding to the 5' end
15 of said sequence of SEQ ID NO:27 from nucleotide 105 to nucleotide 365, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 105 to nucleotide 365. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 147 to nucleotide 365, and extending contiguously from a
20 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 147 to nucleotide 365, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 147 to nucleotide 365.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group
25 consisting of:

- (a) the amino acid sequence of SEQ ID NO:28;
- (b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and
- (c) the amino acid sequence encoded by the cDNA insert of clone
30 vc39_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:28. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:28.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
10 NO:29 from nucleotide 35 to nucleotide 1066;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc40_1 deposited with the ATCC under
15 accession number 98862;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;
- (f) a polynucleotide comprising the nucleotide sequence of a mature
20 protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;
- (h) a polynucleotide encoding a protein comprising the amino acid
25 sequence of SEQ ID NO:30;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of
30 (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:29.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 35 to nucleotide 1066; the nucleotide sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066; the nucleotide sequence of the full-length protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 167 to amino acid 176 of SEQ ID NO:30.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:29.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29; and

(bb) the nucleotide sequence of the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 35 to nucleotide 1066, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 35 to nucleotide 1066, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 35 to nucleotide 1066. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:30;

- (b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;
- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:30. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
- 10 of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 167 to amino acid 176 of SEQ ID NO:30.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
- 20 NO:31 from nucleotide 104 to nucleotide 553;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862;
- (e) a polynucleotide encoding the full-length protein encoded by the
- 25 cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862;
- 30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:32;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;

5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

10 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:31.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553; the nucleotide sequence of SEQ ID NO:31
15 from nucleotide 104 to nucleotide 553; the nucleotide sequence of the full-length protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert
20 of clone vc46_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a polynucleotide
25 encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 81 to amino acid 90 of SEQ ID NO:32.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:31.

30 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (aa) SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31; and

(ab) the nucleotide sequence of the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

10 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31; and

20 (bb) the nucleotide sequence of the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

25 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:31, but excluding the poly(A) tail at the 3' end of SEQ ID NO:31. Also preferably the
30 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide

38 to nucleotide 553. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 104 to nucleotide 553, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:31 from
5 nucleotide 104 to nucleotide 553, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 104 to nucleotide 553.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:32;
- (b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:32. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
20 of SEQ ID NO:32, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 81 to amino acid 90 of SEQ ID NO:32.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:33 from nucleotide 164 to nucleotide 2548;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:33 from nucleotide 242 to nucleotide 2548;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
- 5 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
- 10 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:34;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:34;
- 15 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:33.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:33 from nucleotide 164 to nucleotide 2548; the nucleotide sequence of SEQ ID NO:33 from nucleotide 242 to nucleotide 2548; the nucleotide sequence of the full-length protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a polynucleotide

encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 392 to amino acid 401 of SEQ ID NO:34.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
5 ID NO:33.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

10 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33; and

15 (ab) the nucleotide sequence of the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

20 and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

25 (ba) SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33; and

(bb) the nucleotide sequence of the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;

30 (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33, and

extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:33 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:33, but excluding the poly(A) tail at the 3' end of SEQ ID NO:33. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence
5 corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 164 to nucleotide 2548, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 164 to nucleotide 2548, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 164 to nucleotide 2548. Also preferably the polynucleotide isolated according to the above
10 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 242 to nucleotide 2548, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 242 to nucleotide 2548, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 242 to nucleotide 2548.

15 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:34;
- (b) a fragment of the amino acid sequence of SEQ ID NO:34, the
20 fragment comprising eight contiguous amino acids of SEQ ID NO:34; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:34. In further preferred
25 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence
30 from amino acid 392 to amino acid 401 of SEQ ID NO:34.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
- 10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
- 15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:36;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:36;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:35.
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776; the nucleotide sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776; the nucleotide sequence of the full-length protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc50_1 deposited

with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:36.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:35.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 15 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 20 (aa) SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 25 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - 30 (i) preparing one or more polynucleotide primers that hybridize in 5X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35; and

- (bb) the nucleotide sequence of the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ

10 ID NO:35 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:35, but excluding the poly(A) tail at the 3' end of SEQ ID NO:35. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776, and extending contiguously from a nucleotide sequence corresponding to the 5' end

15 of said sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776, and extending contiguously from a

20 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group

25 consisting of:

- (a) the amino acid sequence of SEQ ID NO:36;
- (b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and
- (c) the amino acid sequence encoded by the cDNA insert of clone
- 30 vc50_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:36. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:36.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
10 NO:37 from nucleotide 139 to nucleotide 1308;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:37 from nucleotide 211 to nucleotide 1308;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc51_1 deposited with the ATCC under
15 accession number 98862;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
- (f) a polynucleotide comprising the nucleotide sequence of a mature
20 protein coding sequence of clone vc51_1 deposited with the ATCC under accession number 98862;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
- (h) a polynucleotide encoding a protein comprising the amino acid
25 sequence of SEQ ID NO:38;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:38;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of
30 (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:37.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308; the nucleotide sequence of SEQ ID NO:37 from nucleotide 211 to nucleotide 1308; the nucleotide sequence of the full-length protein coding sequence of clone vc51_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc51_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 190 to amino acid 199 of SEQ ID NO:38.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:37.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37; and

(bb) the nucleotide sequence of the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:37, but excluding the poly(A) tail at the 3' end of SEQ ID NO:37. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 211 to nucleotide 1308, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 211 to nucleotide 1308, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 211 to nucleotide 1308.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:38;

- (b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:38. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
- 10 of SEQ ID NO:38, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 190 to amino acid 199 of SEQ ID NO:38.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
- 20 NO:39 from nucleotide 114 to nucleotide 1142;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862;
- (e) a polynucleotide encoding the full-length protein encoded by the
- 25 cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862;
- 30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:40;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;

5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

10 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:39.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142; the nucleotide sequence of SEQ ID NO:39 from nucleotide 114 to nucleotide 1142; the nucleotide sequence of the full-length protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862; or the nucleotide sequence of a mature protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 182 to amino acid 191 of SEQ ID NO:40.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:39.

30 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (aa) SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39; and

(ab) the nucleotide sequence of the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

10 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39; and

20 (bb) the nucleotide sequence of the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

25 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:39, but excluding the poly(A) tail at the 3' end of SEQ ID NO:39. Also preferably the
30 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide

21 to nucleotide 1142. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 114 to nucleotide 1142, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from
 5 nucleotide 114 to nucleotide 1142, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 114 to nucleotide 1142.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:40;
- (b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:40. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
 20 of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 182 to amino acid 191 of SEQ ID NO:40.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
 30 NO:41 from nucleotide 346 to nucleotide 1416;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;

5 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;

10 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:42;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;

15 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:41.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416; the nucleotide sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416; the nucleotide sequence of the full-length protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a polynucleotide

encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 229 to amino acid 238 of SEQ ID NO:42.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:41.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41; and
 - (bb) the nucleotide sequence of the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and

extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:41 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:41, but excluding the poly(A) tail at the 3' end of SEQ ID NO:41. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence

5 corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416. Also preferably the polynucleotide isolated according to the above

10 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416.

15 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:42;
- (b) a fragment of the amino acid sequence of SEQ ID NO:42, the
- 20 fragment comprising eight contiguous amino acids of SEQ ID NO:42; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:42. In further preferred

25 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence

30 from amino acid 229 to amino acid 238 of SEQ ID NO:42.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;
- 10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;
- 15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:44;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:43.
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461; the nucleotide sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461; the nucleotide sequence of the full-length protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vc34_1 deposited

with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 200 to amino acid 209 of SEQ ID NO:44.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:43.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 15 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 20 (aa) SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 25 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - 30 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43; and

- (bb) the nucleotide sequence of the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:43, but excluding the poly(A) tail at the 3' end of SEQ ID NO:43. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:44;
- (b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:44. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:44, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 200 to amino acid 209 of SEQ ID NO:44.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
10 NO:45 from nucleotide 1922 to nucleotide 2350;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:45 from nucleotide 2237 to nucleotide 2350;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc47_1 deposited with the ATCC under
15 accession number 98886;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;
- (f) a polynucleotide comprising the nucleotide sequence of a mature
20 protein coding sequence of clone vc47_1 deposited with the ATCC under accession number 98886;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;
- (h) a polynucleotide encoding a protein comprising the amino acid
25 sequence of SEQ ID NO:46;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of
30 (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:45.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350; the nucleotide sequence of SEQ ID NO:45 from nucleotide 2237 to nucleotide 2350; the nucleotide sequence of the full-length protein coding sequence of clone vc47_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vc47_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886.

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID NO:46.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:45.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:45, but excluding the poly(A) tail at the 3' end of SEQ ID NO:45; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:45, but excluding the poly(A) tail at the 3' end of SEQ ID NO:45; and

(bb) the nucleotide sequence of the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:45 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:45, but excluding the poly(A) tail at the 3' end of SEQ ID NO:45. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 2237 to nucleotide 2350, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 2237 to nucleotide 2350, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 2237 to nucleotide 2350.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:46;

(b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;

- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:46. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
- 10 of SEQ ID NO:46, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 66 to amino acid 75 of SEQ ID NO:46.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 111 to nucleotide 1337;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337;
- 20

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
- 25

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886;

- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
- 30

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:48;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:47.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 111 to nucleotide 1337; the nucleotide sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337; the nucleotide sequence of the full-length protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 199 to amino acid 208 of SEQ ID NO:48.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:47.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (aa) SEQ ID NO:47, but excluding the poly(A) tail at the 3' end of SEQ ID NO:47; and

(ab) the nucleotide sequence of the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

10 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:47, but excluding the poly(A) tail at the 3' end of SEQ ID NO:47; and

20 (bb) the nucleotide sequence of the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

25 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:47, but excluding the poly(A) tail at the 3' end of SEQ ID NO:47. Also preferably the
30 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 111 to nucleotide 1337, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 111 to nucleotide 1337, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide

111 to nucleotide 1337. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from
5 nucleotide 246 to nucleotide 1337, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:48;
- (b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:48. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
20 of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 199 to amino acid 208 of SEQ ID NO:48.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:49 from nucleotide 270 to nucleotide 1637;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc57_1 deposited with the ATCC under accession number 98886;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;

5 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc57_1 deposited with the ATCC under accession number 98886;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;

10 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:50;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;

15 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:49.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637; the nucleotide sequence of SEQ ID NO:49 from nucleotide 270 to nucleotide 1637; the nucleotide sequence of the full-length protein coding sequence of clone vc57_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vc57_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a polynucleotide

encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence from amino acid 236 to amino acid 245 of SEQ ID NO:50.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
5 ID NO:49.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize
10 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:49, but excluding the poly(A) tail at the
3' end of SEQ ID NO:49; and
 - (ab) the nucleotide sequence of the cDNA insert of clone
15 vc57_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said probe(s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the
probe(s);
- 20 and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:
 - 25 (ba) SEQ ID NO:49, but excluding the poly(A) tail at the
3' end of SEQ ID NO:49; and
 - (bb) the nucleotide sequence of the cDNA insert of clone
vc57_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said primer(s) to human genomic DNA in
30 conditions at least as stringent as 4X SSC at 50 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49, and

extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:49 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:49, but excluding the poly(A) tail at the 3' end of SEQ ID NO:49. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence
 5 corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637. Also preferably the polynucleotide isolated according to the above
 10 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 270 to nucleotide 1637, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 270 to nucleotide 1637, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 270 to nucleotide 1637.

15 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:50;
- (b) a fragment of the amino acid sequence of SEQ ID NO:50, the
 20 fragment comprising eight contiguous amino acids of SEQ ID NO:50; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:50. In further preferred
 25 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino acid sequence
 30 from amino acid 236 to amino acid 245 of SEQ ID NO:50.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ve13_1 deposited with the ATCC under accession number 98886;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
- 10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ve13_1 deposited with the ATCC under accession number 98886;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
- 15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:51.
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934; the nucleotide sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934; the nucleotide sequence of the full-length protein coding sequence of clone ve13_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone

ve13_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886.

In further preferred embodiments, the present invention provides a polynucleotide
5 encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of
10 SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 315 to amino acid 324 of SEQ ID NO:52.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:51.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 15 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 20 (aa) SEQ ID NO:51, but excluding the poly(A) tail at the 3' end of SEQ ID NO:51; and
 - (ab) the nucleotide sequence of the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 25 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that
30 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:51, but excluding the poly(A) tail at the 3' end of SEQ ID NO:51; and

- (bb) the nucleotide sequence of the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ

10 ID NO:51 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:51, but excluding the poly(A) tail at the 3' end of SEQ ID NO:51. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934, and extending contiguously from a nucleotide sequence corresponding to the 5' end

15 of said sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934, and extending contiguously from a

20 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group

25 consisting of:

- (a) the amino acid sequence of SEQ ID NO:52;
- (b) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and
- (c) the amino acid sequence encoded by the cDNA insert of clone
- 30 ve13_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:52. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 315 to amino acid 324 of SEQ ID NO:52.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53;
- 10 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ve16_1 deposited with the ATCC under
15 accession number 98886;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;
- (f) a polynucleotide comprising the nucleotide sequence of a mature
20 protein coding sequence of clone ve16_1 deposited with the ATCC under accession number 98886;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;
- (h) a polynucleotide encoding a protein comprising the amino acid
25 sequence of SEQ ID NO:54;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of
30 (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:53.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
5 NO:53 from nucleotide 240 to nucleotide 503; the nucleotide sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503; the nucleotide sequence of the full-length protein coding sequence of clone ve16_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone ve16_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the
10 polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty,
15 most preferably thirty) contiguous amino acids of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:54.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
20 ID NO:53.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize
25 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and
 - (ab) the nucleotide sequence of the cDNA insert of clone
30 ve16_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53; and

(bb) the nucleotide sequence of the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:53 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:53, but excluding the poly(A) tail at the 3' end of SEQ ID NO:53. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:54;

(b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and

(c) the amino acid sequence encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:54. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
10 of SEQ ID NO:54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 39 to amino acid 48 of SEQ ID NO:54.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063;

20 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886;

25 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886;

30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:56;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;

5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

10 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:55.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063; the nucleotide sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063; the nucleotide sequence of the full-length protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 170 to amino acid 179 of SEQ ID NO:56.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:55.

30 Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (aa) SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55; and

(ab) the nucleotide sequence of the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

10 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55; and

20 (bb) the nucleotide sequence of the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

25 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:55 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:55, but excluding the poly(A) tail at the 3' end of SEQ ID NO:55. Also preferably the
30 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide

11 to nucleotide 1063. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from
5 nucleotide 71 to nucleotide 1063, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:56;
- (b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:56. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
20 of SEQ ID NO:56, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 170 to amino acid 179 of SEQ ID NO:56.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:57 from nucleotide 755 to nucleotide 886;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;
- 5 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;
- 10 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:58;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:58;
- 15 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- 20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:57.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886; the nucleotide sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886; the nucleotide sequence of the full-length protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a polynucleotide

encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 52 to amino acid 61 of SEQ ID NO:58.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:57.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57; and

(ab) the nucleotide sequence of the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57; and

(bb) the nucleotide sequence of the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57, and

extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:57 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:57, but excluding the poly(A) tail at the 3' end of SEQ ID NO:57. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence
5 corresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886. Also preferably the polynucleotide isolated according to the above
10 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886.

15 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:58;
- (b) a fragment of the amino acid sequence of SEQ ID NO:58, the
20 fragment comprising eight contiguous amino acids of SEQ ID NO:58; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:58. In further preferred
25 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence
30 from amino acid 52 to amino acid 61 of SEQ ID NO:58.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59;

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59 from nucleotide 30 to nucleotide 344;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:59 from nucleotide 84 to nucleotide 344;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp7_1 deposited with the ATCC under accession number 98886;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886;
- 10 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp7_1 deposited with the ATCC under accession number 98886;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886;
- 15 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:60;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;
- 20 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:59.
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:59 from nucleotide 30 to nucleotide 344; the nucleotide sequence of SEQ ID NO:59 from nucleotide 84 to nucleotide 344; the nucleotide sequence of the full-length protein coding sequence of clone vp7_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vp7_1 deposited

with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:60.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:59.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 15 (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - 20 (aa) SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 25 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - 30 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:59, but excluding the poly(A) tail at the 3' end of SEQ ID NO:59; and

- (bb) the nucleotide sequence of the cDNA insert of clone
vp7_1 deposited with the ATCC under accession number 98886;
- (ii) hybridizing said primer(s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a
nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59, and
extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
10 ID NO:59 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:59, but
excluding the poly(A) tail at the 3' end of SEQ ID NO:59. Also preferably the
polynucleotide isolated according to the above process comprises a nucleotide sequence
corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 30 to nucleotide
344, and extending contiguously from a nucleotide sequence corresponding to the 5' end
15 of said sequence of SEQ ID NO:59 from nucleotide 30 to nucleotide 344, to a nucleotide
sequence corresponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide
30 to nucleotide 344. Also preferably the polynucleotide isolated according to the above
process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
NO:59 from nucleotide 84 to nucleotide 344, and extending contiguously from a
20 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:59 from
nucleotide 84 to nucleotide 344, to a nucleotide sequence corresponding to the 3' end of
said sequence of SEQ ID NO:59 from nucleotide 84 to nucleotide 344.

In other embodiments, the present invention provides a composition comprising
a protein, wherein said protein comprises an amino acid sequence selected from the group
25 consisting of:

- (a) the amino acid sequence of SEQ ID NO:60;
- (b) a fragment of the amino acid sequence of SEQ ID NO:60, the
fragment comprising eight contiguous amino acids of SEQ ID NO:60; and
- (c) the amino acid sequence encoded by the cDNA insert of clone
30 vp7_1 deposited with the ATCC under accession number 98886;
- the protein being substantially free from other mammalian proteins. Preferably such
protein comprises the amino acid sequence of SEQ ID NO:60. In further preferred
embodiments, the present invention provides a protein comprising a fragment of the
amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:60.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61;

10 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757;

15 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;

20 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;

25 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:62;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;

30 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:61.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757; the nucleotide sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757; the nucleotide sequence of the full-length protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886; or the nucleotide sequence of a mature protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:62.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:61.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:61, but excluding the poly(A) tail at the 3' end of SEQ ID NO:61; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

5 A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting
10 formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

15 Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

Receptor/Ligand Activity

20 A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands,
25 receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant
30 receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al.

of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues,
5 and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured
10 by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

15 Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

20 Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present
25 invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-
30 β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation

Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY. 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY. 1994.

5

Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns,
10 incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as
15 well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal
20 disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue
25 destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in
30 circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and

cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. *Cellular Biology* 15:141-151, 1995; Keller et al., *Molecular and Cellular Biology* 13:473-486, 1993; McClanahan et al., *Blood* 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., *Proc. Natl. Acad. Sci. USA* 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, NY. 1994; Neben et al., *Experimental Hematology* 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, NY. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and

D.H. Margulies, E.M. Shevach, W Strober, Pub. Green Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.

- 5 Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995;
- 10 Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

- Assays for lymphocyte survival/apoptosis (which will identify, among others,
- 15 proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993;
- 20 Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

- Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

25

Hematopoiesis Regulating Activity

- A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell
- 30 lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid

microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated
 5 immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated
 10 immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without
 15 limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al.,
 20 J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al.,
 25 Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: *In vitro*
 30 antibody production, Mond, J.J. and Brunswick, M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek,

response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (*e.g.*, sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (*e.g.*, a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2

tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

- 5 The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.
- 10 Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.
- 15 Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/*lpr/lpr* mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and
- 20 murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).
- 25 Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune
- 30

Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present
5 invention.

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by
10 suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and
15 persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), *e.g.*, preventing
20 high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys
25 the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the
30 molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term

Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitus, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease.

induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is
5 evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

- 10 Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986;
15 Bertagnolli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnolli et al., *Cellular Immunology* 133:327-341, 1991; Bertagnolli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

- Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell
20 stimulation, Kruisbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon γ , Schreiber, R.D. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.

- Assays for proliferation and differentiation of hematopoietic and lymphopoietic
25 cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature* 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983;
30 Measurement of mouse and human interleukin 6 - Nordan, R. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; Measurement of human Interleukin 11 - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols in Immunology*. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991;

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine
5 levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially
10 binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed in to reagent
15 grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to
20 Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein
25 or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention
30 can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may

given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

USES AND BIOLOGICAL ACTIVITY

5 The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies
10 or vectors suitable for introduction of DNA).

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express
15 recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare
20 with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for
25 examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those
30 described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to
5 provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which
10 are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by
15 virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement,
20 insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement,
25 insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds.,

- 5 John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or
10 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide encoding the protein of the invention may be operably
15 linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined
20 herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the
25 protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

30 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) [†]	Hybridization Temperature and Buffer [*]	Wash Temperature and Buffer [*]
5	A	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
	B	<50	T _B [*] ; 1xSSC	T _B [*] ; 1xSSC
	C	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
	D	<50	T _D [*] ; 1xSSC	T _D [*] ; 1xSSC
	E	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
	F	<50	T _F [*] ; 1xSSC	T _F [*] ; 1xSSC
10	G	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
	H	<50	T _H [*] ; 4xSSC	T _H [*] ; 4xSSC
	I	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
	J	<50	T _J [*] ; 4xSSC	T _J [*] ; 4xSSC
	K	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
	L	<50	T _L [*] ; 2xSSC	T _L [*] ; 2xSSC
15	M	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
	N	<50	T _N [*] ; 6xSSC	T _N [*] ; 6xSSC
	O	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
	P	<50	T _P [*] ; 6xSSC	T _P [*] ; 6xSSC
	Q	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
	R	<50	T _R [*] ; 4xSSC	T _R [*] ; 4xSSC

[†]: The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

^{*}: SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

^{*}T_B - T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer ([Na⁺] for 1xSSC = 0.165 M).

identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and
5 screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly
10 stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*, *Aotus trivirgatus*, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, *Cricetulus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuánez, 1988, *Ann. Rev. Genet.* **22**: 323-351; O'Brien *et al.*, 1993, *Nature Genetics* **3**:103-112; Johansson *et al.*, 1995, *Genomics* **25**: 682-690; Lyons *et al.*, 1997, *Nature Genetics* **15**: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* **13**(10): 393-399; Carver and Stubbs, 1997, *Genome Research* **7**:1123-1137; all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity, most preferably at least 90%

proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

- 5 In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics. Doolittle *ed.*, *Methods in Enzymology* 266: 460-480; Altschul *et al.*, 1990, Basic local alignment search tool, *Journal of*
- 10 *Molecular Biology* 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, *Nature Genetics* 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, *Proc. Natl. Acad. Sci. USA* 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX
- 15 platforms can be downloaded from <ftp://blast.wustl.edu/blast/executables>. The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTN, and TBLASTX) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely
- 20 used for commercial, nonprofit, or academic purposes. In all search programs in the suite -- BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length
- 25 one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six,
- 30 seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps.

also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through
5 deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* 14(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination,
10 preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988, *Nature* 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for
15 the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part
20 or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of
25 transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmembrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most
30 preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are

has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately
5 labeled polynucleotides of the present invention to chromosomes *in situ*. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences
10 disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address <http://www.ncbi.nlm.nih.gov/UniGene/>, in order to
15 identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense
20 polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* 15(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* 62(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* 58: 1-39; all of which are incorporated by reference herein). The desired change in gene expression can also be achieved through the use of double-stranded ribonucleotide
25 molecules having some complementarity to the mRNA transcribed from the gene, and which interfere with the transcription, stability, or expression of the mRNA ("RNA interference" or "RNAi"; Fire *et al.*, 1998, *Nature* 391 (6669): 806-811; Montgomery *et al.*, 1998, *Proc. Natl. Acad. Sci. USA* 95 (26): 15502-15507; and Sharp, 1999, *Genes Dev.* 13 (2): 139-141; all of which are incorporated by reference herein). Transgenic animals that have
30 multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting
5 biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, *Bio/Technology* 10, 773-778 (1992) and in R.S. McDowell, *et al.*, *J. Amer. Chem. Soc.* 114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as
10 immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a
15 decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length
20 polynucleotide (preferably those deposited with the ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that
25 are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can
30 be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
 - (b) It should be designed to have a T_m of approx. 80 °C (assuming 2° for each A or T and 4 degrees for each G or C).
- 5 The oligonucleotide should preferably be labeled with γ - ^{32}P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated
- 10 by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately $4\text{e}+6$ dpm/pmole.

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μl of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 $\mu\text{g}/\text{ml}$. The culture should preferably be

15 grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 $\mu\text{g}/\text{ml}$ and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other

20 known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with

25 NaOH) containing 0.5% SDS, 100 $\mu\text{g}/\text{ml}$ of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to $1\text{e}+6$ dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed

30 by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

	vc46_1	SEQ ID NO:96
	vc49_1	SEQ ID NO:97
	vc50_1	SEQ ID NO:98
	vc51_1	SEQ ID NO:99
5	vc52_1	SEQ ID NO:100
	vc33_1	SEQ ID NO:101
	vc34_1	SEQ ID NO:102
	vc47_1	SEQ ID NO:103
	vc54_1	SEQ ID NO:104
10	vc57_1	SEQ ID NO:105
	ve13_1	SEQ ID NO:106
	ve16_1	SEQ ID NO:107
	vf3_1	SEQ ID NO:108
	vj2_1	SEQ ID NO:109
15	vp7_1	SEQ ID NO:110
	vp8_1	SEQ ID NO:111
	vb22_1	SEQ ID NO:112
	vc48_1	SEQ ID NO:113
	vp3_1	SEQ ID NO:114
20	vc61_1	SEQ ID NO:115
	vp15_1	SEQ ID NO:116
	vp17_1	SEQ ID NO:117
	vp19_1	SEQ ID NO:118
	vq1_1	SEQ ID NO:119
25	vp14_1	SEQ ID NO:120

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

The design of the oligonucleotide probe should preferably follow these parameters:

("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

	<u>Clone</u>	<u>Probe Sequence</u>
20	vb11_1	SEQ ID NO:81
	vb12_1	SEQ ID NO:82
	vb14_1	SEQ ID NO:83
	ve11_1	SEQ ID NO:84
	vf2_1	SEQ ID NO:85
25	vg2_1	SEQ ID NO:86
	vj1_1	SEQ ID NO:87
	vl1_1	SEQ ID NO:88
	vk2_1	SEQ ID NO:89
	vb21_1	SEQ ID NO:90
30	vc35_1	SEQ ID NO:91
	vc36_1	SEQ ID NO:92
	vc38_1	SEQ ID NO:93
	vc39_1	SEQ ID NO:94
	vc40_1	SEQ ID NO:95

Clones vb21_1, vc35_1, vc36_1, vc38_1, vc39_1, vc40_1, vc46_1, vc49_1, vc50_1, vc51_1, and vc52_1 were deposited on September 2, 1998 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98862, from which each clone comprising a particular polynucleotide is obtainable.

Clones vc33_1, vc34_1, vc47_1, vc54_1, vc57_1, ve13_1, ve16_1, vf3_1, vj2_1, vp7_1, and vp8_1 were deposited on September 22, 1998 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98886, from which each clone comprising a particular polynucleotide is obtainable.

Clones vb22_1, vc48_1, and vp3_1 were deposited on October 16, 1998 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98933, from which each clone comprising a particular polynucleotide is obtainable.

Clones vc61_1, vp15_1, vp17_1, vp19_1, and vq1_1 were deposited on December 23, 1998 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 207012, from which each clone comprising a particular polynucleotide is obtainable.

Clone vp14_1 was deposited on December 23, 1998 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number 207011, from which the vp14_1 clone comprising a particular polynucleotide is obtainable.

All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp14_1 should be approximately 1355 bp.

The nucleotide sequence disclosed herein for vp14_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp14_1 demonstrated at least some similarity with sequences identified as AI052724 (oz27a12.x1 Soares_total_fetus_Nb2HF8_9w Homo sapiens cDNA clone IMAGE:1676542 3' similar to SW:YQJQ_BACSU P54554 HYPOTHETICAL OXIDOREDUCTASE IN GLNQ-ANSR INTERGENIC REGION; mRNA sequence) and T20001 (Human gene signature HUMGS01138). The predicted amino acid sequence disclosed herein for vp14_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vp14_1 protein demonstrated at least some similarity to sequences identified as R61477 (Clavulanic acid dehydrogenase sequence) and Z99116 (similar to ketoacyl reductase [Bacillus subtilis]). The predicted vp14_1 protein shows some amino acid similarity to various dehydrogenases due to the presence of a short-chain alcohol dehydrogenase family signature at amino acids 51 to 240 of SEQ ID NO:80, as detected by motifs and hidden markov model analysis. Based upon sequence similarity, vp14_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four additional potential transmembrane domains within the vp14_1 protein sequence, centered around amino acids 55, 195, 230, and 300 of SEQ ID NO:80, respectively.

Deposit of Clones

Clones vb11_1, vb12_1, vb14_1, ve11_1, vf2_1, vg2_1, vj1_1, and vl1_1 were deposited on August 20, 1998 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number 98846, from which each clone comprising a particular polynucleotide is obtainable.

Clone vk2_1 was deposited on August 20, 1998 with the ATCC (American Type Culture Collection, 10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number 98838, from which the vk2_1 clone comprising a particular polynucleotide is obtainable.

of SEQ ID NO:78 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 30. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vq1_1 protein. If a "T" residue were inserted between nucleotides 332 and 333 of SEQ ID NO:77, nucleotides 54 to 496 of the resulting nucleotide sequence would encode a protein having an amino acid sequence reported as SEQ ID NO:132.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vq1_1 should be approximately 873 bp.

The nucleotide sequence disclosed herein for vq1_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vq1_1 demonstrated at least some similarity with sequences identified as No hits were found in the databases. The TopPredII computer program predicts an additional potential transmembrane domain within the vq1_1 protein sequence, extending from about amino acid 36 to about amino acid 76 of SEQ ID NO:78. The nucleotide sequence of vq1_1 indicates that it may contain an Alu repetitive element.

Clone "vp14_1"

A polynucleotide of the present invention has been identified as clone "vp14_1". vp14_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp14_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp14_1 protein").

The nucleotide sequence of vp14_1 as presently determined is reported in SEQ ID NO:79, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp14_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:80. Amino acids 5 to 17 of SEQ ID NO:80 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 18. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp14_1 protein.

Clone "vp19_1"

A polynucleotide of the present invention has been identified as clone "vp19_1". vp19_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp19_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp19_1 protein").

The nucleotide sequence of vp19_1 as presently determined is reported in SEQ ID NO:75, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp19_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:76.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp19_1 should be approximately 971 bp.

The nucleotide sequence disclosed herein for vp19_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp19_1 demonstrated at least some similarity with sequences identified as AA716408 (zg64b02.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 398091 3', mRNA sequence) and T20711 (Human gene signature HUMGS01928). Based upon sequence similarity, vp19_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the vp19_1 protein sequence centered around amino acid 23 of SEQ ID NO:76; due to its hydrophobic nature, this region (amino acids 20 to 32) could also be a leader/signal sequence, with the mature protein beginning at amino acid 33 of SEQ ID NO:76.

Clone "vq1_1"

A polynucleotide of the present invention has been identified as clone "vq1_1". vq1_1 was isolated from a human adult lung cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vq1_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vq1_1 protein").

The nucleotide sequence of vq1_1 as presently determined is reported in SEQ ID NO:77, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vq1_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:78. Amino acids 17 to 29

is incorporated by reference herein). Based upon sequence similarity, vp15_1 proteins and each similar protein or peptide may share at least some activity.

vp15_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 24 kDa was detected in conditioned medium and
5 membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "vp17_1"

A polynucleotide of the present invention has been identified as clone "vp17_1". vp17_1 was isolated from a human adult prostate cDNA library and was identified as
10 encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp17_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp17_1 protein").

The nucleotide sequence of vp17_1 as presently determined is reported in SEQ ID NO:73, and includes a poly(A) tail. What applicants presently believe to be the proper
15 reading frame and the predicted amino acid sequence of the vp17_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:74. Amino acids 10 to 22 of SEQ ID NO:74 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain
20 should the predicted leader/signal sequence not be separated from the remainder of the vp17_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp17_1 should be approximately 3150 bp.

The nucleotide sequence disclosed herein for vp17_1 was searched against the
25 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp17_1 demonstrated at least some similarity with sequences identified as AI056890 (oz03g07.x1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE 1674300 3' mRNA sequence) and T64815 (Tumour suppressor activated pathway gene TSAP6). Based upon sequence similarity, vp17_1 proteins and
30 each similar protein or peptide may share at least some activity. The TcpPredII computer program predicts two additional potential transmembrane domains within the vp17_1 protein sequence, one centered around amino acid 50 and another around amino acid 80 of SEQ ID NO:74.

Clone "vp15_1"

A polynucleotide of the present invention has been identified as clone "vp15_1". vp15_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp15_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp15_1 protein").

The nucleotide sequence of vp15_1 as presently determined is reported in SEQ ID NO:71, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp15_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:72. Amino acids 4 to 16 of SEQ ID NO:72 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp15_1 protein. If a "C" residue were inserted between nucleotides 458 and 459 of SEQ ID NO:71, nucleotides 44 to 568 of the resulting nucleotide sequence would encode a protein having an amino acid sequence reported as SEQ ID NO:131.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp15_1 should be approximately 2033 bp.

The nucleotide sequence disclosed herein for vp15_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp15_1 demonstrated at least some similarity with sequences identified as AI033082 (ow97g04.s1 Soares_fetal_liver_spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE 1654806 3', mRNA sequence) and T21877 (Human gene signature HUMGS03418). The predicted amino acid sequence disclosed herein for vp15_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vp15_1 protein demonstrated at least some similarity to sequences identified as R45335 (Thrombomodulin analogue Q336N, Q365E) and U94333 (C1qR(p) [Homo sapiens]). The predicted vp15_1 protein shows some amino acid similarity to multiple thrombomodulin analogues (such as GeneSeq accession number R45335), and shows some end-to-end similarity to GenPept accession number U94333, which is described as a "... human C1q/MBL/SPA receptor that mediates enhanced phagocytosis *in vitro*" (Nepomuceno *et al.*, 1997, *Immunity* 6(2): 119-129, which

reading frame and the predicted amino acid sequence of the vc61_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:70. Amino acids 16 to 28 of SEQ ID NO:70 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 29. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc61_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc61_1 should be approximately 3199 bp.

The nucleotide sequence disclosed herein for vc61_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc61_1 demonstrated at least some similarity with sequences identified as AI028115 (ow51d09.x1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone IMAGE 1650353 3' similar to gb S67859 TRANSCRIPTION INITIATION FACTOR IIE-ALPHA CHAIN (HUMAN); mRNA), V20913 (Human induced tumour protein cDNA), and Z99129 (Human DNA sequence from clone 425C14 on chromosome 6q22 Contains the HSF2 gene for Heat Shock Factor 2 (Heat Shock Transcription Factor 2, HSTF 2) and an unknown gene similar to the placental protein DIFF33 gene; Contains ESTs, STSs and GSSs, complete sequence). The predicted amino acid sequence disclosed herein for vc61_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc61_1 protein demonstrated at least some similarity to sequences identified as W52812 (Human induced tumour protein) and Z99129 (dJ425C14.2 (Placental protein DIFF33 LIKE) [Homo sapiens]). The deduced vc61_1 protein has amino acid similarity to human and mouse diff33 protein. Diff33 is a transmembrane protein which is overexpressed in testicular tumors from polyomavirus large T-antigen transgenic mice. Based upon sequence similarity, vc61_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts nine additional potential transmembrane domains within the vc61_1 protein sequence, centered around amino acids 50, 100, 150, 210, 240, 270, 320, 390, and 430 of SEQ ID NO:70, respectively. The nucleotide sequence of vc61_1 indicates that it may contain an Alu repetitive element.

Clone "vp3_1"

A polynucleotide of the present invention has been identified as clone "vp3_1". vp3_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp3_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp3_1 protein").

The nucleotide sequence of vp3_1 as presently determined is reported in SEQ ID NO:67, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp3_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:68. Amino acids 19 to 31 of SEQ ID NO:68 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 32. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp3_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp3_1 should be approximately 552 bp.

The nucleotide sequence disclosed herein for vp3_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp3_1 demonstrated at least some similarity with sequences identified as AA225045 (nc34c06.r1 NCI_CGAP_Pr2 Homo sapiens cDNA clone IMAGE 1010026, mRNA sequence), M18157 (Human glandular kallikrein gene, complete cds), and T35868 (Prostate-specific antigen gene partial sequence; standard; DNA). Based upon sequence similarity, vp3_1 proteins and each similar protein or peptide may share at least some activity.

Clone "vc61_1"

A polynucleotide of the present invention has been identified as clone "vc61_1". vc61_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc61_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc61_1 protein").

The nucleotide sequence of vc61_1 as presently determined is reported in SEQ ID NO:69, and includes a poly(A) tail. What applicants presently believe to be the proper

Clone "vc48_1"

A polynucleotide of the present invention has been identified as clone "vc48_1". vc48_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc48_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc48_1 protein").

The nucleotide sequence of vc48_1 as presently determined is reported in SEQ ID NO:65, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc48_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:66. Amino acids 7 to 19 of SEQ ID NO:66 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc48_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc48_1 should be approximately 3096 bp.

The nucleotide sequence disclosed herein for vc48_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc48_1 demonstrated at least some similarity with sequences identified as AA292779 (zt56c06.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 726346 3', mRNA sequence). The predicted amino acid sequence disclosed herein for vc48_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc48_1 protein demonstrated at least some similarity to sequences identified as AL031765 (Drosophila genomic product 22E5.z) and Z81058 (F11E6.e [Caenorhabditis elegans]). Based upon sequence similarity, vc48_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four potential transmembrane domains within the vc48_1 protein sequence, one centered around amino acid 39 and others around amino acids 69, 107 and 134 of SEQ ID NO:66, respectively. The nucleotide sequence of vc48_1 appears to contain a simple nucleotide repeat ("AC") and one or more of the following repetitive elements: Alu and MIR.

vp8_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 34 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

5 Clone "vb22_1"

A polynucleotide of the present invention has been identified as clone "vb22_1". vb22_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb22_1 is a full-length clone, including the
10 entire coding sequence of a secreted protein (also referred to herein as "vb22_1 protein").

The nucleotide sequence of vb22_1 as presently determined is reported in SEQ ID NO:63, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb22_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:64.
15 Another potential vb22_1 reading frame and predicted amino acid sequence is encoded by basepairs 152 to 1006 of SEQ ID NO:63 and is reported in SEQ ID NO:130.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb22_1 should be approximately 4176 bp.

The nucleotide sequence disclosed herein for vb22_1 was searched against the
20 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb22_1 demonstrated at least some similarity with sequences identified as L10335 (Homo sapiens neuroendocrine-specific protein C (NSP) mRNA, complete cds), N21304 (yx53f07.s1 Homo sapiens cDNA clone 265477 3' similar to SP:A60021 A60021 TROPOMYOSIN-RELATED PROTEIN, NEURONAL), and V23695
25 (Human NSPLP protein A coding sequence; standard; cDNA). The predicted amino acid sequence disclosed herein for vb22_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vb22_1 protein demonstrated at least some similarity to sequences identified as L10333 (nueroendocrine-specific protein A [Homo sapiens]) and W53947 (Human NSPLP protein
30 A). Based upon sequence similarity, vb22_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the vb22_1 protein sequence, one centered around amino acid 730 and another around amino acid 846 of SEQ ID NO:64. The nucleotide sequence of vb22_1 appears to contain a short simple nucleotide repeat ("GGA") region.

Clone "vp8_1"

A polynucleotide of the present invention has been identified as clone "vp8_1". vp8_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp8_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vp8_1 protein").

The nucleotide sequence of vp8_1 as presently determined is reported in SEQ ID NO:61, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp8_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:62. Amino acids 20 to 32 of SEQ ID NO:62 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 33. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp8_1 protein. If two insertions of "C" residues were made in the nucleotide sequence of SEQ ID NO:61, one after the "A" at position 380 and another after the "G" at position 382, the resulting nucleotide sequence would be predicted to encode the amino acid sequence reported in SEQ ID NO:129.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp8_1 should be approximately 1513 bp.

The nucleotide sequence disclosed herein for vp8_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp8_1 demonstrated at least some similarity with sequences identified as AA284421 (zs59c10.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 701778 5' similar to contains Alu repetitive element; mRNA sequence) and AC002086 (Human PAC clone DJ525N14 from Xq23, complete sequence). Based upon sequence similarity, vp8_1 proteins and each similar protein or peptide may share at least some activity. Profile hidden markov model analysis reveals the presence of an SH2 domain in the predicted vp8_1 protein (SEQ ID NO:62). SH2 domains function as regulatory modulators of intra-cellular signalling cascades by interacting with high affinity to phosphotyrosine-containing target peptides in a sequence-specific and strictly phosphorylation-dependent manner. The nucleotide sequence of vp8_1 indicates that it may contain one or more Alu repeat sequences.

domains within the vj2_1 protein sequence, centered around amino acids 30, 67, and 90 of SEQ ID NO:58, respectively. The nucleotide sequence of vj2_1 indicates that it may contain one or more repetitive elements.

5 Clone "vp7_1"

A polynucleotide of the present invention has been identified as clone "vp7_1". vp7_1 was isolated from a human adult prostate cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vp7_1 is a full-length clone, including the
10 entire coding sequence of a secreted protein (also referred to herein as "vp7_1 protein").

The nucleotide sequence of vp7_1 as presently determined is reported in SEQ ID NO:59, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vp7_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:60. Amino acids 6 to 18
15 of SEQ ID NO:60 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 19. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vp7_1 protein. Another potential vp7_1 reading frame and predicted amino acid sequence that
20 could be encoded by basepairs 2071 to 2430 of SEQ ID NO:59 is reported in SEQ ID NO:128.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vp7_1 should be approximately 2638 bp.

The nucleotide sequence disclosed herein for vp7_1 was searched against the
25 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vp7_1 demonstrated at least some similarity with sequences identified as N49433 (yv21e12.r1 Homo sapiens cDNA clone 243406 5') and Q63862 (AP2 sequence obtained by PCR for tumour specific DNA; standard; cDNA). Based upon sequence similarity, vp7_1 proteins and each similar protein or peptide may share at least
30 some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vp7_1 protein sequence centered around amino acid 75 of SEQ ID NO:60. The nucleotide sequence of vp7_1 indicates that it may contain one or more Alu repeat sequences.

additional potential transmembrane domains within the vf3_1 protein sequence, one centered around amino acid 242 and another around amino acid 275 of SEQ ID NO:56.

vf3_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 39 kDa was detected in membrane fractions using SDS
5 polyacrylamide gel electrophoresis.

Clone "vj2_1"

A polynucleotide of the present invention has been identified as clone "vj2_1". vj2_1 was isolated from a human fetal brain (whole brain, enriched for G-protein-coupled
10 receptors) cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vj2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vj2_1 protein").

The nucleotide sequence of vj2_1 as presently determined is reported in SEQ ID
15 NO:57, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vj2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:58. Amino acids 59 to 71 of SEQ ID NO:58 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 72. Due to the hydrophobic nature of the
20 predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vj2_1 protein.

Another potential vj2_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 146 to 400 of SEQ ID NO:57 is reported in SEQ ID NO:127.
25 The TopPredII computer program predicts two potential transmembrane domains within the amino acid sequence of SEQ ID NO:127.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vj2_1 should be approximately 1762 bp.

The nucleotide sequence disclosed herein for vj2_1 was searched against the
30 GenBank and GenSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vj2_1 demonstrated at least some similarity with sequences identified as N36445 (yx83c04.r1 Homo sapiens cDNA clone 268326 5'). Based upon sequence similarity, vj2_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane

The nucleotide sequence disclosed herein for ve16_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. No hits were found in the databases. The nucleotide sequence of ve16_1 indicates that it may contain one or more of the following repetitive elements:

5 Alu, MER.

Clone "vf3_1"

A polynucleotide of the present invention has been identified as clone "vf3_1". vf3_1 was isolated from a human adult heart cDNA library and was identified as
10 encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vf3_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vf3_1 protein").

The nucleotide sequence of vf3_1 as presently determined is reported in SEQ ID NO:55, and includes a poly(A) tail. What applicants presently believe to be the proper
15 reading frame and the predicted amino acid sequence of the vf3_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:56. Amino acids 8 to 20 of SEQ ID NO:56 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should
20 the predicted leader/signal sequence not be separated from the remainder of the vf3_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vf3_1 should be approximately 2987 bp.

The nucleotide sequence disclosed herein for vf3_1 was searched against the
25 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vf3_1 demonstrated at least some similarity with sequences identified as Z78394 (H.sapiens mRNA, expressed sequence tag ICRFp507K11187 (5'), mRNA sequence). The predicted amino acid sequence disclosed herein for vf3_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the
30 BLASTX search protocol. The predicted vf3_1 protein demonstrated at least some similarity to the sequence identified as U41558 (K02B2.3 gene product [Caenorhabditis elegans]). Based upon sequence similarity, vf3_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two

the predicted leader/signal sequence not be separated from the remainder of the ve13_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ve13_1 should be approximately 3046 bp.

5 The nucleotide sequence disclosed herein for ve13_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ve13_1 demonstrated at least some similarity with sequences identified as AA587395 (nn82h06.s1 NCI_CGAP_Co9 Homo sapiens cDNA clone IMAGE:1090427 similar to contains element THR repetitive element; mRNA sequence)
10 and Q76778 (Human genome fragment (Preferred); standard; DNA). The predicted amino acid sequence disclosed herein for ve13_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted ve13_1 protein demonstrated at least some similarity to the sequence identified as U50828 (sel-1 gene product [Caenorhabditis elegans]). Based upon sequence similarity, ve13_1 proteins
15 and each similar protein or peptide may share at least some activity.

Clone "ve16_1"

A polynucleotide of the present invention has been identified as clone "ve16_1". ve16_1 was isolated from a human adult brain (Alzheimer's hippocampus level 7) cDNA
20 library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ve16_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ve16_1 protein").

The nucleotide sequence of ve16_1 as presently determined is reported in SEQ ID
25 NO:53, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ve16_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:54. Amino acids 14 to 26 of SEQ ID NO:54 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the
30 predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ve16_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ve16_1 should be approximately 2033 bp.

predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc57_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
5 vc57_1 should be approximately 2564 bp.

The nucleotide sequence disclosed herein for vc57_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc57_1 demonstrated at least some similarity with sequences identified as AA156231 (zl50a11.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA
10 clone 505340 3', mRNA sequence). The predicted amino acid sequence disclosed herein for vc57_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc57_1 protein demonstrated at least some similarity to the sequence identified as U41635 (OS-9 precursor [Homo sapiens]). Based upon sequence similarity, vc57_1 proteins and each similar protein or peptide may
15 share at least some activity.

vc57_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 51 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

20 Clone "ve13_1"

A polynucleotide of the present invention has been identified as clone "ve13_1". ve13_1 was isolated from a human adult brain (Alzheimer's hippocampus level 7) cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ve13_1 is a full-
25 length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ve13_1 protein").

The nucleotide sequence of ve13_1 as presently determined is reported in SEQ ID NO:51, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ve13_1 protein corresponding
30 to the foregoing nucleotide sequence is reported in SEQ ID NO:52. Amino acids 551 to 563 of SEQ ID NO:52 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 564. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should

the predicted leader/signal sequence not be separated from the remainder of the vc54_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc54_1 should be approximately 2083 bp.

- 5 The nucleotide sequence disclosed herein for vc54_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc54_1 demonstrated at least some similarity with sequences identified as AF007152 (Homo sapiens clone 23649 and 23755 unknown mRNA, partial cds), Q76901 (Human genome fragment (Preferred); standard; DNA), and T46905 (EST014
- 10 BL29 Burkitt's lymphoma, Pascalis Sideras Homo sapiens cDNA clone BL29-14 5', mRNA sequence). The predicted amino acid sequence disclosed herein for vc54_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc54_1 protein demonstrated at least some similarity to the sequence identified as AF007152 (unknown [Homo sapiens]). Based upon sequence
- 15 similarity, vc54_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vc54_1 protein sequence, one centered around amino acid 220 and another around amino acid 247 of SEQ ID NO:48.

- vc54_1 protein was expressed in a COS cell expression system, and an expressed
- 20 protein band of approximately 44 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "vc57_1"

- A polynucleotide of the present invention has been identified as clone "vc57_1".
- 25 vc57_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc57_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc57_1 protein").

- The nucleotide sequence of vc57_1 as presently determined is reported in SEQ ID
- 30 NO:49, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc57_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:50. Amino acids 15 to 27 of SEQ ID NO:50 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the

the predicted leader/signal sequence not be separated from the remainder of the vc47_1 protein.

Another potential vc47_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 1047 to 1322 of SEQ ID NO:45 is reported in SEQ ID
5 NO:126. Amino acids 11 to 23 of SEQ ID NO:126 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 24. Due to the hydrophobic nature of this predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO:126.

10 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc47_1 should be approximately 3676 bp.

The nucleotide sequence disclosed herein for vc47_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc47_1 demonstrated at least some similarity with sequences
15 identified as AA339320 (EST44392 Fetal brain I Homo sapiens cDNA 5' end, mRNA sequence) and R02462 (ye82h04.r1 Homo sapiens cDNA clone 124279 5'). Based upon sequence similarity, vc47_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vc47_1 indicates that it may contain one or more of the following repetitive elements: Alu, L1MB7.

20

Clone "vc54_1"

A polynucleotide of the present invention has been identified as clone "vc54_1". vc54_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the
25 amino acid sequence of the encoded protein. vc54_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc54_1 protein").

The nucleotide sequence of vc54_1 as presently determined is reported in SEQ ID NO:47, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc54_1 protein corresponding
30 to the foregoing nucleotide sequence is reported in SEQ ID NO:48. Amino acids 33 to 45 of SEQ ID NO:48 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 46. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should

to the foregoing nucleotide sequence is reported in SEQ ID NO:44. Amino acids 4 to 16 of SEQ ID NO:44 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 17. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc34_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc34_1 should be approximately 3062 bp.

The nucleotide sequence disclosed herein for vc34_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc34_1 demonstrated at least some similarity with sequences identified as AA927558 (om71e04.s1 NCI_CGAP_GC4 Homo sapiens cDNA clone IMAGE 1552638 3', mRNA sequence) and U79281 (Human clone 23588 mRNA sequence). Based upon sequence similarity, vc34_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vc34_1 protein sequence, one centered around amino acid 251 and another around amino acid 283 of SEQ ID NO:44.

vc34_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 72 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "vc47_1"

A polynucleotide of the present invention has been identified as clone "vc47_1". vc47_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc47_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc47_1 protein").

The nucleotide sequence of vc47_1 as presently determined is reported in SEQ ID NO:45, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc47_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:46. Amino acids 93 to 105 of SEQ ID NO:46 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 106. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should

predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc33_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
5 vc33_1 should be approximately 2877 bp.

The nucleotide sequence disclosed herein for vc33_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc33_1 demonstrated at least some similarity with sequences identified as AA846599 (aj97g02.s1 Soares parathyroid tumor NbHPA Homo sapiens
10 cDNA clone IMAGE:1404434 3' similar to gb:M95549 SODIUM/GLUCOSE COTRANSPORTER-LIKE (HUMAN); mRNA sequence), M95549 (Homo sapiens sodium/glucose cotransporter-like protein mRNA, complete cds), and Q89779 (Cotransporter protein SNST1 cDNA; standard; cDNA). The predicted amino acid
15 amino acid sequence disclosed herein for vc33_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc33_1 protein demonstrated at least some similarity to sequences identified as M95549 (sodium/glucose cotransporter-like protein [Homo sapiens]) and R73593 (Cotransporter protein SNST1). Based upon sequence similarity, vc33_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts
20 three additional potential transmembrane domains within the vc33_1 protein sequence, centered around amino acids 186, 260, and 324 of SEQ ID NO:42, respectively.

vc33_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 45 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

25

Clone "vc34_1"

A polynucleotide of the present invention has been identified as clone "vc34_1". vc34_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the
30 amino acid sequence of the encoded protein. vc34_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc34_1 protein").

The nucleotide sequence of vc34_1 as presently determined is reported in SEQ ID NO:43, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc34_1 protein corresponding

the predicted leader/signal sequence not be separated from the remainder of the vc52_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc52_1 should be approximately 2018 bp.

5 The nucleotide sequence disclosed herein for vc52_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc52_1 demonstrated at least some similarity with sequences identified as AA075627 (zm89a01.s1 Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 545064 3', mRNA sequence) and T24879 (Human gene signature
10 HUMGS06985; standard; cDNA to mRNA). The predicted amino acid sequence disclosed herein for vc52_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc52_1 protein demonstrated at least some similarity to sequences identified as AL021890 (putative protein [Arabidopsis thaliana]), L47993 (ORF YJR072c [Saccharomyces cerevisiae]), and U10402
15 (undefined protein [Caenorhabditis elegans]). Based upon sequence similarity, vc52_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the vc52_1 protein sequence centered around amino acid 145 of SEQ ID NO:40.

vc52_1 protein was expressed in a COS cell expression system, and an expressed
20 protein band of approximately 44 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "vc33_1"

A polynucleotide of the present invention has been identified as clone "vc33_1".
25 vc33_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc33_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc33_1 protein").

The nucleotide sequence of vc33_1 as presently determined is reported in SEQ ID
30 NO:41, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc33_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:42. Amino acids 99 to 111 of SEQ ID NO:42 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 112. Due to the hydrophobic nature of the

encoded by basepairs 333 to 1310 of SEQ ID NO:37 and by basepairs 139 to 522 of SEQ ID NO:37 are reported in SEQ ID NO:124 and SEQ ID NO:125, respectively.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc51_1 should be approximately 1992 bp.

5 The nucleotide sequence disclosed herein for vc51_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc51_1 demonstrated at least some similarity with sequences identified as T21514 (Human gene signature HUMGS02887; standard; cDNA to mRNA) and W52782 (zd13h06.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 340571
10 5', mRNA sequence). The predicted amino acid sequence disclosed herein for vc51_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc51_1 protein demonstrated at least some similarity to sequences identified as U90716 (human cell surface protein HCAR), Y07593 (coxsackie and adenovirus receptor protein [Homo sapiens]), Y10320 (mouse coxsackie
15 and adenovirus receptor homolog), and W14146 (Human A33 antigen). Based upon sequence similarity, vc51_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four additional potential transmembrane domains within the vc51_1 protein sequence centered around amino acids 17, 216, 260, and 373 of SEQ ID NO:38, respectively.

20

Clone "vc52_1"

A polynucleotide of the present invention has been identified as clone "vc52_1". vc52_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the
25 amino acid sequence of the encoded protein. vc52_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc52_1 protein").

The nucleotide sequence of vc52_1 as presently determined is reported in SEQ ID NO:39, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc52_1 protein corresponding
30 to the foregoing nucleotide sequence is reported in SEQ ID NO:40. Amino acids 19 to 31 of SEQ ID NO:40 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 32. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should

FASTA search protocols. vc50_1 demonstrated at least some similarity with sequences identified as AA193122 (zr39d05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 665769 5', mRNA sequence), T26031 (Human gene signature HUMGS08267; standard; cDNA to mRNA), Z31718 (H.sapiens gene for myelin protein zero), and Z99943 (Human DNA sequence from PAC 313L4 on chromosome 1q24). The predicted amino acid sequence disclosed herein for vc50_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc50_1 protein demonstrated at least some similarity to the sequence identified as K03242 (rat P0 myelin prepeptide), L24893 (myelin protein zero [Homo sapiens]), and M62860 (mouse peripheral myelin protein). Based upon sequence similarity, vc50_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vc50_1 protein sequence centered around amino acid 181 of SEQ ID NO:36.

vc50_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 26 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

Clone "vc51_1"

A polynucleotide of the present invention has been identified as clone "vc51_1". vc51_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc51_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc51_1 protein").

The nucleotide sequence of vc51_1 as presently determined is reported in SEQ ID NO:37, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc51_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:38. Amino acids 12 to 24 of SEQ ID NO:38 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 25. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc51_1 protein. If the "C" residue at position 388 of SEQ ID NO:37 were deleted, two alternative potential vc51_1 reading frames and predicted amino acid sequences that could be

protein sequence, one definite transmembrane domain centered around amino acid 700 and another possible transmembrane domain centered around amino acid 260 of SEQ ID NO:34. Profile hidden markov model and motifs analyses of the predicted vc49_1 protein sequence have revealed it to contain five cadherin extracellular repeated domain
5 signatures at amino acids 142 to 242, 251 to 347, 356 to 451, 460 to 561, and 576 to 671 of SEQ ID NO:34. Cadherins are a family of animal glyco-proteins responsible for calcium-dependent cell-cell adhesion. Cadherins preferentially interact with themselves in a homophilic manner in connecting cells; thus acting as both receptor and ligand. Structurally, cadherins are built of the following domains: a signal sequence, followed by
10 a propeptide of about 130 residues, then an extracellular domain of around 600 residues, then a transmembrane region, and finally a C-terminal cytoplasmic domain of about 150 residues. The predicted vc49_1 protein sequence almost exactly follows this structure (its cytoplasmic domain being approximately 100 amino acids). Clearly, vc49_1 protein appears to represent a novel member of the cadherin superfamily.

15

Clone "vc50_1"

A polynucleotide of the present invention has been identified as clone "vc50_1". vc50_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the
20 amino acid sequence of the encoded protein. vc50_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc50_1 protein").

The nucleotide sequence of vc50_1 as presently determined is reported in SEQ ID NO:35, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc50_1 protein corresponding
25 to the foregoing nucleotide sequence is reported in SEQ ID NO:36. Amino acids 20 to 32 of SEQ ID NO:36 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 33. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc50_1
30 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc50_1 should be approximately 3819 bp.

The nucleotide sequence disclosed herein for vc50_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and

vc46_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 19 kDa was detected in conditioned medium and membrane fractions using SDS polyacrylamide gel electrophoresis.

5 Clone "vc49_1"

A polynucleotide of the present invention has been identified as clone "vc49_1". vc49_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc49_1 is a full-length clone, including the
10 entire coding sequence of a secreted protein (also referred to herein as "vc49_1 protein").

The nucleotide sequence of vc49_1 as presently determined is reported in SEQ ID NO:33, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc49_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:34. Amino acids 14 to 26
15 of SEQ ID NO:34 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 27. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc49_1 protein.

20 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc49_1 should be approximately 3471 bp.

The nucleotide sequence disclosed herein for vc49_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc49_1 demonstrated at least some similarity with sequences
25 identified as AI075929 (ov46h11.x1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE 1640421 3' similar to TR Q63418 Q63418 PROTOCADHERIN-3; mRNA sequence), I79964 (Sequence 109 from patent US 5708143), and T03572 (Human protocadherin pc3 coding sequence; standard; cDNA). The predicted amino acid sequence disclosed herein for vc49_1 was searched against the GenPept and GeneSeq amino acid sequence databases
30 using the BLASTX search protocol. The predicted vc49_1 protein demonstrated at least some similarity to sequences identified as L43592 (protocadherin-3 [Rattus norvegicus]) and R86865 (Human protocadherin pc3). Based upon sequence similarity, vc49_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the vc49_1

identified as AA143014 (zl48g04.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 505206 5', mRNA sequence) and T20006 (Human gene signature HUMGS01143; standard; cDNA to mRNA). Based upon sequence similarity, vc40_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer
5 program predicts three additional potential transmembrane domains within the vc40_1 protein sequence, centered around amino acids 101, 136, and 182 of SEQ ID NO:30, respectively.

Clone "vc46_1"

10 A polynucleotide of the present invention has been identified as clone "vc46_1". vc46_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc46_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc46_1 protein").

15 The nucleotide sequence of vc46_1 as presently determined is reported in SEQ ID NO:31, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc46_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:32. Amino acids 10 to 22 of SEQ ID NO:32 are a predicted leader/signal sequence, with the predicted mature
20 amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc46_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
25 vc46_1 should be approximately 2938 bp.

The nucleotide sequence disclosed herein for vc46_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc46_1 demonstrated at least some similarity with sequences identified as AA029404 (ze94e06.r1 Soares fetal heart NbHH19W Homo sapiens cDNA
30 clone 366658 5', mRNA sequence) and AQ071029 (human genomic fragment). Based upon sequence similarity, vc46_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vc46_1 protein sequence, one centered around amino acid 70 and another around amino acid 130 of SEQ ID NO:32.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc39_1 should be approximately 2048 bp.

The nucleotide sequence disclosed herein for vc39_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc39_1 demonstrated at least some similarity with sequences identified as AA631722 (np79d04.s1 NCI_CGAP_Pr2 Homo sapiens cDNA clone IMAGE:1132519 similar to gb:M21121 T-CELL SPECIFIC RANTES PROTEIN PRECURSOR (HUMAN); contains Alu repetitive element; mRNA sequence). Based upon sequence similarity, vc39_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential transmembrane domain within the vc39_1 protein sequence centered around amino acid 40 of SEQ ID NO:28. The nucleotide sequence of vc39_1 indicates that it may contain an Alu/SVA repetitive element.

Clone "vc40_1"

A polynucleotide of the present invention has been identified as clone "vc40_1". vc40_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc40_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc40_1 protein").

The nucleotide sequence of vc40_1 as presently determined is reported in SEQ ID NO:29, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc40_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:30. Amino acids 19 to 31 of SEQ ID NO:30 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 32. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc40_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc40_1 should be approximately 2297 bp.

The nucleotide sequence disclosed herein for vc40_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc40_1 demonstrated at least some similarity with sequences

The nucleotide sequence disclosed herein for vc38_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc38_1 demonstrated at least some similarity with sequences identified as AF037400 (neuropeptide Y/peptide YY receptor Ya [Danio rerio]).

5 analysis and profile hidden markov model analysis of the predicted vc38_1 protein both reveal the presence of the G-protein-coupled receptor signature. G-protein-coupled receptors (also called R7G) are an extensive group of hormones, neurotransmitters, odorants, and light receptors which transduce extracellular signals by interaction with guanine nucleotide-binding (G) proteins. Most G-protein-coupled receptors lack a signal
10 peptide, as does the predicted vc38_1 protein. Based upon sequence similarity, vc38_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts seven potential transmembrane domains within the vc38_1 protein sequence, centered around amino acids 60, 90, 130, 170, 225, 280, and 318 of SEQ ID NO:26, respectively.

15 vc38_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 71 kDa was detected in conditioned medium using SDS polyacrylamide gel electrophoresis.

Clone "vc39_1"

20 A polynucleotide of the present invention has been identified as clone "vc39_1". vc39_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc39_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc39_1 protein").

25 The nucleotide sequence of vc39_1 as presently determined is reported in SEQ ID NO:27, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc39_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:28. Amino acids 2 to 14 of SEQ ID NO:28 are a predicted leader/signal sequence, with the predicted mature
30 amino acid sequence beginning at amino acid 15. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc39_1 protein.

amino acid sequence of the encoded protein. vc36_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc36_1 protein").

The nucleotide sequence of vc36_1 as presently determined is reported in SEQ ID NO:23, and includes a poly(A) tail. What applicants presently believe to be the proper
5 reading frame and the predicted amino acid sequence of the vc36_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:24. Amino acids 24 to 36 of SEQ ID NO:24 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 37. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should
10 the predicted leader/signal sequence not be separated from the remainder of the vc36_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc36_1 should be approximately 1395 bp.

The nucleotide sequence disclosed herein for vc36_1 was searched against the
15 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc36_1 demonstrated at least some similarity with sequences identified as AA259070 (zs33c04.r1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 686982 5', mRNA sequence) and W67508 (zd40f11.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 343149 3', mRNA sequence). Based upon sequence similarity, vc36_1
20 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of vc36_1 indicates that it may contain repetitive elements.

Clone "vc38_1"

A polynucleotide of the present invention has been identified as clone "vc38_1".
25 vc38_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc38_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc38_1 protein").

The nucleotide sequence of vc38_1 as presently determined is reported in SEQ ID
30 NO:25, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc38_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:26.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc38_1 should be approximately 2468 bp.

Clone "vc35_1"

A polynucleotide of the present invention has been identified as clone "vc35_1". vc35_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vc35_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vc35_1 protein").

The nucleotide sequence of vc35_1 as presently determined is reported in SEQ ID NO:21, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vc35_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:22. Amino acids 38 to 50 of SEQ ID NO:22 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 51. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vc35_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vc35_1 should be approximately 3042 bp.

The nucleotide sequence disclosed herein for vc35_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vc35_1 demonstrated at least some similarity with sequences identified as AA532364 (nj12a08.s1 NCI_CGAP_Pr22 Homo sapiens cDNA clone IMAGE:986102, mRNA sequence), AF029343 (human protocadherin 68), and T22263 (Human gene signature HUMGS03835; standard; cDNA to mRNA). The predicted amino acid sequence disclosed herein for vc35_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vc35_1 protein demonstrated at least some similarity to sequences identified as Y08715 (protocadherin-4 [Mus musculus]). Based upon sequence similarity, vc35_1 proteins and each similar protein or peptide may share at least some activity.

Clone "vc36_1"

A polynucleotide of the present invention has been identified as clone "vc36_1". vc36_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the

Clone "vb21_1"

A polynucleotide of the present invention has been identified as clone "vb21_1". vb21_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb21_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb21_1 protein").

The nucleotide sequence of vb21_1 as presently determined is reported in SEQ ID NO:19, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb21_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:20. Amino acids 296 to 308 of SEQ ID NO:20 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 309. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb21_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb21_1 should be approximately 4159 bp.

The nucleotide sequence disclosed herein for vb21_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb21_1 demonstrated at least some similarity with sequences identified as AA026150 (zj99c10.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 469170 3', mRNA sequence), T72108 (Human semaphorin Z gene; standard; cDNA to mRNA), U52840 (Human semaphorin F homolog), X97817 (M. musculus mRNA for semaphorin F), and X97818 (M. musculus mRNA for semaphorin G). The predicted amino acid sequence disclosed herein for vb21_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vb21_1 protein demonstrated at least some similarity to sequences identified as W19857 (Human semaphorin Z) and X97818 (semaphorin G [Mus musculus]). Semaphorins are important membrane proteins involved in axonal guidance in the embryonic stage, and may also have a role in nerve regeneration after injury. Based upon sequence similarity, vb21_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts four additional potential transmembrane domains within the vb21_1 protein sequence, centered around amino acids 237, 523, 769, and 895 of SEQ ID NO:20, respectively.

Clone "vk2_1"

A polynucleotide of the present invention has been identified as clone "vk2_1". vk2_1 was isolated from a human adult brain cDNA library (enriched for G-protein-coupled receptors) and was identified as encoding a secreted or transmembrane protein
5 on the basis of computer analysis of the amino acid sequence of the encoded protein. vk2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vk2_1 protein").

The nucleotide sequence of vk2_1 as presently determined is reported in SEQ ID NO:17, and includes a poly(A) tail. What applicants presently believe to be the proper
10 reading frame and the predicted amino acid sequence of the vk2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:18. Amino acids 10 to 22 of SEQ ID NO:18 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 23. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should
15 the predicted leader/signal sequence not be separated from the remainder of the vk2_1 protein. Basepairs 416 to 418 of SEQ ID NO:17 may represent the site of an alternatively spliced exon that is not present in clone vk2_1.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vk2_1 should be approximately 1284 bp.

20 The nucleotide sequence disclosed herein for vk2_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vk2_1 demonstrated at least some similarity with sequences identified as AA152101 (zl49f09.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 505289 3', mRNA sequence) and Q78696 (Sequence encoding therapeutic
25 polypeptide from glioblastoma cell line; standard; cDNA to mRNA). The predicted amino acid sequence disclosed herein for vk2_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vk2_1 protein demonstrated at least some similarity to the sequence identified as R66278 (Therapeutic polypeptide from glioblastoma cell line). Based upon sequence similarity,
30 vk2_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vk2_1 protein sequence, one centered around amino acid 61 and another around amino acid 97 of SEQ ID NO:18.

amino acid sequence of the encoded protein. vl1_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vl1_1 protein").

The nucleotide sequence of vl1_1 as presently determined is reported in SEQ ID NO:15, and includes a poly(A) tail. What applicants presently believe to be the proper
5 reading frame and the predicted amino acid sequence of the vl1_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:16. Amino acids 187 to 199 of SEQ ID NO:16 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 200. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should
10 the predicted leader/signal sequence not be separated from the remainder of the vl1_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vl1_1 should be approximately 1936 bp.

The nucleotide sequence disclosed herein for vl1_1 was searched against the
15 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vl1_1 demonstrated at least some similarity with sequences identified as AA464362 (zx81b12.r1 Soares ovary tumor NbHOT Homo sapiens cDNA clone 810143 5', mRNA sequence), M90089 (Mouse inositol 1,4,5-triphosphate receptor mRNA sequence), and T21689 (Human gene signature HUMGS03131; standard; cDNA
20 to mRNA). The predicted amino acid sequence disclosed herein for vl1_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vl1_1 protein demonstrated at least some similarity to the sequence identified as U80846 (partial CDS [Caenorhabditis elegans]). Based upon sequence similarity, vl1_1 proteins and each similar protein or peptide may share at least
25 some activity. The TopPredII computer program predicts two additional potential transmembrane domains within the vl1_1 protein sequence, one centered around amino acid 192 and another around amino acid 234 of SEQ ID NO:16.

vl1_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 37 kDa was detected in membrane fractions using SDS
30 polyacrylamide gel electrophoresis.

Clone "vj1_1"

A polynucleotide of the present invention has been identified as clone "vj1_1". vj1_1 was isolated from a human fetal brain cDNA library (enriched for G-protein-coupled receptors) and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vj1_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vj1_1 protein").

The nucleotide sequence of vj1_1 as presently determined is reported in SEQ ID NO:13. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vj1_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:14. Amino acids 1 to 12 of SEQ ID NO:14 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 13. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vj1_1 protein. Another potential vj1_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 1795 to 2064 of SEQ ID NO:13 is reported in SEQ ID NO:123.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vj1_1 should be approximately 2895 bp.

The nucleotide sequence disclosed herein for vj1_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vj1_1 demonstrated at least some similarity with sequences identified as AA410352 (zv11f01.r1 Soares NhHMPu S1 Homo sapiens cDNA clone 753337 5', mRNA sequence). Based upon sequence similarity, vj1_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the vj1_1 protein sequence centered around amino acid 70 of SEQ ID NO:14. The nucleotide sequence of vj1_1 indicates that it may contain repetitive elements.

Clone "vl1_1"

A polynucleotide of the present invention has been identified as clone "vl1_1". vl1_1 was isolated from a human fetal cartilage cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the

the predicted leader/signal sequence not be separated from the remainder of the vg2_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vg2_1 should be approximately 1993 bp.

- 5 The nucleotide sequence disclosed herein for vg2_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vg2_1 demonstrated at least some similarity with sequences identified as AA830272 (oc45g11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA clone IMAGE 1352708 3' similar to TR Q92853 Q92853 HU-K4; mRNA sequence) and D31740
- 10 (Homo sapiens DNA, CpG island). The predicted amino acid sequence disclosed herein for vg2_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted vg2_1 protein demonstrated at least some similarity to sequences identified as AF026124 (schwannoma-associated protein [Mus musculus]) and U60644 (HU-K4 [Homo sapiens]). Based upon sequence similarity,
- 15 vg2_1 proteins and each similar protein or peptide may share at least some activity. Profile hidden markov model analysis (Eddy, S. R., 1996, *Curr. Opin. Struct. Biol.* 6(3): 361-365; incorporated by reference herein) of the predicted vg2_1 protein revealed two phospholipase D active sites (amino acid residues 209 to 236 and 423 to 449 of SEQ ID NO:12). Phospholipase D (PLD) genes are members of a superfamily that is defined by
- 20 several highly conserved motifs. In mammals, it has been proposed that phospholipase D plays a role in membrane vesicular trafficking and in signal transduction. Using site-directed mutagenesis, twenty-five point mutants have been made in human PLD1 (hPLD1) and then characterized (Sung *et al.*, 1997, *EMBO J.* 16(15): 4519-4530; which is incorporated by reference herein). Sung *et al.* found that a motif (HxKxxxxD; see for
- 25 example amino acids 214-221 of SEQ ID NO:12) and a serine/threonine conserved in all members of the PLD superfamily are critical for PLD biochemical activity, suggesting a possible catalytic mechanism. The vg2_1 clone appears to encode a membrane protein that may be a phospholipase related to the phospholipase D family. The TopPredII computer program predicts four potential transmembrane domains within the vg2_1
- 30 protein sequence, centered around amino acids 40, 305, 330, and 455 of SEQ ID NO:12, respectively.

of SEQ ID NO:10 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 33. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vf2_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vf2_1 should be approximately 1162 bp.

The nucleotide sequence disclosed herein for vf2_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vf2_1 demonstrated at least some similarity with sequences identified as AA605037 (no68h10.s1 NCI_CGAP_AA1 Homo sapiens cDNA clone IMAGE:1112035 similar to contains Alu repetitive element;contains element THR repetitive element; mRNA sequence). Based upon sequence similarity, vf2_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts two potential transmembrane domains within the vf2_1 protein sequence, one centered around amino acid 30 and another around amino acid 70 of SEQ ID NO:10. The nucleotide sequence of vf2_1 indicates that it may contain an Alu repetitive element.

Clone "vg2_1"

A polynucleotide of the present invention has been identified as clone "vg2_1". vg2_1 was isolated from a human adult brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vg2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vg2_1 protein").

The nucleotide sequence of vg2_1 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vg2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino acids 34 to 46 of SEQ ID NO:12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should

of computer analysis of the amino acid sequence of the encoded protein. ve11_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ve11_1 protein").

The nucleotide sequence of ve11_1 as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ve11_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 1 to 9 of SEQ ID NO:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 10. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the ve11_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ve11_1 should be approximately 984 bp.

The nucleotide sequence disclosed herein for ve11_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ve11_1 demonstrated at least some similarity with sequences identified as F22745 (H.sapiens EST sequence (LL45/C09) from skeletal muscle, mRNA sequence) and Q60824 (Human brain Expressed Sequence Tag EST00928; standard; DNA). Based upon sequence similarity, ve11_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the ve11_1 protein sequence centered around amino acid 35 of SEQ ID NO:8.

Clone "vf2_1"

A polynucleotide of the present invention has been identified as clone "vf2_1". vf2_1 was isolated from a human adult heart cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vf2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vf2_1 protein").

The nucleotide sequence of vf2_1 as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vf2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10. Amino acids 20 to 32

Clone "vb14_1"

A polynucleotide of the present invention has been identified as clone "vb14_1". vb14_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb14_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb14_1 protein").

The nucleotide sequence of vb14_1 as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb14_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Amino acids 79 to 91 of SEQ ID NO:6 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 92. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb14_1 protein. Another potential vb14_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 182 to 484 of SEQ ID NO:5 is reported in SEQ ID NO:122.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb14_1 should be approximately 2377 bp.

The nucleotide sequence disclosed herein for vb14_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb14_1 demonstrated at least some similarity with sequences identified as AF007149 (Homo sapiens clone 23568, 23621, 23795, 23873 and 23874 mRNA sequences), AF070612 (Homo sapiens clone 24771 mRNA sequence), T23635 (Human gene signature HUMGS05495; standard; cDNA to mRNA), and W02197 (za57e04.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 296670 5', mRNA sequence). Based upon sequence similarity, vb14_1 proteins and each similar protein or peptide may share at least some activity.

Clone "ve11_1"

A polynucleotide of the present invention has been identified as clone "ve11_1". ve11_1 was isolated from a human adult brain (Alzheimer's hippocampus level 7) cDNA library and was identified as encoding a secreted or transmembrane protein on the basis

domain within the vb11_1 protein sequence centered around amino acid 27 of SEQ ID NO:2.

Clone "vb12_1"

5 A polynucleotide of the present invention has been identified as clone "vb12_1". vb12_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb12_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb12_1 protein").

10 The nucleotide sequence of vb12_1 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb12_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 34 to 46 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted
15 mature amino acid sequence beginning at amino acid 47. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the vb12_1 protein.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone
20 vb12_1 should be approximately 2289 bp.

The nucleotide sequence disclosed herein for vb12_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb12_1 demonstrated at least some similarity with sequences identified as AA426009 (zw49e11.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA
25 clone 773420 3', mRNA sequence). Based upon sequence similarity, vb12_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three additional potential transmembrane domains within the vb12_1 protein sequence, centered around amino acids 11, 60, and 104 of SEQ ID NO:4, respectively. The nucleotide sequence of vb12_1 indicates that it may contain a THE1B
30 repeat sequence.

vb12_1 protein was expressed in a COS cell expression system, and an expressed protein band of approximately 17 kDa was detected in membrane fractions using SDS polyacrylamide gel electrophoresis.

determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

10 Clone "vb11_1"

A polynucleotide of the present invention has been identified as clone "vb11_1". vb11_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. vb11_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "vb11_1 protein").

The nucleotide sequence of vb11_1 as presently determined is reported in SEQ ID NO:1, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the vb11_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:2. Another potential vb11_1 reading frame and predicted amino acid sequence that could be encoded by basepairs 84 to 236 of SEQ ID NO:1 is reported in SEQ ID NO:121. Amino acids 13 to 25 of SEQ ID NO:121 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 26 of SEQ ID NO:121. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the protein of SEQ ID NO:121.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone vb11_1 should be approximately 1751 bp.

The nucleotide sequence disclosed herein for vb11_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. vb11_1 demonstrated at least some similarity with sequences identified as N94870 (yy63b05.r1 Homo sapiens cDNA clone 278193 5'). Based upon sequence similarity, vb11_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane

In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or
5 modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

- (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and
- 10 (b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which
15 specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

20

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

25

DETAILED DESCRIPTION

ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone
30 in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:79 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:79, but excluding the poly(A) tail at the 3' end of SEQ ID NO:79. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 2 to nucleotide 1018, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:79 from nucleotide 2 to nucleotide 1018, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:79 from nucleotide 2 to nucleotide 1018. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:79 from nucleotide 53 to nucleotide 1018, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:79 from nucleotide 53 to nucleotide 1018, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:79 from nucleotide 53 to nucleotide 1018.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:80;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:80. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 164 to amino acid 173 of SEQ ID NO:80.

polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:80, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising the amino acid sequence from amino acid 164 to amino acid 173 of SEQ ID NO:80.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:79.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:79, but excluding the poly(A) tail at the 3' end of SEQ ID NO:79; and

(ab) the nucleotide sequence of the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:79, but excluding the poly(A) tail at the 3' end of SEQ ID NO:79; and

(bb) the nucleotide sequence of the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp14_1 deposited with the ATCC under accession number 207011;

5 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp14_1 deposited with the ATCC under accession number 207011;

10 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:80;

15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:80;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

20 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

25 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:79.

30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:79 from nucleotide 2 to nucleotide 1018; the nucleotide sequence of SEQ ID NO:79 from nucleotide 53 to nucleotide 1018; the nucleotide sequence of the full-length protein coding sequence of clone vp14_1 deposited with the ATCC under accession number 207011; or the nucleotide sequence of a mature protein coding sequence of clone vp14_1 deposited with the ATCC under accession number 207011. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011. In further preferred embodiments, the present invention provides a

sequence corresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 51 to nucleotide 332, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 51 to nucleotide 332, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:77 from
5 nucleotide 51 to nucleotide 332.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:78;
- 10 (b) the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 93;
- (c) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78; and
- (d) the amino acid sequence encoded by the cDNA insert of clone
15 vq1_1 deposited with the ATCC under accession number 207012;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:78 or the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 93. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid
20 sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:78.

25 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:79 from nucleotide 2 to nucleotide 1018;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:79 from nucleotide 53 to nucleotide 1018;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

5 and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

10 (ba) SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77; and

(bb) the nucleotide sequence of the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

15 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77, and
20 extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:77 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:77 from nucleotide 54 to nucleotide
25 368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 54 to nucleotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:77 from nucleotide 54 to nucleotide 368. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID
30 NO:77 from nucleotide 141 to nucleotide 368, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:77 from nucleotide 141 to nucleotide 368, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:77 from nucleotide 141 to nucleotide 368. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:77.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:77 from nucleotide 54 to nucleotide 368; the nucleotide sequence of SEQ ID NO:77 from nucleotide 141 to nucleotide 368; the nucleotide sequence of SEQ ID NO:77 from nucleotide 51 to nucleotide 332; the nucleotide sequence of the full-length protein coding sequence of clone vq1_1 deposited with the ATCC under accession number 207012; or the nucleotide sequence of a mature protein coding sequence of clone vq1_1 deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 93. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:78, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising the amino acid sequence from amino acid 47 to amino acid 56 of SEQ ID NO:78.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:77.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:77, but excluding the poly(A) tail at the 3' end of SEQ ID NO:77; and
(ab) the nucleotide sequence of the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77;
- 5 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 54 to nucleotide 368;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 141 to nucleotide 368;
- 10 (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:77 from nucleotide 51 to nucleotide 332;
- (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vq1_1 deposited with the ATCC under accession number 207012;
- 15 (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vq1_1 deposited with the ATCC under accession number 207012;
- 20 (h) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:78;
- 25 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:78;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- 30 (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

(bb) the nucleotide sequence of the cDNA insert of clone vp19_1 deposited with the ATCC under accession number 207012;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

5 (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
10 ID NO:75 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:75 from nucleotide 144 to nucleotide 461, and extending contiguously from a nucleotide sequence corresponding to the 5' end
15 of said sequence of SEQ ID NO:75 from nucleotide 144 to nucleotide 461, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:75 from nucleotide 144 to nucleotide 461.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group
20 consisting of:

(a) the amino acid sequence of SEQ ID NO:76;

(b) a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76; and

(c) the amino acid sequence encoded by the cDNA insert of clone
25 vp19_1 deposited with the ATCC under accession number 207012;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:76. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably
30 comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:76.

number 207012; or the nucleotide sequence of a mature protein coding sequence of clone vp19_1 deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp19_1 deposited with the ATCC under accession number 207012. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:76, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:76.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:75.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75; and

(ab) the nucleotide sequence of the cDNA insert of clone vp19_1 deposited with the ATCC under accession number 207012;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:75, but excluding the poly(A) tail at the 3' end of SEQ ID NO:75; and

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75;
- 5 (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:75 from nucleotide 144 to nucleotide 461;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp19_1 deposited with the ATCC under accession number 207012;
- 10 (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp19_1 deposited with the ATCC under accession number 207012;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp19_1 deposited with the ATCC under
15 accession number 207012;
- (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp19_1 deposited with the ATCC under accession number 207012;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:76;
- 20 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:76;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 25 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and
- (l) a polynucleotide that hybridizes under stringent conditions to any
30 one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:75.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:75 from nucleotide 144 to nucleotide 461; the nucleotide sequence of the full-length protein coding sequence of clone vp19_1 deposited with the ATCC under accession

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:73 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:73, but excluding the poly(A) tail at the 3' end of SEQ ID NO:73. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 348 to nucleotide 743, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:73 from nucleotide 348 to nucleotide 743, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:73 from nucleotide 348 to nucleotide 743. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:73 from nucleotide 414 to nucleotide 743, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:73 from nucleotide 414 to nucleotide 743, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:73 from nucleotide 414 to nucleotide 743.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:74;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74, and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:74. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:74.

polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:74, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising the amino acid sequence from amino acid 61 to amino acid 70 of SEQ ID NO:74.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:73.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:73, but excluding the poly(A) tail at the 3' end of SEQ ID NO:73; and

(ab) the nucleotide sequence of the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:73, but excluding the poly(A) tail at the 3' end of SEQ ID NO:73; and

(bb) the nucleotide sequence of the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp17_1 deposited with the ATCC under accession number 207012;

5 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp17_1 deposited with the ATCC under accession number 207012;

10 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:74;

15 (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:74;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

20 (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

25 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:73.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:73 from nucleotide 348 to nucleotide 743; the nucleotide sequence of SEQ ID NO:73 from nucleotide 414 to nucleotide 743; the nucleotide sequence of the full-length protein coding sequence of clone vp17_1 deposited with the ATCC under accession number 30 207012; or the nucleotide sequence of a mature protein coding sequence of clone vp17_1 deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012. In further preferred embodiments, the present invention provides a

said sequence of SEQ ID NO:71 from nucleotide 92 to nucleotide 1513. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 1 to nucleotide 458, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:71 from nucleotide 1 to nucleotide 458, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:71 from nucleotide 1 to nucleotide 458.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:72;
- (b) the amino acid sequence of SEQ ID NO:72 from amino acid 1 to amino acid 139;
- (c) a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO:72; and
- (d) the amino acid sequence encoded by the cDNA insert of clone vp15_1 deposited with the ATCC under accession number 207012;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:72 or the amino acid sequence of SEQ ID NO:72 from amino acid 1 to amino acid 139. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:72, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:72.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 348 to nucleotide 743;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:73 from nucleotide 414 to nucleotide 743;

- (ab) the nucleotide sequence of the cDNA insert of clone vp15_1 deposited with the ATCC under accession number 207012;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that
- 10 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:71, but excluding the poly(A) tail at the 3' end of SEQ ID NO:71; and
- (bb) the nucleotide sequence of the cDNA insert of clone
- 15 vp15_1 deposited with the ATCC under accession number 207012;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).
- 20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:71 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:71, but excluding the poly(A) tail at the 3' end of SEQ ID NO:71. Also preferably the
- 25 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 44 to nucleotide 1513, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:71 from nucleotide 44 to nucleotide 1513, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:71 from nucleotide
- 30 44 to nucleotide 1513. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:71 from nucleotide 92 to nucleotide 1513, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:71 from nucleotide 92 to nucleotide 1513, to a nucleotide sequence corresponding to the 3' end of

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j); and

(n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:71.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:71 from nucleotide 44 to nucleotide 1513; the nucleotide sequence of SEQ ID NO:71 from nucleotide 92 to nucleotide 1513; the nucleotide sequence of SEQ ID NO:71 from nucleotide 1 to nucleotide 458; the nucleotide sequence of the full-length protein coding sequence of clone vp15_1 deposited with the ATCC under accession number 207012; or the nucleotide sequence of a mature protein coding sequence of clone vp15_1 deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp15_1 deposited with the ATCC under accession number 207012. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:72 from amino acid 1 to amino acid 139. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:72, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment comprising the amino acid sequence from amino acid 240 to amino acid 249 of SEQ ID NO:72.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:71.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:71, but excluding the poly(A) tail at the 3' end of SEQ ID NO:71; and

comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 221 to amino acid 230 of SEQ ID NO:70.

5 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID
10 NO:71 from nucleotide 44 to nucleotide 1513;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71 from nucleotide 92 to nucleotide 1513;
- (d) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:71 from nucleotide 1 to nucleotide 458;
- 15 (e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp15_1 deposited with the ATCC under accession number 207012;
- (f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp15_1 deposited with the ATCC under accession number
20 207012;
- (g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp15_1 deposited with the ATCC under accession number 207012;
- (h) a polynucleotide encoding a mature protein encoded by the cDNA
25 insert of clone vp15_1 deposited with the ATCC under accession number 207012;
- (i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:72;
- (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72 having biological activity, the fragment
30 comprising eight contiguous amino acids of SEQ ID NO:72;
- (k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
- (l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ;

- (bb) the nucleotide sequence of the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- 5 (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
10 ID NO:69 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:69, but excluding the poly(A) tail at the 3' end of SEQ ID NO:69. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69 from nucleotide 29 to nucleotide 1387, and extending contiguously from a nucleotide sequence corresponding to the 5' end
15 of said sequence of SEQ ID NO:69 from nucleotide 29 to nucleotide 1387, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:69 from nucleotide 29 to nucleotide 1387. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:69 from nucleotide 113 to nucleotide 1387, and extending contiguously from a
20 nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:69 from nucleotide 113 to nucleotide 1387, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:69 from nucleotide 113 to nucleotide 1387.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group
25 consisting of:

- (a) the amino acid sequence of SEQ ID NO:70;
- (b) a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO:70; and
- (c) the amino acid sequence encoded by the cDNA insert of clone
30 vc61_1 deposited with the ATCC under accession number 207012;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:70. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably

deposited with the ATCC under accession number 207012. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012. In further preferred embodiments, the present invention provides a
5 polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid
10 sequence from amino acid 221 to amino acid 230 of SEQ ID NO:70.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:69.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- 15 (a) a process comprising the steps of:
- (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:69, but excluding the poly(A) tail at the
20 3' end of SEQ ID NO:69; and
 - (ab) the nucleotide sequence of the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
 - 25 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that
30 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:69, but excluding the poly(A) tail at the 3' end of SEQ ID NO:69; and

- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69 from nucleotide 29 to nucleotide 1387;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69 from nucleotide 113 to nucleotide 1387;
- 5 (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc61_1 deposited with the ATCC under accession number 207012;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc61_1 deposited with the ATCC under accession number
- 10 207012;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc61_1 deposited with the ATCC under accession number 207012;
- (g) a polynucleotide encoding a mature protein encoded by the cDNA
- 15 insert of clone vc61_1 deposited with the ATCC under accession number 207012;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:70;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment
- 20 comprising eight contiguous amino acids of SEQ ID NO:70;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;
- 25 (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
- (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:69.
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:69 from nucleotide 29 to nucleotide 1387; the nucleotide sequence of SEQ ID NO:69 from nucleotide 113 to nucleotide 1387; the nucleotide sequence of the full-length protein coding sequence of clone vc61_1 deposited with the ATCC under accession number 207012; or the nucleotide sequence of a mature protein coding sequence of clone vc61_1

extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:67 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:67, but excluding the poly(A) tail at the 3' end of SEQ ID NO:67. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence
5 corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457. Also preferably the polynucleotide isolated according to the above
10 process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 158 to nucleotide 457, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:67 from nucleotide 158 to nucleotide 457, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:67 from nucleotide 158 to nucleotide 457.

15 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:68;
- (b) a fragment of the amino acid sequence of SEQ ID NO:68, the
20 fragment comprising eight contiguous amino acids of SEQ ID NO:68; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:68. In further preferred
25 embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:68, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence
30 from amino acid 60 to amino acid 69 of SEQ ID NO:68.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:69;

encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino acid 60 to amino acid 69 of SEQ ID NO:68.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
5 ID NO:67.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize
10 in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:67, but excluding the poly(A) tail at the
3' end of SEQ ID NO:67; and

(ab) the nucleotide sequence of the cDNA insert of clone
15 vp3_1 deposited with the ATCC under accession number 98933;

(ii) hybridizing said probe(s) to human genomic DNA in
conditions at least as stringent as 4X SSC at 50 degrees C; and

(iii) isolating the DNA polynucleotides detected with the
probe(s);

20 and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that
hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from
the group consisting of:

(ba) SEQ ID NO:67, but excluding the poly(A) tail at the
25 3' end of SEQ ID NO:67; and

(bb) the nucleotide sequence of the cDNA insert of clone
vp3_1 deposited with the ATCC under accession number 98933;

(ii) hybridizing said primer(s) to human genomic DNA in
30 conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67, and

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;

5 (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;

10 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:68;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:68;

15 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

20 (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:67.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457; the nucleotide sequence of SEQ ID NO:67 from nucleotide 158 to nucleotide 457; the nucleotide sequence of the full-length protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933; or the nucleotide sequence of a mature protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:68, or a polynucleotide

134 to nucleotide 667. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 191 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:65 from
5 nucleotide 191 to nucleotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:65 from nucleotide 191 to nucleotide 667.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- 10 (a) the amino acid sequence of SEQ ID NO:66;
- (b) a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
- 15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:66. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
20 of SEQ ID NO:66, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ ID NO:66.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 25 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:67 from nucleotide 55 to nucleotide 457;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID
30 NO:67 from nucleotide 158 to nucleotide 457;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933;

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

5 (aa) SEQ ID NO:65, but excluding the poly(A) tail at the 3' end of SEQ ID NO:65; and

(ab) the nucleotide sequence of the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and

10 (iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

15 (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:65, but excluding the poly(A) tail at the 3' end of SEQ ID NO:65; and

20 (bb) the nucleotide sequence of the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

25 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:65 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:65, but excluding the poly(A) tail at the 3' end of SEQ ID NO:65. Also preferably the

30 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:65 from nucleotide

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:66;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ;

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and

(m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:65.

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667; the nucleotide sequence of SEQ ID NO:65 from nucleotide 191 to nucleotide 667; the nucleotide sequence of the full-length protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933; or the nucleotide sequence of a mature protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 84 to amino acid 93 of SEQ ID NO:66.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:65.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(b) a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:64. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
10 of SEQ ID NO:64, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 441 to amino acid 450 of SEQ ID NO:64.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667;

20 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65 from nucleotide 191 to nucleotide 667;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933;

25 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933;

30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:66;

- (ab) the nucleotide sequence of the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; and
- 5 (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
- (i) preparing one or more polynucleotide primers that
- 10 hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
- (ba) SEQ ID NO:63, but excluding the poly(A) tail at the 3' end of SEQ ID NO:63; and
- (bb) the nucleotide sequence of the cDNA insert of clone
- 15 vb22_1 deposited with the ATCC under accession number 98933;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;
- (iii) amplifying human DNA sequences; and
- (iv) isolating the polynucleotide products of step (b)(iii).
- 20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:63 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:63, but excluding the poly(A) tail at the 3' end of SEQ ID NO:63. Also preferably the
- 25 polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1048 to nucleotide 3726, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from nucleotide 1048 to nucleotide 3726, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide
- 30 1048 to nucleotide 3726.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:64;

(i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;

(j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;

5 (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:63.

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:63 from nucleotide 1048 to nucleotide 3726; the nucleotide sequence of the full-length protein coding sequence of clone vb22_1 deposited with the ATCC under accession number 98933; or the nucleotide sequence of a mature protein coding sequence of clone vb22_1 deposited with the ATCC under accession number 98933. In other preferred
15 embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933.

In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably
20 twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 441 to amino acid 450 of SEQ ID NO:64.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
25 ID NO:63.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:63, but excluding the poly(A) tail at the 3' end of SEQ ID NO:63; and

(b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and

(c) the amino acid sequence encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;

- 5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:62. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids
- 10 of SEQ ID NO:62, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:62.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 15 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:63 from nucleotide 1048 to nucleotide 3726;

- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone vb22_1 deposited with the ATCC under accession number 98933;
- 20

(d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;

- 25 (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone vb22_1 deposited with the ATCC under accession number 98933;

(f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;

- 30 (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:64;

(h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:64;

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:61, but excluding the poly(A) tail at the 3' end of SEQ ID NO:61; and

(bb) the nucleotide sequence of the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:61 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:61, but excluding the poly(A) tail at the 3' end of SEQ ID NO:61. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:62;

```
<210> 43
<211> 2980
<212> DNA
<213> Homo sapiens
```

<400> 43

aagaaaaaact	tttttgttat	tgggcttttc	aggtggagtt	cagaaccagt	gactcacact	60
tctcagtcct	gggagcaatt	tatttgcctac	tgggaggggt	tgtagaagaaa	gccagtgaga	120
aagcagactc	ccccacacaac	acagatccac	tgtggacccc	caaaacctgt	cctgtccccc	180
tcttttaaga	ctccagccac	ccctcttggg	ctctctactt	ccacggggca	catgctgatg	240
ccctctgttg	ggctgctctg	gtggctggtg	tgctgtctgt	ccggctggta	ctgctatgga	300
ttgtgtgccc	cagcccccca	gatgttgcgc	caccagggtc	tctccaagtg	cgctgtccgc	360
atgctcttca	atgacctgaa	ggttttctta	ctgcggcgcc	ctcctcaage	gccccctgcc	420
atgcacggcg	acccccagcc	ccccggtttg	gcggccaaaca	acacccttcc	ggctctgggc	480
gccgggggggt	gggtaggctg	gaggggcccc	cgagaagtgg	tgggcaggga	gccccctcct	540
gtgccacctc	cacccccctt	gccaccttct	tctgtggaag	atgactgggg	tggccccagcc	600
acagaggccac	ctgcctcgct	gctcagcagt	gcttctctag	atgactcttg	taaggagaag	660
accgaggatc	gctactactc	gggcagcagc	ttggacagtg	gtatgaggac	cccaactctgc	720
cgcactctgt	tccaggggcc	agaacagggg	gagctgctga	gcccatgccg	crgtgatggc	780
tgggtcaagt	gcacacaccca	gccttgcttc	atcaagtgga	tcagcgagcg	gggctgcttg	840
agctgcgagc	tgtgctacta	caagtaccac	gtcatcgcca	taagcacaaa	aaatcctctg	900
cagtggccagg	ccatctctct	gacggctcat	gagaaggttc	aggttgccag	cgccatctct	960
ggctccctct	tctctatctc	cagttattct	tggctcatct	ggtcaacttt	cagccccctg	1020
cgaaagtggc	agcgccaaga	ccttctcttc	cagatctgct	acgggtagta	tggctcatg	1080
gacgtggtgt	gcataggtct	catcatccat	gaaggacctt	cggtgtaccg	cctctttaaa	1140
cgggtggcagg	ctgtcaacca	gcagtggaaa	gtgctgaact	atgacaagac	aaaagacctg	1200
gaggatcaaa	aggcaggagg	caggaccaac	ccnccgacct	cctcatccac	ccaggccaat	1260
atccccctct	cggaaagagg	caccgcaggc	acctctgcc	ctgagcaggg	cctctgccac	1320
gctgccggcc	acccctcagg	ccctctgtcc	catcaccact	gtgcttatac	cattccgcac	1380
atcctgagtc	acttgagacc	tcatgaacag	cgaagctccc	cagtcagcag	ccgaagactg	1440

1	5	10	15
Gly Ser Gly Glu Ala Arg Gly Cys Arg Ala Ala Ala Asp Gly Ser Leu	20	25	30
Gln Trp Glu Val Gly Gly Trp Arg Trp Trp Gly Leu Ser Arg Ala Phe	35	40	45
Thr Val Lys Pro Glu Gly Arg Asp Ala Gly Glu Val Gly Ala Ser Gly	50	55	60
Ala Pro Ser Pro Pro Leu Ser Gly Leu Gln Ala Val Phe Leu Pro Gln	65	70	75
Gly Phe Pro Asp Ser Val Ser Pro Asp Tyr Leu Pro Tyr Gln Leu Trp	85	90	95
Asp Ser Val Gln Ala Phe Ala Ser Ser Leu Ser Gly Ser Leu Ala Thr	100	105	110
Gln Ala Val Leu Leu Gly Ile Gly Val Gly Asn Ala Lys Ala Thr Val	115	120	125
Ser Ala Ala Thr Ala Thr Trp Leu Val Lys Asp Ser Thr Gly Met Leu	130	135	140
Gly Arg Ile Val Phe Ala Trp Trp Lys Gly Ser Lys Leu Asp Cys Asn	145	150	155
Ala Lys Gln Trp Arg Leu Phe Ala Asp Ile Leu Asn Asp Val Ala Met	165	170	175
Phe Leu Glu Ile Met Ala Pro Val Tyr Pro Ile Cys Phe Thr Met Thr	180	185	190
Val Ser Thr Ser Asn Leu Ala Lys Cys Ile Val Ser Val Ala Gly Gly	195	200	205
Ala Thr Arg Ala Ala Leu Thr Val His Gln Ala Arg Arg Asn Asn Met	210	215	220
Ala Asp Val Ser Ala Lys Asp Ser Ser Gln Glu Thr Leu Val Asn Leu	225	230	235
Ala Gly Leu Leu Val Ser Leu Leu Met Leu Pro Leu Val Ser Gly Cys	245	250	255
Pro Gly Phe Ser Leu Gly Cys Phe Phe Phe Leu Thr Ala Leu His Ile	260	265	270
Tyr Ala Asn Tyr Arg Ala Val Arg Ala Leu Val Met Glu Thr Leu Asn	275	280	285
Glu Gly Arg Leu Arg Leu Val Leu Lys His Tyr Leu Gln Arg Gly Glu	290	295	300
Val Leu Asp Pro Thr Ala Ala Asn Arg Met Glu Pro Leu Trp Thr Gly	305	310	315
Phe Trp Pro Ala Pro Ser Leu Ser Leu Gly Val Pro Leu His Arg Ieu			320

<211> 2795
 <212> DNA
 <213> Homo sapiens

<400> 41
 aaaaagctcg gcatggctga cgacgcgggt ttggagaccc cgctgtgttc cgagcagttc 60
 ggctccgggg aggcacgggg ctgccgcgcc gccgcggacg ggagcctgca gtgggagggtc 120
 gggggctggc gctggtgggg gctctccagg gccttcacgg tcaaacctga aggacagat 180
 gcgggcgaag tgggggcttc cggggccccc tcaccgcccc tctccgggct ccaggccgtg 240
 ttctgcctc agggcttccc tgatagegtc agcccggaact acttgcccta ccagctgtgg 300
 gattccgtgc aggcgtttgc ttccagcctc tccggctccc tagccacca ggcagctttg 360
 ctgggcatag ggggtgggaa cgcaaaagcc actgtttcag ctgccacggc cacctggctc 420
 gtgaaagatt caactggcat gctgggccgc atcgtctttg cctggtggaa agggagcaaa 480
 ctggactgca atgccaagca gtggaggctt tttcggaca tcctcaatga cgtagccatg 540
 ttcttgaga ttatggctcc tgtataccca atctgtttca ccatgaccgt ctccaccagc 600
 aacctagcca agtgcacgt gagtgttgct ggtggggcca ctgggctgc cctgaccgtg 660
 caccaggctc ggaggaacaa catggctgac gtgtcagcca aggacagcag aggcccaag 720
 ctggtgaacc tggcggggct cttggtcagc ctctgatgc tccctctggt gtcaggttgc 780
 cctggcttca gccttggatg tttcttcttc ctactgccc tccacatcta cgccaactac 840
 cgcgcggtcc gagccctggt catggagacc ttgaacgaag gccggctccg gctggtcctg 900
 aagcactacc ttccagaggg agaggtactc gacccaactc cagccaatcg catggagccg 960
 ctgtggacag gttcttggcc agctccgtct ctatccctgg gggtccctt acaccgcttg 1020
 gtctccagtg tctttgagct gcagcagctg gttgaggggc accaagaatc ctacctctc 1080
 tgctgggacc agtcacaaaa ccagggtacag gtatgtctga accagaaggc aggcccaag 1140
 accatcctaa gggccgccac acatgggctg atgcttgggg cctgcaggg agatggagcc 1200
 ctccagcag agctggagga gctgaggaa cgggtgcggg caggctcctaa gaaagagagc 1260
 tgggtcgtcg tcaaggagac acacgaagtg ttggacatgc tgttcccaaa gttcttgaaa 1320
 ggactgcagg atgcgggctg gaagaccgag aagcaccagc tagaggtgga tgagtggagg 1380
 gccacatggc ttctgtctcc cgaaaagaag gtcttgtgag cagcccagac ggaggcccaa 1440
 gccagggca ggaacctgga gcaaggacac tttggccaca gcaggacagg ggaaaggcag 1500
 ctttatTTTT ccttagggca actgcagcgg gtgggccagg cctcatggg aagtgcactg 1560
 caatcagatg cagtgggccc caggcagagg aagycgggga gaaggggagc caggaccttc 1620
 tcacccact gcccttccc cttttctggg gagcaccgca ggctcctcac cccacttcc 1680
 tgtgaggctg tggcttatgg tgtccaacgc agttggctct aggcatagaa gcccagagg 1740
 aacacggcca ctgccatcat gagcagggca ttgaggttga ccacacgggc ccagctcggg 1800
 tcctcgctga tgtctccag ccgcctggct gctgcgctg cctcctcctg ggtaggggg 1860
 ggaggactgc ccaccccacc tctgtcatt ccacaaaacc agagcaggca ctggcggaag 1920
 aggcttgggt cgggggctg gggctctgag ggaattgag gccctgcagt tagtttgcgg 1980
 gaactcagct cctccagccc cactcccag catggtgccc taccattcat ctccatggca 2040
 ctctctgggc acccattctg tacagggagt gaggagcctt gctgctcatc agcatccagg 2100
 tcctccctgt cctccttgt atgcccggaga ctgaagacca yggggtggag ctggggaggg 2160
 tgggagcag aacgaggtg gatttctgt ccccatgccc tggccctaaa gtctcttgca 2220
 caccagctcg tcactgcctg cctaccacac ctctgtccag tctacacacc cagccaggc 2280
 ttaactcatg ccaactccac cctacatggc tgccctgtgc cctcgggata aaccccaagc 2340
 ccctgagctt gtgtttaaag ccgttggcct tgcctcccca gcttgtcag ctccaggtctg 2400
 tctacacca gatggtagcg cttgtgacac tggcctggca gtcctgctca cagtgtctg 2460
 tgcctgtgtg ctcccacct ttctcctgc tgcctcagaa acccgccat ccttccacac 2520
 ccagatctct tgtcctgtcc tcaccccacc ctgccaccat cagccctgac tggagccacc 2580
 tgccctttgg caacaaaacc aaacctttt gtgggcgttc aagatgggat tgtgcccacc 2640
 agtcagatcc tgtgttttga gtcccaagg ccatgccaa gattggcctt gggaggttt 2700
 aatcaccaac ccatcaacat caagcctccc ccaggccggt tcaataaat gtatttaaat 2760
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaa 2795

<210> 42
 <211> 468
 <212> PRT
 <213> Homo sapiens

<400> 42
 Met Ala Asp Asp Ala Gly Leu Glu Thr Pro Leu Cys Ser Glu Gln Phe

<210> 42

<210> 39
 <211> 1933
 <212> DNA
 <213> Homo sapiens

<400> 39
 ggggtggggc caggaggaag atggcgccgt ccgcagctgc cgctgagctc caggcttctg 60
 ggggtccgcg gcacccagtg tgtctgttgg tgttgggaat ggcgggatcc gggaaaacca 120
 cttttgtaca gaggttcaca ggacacctgc atgcccagg cactccaccg tatgtgatca 180
 acctggatcc agcagtacat gaagtccctt ttcttgccaa tattgatatt cgtgatattg 240
 taaaagtataa agaagtaatg aaacaatatg gacttggacc caatggcggc atagtgcct 300
 cactcaatct ctttgcctacc agatttgatc aggtgatgaa atttattgag aaggcccaga 360
 acatgtccaa atatgtgttg attgacacac ctggacagat tgaggrattc acctggtcag 420
 cttctgggac aattatcact gaagcccttg catcctcatt tccaacagtt gtcattctatg 480
 taatggacac atcgagaagt accaaccag tgaccttcat gtccaacatg ctctatgcct 540
 gcagcatctt atacaaaacc aagctgcctt tcatttgtgt catgaataaa actgacatca 600
 ttgaccacag ctttgcagtg gaatggatgc aggtatttga ggctttccaa gatgacttga 660
 atcaagagac tacatacgtc agtaacctga ctcgttcaat gagccttggt ttagatgagt 720
 tttacagctc actcaggtg gtgggtgtct ctgctgttct gggacttga ttagatgaac 780
 tctttgtgca agttaccagt gctgccgaag aatatgaaag ggagatcct cctgaatatg 840
 aacgtctgaa aaaatcactg gccaacgcag agagccaaca gcagagagaa caactggaac 900
 gccttcgaaa aatatgggtt tctgtagcct tggatgcagg gactgccaan gacagcttat 960
 ctctctgtct ccaccttctt gatttgatcc tgactcgagg aaccttggat gaagaggatg 1020
 aggaagcaga cagcgatact gatgacattg accacagagt tcagaggaag agccatgaag 1080
 agccagcatt ccagaatttt atgcaagaat cgatggcaca atactggaag agaaacaata 1140
 aataggagac tttagcacac ttcacttgtt tctagaagtc cagaattttg gacctccacg 1200
 tgaaagaact gttcttacct ctgaactggg ggctcccata agggataatt ttctcagag 1260
 tagcaaaagt tctcttatta gagaaatctt gtgactcaga tgaagtgcagg gatagaagac 1320
 ccttggacct ggcagggtta tgctgattat tccttggcct ttcccttgta tttatgcaag 1380
 gaaggatata ctgagctgat actcttccaa gctacaact tcaagtttta tcatttgaac 1440
 tcaagtactt ttgctgctga ggaatggaat caaaagaacg tagtctcctg gtaaccacct 1500
 cagatctcta ttattaggct agatgtatag cctctactcc cccagcttct tgctcttgac 1560
 cctgcactgt aagttgccct tctattagca gccaaggaaa agggaaacat gagcttatcc 1620
 agaacgggtg cagagtctcc ttggcaatca accaacgttg ctatgaaata tgcctcacac 1680
 tgtatagctc attataggac gtcaggtttg ttgaaaaaag tgggcaagac atgattaatg 1740
 aatcagaatc ctgtttcatt ggtgacttgg ataaagactt ttttaatttta actttgaaaa 1800
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1920
 aaaaaaaaaa aaa 1933

<210> 40
 <211> 374
 <212> PRT
 <213> Homo sapiens

<400> 40
 Met Ala Ala Ser Ala Ala Ala Ala Glu Leu Gln Ala Ser Gly Gly Pro
 1 5 10 15
 Arg His Pro Val Cys Leu Leu Val Leu Gly Met Ala Gly Ser Gly Lys
 20 25 30
 Thr Thr Phe Val Gln Arg Leu Thr Gly His Leu His Ala Gln Gly Thr
 35 40 45
 Pro Pro Tyr Val Ile Asn Leu Asp Pro Ala Val His Glu Val Pro Phe
 50 55 60
 Pro Ala Asn Ile Asp Ile Arg Asp Thr Val Lys Tyr Lys Glu Val Met
 65 70 75 80

85	90	95
Gly Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg		
100	105	110
Leu Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val		
115	120	125
Asn Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser Ile Lys Thr		
130	135	140
Leu Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser Cys Arg Leu		
145	150	155
Gln Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser		
165	170	175
Pro Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro		
180	185	190
Ser Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile Arg Gly Ser		
195	200	205
Leu Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val Tyr Val Cys		
210	215	220
Lys Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val Thr Leu Glu		
225	230	235
Val Ser Thr Gly Pro Gly Ala Ala Val Val Ala Gly Ala Val Val Gly		
245	250	255
Thr Leu Val Gly Leu Gly Leu Leu Ala Gly Leu Val Leu Leu Tyr His		
260	265	270
Arg Arg Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile Lys Glu Asp		
275	280	285
Ala Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser Ser Asp Thr Ile		
290	295	300
Ser Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg		
305	310	315
Pro Pro His Gly Pro Pro Arg Pro Gly Ala Leu Thr Pro Thr Pro Ser		
325	330	335
Leu Ser Ser Gln Ala Leu Pro Ser Pro Arg Leu Pro Thr Thr Asp Gly		
340	345	350
Ala His Pro Gln Pro Ile Ser Pro Ile Pro Gly Gly Val Ser Ser Ser		
355	360	365
Gly Leu Ser Arg Met Gly Ala Val Pro Val Met Val Pro Ala Gln Ser		
370	375	380
Gln Ala Gly Ser Leu Val		
385	390	

<212> DNA

<213> Homo sapiens

<400> 37

```

gagacttggg ctggagccgc cctgggtgtc agcgggctcg gctcccgcgc acgctccggc 60
cgctcgcgag cctcggcacc tgcaggtccg tgcgtccgcg ggctggcgcc cctgactccg 120
tcccggccag ggagggccat gatttccctc ccggggcccc tggtgaccaa cttgctgcgg 180
tttttgttcc tggggctgag tgccctcgcg ccccccctgc gggcccagct gcaactgcac 240
ttgcccgcga accggttgca ggcggtggag ggaggggaag tgggtgcttc agcgtggtac 300
accttgcaag gggaggtgtc ttcattccag ccattggagg tgccctttgt gatgtggttc 360
ttcaaacaga aagaaaagga ggatcaggtg ttgtcctaca tcaatggggt cacaacaagc 420
aaacctggag tatccttggg ctactccatg cctcccgcga acctgtccct gcggctggag 480
ggcttcagg agaaagactc tggcccttac agctgctccg tgaatgtgca agacaaacaa 540
ggcaaatcta ggggccacag catcaaaacc ttagaactca atgtactggt tcctccagct 600
cctccatcct gccgtctcca ggggtgtgcc catgtggggg caaacgtgac cctgagctgc 660
cagctctcaa ggagtaagcc cgctgtccaa taccagtggg atcggcagct tccatccttc 720
cagactttct ttgcaccagc attagatgtc atccgtgggt ctttaagcct caccacacct 780
tcgtcttcca tggctggagt ctatgtctgc aaggccacaa atgaggtggg cactgcccac 840
tgtaatgtga cgctggaagt gagcacaggg cctggagctg cagtgggtgc tggagctggt 900
gtgggtaccc tgggtggact ggggtgtctg gctgggctgg tccctcttga ccaccgccgg 960
ggcaaggccc tggaggagcc agccaatgat atcaaggagg atgccattgc tcccgggacc 1020
ctgcccctggc ccaagagctc agacacaatc tccaagaatg ggacccttcc ctctgtcacc 1080
tccgcacgag cctccggcc accccatggc cctcccaggc ttggtgcatt gacccccacg 1140
ccagctctct ccagccaggc cctgcccctca ccaagactgc ccacgacaga tggggccac 1200
cctcaaccaa tatcccccat cctgggtggg gtttcttctc ctggcttgag ccgcatgggt 1260
gctgtgcctg tgatgggtgc tgcacagagt caagctggct ctctggtatg atgacccac 1320
cactcattgg cttaaaggatt tgggtctctc ccttccctata agggtcacct ctagcacaga 1380
ggcctgagtc atgggaaaga gtcacactcc tgacccttag tactctgccc ccacctctct 1440
ttactgtggg aaaaccatct cagtaagacc taagtgtcca ggagacagaa ggagaagagg 1500
aagtggatct ggaattggga ggagcctcca cccaccctg actcctctct atgaagccag 1560
ctgctgaaat tagctactca ccaagagtga ggggcagaga cttccagtca ctgagctctc 1620
caggccccct tgatctgtac cccaccctca tctaaccaca ccttggctc cactccagc 1680
tccctgtatt gatataacct gtcaggctgg cttggttagg ttttactggg gcagaggata 1740
gggaatctct tattaaaact aacatgaaat atgtgtgtgt ttcatttga aatttaata 1800
aagatacata atgtttgtat gaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1860
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1920
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 1954

```

<210> 38

<211> 390

<212> PRT

<213> Homo sapiens

<400> 38

```

Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Leu Arg Phe Leu
  1                      5                      10                     15

Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln Leu Gln
                20                      25                     30

Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Gly Gly Glu Val
                35                      40                     45

Val Leu Pro Ala Trp Tyr Thr Leu His Gly Glu Val Ser Ser Ser Gln
                50                      55                     60

Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys
                65                      70                     75                     80

Glu Asp Gln Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro

```

```

ggtttccttg aaggaagctg ctcacactga gatgagcctc tcagggcagg acctcttccc 3420
aagccctgca caccacccc tgcagccctt ttggctcccc ttttcctgt gcctcagcac 3480
tcctttcctg gttgcagata acgaactaag gttgcctaaa gggcagatct gccctctcca 3540
tgtcttcgtc ctggcaaaca gggctcgtctt aaaattatgc gctaattctg tatgggagca 3600
ctcaaaaggc attacttaga gattgaaatt tcaaactatc tctagttttt caatggaaat 3660
atatcagcta gggaaaaacc atcaagctca ttattatttt ttgatcttca gttgtatttt 3720
tgtgaatatt ttaatacatc tttttcaatt tctgaaaaaa aaaaaaaaaa aaaaaaaaaa 3780
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3809

```

<210> 36

<211> 209

<212> PRT

<213> Homo sapiens

<400> 36

```

Met Ala Ala Ser Ala Gly Ala Gly Ala Val Ile Ala Ala Pro Asp Ser
  1             5             10             15

Arg Arg Trp Leu Trp Ser Val Leu Ala Ala Ala Leu Gly Leu Leu Thr
      20             25             30

Ala Gly Val Ser Ala Leu Glu Val Tyr Thr Pro Lys Glu Ile Phe Val
      35             40             45

Ala Asn Gly Thr Gln Gly Lys Leu Thr Cys Lys Phe Lys Ser Thr Ser
      50             55             60

Thr Thr Gly Gly Leu Thr Ser Val Ser Trp Ser Phe Gln Pro Glu Gly
      65             70             75             80

Ala Asp Thr Thr Val Ser Phe Phe His Tyr Ser Gln Gly Gln Val Tyr
      85             90             95

Leu Gly Asn Tyr Pro Pro Phe Lys Asp Arg Ile Ser Trp Ala Gly Asp
      100            105            110

Leu Asp Lys Lys Asp Ala Ser Ile Asn Ile Glu Asn Met Gln Phe Ile
      115            120            125

His Asn Gly Thr Tyr Ile Cys Asp Val Lys Asn Pro Pro Asp Ile Val
      130            135            140

Val Gln Pro Gly His Ile Arg Leu Tyr Val Val Glu Lys Glu Asn Leu
      145            150            155            160

Pro Val Phe Pro Val Trp Val Val Val Gly Ile Val Thr Ala Val Val
      165            170            175

Leu Gly Leu Thr Leu Leu Ile Ser Met Ile Leu Ala Val Leu Tyr Arg
      180            185            190

Arg Lys Asn Ser Lys Arg Asp Tyr Thr Gly Ala Gln Ser Tyr Met His
      195            200            205

Ser

```

<210> 37

<211> 1954

<212> DNA

<213> Homo sapiens

<400> 35

```

ggggaccgga gtggggagcg cggcggtggag gtgccaccgc gcycgggtgg cggagagatc 60
agaagcctct tccccaagcc gagccaacct cagcggggac cggggctcag ggacgcggcg 120
gcggcgcgcg cgactgcagt ggctggacga tggcagcgtc cggcggagcc ggggcggtga 180
ttgcagcccc agacagcccg cgctggctgt ggtcgggtgt ggcggcgggc cttgggctct 240
tgacagctgg agtatcagcc ttggaagtat atacgccaac agaaatcttc gtggcaaatg 300
gtacacaagg gaagctgacc tgcaagttca agtctactag tacgactggc ggggtgacct 360
cagtcctctg gagcttcag ccagaggggg ccgacactac tgtgtcgttt tccactact 420
cccaagggca agtgtacctt ggggaattat caccatttaa agacagaatc agctgggctg 480
gagaccttga caagaaagat gcatcaatca acatagaaaa tatgcagttt atacacaatg 540
gcacctatat ctgtgatgtc aaaaaccctc ctgacatcgt tgtccagcct ggacacatta 600
ggctctatgt cgtagaaaaa gagaatttgc ctgtgtttcc agtttgggta gtgggtggga 660
tagttactgc tgtggtccta ggtctcactc tgctcatcag catgattctg gctgtcctct 720
atagaaggaa aaactctaaa cgggattaca ctggggccca gtcatatatg cacagttaga 780
ccactccggc ggacatcaca gtgacaagat taacaagtca gagtctgtgg tgtatgcgga 840
tatccgaaag aattaagaga atacctagaa catatcctca gcaagaaaca aaaccaaact 900
ggactctcgt gcagaaaatg tagcccatca ccacatgtag ccttggagac ccaggcaagg 960
acaagtacac gtgtactcac agaggggagag aaagatgtgt acaaggata tgtataaata 1020
ttctatattg tcatcctgat atgaggagcc agtgttgcag gatgaaaaga ttgtatgatt 1080
ctacatatgt acccattctc ttgctgtttt tgtactttct tttcaggtea tttacaattg 1140
ggagatttca gaaacattcc tttcaccatc atttagaaat ggtttgcctt aatggagata 1200
atagcagatc ctgtagtatt tccagtagac atggcctttt aatctaaagg ctttaagactg 1260
attagtctta gcatttactg tagttggagg atggagatgc tatgatggaa gcatacccag 1320
ggtggccttt agcacagtat cagtaccatt tatttgtctg ccgcttttaa aaaataccca 1380
ttggctatgc cacttgaaaa caatttgaga agtttttttg aagtttttct cactaaaaata 1440
tggggcaatt gttagcctta catgttgtgt agacttactt taagtttgca cccttgaaat 1500
gtgtcatatc aatttctgga ttcataatag caagattagc aaaggataaa tgccgaagg 1560
cacttcattc tggacacagt tggatcaata ctgattaagt agaaaatcca agctttgctt 1620
gagaactttt gtaacgtgga gagtaaaaag tatcggtttt attctttgct gatgtccttt 1680
ctgcttgaaa taacagtcac catacagcta aaggagagga gtttctttcc ttctaagtag 1740
gcagaaatgg tatcattatg ttgcgcctct ccaatctccc agagctcgtt ctctagagaa 1800
tcaccttctt tcgctttttt ttttttttga ggtagagtct cactt.tggtg ccagactag 1860
ccttgaaactc ttgggctcaa gtgattctcc ctctcagcc tcccagtag ctggaacgaa 1920
ctatagttgc accactgcag ctggcaagaa tcaccttttt tataaagcgt cagtcatgct 1980
tccagcaaga ggcagcatca gtcattggct tataacagct tcattggtgc tcaaagactg 2040
ttgagggtta tgagagccta gattagacag tttggctgtc cttccctaaa acttgttttc 2100
tcttattcac tactccccac cgcacttaaa atctatgagt ttttactttt tactgggaat 2160
ggaaagtgtg gtgaagatca ttcaacactt atgttgtcat ttctcccat tcttgaattt 2220
ttttttaaat ttccccctt ttaaaattgt tcgaaagccc acagttatgg aaagaattac 2280
tgtctagatg gtctgcagaa cgtgtttggg gtgagtgga gtgaggggca atgttacttt 2340
ttctccttgt agtttggagt ccattatgag ctgctgcctt ttcttctcat cttgtcatct 2400
tctggggatg tttgaaggct gagttccaac agaattcaca aagggaataa aacaggattg 2460
agatttttag gtgtgcacaa ggtggttaaga taaaggcat atgagcttca aaactaatgc 2520
tgttgcatac atgaagcctt ttgttttttg aggagctatt tttgttatc ttgtaacgct 2580
ccaccttaca tgccacgtct gtgtgagtca acagggatca ggtttggtca ccacacatgt 2640
ctgaagctgg gcagcgtctg ctctgtgttc tgtgtggaat ggagaaaaaa acgcctgccc 2700
tgctgccttc catgttccata ggcagccc aagagagtga cacacagtgc tggccctgag 2760
acatttccac aaagtgggtca actctgcctt gcactcctaaa actttttggg catctatatt 2820
gaaaactata ggagcctttg gaaggcctct tatgtttgga gyggaagggg gttgagattg 2880
tcaccatcct tcaagctgag actcctgggtg agcctttgcc accatgaaaa ccacatagct 2940
gaccagggct gtgcttgagg tacagaggac acacatcgta gacaggcctg tgtcatgttt 3000
ccttacagtc gttttttaca gagaaaaggg gcattgtttt ttcactgctt tctcaacagt 3060
tcctgtgaat aaatgaaaca tttcgagct ccttgagagc aagagccttc acttctctct 3120
gcggtgccgg garcatgtgt tggtagaagt ggtgctgtgg gggcactca ctcgaatgac 3180
acctggaggc ctgttccctc cttaccactc ccttcccag ccgaacttct tggcctctg 3240
cccaaccaga cactcaaac tctgtcagcg ccttggcatt ctggtagaga atctcacc 3300
gttctcacca accttcccc caggaagggt cagctgccag catggtgctc tgccaggaca 3360

```

His Leu Pro Leu Ala Ser Leu Val Ser Ile Asn Ala Asp Asn Gly His
 500 505 510
 Leu Phe Ala Leu Arg Ser Leu Asp Tyr Glu Ala Leu Gln Gly Phe Gln
 515 520 525
 Phe Arg Val Gly Ala Thr Asp His Gly Ser Pro Ala Leu Ser Ser Glu
 530 535 540
 Ala Leu Val Arg Val Leu Val Leu Asp Ala Asn Asp Asn Ser Pro Phe
 545 550 555 560
 Val Leu Tyr Pro Leu Gln Asn Gly Ser Ala Pro Cys Thr Glu Leu Val
 565 570 575
 Pro Trp Ala Ala Glu Pro Gly Tyr Leu Val Thr Lys Val Val Ala Val
 580 585 590
 Asp Gly Asp Ser Gly Gln Asn Ala Trp Leu Ser Tyr Gln Leu Leu Lys
 595 600 605
 Ala Thr Glu Pro Gly Leu Phe Gly Val Trp Ala His Asn Gly Glu Val
 610 615 620
 Arg Thr Ala Arg Leu Leu Ser Glu Arg Asp Ala Ala Lys His Arg Leu
 625 630 635 640
 Val Val Leu Val Lys Asp Asn Gly Glu Pro Pro Arg Ser Ala Thr Ala
 645 650 655
 Thr Leu His Val Leu Leu Val Asp Gly Phe Ser Gln Pro Tyr Leu Pro
 660 665 670
 Leu Pro Glu Ala Ala Pro Ala Gln Ala Gln Ala Asp Ser Leu Thr Val
 675 680 685
 Tyr Leu Val Val Ala Leu Ala Ser Val Ser Ser Leu Phe Leu Phe Ser
 690 695 700
 Val Leu Leu Phe Val Ala Val Arg Leu Cys Arg Arg Ser Arg Ala Ala
 705 710 715 720
 Pro Val Gly Arg Cys Ser Val Pro Glu Gly Pro Phe Pro Gly His Leu
 725 730 735
 Val Asp Val Ser Gly Thr Gly Thr Leu Ser Gln Ser Tyr His Tyr Glu
 740 745 750
 Val Cys Val Thr Gly Gly Ser Arg Ser Asn Lys Phe Lys Phe Leu Lys
 755 760 765
 Pro Ile Ile Pro Asn Phe Leu Pro Gln Ser Thr Gly Ser Glu Val Glu
 770 775 780
 Glu Asn Pro Pro Phe Gln Asn Asn Leu Gly Phe
 785 790 795

<210> 35

<211> 3809

His Phe His Val Lys Ile Arg Val Asn Pro Asp Asn Arg Lys Tyr Pro
 180 185 190
 Glu Leu Val Leu Asp Lys Ala Leu Asp Tyr Glu Glu Arg Pro Glu Leu
 195 200 205
 Ser Phe Ile Leu Thr Ala Leu Asp Gly Gly Ser Pro Pro Arg Ser Gly
 210 215 220
 Thr Ala Leu Val Arg Val Val Val Val Asp Ile Asn Asp Asn Ser Pro
 225 230 235 240
 Glu Phe Glu Gln Ala Phe Tyr Glu Val Lys Ile Leu Glu Asn Ser Ile
 245 250 255
 Leu Gly Ser Leu Val Val Thr Val Ser Ala Trp Asp Leu Asp Ser Gly
 260 265 270
 Thr Asn Ser Glu Leu Ser Tyr Thr Phe Ser His Ala Ser Glu Asp Ile
 275 280 285
 Arg Lys Thr Phe Glu Ile Asn Gln Lys Ser Gly Asp Ile Thr Leu Thr
 290 295 300
 Ala Pro Leu Asp Phe Glu Ala Ile Glu Ser Tyr Ser Ile Ile Ile Gln
 305 310 315 320
 Ala Thr Asp Gly Gly Gly Leu Phe Gly Lys Ser Thr Val Arg Ile Gln
 325 330 335
 Val Met Asp Val Asn Asp Asn Ala Pro Glu Ile Thr Val Ser Ser Ile
 340 345 350
 Thr Ser Pro Ile Pro Glu Asn Thr Pro Glu Thr Val Val Met Val Phe
 355 360 365
 Arg Ile Arg Asp Arg Asp Ser Gly Asp Asn Gly Lys Met Val Cys Ser
 370 375 380
 Ile Pro Glu Asp Ile Pro Phe Val Leu Lys Ser Ser Val Asn Asn Tyr
 385 390 395 400
 Tyr Thr Leu Glu Thr Glu Arg Pro Leu Asp Arg Glu Ser Arg Ala Glu
 405 410 415
 Tyr Asn Ile Thr Ile Thr Val Thr Asp Leu Gly Thr Pro Arg Leu Lys
 420 425 430
 Thr Glu His Asn Ile Thr Val Leu Val Ser Asp Val Asn Asp Asn Ala
 435 440 445
 Pro Ala Phe Thr Gln Thr Ser Tyr Ala Leu Phe Val Arg Glu Asn Asn
 450 455 460
 Ser Pro Ala Leu His Ile Gly Ser Ile Ser Ala Thr Asp Arg Asp Ser
 465 470 475 480
 Gly Thr Asn Ala Gln Val Asn Tyr Ser Leu Leu Pro Ser Gln Asp Pro
 485 490 495

```

cactgtctac ctggtggtgg cggtggcctc agtgcgtcg ctcttcctct tctcgggtgct 2280
cctgttcgtg gcggtgcggc tgtgcaggag gagcagggag gccccgggtg gtcgctgctc 2340
gggtgcctgag ggcccttttc caggacatct ggtggacgtg agtggcaccg ggaccctgtc 2400
ccagagctac cactatgagg tgtgtgtgac tggaggctcc aggtcaaata agttcaaatt 2460
tctgaaacca attatcccca acttcctacc ccagagcaca ggtagtgaag tcgaagaaaa 2520
tccccattt cagaataatt tgggtttctg ataaagaatg aaaaataaaa cctgtgttta 2580
tgaatacatt tataattagg aacttatcgt gaggtgcctg taaagtagta tttttgatca 2640
cttcaaatac atactcttca agtcaagaaa taaatttctt tacatagaaa aggatacaga 2700
tttagtacca agaacacttc acaaagcagg aaatgtgcat gtgtaatggt ttatgtcaaa 2760
caattatgct taatataaag tctattaagt ggtaagtctt gtttcagata ttttaaattg 2820
ctttccattg ttttcaatat ttactgtgac ttttgttttc tgagttgatt agaatgctgt 2880
tcgagtatac ctaccctagt ttcagaagca tagattgtag tgtacctttt taaactttat 2940
ttttttaaaa aaagtgtgtt tatgaatcat acactatttt cacactttta atctcagaag 3000
aaacatatgt gacatggtat tttagtaatg accaaataga cggctcttaga gattcagtaa 3060
gttactaag gtccactaac taataagtga caaaactgag catccatcct agatctgcct 3120
gactctaagt cagtgacttt gctcccatc catactgttt ttgtcattgg atatcacctg 3180
gcaagtttct gcctaactaa agagaagaaa agtttttctc gtattcatat tactgttcaa 3240
tctttattta gaaataaact ttatctatga tttcattttc ttataaacca gtaatcttgc 3300
ttttctgggt aaattttcag ctattattac taatgctctg atctgccccaa atcttaagta 3360
aaaaacaaaa ttgaaagagc aaaaaaaaaa aaaaaaaaaa aaaaaa 3406

```

<210> 34

<211> 795

<212> PRT

<213> Homo sapiens

<400> 34

```

Met Glu Asn Gly Gly Ala Gly Thr Leu Gln Ile Arg Gln Val Leu Leu
  1                      5                      10                      15

Phe Phe Val Leu Leu Gly Met Ser Gln Ala Gly Ser Glu Thr Gly Asn
  20                      25                      30

Phe Leu Val Met Glu Glu Leu Gln Ser Gly Ser Phe Val Gly Asn Leu
  35                      40                      45

Ala Lys Thr Leu Gly Leu Glu Val Ser Glu Leu Ser Ser Arg Gly Ala
  50                      55                      60

Arg Val Val Ser Asn Asp Asn Lys Glu Cys Leu Gln Leu Asp Thr Asn
  65                      70                      75                      80

Thr Gly Asp Leu Leu Leu Arg Glu Met Leu Asp Arg Glu Glu Leu Cys
  85                      90                      95

Gly Ser Asn Glu Pro Cys Val Leu Tyr Phe Gln Val Leu Met Lys Asn
 100                      105                      110

Pro Thr Gln Phe Leu Gln Ile Glu Leu Gln Val Arg Asp Ile Asn Asp
 115                      120                      125

His Ser Pro Val Phe Leu Glu Lys Glu Met Leu Leu Glu Ile Pro Glu
 130                      135                      140

Asn Ser Pro Val Gly Ala Val Phe Leu Leu Glu Ser Ala Lys Asp Leu
 145                      150                      155                      160

Asp Val Gly Ile Asn Ala Val Lys Ser Tyr Thr Ile Asn Pro Asn Ser
 165                      170                      175

```

Asn Val Ser Tyr Thr Arg Gln Pro Pro Asn Pro Gly Pro Gly Ala Gln
100 105 110

Gln Pro Gly Pro Pro Tyr Tyr Thr Asp Pro Gly Gly Pro Gly Met Asn
115 120 125

Pro Val Gly Asn Ser Met Ala Met Ala Phe Gln Val Pro Pro Asn Ser
130 135 140

Pro Gln Gly Ser Val Ala Cys Pro Pro Pro Pro Ala Tyr Cys Asn Thr
145 150 155 160

Pro Pro Pro Pro Tyr Glu Gln Val Val Lys Ala Lys
165 170

<210> 33

<211> 3406

<212> DNA

<213> Homo sapiens

<400> 33

```
ttaaagaacaa tcctttaagg gagaacctag aagccattca acaagggttaa aatcttcagg 60
cttccgagga ttgggtagac agattagagg cacgtttccc acaactgcga agaggcgtg 120
aggcaattct gcaagaagat ttgggggttt tggaaaagaa gctatggaaa acggaggggc 180
aggcactctg cagataaggc aagtcctgct tttctttgtt ttgctgggaa tgtctcaggc 240
gggctctgaa actgggaact ttttgggtgat ggaggaattg cagagcggga gctttgtagg 300
aaattttgga aagaccctgg gactcgaggt gactgagctg tcttcgctgg gggtctgggt 360
ggttttctaag gataacaaaag agtgtttgca gctggacaca aacactgggg atttgcctct 420
gagagaaatg ctagacaggg aggagctctg ttgctccaat gagecttggt tgctgtattt 480
ccaagtgtta atgaaaaacc ccacgcagtt tttacaaatt gagctcagg tcagggatat 540
aatgatcac tctcccgctc tcttggaata agaaatgctc ttagaaatcc cagagaacag 600
tctgttggt gctgtgttct tgcttgaaag tgcaaggat ttagatgtag gaatcaatgc 660
tgtaaaaagc tacacaataa atccgaactc tcattttccac gttaaaaaa gagtcaatcc 720
agacaatagg aaataccctg agttagttct ggacaaggcg ctggattatg aagagcgccc 780
ggagctcagt ttcactctca ctgctctgga tggcgggtcc cctccagggt ctggaactgc 840
cttggtcagg gtgggtggtg tagatattaa tgacaactcc cctgagtttg agcaggcttt 900
ttatgaggtg aagattcttg agaatagcat ccttggctcc ctgggttgga cctgtctcagc 960
ctgggattta gactctggaa caaacagtga actatcctat accttttccc atgcctcaga 1020
agatatctgc aagacatttg aaattaatca aaagtctggt gacattactt taacagcacc 1080
tttggatttt gaagcaattg agtcatactc aataatcatt caagccacag atgggggagg 1140
actttttgga aaatctacag tcagaattca ggtgatggat gtaaacgaca acgctcctga 1200
aatcactgtg tcatcaatta ccagtcctaat cccagaaaac actccagaga ctgtggttat 1260
ggttttcagg atacgagaca gagactctgg ggacaacgga aagatgggtt gttctatccc 1320
ggaggacatc ccattcgtgc taaaaatctc ggtaaaataat tactacactt tggaaacaga 1380
gagaccgctg gagagagaga gcagagccga gtacaacatc accatcaccc tcaccgactt 1440
ggggaccccc aggtctaaaaa ccgagcacaa cataaccgtg ctgggtctccg acgtcaatga 1500
caacgcccc cccttcaccc aaacttccca cgcctgttcc gtccgcgaga acaacagccc 1560
cgccctgcac atcgggcagca tcagcgccac agacagagac tcyggcagcc acgcccagggt 1620
caactactcg ctgctgccc cccaggaccc gcacctgccc ctgcctccc tgggtctccat 1680
caacgcggac aacggccacc tgtttgccct caggctcgtg gactacgagg ccttcgaggg 1740
gttcacgttc cgcgtgggag ccacagacca cggctccccg gttttgagca gcgaggcgtc 1800
ggtgcgctg ctggtgctgg acgccaacga caactcgccc ttcgtgtgtt acccggtcca 1860
gaacggctcc gcgccctgca ccgagctggt gccctggggc gccgagccgg gctacctggg 1920
gaccaagggt gtggcggtgg acggtgactc gggccagaac gccctggctg cgtaccagct 1980
gctcaaggcc acggagcccg ggcatttcgg cgtgtgggag cacaatggcg aggtgcgcac 2040
cgccaggctg ctgagcgagc gcgacgcggc caagcacagg ctgggtggtg tgggtcaagg 2100
caatggcgag cctcccgctc cggccacccc cagctgcac gtgtctctgg tggacgctt 2160
ctcccagccc tactgtctc tccgggaggg ggcctcgccc caggcccagg ccgactcgtc 2220
```

atatatgaac tcacactttg tctcctctgt tgcctctgtt tctgacgcag tctgtgctct 780
 cacatggtag tgtgggtgaca gtcccccagg gctgacgtcc ttacgggtggc gtgaccagat 840
 ctacaggaga gagactgaga ggaagaaggc agtgctggag gtgcagggtg catgtagagg 900
 ggccaggccg agcatccag gcaagcatcc ttctgcccgg gtattaatag gaagcccat 960
 gccgggcccgc tcagccgatg aagcagcagc cgactgagct gagcccagca ggtcatctgc 1020
 tccagcctgt cctctcgtca gccttctct tccagaagct gttggagaga cattcaggag 1080
 agagcaagcc ccttgctcatg tttctgtctc tgttcatatc cttaaagatag acttctctctg 1140
 caccgccagg gaagggtagc acgtgcagct ctcaccgcag gatggggcct agaattcaggc 1200
 ttgccttggg gccctgacag tgatctgaca tccactaagc aaatttattt aaattcatgg 1260
 gaaatcactt cctgcccacaa actgagacat tgcattttgt gagctcttgg tctgatttgg 1320
 agaaaggact gttaccatt tttttggtgt gtttatggaa gtgcatgtag agcgtcctgc 1380
 cctttgaaat cagactgggt gtgtgtcttc cctggacatc actgcctctc caggggcatc 1440
 tcaggcccgg ggggtctcct cctcaggca gctccagtgg tgggttctga aggggtgctt 1500
 caaacagggg cacatctggc tgggaagtca catggactct tccagggaga gagaccagct 1560
 gagggcgtctc tctctgaggt tgtgttgggt ctaagcgggt gtgtgttggg ctccaaggag 1620
 gaggagcttg ctgggaaaag acaggagaag tactgactca actgcactga ccatgttgtc 1680
 ataattagaa taaagaagaa gtgtctggaa atgcacattc ctggatagga atcacagctc 1740
 accccaggat ctcacaggta gtctcctgag tagttgacgg ctacggggga gctagtctcg 1800
 ccgcatagtt atagtgttga tgtgtgaacg ctgacctgtc ctgtgtgcta agagctatgc 1860
 agcttagctg aggcgcctag attactagat gtgctgtatc acgggggaatg aggtgggggt 1920
 gcttattttt taatgaacta atcagagcct cttgagaaat tgttactcat tgaactggag 1980
 catcaagaca tctcatggaa gtggatacgg agtgatttgg tgtccatgct tttcactctg 2040
 aggacattta atcggagaac ctctggggga attttgtggg agacacttgg gaacaaaaca 2100
 gacacccctgg gaatgcagtt gcaagcacag atgctgccac cagtgtctct gaccaccctg 2160
 gtgtgactgc tgaactgccag cgtggtacct cccatgctgc aggcctccat ctaaaatgaga 2220
 caacaaagca caatgttcac tgtttacaac caagacaact gcgtgggtcc aaacactcct 2280
 ctctctccag gtcatattgt ttgcattttt aatgtcttta tttttttaa tgaaaaagca 2340
 cactaagctg cccctggaaat cgggtgcagc tgaataggca cccaaaagtc cgtgactaaa 2400
 tttcgtttgt ctttttgata gcaaatattg ttaagagaca gtgatggcta gggctcaaca 2460
 attttgtatt cccatgtttg tgtgagacag agtttgtttt cctttgaact tggttagaat 2520
 tgtgtactcg tgaacgctga tcttgcatac ggaagtcccg ctctgggtgac atttctctggc 2580
 cattcttgtt tccattgtgt ggtatgggtgg ttgtgcccac ttcttggagt gagacagctc 2640
 ctgggtgtgta gaattcccgg agcgtccgtg gtccagagta aacttgaagc agatctgtgc 2700
 atgcttttct ctgcaacaat tggctcgttt ctcttttttg ttctcttttg ataggatcct 2760
 gtttctctatg tgtgcaaaaat aaaaataaat ttgggcaaaa aa:aaaaaaaa aaaaaaaaaa 2820
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2880

<210> 32

<211> 172

<212> PRT

<213> Homo sapiens

<400> 32

Met Arg Arg Gln Pro Ala Lys Val Ala Ala Leu Leu Leu Gly Leu Leu
 1 5 10 15
 Leu Glu Cys Thr Glu Ala Lys Lys His Cys Trp Tyr Phe Glu Gly Leu
 20 25 30
 Tyr Pro Thr Tyr Tyr Ile Cys Arg Ser Tyr Glu Asp Cys Cys Gly Ser
 35 40 45
 Arg Cys Cys Val Arg Ala Leu Ser Ile Gln Arg Leu Trp Tyr Phe Trp
 50 55 60
 Phe Leu Leu Met Met Gly Val Leu Phe Cys Cys Gly Ala Gly Phe Phe
 65 70 75 80
 Ile Arg Arg Arg Met Tyr Pro Pro Pro Leu Ile Glu Glu Pro Ala Phe
 85 90 95

130 135 140
 Ile Pro Arg Val Gln Val Ala Gln Ile Leu Gly Pro Leu Ser Ile Thr
 145 150 155 160
 Asn Lys Thr Leu Ile Tyr Ile Leu Gly Leu Gln Leu Phe Thr Ser Gly
 165 170 175
 Ser Tyr Ile Trp Ile Val Ala Ile Ser Gly Leu Met Ser Gly Leu Cys
 180 185 190
 Tyr Asp Ser Lys Met Phe Gln Val His Gln Val Leu Cys Ile Pro Ser
 195 200 205
 Trp Met Ala Lys Phe Phe Ser Trp Thr Leu Glu Pro Ile Phe Ser Ser
 210 215 220
 Ser Glu Pro Thr Ser Glu Ala Arg Ile Gly Met Gly Ala Thr Leu Asp
 225 230 235 240
 Ile Gln Arg Gln Gln Arg Met Glu Leu Leu Asp Arg Gln Leu Met Phe
 245 250 255
 Ser Gln Phe Ala Gln Gly Arg Arg Gln Arg Gln Gln Gln Gly Gly Met
 260 265 270
 Ile Asn Trp Asn Arg Leu Phe Pro Pro Leu Arg Gln Arg Gln Asn Val
 275 280 285
 Asn Tyr Gln Gly Gly Arg Gln Ser Glu Pro Ala Ala Pro Pro Leu Glu
 290 295 300
 Val Ser Glu Glu Gln Val Ala Arg Leu Met Glu Met Gly Phe Ser Arg
 305 310 315 320
 Gly Asp Ala Leu Glu Ala Leu Arg Ala Ser Asn Asn Asp Leu Asn Val
 325 330 335
 Ala Thr Asn Phe Leu Leu Gln His
 340

<210> 31

<211> 2880

<212> DNA

<213> Homo sapiens

<400> 31

ccggcgctccg ggcgcgctgg agaggacgcg aggagccatg aggcgccagc ctgcgaaggt 60
 ggcgcgctcg ctgctcgggc tgcctcttga gtgcacagaa gccaaaaagc attgctggta 120
 ttctgaagga ctctatccaa cctattatat atgccgctcc tacgaggact gctgtggctc 180
 caggtgctgt gtgcgggccc tctccataca gaggtgtgtg tacttctgtt tcttctgat 240
 gatgggctgt cttttctgct gcggagccgg cttcttcac cggaggcgca tgtaccccc 300
 gccgctgac gagagccag cttcaatgt gtctacacc aggcagcccc caaatcccg 360
 cccaggagcc cagcagccgg ggccgcctta ttacaccgac ccaggaggac cggggatgaa 420
 ccctgtcggg aattccatgg caatggcttt ccaggtccca cccaactcac cccaggggag 480
 tgtggcctgc ccgccccctc cagcctactg caacacgct cgcgcccggt acgaacaggt 540
 agtgaaggcc aagtagtggg gtgcccacgt gcaagaggag agacaggaga gggcctttcc 600
 ctggcctttc tgtcttcgtt gatgttact tccaggaacg gtctcgtggg ctgctaaggg 660
 cagttcctct gatatcctca cagcaagcac agctctcttt caggctttcc atggagtaca 720

```

actgcagctt ttcacctctg gttcctacat ctggattgta gccataagtg gacttatgtc 600
cggctctgtc tacgacagca aaatgttcca ggtgcatcag gtgctctgca tccccagctg 660
gatggcaaaa ttcttttctt ggacacttga acccatcttc tcttcttcag aaccaccag 720
cgaagccaga attgggatgg gagccacgct ggacatccag agacagcaga gaatggagct 780
gctggaccgg cagctgatgt tctctcagtt tgcacaaggg aggcgacaga gacagcagca 840
gggaggaatg atcaattgga atcgtctttt tctctcttta cgtcagcgac aaaacgtaaa 900
ctatcagggc ggtcggcagt ctgagccagc agcgccccct ctagaagttt ctgaggaaaca 960
ggtcggccgg ctcatggaga tgggattttc cagaggtgat gcttttgaag ccctgagagc 1020
ttcaaacaaat gacctcaatg tcgccaccaa ctctctgctg cagcactgat agtcccaggc 1080
caactactgg accggaccgg cagccgagtg acagtgcgtg gtccccacca tcagatcagc 1140
ccggggaccg agcatctctg gtgctgatgt tcttggtgga agagggaggt tccaccgcac 1200
ccctgccctc aaccgcaaga ctggtgccgt tttagtgtgg agataagttt gccattacat 1260
tagcatgtat tttctatcta tatttttatt gggcattttc cctaggttgg agagtcagca 1320
ctcgttttga atgtgtttta aatgcattaa aatggaagat ttctgcaggc agttgaaatg 1380
cactccagat ggggaattgc tgaaccctc ttactgtaac atgtcatctc ctgcgtcgtg 1440
atggggagag ggtaatgtta cttcacaag gacatgtcag atccttcttc atggactttt 1500
ttagtactg ttttttctct caaacttggt ttcgaatctc ctgggagtga gggagaaaca 1560
gggagctgaa tctccccca agctgttcca ggccagagga ctctgcagta gcttctccta 1620
catctagtaa caaagaatgg tgataacat gactgggttc aaggttctgg agttctccat 1680
gaaacttggg ttaattttgc tcagagtatc cagagttagc cactaggctg cgggtgaaat 1740
gggatggaga agaacaacag caggcttctc ggagccacat gggctgacta gggcactctg 1800
tggtggcat ggcattgggt cagcccagga agaggagaaa cgatcccttg cctgccctc 1860
cctgtggcag ggctaactgc ctggccctcc tggctgcag ccagccagcc ccctggcagc 1920
aggttctctc cagggcttgg gtcttcaacc tgtggcgaca ggaggcaggg cagactgtgg 1980
aggacaggat gcaggtcagg gagaggggaag gcaggggtgg accgccatga gcatgaaaag 2040
acccgaagca agttgactct tgcaatgtgc aactgttatg ttctgcaaaa tgagcaacga 2100
tgtatcaaat tgatgcaaat ttagatgttg atacttacaa taagttttt aatgtgtttt 2160
aaaaaaaaa aaaaaaaaaa aaaa
2184

```

<210> 30
 <211> 344
 <212> PRT
 <213> Homo sapiens

<400> 30
 Met Phe Thr Ser Thr Gly Ser Ser Gly Leu Tyr Lys Ala Pro Leu Ser
 1 5 10 15
 Lys Ser Leu Leu Leu Val Pro Ser Ala Leu Ser Leu Leu Leu Ala Leu
 20 25 30
 Leu Leu Pro His Cys Gln Lys Leu Phe Val Tyr Asp Leu His Ala Val
 35 40 45
 Lys Asn Asp Phe Gln Ile Trp Arg Leu Ile Cys Gly Arg Ile Ile Cys
 50 55 60
 Leu Asp Leu Lys Asp Thr Phe Cys Ser Ser Leu Leu Ile Tyr Asn Phe
 65 70 75 80
 Arg Ile Phe Glu Arg Arg Tyr Gly Ser Arg Lys Phe Ala Ser Phe Leu
 85 90 95
 Leu Gly Ser Trp Val Leu Ser Ala Leu Phe Asp Phe Leu Leu Ile Glu
 100 105 110
 Ala Met Gln Tyr Phe Phe Gly Ile Thr Ala Ala Ser Asn Leu Pro Ser
 115 120 125
 Gly Phe Leu Ala Pro Val Phe Ala Leu Phe Val Pro Phe Tyr Cys Ser

```

gcatgttttc tagcgattgt gtgaatgagg gtgagctggc tgaggcatcg ctcaagctgg 900
gggggtggtgt gtaagaagca cgtggagcca caagaggcac ctccatagat cagctaaggg 960
cttccctttc tgcgccagc ttttgggtga aggggtgatt ctactagaca catctgtgct 1020
tcagtcatag atgttaatag aggaagcagt tttcctgctg cagattcctg aatagagttg 1080
ctgaaagagt ctacttctgg actcgggaag ttgaaggcca gtctgtgtag aaaggctgag 1140
gcaacgggga aagacctgac agctagttag atacgctctg acatagtact cccatgatgg 1200
cttccagtga cacatgtgct gatagaattc taaacctctg gaatttcctt gctggcgact 1260
tctatggccg ttgactgtac agggtaacct gatgccagat gctatgggag tgatgagaac 1320
tagagcattg cagcatggag gaaactgtga ggcaccagat cctgtgcttc tgcaggccat 1380
tttctgaaaa cccctgttag gaaggttga tttggcgtga cttgcttgag caagagtcct 1440
ggggagagat ttgagggtt aatttaacgg tatatccaga gctaacagtg actcaactcg 1500
tctagtcttg caagtcagat gtatacttag agtctctctg tgaagggtt gggctctgagc 1560
tgtatagtat gtcaaaactgc cagtaagcca gcccctcacc ctctgataga tattccttta 1620
atgcaccaga cttcatgttt gataaatgat taatggttga aattgtttct cttcttttgt 1680
gttttccag ttaatagatg gtcactgttt ccacaatgtt ttatacttct agctttttgt 1740
aacttaacta taattactta attttatatt tttaaagctt gttgtggtct aatgagaagt 1800
atttttcagt gcataatgtt tttctgagct tctgtaaatg ccattccaat gtggtttggt 1860
tttgttgaa acgaaacaaa ataaatttca aaatgttaaa aaaaaaaaaa aaaaaaaaaa 1920
aaaaaaaaaa aaaaaaaaaa aaaaaa 1945

```

<210> 28

<211> 87

<212> PRT

<213> Homo sapiens

<400> 28

```

Met Leu Ser Tyr Leu Leu Ser Met Val Thr Phe Leu Arg Thr Ser Arg
  1             5             10             15

```

```

Val Gln Phe Leu Leu Ala Glu Arg Phe Ser Phe Ser Met Pro Tyr Gly
          20             25             30

```

```

Cys Asp Ser Asn Glu Gly Ser His Ser Phe Ser Trp Leu Pro Leu Ala
          35             40             45

```

```

Val Thr Leu Tyr Met Leu Gly Phe Ala Leu Lys Glu Glu Ser Arg Lys
          50             55             60

```

```

Lys Gly Trp Phe Gln Lys Pro Arg Gly Ser Ala Val Asp Ala Tyr Ile
          65             70             75             80

```

```

Leu Ser Arg Ser Pro Gln Ser
          85

```

<210> 29

<211> 2184

<212> DNA

<213> Homo sapiens

<400> 29

```

ggggcgccctc tggggctccg agcccgggcg gaccatgttc accagcaccg gctccagtgg 60
gctctacaag gcgcctctgt cgaagagcct tctgctggtc cccagtggcc tctccctcct 120
gctcgccctc ctccctgcctc actgccagaa gctctttgtg tatgacctc acgcagtcac 180
gaacgacttc cagatttggg ggttgatatg ttgaagaata atttgccttg atttgaaaga 240
tactttttgc agtagctgac ttatttataa ttttaggata ttgaaagaa gatatggaag 300
cagaaaattt gcatcctttt tgcctgggttc ctgggttttg tcagccttat ttgactttct 360
cctcattgaa gctatgcagt atttcttttg catcactgca gctagtaatt tgccttcttg 420
attcctggca cctgtgtttg ctctgtttgt accattttac tgcctcctac caagagtcca 480
agtggcacia attctgggtc ccttggtccat cacaacaag acattgattt atatttggg 540

```

Leu Pro Leu Met Val Met Leu Ile Leu Tyr Ser Lys Ile Gly Tyr Glu
 225 230 235 240
 Leu Trp Ile Lys Lys Arg Val Gly Asp Gly Ser Val Leu Arg Thr Ile
 245 250 255
 His Gly Lys Glu Met Ser Lys Ile Ala Arg Lys Lys Lys Arg Ala Val
 260 265 270
 Ile Met Met Val Thr Val Val Ala Leu Phe Ala Val Cys Trp Ala Pro
 275 280 285
 Phe His Val Val His Met Met Ile Glu Tyr Ser Asn Phe Glu Lys Glu
 290 295 300
 Tyr Asp Asp Val Thr Ile Lys Met Ile Phe Ala Ile Val Gln Ile Ile
 305 310 315 320
 Gly Phe Ser Asn Ser Ile Cys Asn Pro Ile Val Tyr Ala Phe Met Asn
 325 330 335
 Glu Asn Phe Lys Lys Asn Val Leu Ser Ala Val Cys Tyr Cys Ile Val
 340 345 350
 Asn Lys Thr Phe Ser Pro Ala Gln Arg His Gly Asn Ser Gly Ile Thr
 355 360 365
 Met Met Arg Lys Lys Ala Lys Phe Ser Leu Arg Glu Asn Pro Val Glu
 370 375 380
 Glu Thr Lys Gly Glu Ala Phe Ser Asp Gly Asn Ile Glu Val Lys Leu
 385 390 395 400
 Cys Glu Gln Thr Glu Glu Lys Lys Lys Leu Lys Arg His Leu Ala Leu
 405 410 415
 Phe Arg Ser Glu Leu Ala Glu Asn Ser Pro Leu Asp Ser Gly His
 420 425 430

<210> 27

<211> 1945

<212> DNA

<213> Homo sapiens

<400> 27

atcatgccac tcatttcaga acttgagcaa aacagggcag tcaggatctg atgtctttct 60
 ggtctcccta agaaaactaa gctcttgagg gacagccctt ggcaatgctt tccatctctg 120
 tgagcatggt gaccttcctt aggacttcca gagttcagtt ccttctggca gagagggttt 180
 cttctccat gccatatgga tgtgactcaa atgaggggtc ccacagcttt tcttggtctac 240
 cacttgctgt gaccttatac atgttggggt ttgctcttaa agaggagagc aggaagaaag 300
 gttgggttca gaaaccaaga gggtcggcag tggacgcgta ctttttgtca cggagtccac 360
 agagctgagc ttttgagcag actctgagaa gtatcattgc ttgtgttgaa agaatacaac 420
 aggatttaag tttctcttta aaaattgcac tgaagaaagg ccggycgcgg tggctcccc 480
 tgtaatccca gcgctttggg aggccgaggc ggggggatca cgaggtaag agatcgagac 540
 catcctggcc aacatggtga aaccccgctt ctaataaaaa taaaaaatt agccgggcat 600
 ggtgacgtgc acctgtagtc ccagctacta gataggctga ggcaggagaa ttgcttgaat 660
 ccgggaggcg gaggttgagc tgagccgaga tcgtgccact gaactccaac ctgccaacag 720
 agcgagactc cgtctcaaaa aaaaaaaa aaanaaaaga aatagratg aagaaaatac 780
 cgcacatcag aggaagctt attttctgca tgggtcttt tcaagatag aatatttgaa 840


```

tgacacgagg ctagtccaag tgcagtgatg tttacaacca attgatcaca atcatttaac 1860
agattttctgt gttccttctc attcccactg cttcacttga ctagccttaa aaaagcaaca 1920
tggaaggcca ggcacgggtgg ctcatgcctg taatcccagc actttgggag gcctagacgg 1980
gcggatcacg aggtcaggag atcaaaacca tcctggctaa cacggtgaaa ccccatctct 2040
gctaaaaata caaaaattag cggggcgtgg tggcgggcac ctgtagtccc agctacttgg 2100
gagcctcagg cgggagaatg gtgtgaaccc gggaggcggg gcttgcagtg atccgagatc 2160
atgccactgc actccagcct gggcgaaaga gcgagactcc ccgtctcaaa aaaaattttt 2220
ttgaaaaatt cgtaaaccat acttttaaga ttatttcagt ggatttttaa aaatcttgta 2280
cagaaatcag ggttcttagc tagcagtttt tctcccacgc agtcactgta atgtgactat 2340
gtattgctag attgaataag aaaataaaat aatatcttct tccttgaaaa aaaaaaaaaa 2400
aaaaaaaaa a 2411

```

<210> 26
 <211> 431
 <212> PRT
 <213> Homo sapiens

```

<400> 26
Met Gln Ala Leu Asn Ile Thr Pro Glu Gln Phe Ser Arg Leu Leu Arg
  1             5             10             15

Asp His Asn Leu Thr Arg Glu Gln Phe Ile Ala Leu Tyr Arg Leu Arg
          20             25             30

Pro Leu Val Tyr Thr Pro Glu Leu Pro Gly Arg Ala Lys Leu Ala Leu
          35             40             45

Val Leu Thr Gly Val Leu Ile Phe Ala Leu Ala Leu Phe Gly Asn Ala
          50             55             60

Leu Val Phe Tyr Val Val Thr Arg Ser Lys Ala Met Arg Thr Val Thr
          65             70             75             80

Asn Ile Phe Ile Cys Ser Leu Ala Leu Ser Asp Leu Leu Ile Thr Phe
          85             90             95

Phe Cys Ile Pro Val Thr Met Leu Gln Asn Ile Ser Asp Asn Trp Leu
          100            105            110

Gly Gly Ala Phe Ile Cys Lys Met Val Pro Phe Val Gln Ser Thr Ala
          115            120            125

Val Val Thr Glu Ile Leu Thr Met Thr Cys Ile Ala Val Glu Arg His
          130            135            140

Gln Gly Leu Val His Pro Phe Lys Met Lys Trp Gln Tyr Thr Asn Arg
          145            150            155            160

Arg Ala Phe Thr Met Leu Gly Val Val Trp Leu Val Ala Val Ile Val
          165            170            175

Gly Ser Pro Met Trp His Val Gln Gln Leu Glu Ile Lys Tyr Asp Phe
          180            185            190

Leu Tyr Glu Lys Glu His Ile Cys Cys Leu Glu Glu Trp Thr Ser Pro
          195            200            205

Val His Gln Lys Ile Tyr Thr Thr Phe Ile Leu Val Ile Leu Phe Leu
          210            215            220

```

aaaaaaaaa aaaaaaaaaa

1219

<210> 24

<211> 78

<212> PRT

<213> Homo sapiens

<400> 24

Met Pro Phe Thr Leu Gly Asn Leu Arg Ala Ile Leu Gly Ser Asn Pro
 1 5 10 15

Thr Pro Leu Cys Ser Arg Pro His Leu Trp Leu Ser Leu Trp Ala Gln
 20 25 30

Pro Leu Gln Pro Ser Arg Ser Pro Thr Ala Ala Ser Cys Leu His Cys
 35 40 45

Arg Leu Arg Lys Leu Gln Leu Pro Asp Pro Glu Val Pro Leu Leu Pro
 50 55 60

Ser Val Gly Lys Ser Leu Lys Glu Leu Ala Ser Arg Phe Leu
 65 70 75

<210> 25

<211> 2411

<212> DNA

<213> Homo sapiens

<400> 25

ggccagaagg cggggagcca gaggcgccag gaccctagcg tggcgctcca gcaccccaaga 60
 ccgtggcggc gcctcgccctt aggggaagagc aagggaagaa ctttatttga accgcgaaca 120
 ttttttggtc actgagatcg agtctcccag tgctttggct tcccgccctt ttatcggtggg 180
 tttgatccct gagctgctct cctttcccca acctcccggg gtgcagccca gagccctccc 240
 gcgcggctga ctccagagta gaggaaggga ggccggcctcc ggcctggctcc ccgaagccct 300
 cgctgccccg cagatgcgga tggccagcca gtageggggc gtggccccgc gtcccgggag 360
 cgcacagcaa tgcaggcgct taacattacc ccggagcagt tctctcggt gctgcgggac 420
 cacaacctga cgcgggagca gttcatcgct ctgtaccggc tgcgaccgct cgtctacacc 480
 ccagagctgc cgggacgcgc caagctggcc ctctgtctca ccggcggtgt catcttcgcc 540
 ctggcgctct ttggcaatgc tctggtgttc tacgtgtgtga cccgcagcaa ggccatgcgc 600
 accgtcacca acatctttat ctgctccttg gcgctcagtg acctgtctat caccctcttc 660
 tgcattcccc tcaccatgct ccagaacatt tccgacaact ggctgggggg tgctttcatt 720
 tgcaagatgg tgccatttgt ccagcttacc gctgttgtga cagaaatcct cactatgacc 780
 tgcattgctg tggaaaggca ccagggaact gtgcatectt ttaaaatgaa gtggcaatac 840
 accaaccgaa gggctttcac aatgctaggt gtggtctggc tgggtggagt catcgtagga 900
 tcacccatgt ggcacgtgca acaacttgag atcaaatatg acttcctata tgaaaaggaa 960
 cacatctgct gcttagaaga gtggaccagc cctgtgcacc agaagatcta caccaccttc 1020
 atccttgtca tctcttctct cctgcctctt atggtgatgc ttattctgta cagtaaaatt 1080
 ggttatgaac tttggataaa gaaaagagtt ggggatggtt cagtgtctcg aactattcat 1140
 ggaaaagaaa tgtccaaaat agccaggaag aagaaacgag ctgtcattat gatggtgaca 1200
 gtggtggctc tctttgctgt gtgctgggca ccattccatg ttgtccatat gatgattgaa 1260
 tacagtaatt ttgaaaagga atatgatgat gtcacaatca agatgatttt tgctatcgtg 1320
 caaattattg gattttccaa ctccatctgt aatcccatgt tctatgcatt tatgaatgaa 1380
 aacttcaaaa aaaatgtttt gtctgcagtt tgttattgca tagtaataaa aacctctctt 1440
 ccagcacaaa ggcatggaaa ttcaggaatt acaatgatgc ggaagaaagc aaagttttcc 1500
 ctccagagaga atccagtgga ggaacccaaa ggagaagcat tcagtgatgg caacattgaa 1560
 gtcaaatgtg gtgaacagac agaggagaag aaaaagctca aacgacatct tgctctcttt 1620
 aggtctgaac tggctgagaa ttctccttta gacagtgggc attaattata acaatatctt 1680
 cataattaat gcccttcaga ttgtaacca aagagaaaat tattttgagc aaaggtcaaa 1740
 tactcttttt attcttaaga tgatgaca g aagaaaacaa atcatgtttc cattaaaaaa 1800

His Gln Ser Leu Glu Asp Asp Ala Gln Pro Ala Asp Ser Gly Glu Lys
 290 295 300
 Lys Lys Ser Phe Ser Thr Phe Gly Lys Asp Ser Pro Asn Asp Glu Asp
 305 310 315 320
 Thr Gly Asp Thr Ser Thr Ser Ser Leu Leu Ser Glu Met Ser Ser Val
 325 330 335
 Phe Gln Arg Leu Leu Pro Pro Ser Leu Asp Thr Tyr Ser Glu Cys Ser
 340 345 350
 Glu Val Asp Arg Ser Asn Ser Leu Glu Arg Arg Lys Gly Pro Leu Pro
 355 360 365
 Ala Lys Thr Val Gly Tyr Pro Gln Gly Val Ala Ala Trp Ala Ala Ser
 370 375 380
 Thr His Phe Gln Asn Pro Thr Thr Asn Cys Gly Pro Pro Leu Gly Thr
 385 390 395 400
 His Ser Ser Val Gln Pro Ser Ser Lys Trp Leu Pro Ala Met Glu Glu
 405 410 415
 Ile Pro Glu Asn Tyr Glu Glu Asp Asp Phe Asp Asn Val Leu Asn His
 420 425 430
 Leu Asn Asp Gly Lys His Glu Leu Met Asp Ala Ser Glu Leu Val Ala
 435 440 445
 Glu Ile Asn Lys Leu Leu Gln Asp Val Arg Gln Ser
 450 455 460

<210> 23

<211> 1219

<212> DNA

<213> Homo sapiens

<400> 23

gtggccattc ctcggtacag actagtcctg gtccttgggt gtgggcagtg ggggaggaac 60
 caactggctg aggtttcaga gccaaacctt gcctttgggt ggtgagtcct tgccccccag 120
 gcttgcgctc cagcatgccc ttcacccttg gcaatctcag ggccatcctg ggtagtaacc 180
 ccactcctct ctgctcccg cgcacactgt ggctctcact ctgggctcaa cccctgcaac 240
 cctccaggag ccgacagca gccagctgcc tgcactgtcg cctccgtaag ctccaacttc 300
 cagaccaga agtccctctg ctccctctcg ttggaaaaag cctaaaagaa ttagcttcca 360
 gattcctcta gcccctgctc cattcccacc cagtccttct gaagaggaat gagcaatata 420
 tctgagctgg atttctctct agtcccttct ccagacaaat ccttctttaa gcaaaagtcc 480
 tggctgagca cctgtccttg gggaccgac tgccgtgtga ccagggaag aaagtctccg 540
 aaagcctgtt ccaccaattc tgcctctgtg ttgtgaatcc agtctgcttt ccattagaaa 600
 accgcttcgg cacttatggt cactttaata aatctagtat gtaaaaaaag aaagaagaa 660
 aagaaacaga aaaacytgca ggcaaatgta aaatacaatg ctctctgtaa gataaatatt 720
 tgcctttttt tctaaaaggt gtacgtattc tgtatgtgaa attgtctgta gaaagtttct 780
 atgttcttaa atggcaatuc attccaaaaa ttgtactgta gatatgtata gcaaccgcac 840
 tgggatgggg tagttttgac tgtaatttta tttaaactcc agtttccaca cttgcattct 900
 gcaatgttgg tatggtatat atcagtgcaa angaaaaaac aaaacaaaaa caaaaaaaa 960
 aacaaaaaat cagcgaggtc taaagcacag agtctgacgt acaaaaggaa aaatgctcag 1020
 tattgaagtg tgtgaccttt gttgtaaaatt acatctgtac tgtgaatgag aagtttttac 1080
 aagtataata attgcttcta ttacagctct ggctgagctg tcagcctgag gatatttttt 1140
 aaaaaaaaaa gaattagcat gttggaataa atttgaaaat cccaaaaaaa aaaaaaaaaa 1200

<210> 22

<211> 460

<212> PRT

<213> Homo sapiens

<400> 22

```

Met Ile Phe Glu Tyr Ala Glu Ser Val Thr Ser Thr Ala Met Thr Ser
 1              5              10              15

Val Ser Gln Ala Ser Leu Asp Val Ser Met Ile Ile Ile Ile Ser Leu
          20              25              30

Gly Ala Ile Cys Ala Val Leu Leu Val Ile Met Val Leu Phe Ala Thr
          35              40              45

Arg Cys Asn Arg Glu Lys Lys Asp Thr Arg Ser Tyr Asn Cys Arg Val
          50              55              60

Ala Glu Ser Thr Tyr Gln His His Pro Lys Arg Pro Ser Arg Gln Ile
          65              70              75              80

His Lys Gly Asp Ile Thr Leu Val Pro Thr Ile Asn Gly Thr Leu Pro
          85              90              95

Ile Arg Ser His His Arg Ser Ser Pro Ser Ser Ser Pro Thr Leu Glu
          100             105             110

Arg Gly Gln Met Gly Ser Arg Gln Ser His Asn Ser His Gln Ser Leu
          115             120             125

Asn Ser Leu Val Thr Ile Ser Ser Asn His Val Pro Glu Asn Phe Ser
          130             135             140

Leu Glu Leu Thr His Ala Thr Pro Ala Val Glu Val Ser Gln Leu Leu
          145             150             155             160

Ser Met Leu His Gln Gly Gln Tyr Gln Pro Arg Pro Ser Phe Arg Gly
          165             170             175

Asn Lys Tyr Ser Arg Ser Tyr Arg Tyr Ala Leu Gln Asp Met Asp Lys
          180             185             190

Phe Ser Leu Lys Asp Ser Gly Arg Gly Asp Ser Glu Ala Gly Asp Ser
          195             200             205

Asp Tyr Asp Leu Gly Arg Asp Ser Pro Ile Asp Arg Leu Leu Gly Glu
          210             215             220

Gly Phe Ser Asp Leu Phe Leu Thr Asp Gly Arg Ile Pro Ala Ala Met
          225             230             235             240

Arg Leu Cys Thr Glu Glu Cys Arg Val Leu Gly His Ser Asp Gln Cys
          245             250             255

Trp Met Pro Pro Leu Pro Ser Pro Ser Ser Asp Tyr Arg Ser Asn Met
          260             265             270

Phe Ile Pro Gly Glu Glu Phe Pro Thr Gln Pro Gln Gln Gln His Pro
          275             280             285

```

980

985

990

Gln Arg Cys Phe Pro Asn Ser
995

<210> 21

<211> 2820

<212> DNA

<213> Homo sapiens

<400> 21

```
agaatgggag ctgtcagtta tcattcagga caaaggcaat cctcagctac ataccaaagt 60
ccttctgaag tgcattgatct ttgaatatgc agagtcgggtg acaagtacag caatgacttc 120
agtaagccag gcatccttgg atgtctccat gataataatt atttcccttag gagcaatttg 180
tgcatgtgtg ctgggttatta tgggtctatt tgcaactagg tgtaaccgag agaagaaaga 240
cactagatcc tataactgca ggggtggcga atcaacttac cagcaccacc caaaaaggcc 300
atcccgccag attcacaag gggacatcac attggtgcct accataaatg gcactctgcc 360
catcagatct catcacagat cgtctccatc ttcatctcct accttagaaa gagggcagat 420
gggacgcccag cagagtcaca acagtcacca gtcactcaac agtttgggtga caatctcatc 480
aaaccacgtg ccagagaatt tctcattaga actcaccac gccactcctg ctggtgaggt 540
ctctcagctt ctttcaatgc ttcaccagg gcaatatcag ccaagaccaa gttttcgagg 600
aaacaaatat tccaggagct acagatatgc ctttcaagac atggacaaat ttagcttgaa 660
agacagtggc cgtgggtgaca gtgaggcagg agacagtgat tatgatttgg ggcgagattc 720
tccaatagat aggtctgttg gtgaaggatt cagcgacctg tttctcacag atggaagaat 780
tccagcagct atgagactct gcacggagga gtgcagggtc ctgggacact ctgaccagt 840
ctggatgcca ccaactgccc caccgtcttc tgattatagg agtaacatgt tcattccagg 900
ggaagaattc ccaacgcaac ccagcagca gcatccacat cagagctctg aggatgacgc 960
tcagcctgca gattccgggtg aaaagaagaa gagtttttcc accttggaa aggactcccc 1020
aaacgatgag gacactgggg ataccagcac atcatctctg ctctcgaaa tgagcaggt 1080
gttccagcgt ctcttaccgc ctctccctgga cactattctt gaatgcagtg aggtggatcg 1140
gtccaaactcc ctggagcgca ggaagggacc cttgccagcc aaaactgtgg gttaccaca 1200
ggggtgtagc gcatgggcag ccagtcagca ttttcaaaat cccacacca actgtgggcc 1260
gccacttgga actcactcca gtgtgcagcc ttttcaaaa tggctgccag ccattggagga 1320
gatccctgaa aattatgagg aagatgattt tgacaatgtg ctcaaccacc tcaatgatgg 1380
gaaacacgaa ctcatggatg ccagtgaact ggtggcagag attaacaaac tgcttcaaga 1440
tgtccgccag agctaggaga ttttagcgaa gcatttttct tccatgtat atggaatatag 1500
ggaacaacaa caacaacaaa aaacctgaa agaactggca ttgccaaata gttgcattta 1560
tcataaatgt gtctgtgtat attgaatatt aaatactgta tttctgtatg tacacaatgc 1620
aagtgatgatt attttaattc gtatttttaa aatacatttg tactttatat ttatgtgtaa 1680
tttaacaaac aaattttatt tttttactcc catgacagac atgtttttcc tagtcgtgta 1740
gaaactagcc actgttcaaa tctgatacac tattcaacca caaagtgtaa aggcactgct 1800
tagattagtt ttgttgggga agaattatta tgtgtatga acaacccccc tgaagcatta 1860
tacaattctt aattccatta agtgatccca ctttttttca ataacttttt agaaattaag 1920
aatcattaaa attgttaagc tattttattg ttattttctc tactttctac tagcccaat 1980
agttgaactc ttataggaaa atcgaaagat aaagtgaag tttatttcag gactgagaaa 2040
tatcttgaag gttatttatt agatgactat ctcaaatgaa ctttttatag acaatgatga 2100
aaacagaatt aaagtcaatg tttcctgact cccaggcccc tactattcca ggccatcaca 2160
ctggcctggt ccggagaata tttctctcac aatattatta tctacttata attatggtaa 2220
acaataaatt ttattccatc cttgtagtat gaaacatgct ccaaggaaat ggaatctgtc 2280
ctttaaatgg ataacagtat gtgttcta atggcataaaat attactggat aaaaacagtt 2340
gtgtcagtg ctctcctaag gtagttaata taattgactt attctgaacc cattctatct 2400
tgaatctccc ctttctcttc acaatactg aacattttaa tcttttgaa tattgtcttt 2460
ctttgttata actattcatt tttagctttt gtctccagt catgatctca tatttttgc 2520
tttattttta gtataagaac atttataaaa tcataatttt gttactgcaa ttgttttatt 2580
tgttgtgtgg caaatgagaa atcctttatt tattgtgctg tgatctctct gtgtggaatg 2640
ccttgggtgag agagatgctt attatgacta ttatcatttc tgaccaagct tctattaatg 2700
ttattttctaa taatacacta tcttgattgt actctccaga aaatttttct gtcagtgaag 2760
ataaaagaa aattaaagta aagctcagga accttcaaaa aaaaaaaaaa aaaaaaaaz 2820
```

660										665										670										
Pro	Ala	Asp	Gly	Ser	Gly	Ser	Cys	Asp	Thr	Asp	Ala	Leu	Val	Glu	Asp															
		675						680						685																
Leu	Leu	Arg	Ser	Gly	Ser	Thr	Ser	Pro	His	Thr	Val	Ser	Gly	Gly	Trp															
		690				695							700																	
Ala	Ala	Trp	Gly	Pro	Trp	Ser	Ser	Cys	Ser	Arg	Asp	Cys	Glu	Leu	Gly															
		705			710					715					720															
Phe	Arg	Val	Arg	Lys	Arg	Thr	Cys	Thr	Asn	Pro	Glu	Pro	Arg	Asn	Gly															
				725					730					735																
Gly	Leu	Pro	Cys	Val	Gly	Asp	Ala	Ala	Glu	Tyr	Gln	Asp	Cys	Asn	Pro															
			740					745					750																	
Gln	Ala	Cys	Pro	Val	Arg	Gly	Ala	Trp	Ser	Cys	Trp	Thr	Ser	Trp	Ser															
		755					760						765																	
Pro	Cys	Ser	Ala	Ser	Cys	Gly	Gly	Gly	His	Tyr	Gln	Arg	Thr	Arg	Ser															
		770				775						780																		
Cys	Thr	Ser	Pro	Ala	Pro	Ser	Pro	Gly	Glu	Asp	Ile	Cys	Leu	Gly	Leu															
		785			790					795					800															
His	Thr	Glu	Glu	Ala	Leu	Cys	Ala	Thr	Gln	Ala	Cys	Pro	Glu	Gly	Trp															
				805					810					815																
Ser	Pro	Trp	Ser	Glu	Trp	Ser	Lys	Cys	Thr	Asp	Asp	Gly	Ala	Gln	Ser															
			820					825					830																	
Arg	Ser	Arg	His	Cys	Glu	Glu	Leu	Leu	Pro	Gly	Ser	Ser	Ala	Cys	Ala															
			835				840						845																	
Gly	Asn	Ser	Ser	Gln	Ser	Arg	Pro	Cys	Pro	Tyr	Ser	Glu	Ile	Pro	Val															
		850				855						860																		
Ile	Leu	Pro	Ala	Ser	Ser	Met	Glu	Glu	Ala	Thr	Gly	Cys	Ala	Gly	Phe															
		865			870					875				880																
Asn	Leu	Ile	His	Leu	Val	Ala	Thr	Gly	Ile	Ser	Cys	Phe	Leu	Gly	Ser															
			885					890					895																	
Gly	Leu	Leu	Thr	Leu	Ala	Val	Tyr	Leu	Ser	Cys	Gln	His	Cys	Gln	Arg															
			900					905					910																	
Gln	Ser	Gln	Glu	Ser	Thr	Leu	Val	His	Pro	Ala	Thr	Pro	Asn	His	Leu															
		915					920						925																	
His	Tyr	Lys	Gly	Gly	Gly	Thr	Pro	Lys	Asn	Glu	Lys	Tyr	Thr	Pro	Met															
		930				935						940																		
Glu	Phe	Lys	Thr	Leu	Asn	Lys	Asn	Asn	Leu	Ile	Pro	Asp	Asp	Arg	Ala															
		945			950				955					960																
Asn	Phe	Tyr	Pro	Leu	Gln	Gln	Thr	Asn	Val	Tyr	Thr	Thr	Thr	Tyr	Tyr															
			965					970					975																	
Pro	Ser	Pro	Leu	Asn	Lys	His	Ser	Phe	Arg	Pro	Glu	Ala	Ser	Pro	Gly															

340	345	350
Ala Ser Arg Ser Leu His Gly Cys Tyr Leu Glu Glu Leu His Val Leu		
355	360	365
Pro Pro Gly Arg Arg Glu Pro Leu Arg Ser Leu Arg Ile Leu His Ser		
370	375	380
Ala Arg Ala Leu Phe Val Gly Leu Arg Asp Gly Val Leu Arg Val Pro		
385	390	395
Leu Glu Arg Cys Ala Ala Tyr Arg Ser Gln Gly Ala Cys Leu Gly Ala		
	405	410
Arg Asp Pro Tyr Cys Gly Trp Asp Gly Lys Gln Gln Arg Cys Ser Thr		
	420	425
Leu Glu Asp Ser Ser Asn Met Ser Leu Trp Thr Gln Asn Ile Thr Ala		
	435	440
Cys Pro Val Arg Asn Val Thr Arg Asp Gly Gly Phe Gly Pro Trp Ser		
	450	455
Pro Trp Gln Pro Cys Glu His Leu Asp Gly Asp Asn Ser Gly Ser Cys		
465	470	475
Leu Cys Arg Ala Arg Ser Cys Asp Ser Pro Arg Pro Arg Cys Gly Gly		
	485	490
Leu Asp Cys Leu Gly Pro Ala Ile His Ile Ala Asn Cys Ser Arg Asn		
	500	505
Gly Ala Trp Thr Pro Trp Ser Ser Trp Ala Leu Cys Ser Thr Ser Cys		
	515	520
Gly Ile Gly Phe Gln Val Arg Gln Arg Ser Cys Ser Asn Pro Ala Pro		
	530	535
Arg His Gly Gly Arg Ile Cys Val Gly Lys Ser Arg Glu Glu Arg Phe		
545	550	555
Cys Asn Glu Asn Thr Pro Cys Pro Val Pro Ile Phe Trp Ala Ser Trp		
	565	570
Gly Ser Trp Ser Lys Cys Ser Ser Asn Cys Gly Gly Gly Met Gln Ser		
	580	585
Arg Arg Arg Ala Cys Glu Asn Gly Asn Ser Cys Leu Gly Cys Gly Val		
	595	600
Glu Phe Lys Thr Cys Asn Pro Glu Gly Cys Pro Glu Val Arg Arg Asn		
	610	615
Thr Pro Trp Thr Pro Trp Leu Pro Val Asn Val Thr Gln Gly Gly Ala		
625	630	635
Arg Gln Glu Gln Arg Phe Arg Phe Thr Cys Arg Ala Pro Leu Ala Asp		
	645	650
Pro His Gly Leu Gln Phe Gly Arg Arg Arg Thr Glu Thr Arg Thr Cys		

20	25	30
Tyr Val Arg Val Leu Ile Val Ala Gly Arg Lys Val Phe Met Cys Gly		
35	40	45
Thr Asn Ala Phe Ser Pro Met Cys Thr Ser Arg Gln Val Gly Asn Leu		
50	55	60
Ser Arg Thr Ile Glu Lys Ile Asn Gly Val Ala Arg Cys Pro Tyr Asp		
65	70	75
80		
Pro Arg His Asn Ser Thr Ala Val Ile Ser Ser Gln Gly Glu Leu Tyr		
85	90	95
Ala Ala Thr Val Ile Asp Phe Ser Gly Arg Asp Pro Ala Ile Tyr Arg		
100	105	110
Ser Leu Gly Ser Gly Pro Pro Leu Arg Thr Ala Gln Tyr Asn Ser Lys		
115	120	125
Trp Leu Asn Glu Pro Asn Phe Val Ala Ala Tyr Asp Ile Gly Leu Phe		
130	135	140
Ala Tyr Phe Phe Leu Arg Glu Asn Ala Val Glu His Asp Cys Gly Arg		
145	150	155
160		
Thr Val Tyr Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly Gly		
165	170	175
Arg Phe Leu Leu Glu Asp Thr Trp Thr Thr Phe Met Lys Ala Arg Leu		
180	185	190
Asn Cys Ser Arg Pro Gly Glu Val Pro Phe Tyr Tyr Asn Glu Leu Gln		
195	200	205
Ser Ala Phe His Leu Pro Glu Gln Asp Leu Ile Tyr Gly Val Phe Thr		
210	215	220
Thr Asn Val Asn Ser Ile Ala Ala Ser Ala Val Cys Ala Phe Asn Leu		
225	230	235
240		
Ser Ala Ile Ser Gln Ala Phe Asn Gly Pro Phe Arg Tyr Gln Glu Asn		
245	250	255
Pro Arg Ala Ala Trp Leu Pro Ile Ala Asn Pro Ile Pro Asn Phe Gln		
260	265	270
Cys Gly Thr Leu Pro Glu Thr Gly Pro Asn Glu Asn Leu Thr Glu Arg		
275	280	285
Ser Leu Gln Asp Ala Gln Arg Leu Phe Leu Met Ser Glu Ala Val Gln		
290	295	300
Pro Val Thr Pro Glu Pro Cys Val Thr Gln Asp Ser Val Arg Phe Ser		
305	310	315
320		
His Leu Val Val Asp Leu Val Gln Ala Lys Asp Thr Leu Tyr His Val		
325	330	335
Leu Tyr Ile Gly Thr Glu Ser Gly Thr Ile Leu Lys Ala Leu Ser Thr		


```

aggagctgca cgtgctgccc cccggggcgcc gcgagcccct gcgcagcctg cgcattcctgc 1320
acagcgcccg cgcgctcttc gtggggctga gagacggcgt cctgcgggtc ccactggaga 1380
ggtgcgccgc ctaccgcagc cagggggcat gcctgggggc cggggaccgg tactgtggct 1440
gggacgggaa gcagcaacgt tgcagcacac tcgaggacag ctccaacatg agcctctgga 1500
cccagaacat caccgcctgt cctgtgcgga atgtgacacg ggatgggggc ttcggcccat 1560
ggtcaccatg gcaaccatgt gagcacttgg atggggacaa ctgaggtctt tgctgtgtgc 1620
gagctcgatc ctgtgattcc cctcgacccc gctgtggggg ccttgactgc ctggggccag 1680
ccatccacat cgccaactgc tccaggaatg gggcgtggac cccgtggtca tcgtggggcg 1740
tgtgcagcac gtctgtggc atcggcttcc aggtccgcca gcgaagtgc agcaaccctg 1800
ctccccgcca cgggggcccg atctgcgtgg gcaagagccg ggaggaacgg ttctgtaatg 1860
agaacacgcc ttgcccggtg cccatcttct gggcttctct gggctcctgg agcaagtgca 1920
gcagcaactg tggagggggc atgcagtgcg ggcgtcgggc ctgcgagaa gcgaactcct 1980
gcctgggctg cggcgtggag ttcaagacgt gcaaccccgga gggctgcccc gaagtgcggc 2040
gcaacacccc ctggacgccc tggctgcccc tgaacgtgac gcagggcggg gcacggcagg 2100
agcagcggtt ccgcttcacc tgccgcgcgc ccttgcaga cccgcacggc ctgcagttcg 2160
gcaggagaag gaccgagacg aggacctgtc ccgcggacgy ctccggtctc tgcgacaccg 2220
acgcccgtgt ggaggacctc atgcgcagcg ggagcacctc cccgcacacg gtgagcgggg 2280
gctggggccc ctggggcccc tggctgcctc gctcccggga ctgcgagctg ggtctcccg 2340
tccgcaagag aacgtgact aaccgggagc cccgcaacgg gggcctgccc tgctgtggcg 2400
atgctgccga gtaccaggac tgcaaccccc aggcttgcgc agttcggggg gcttgggtct 2460
gctggacctc atggtctcca tgctcagctt cctgtggtgg gggctcattat caacgcaccc 2520
gttctctcac cagccccgca cctccccag gtgaggacat ctgtctcggg ctgcacacgg 2580
aggaggcact atgtgccaca caggcctgcc cagaaggctg gtcgacctgg tctgagtgga 2640
gtaagtgcac tgacgacgga gcccagagcg gaagccggca ctgtgaggag ctctcccgag 2700
ggtccagcgc ctgtgctgga aacagcagcc agagccgccc ctgccccctac agcgagattc 2760
ccgtcattct gccagcctcc agcatggagg agggcacccg ctgtgcaggg ttcaatctca 2820
tccacttggg ggccacgggc atctcctgct tcttgggctc tgggctcctg accctagcag 2880
tgtacctgtc ttgccagcac tgccagcgtc agtcccagga gtccacactg gtccatctcg 2940
ccacccccaa ccatttgcac tacaagggcg gaggcacccc gaugaatgaa aagtacacac 3000
ccatggaatt caagaccctg aacaagaata acttgatccc tgatgacaga gccaaactct 3060
acccattgca gcagaccaat gtgtacacga ctacttacta cccaagcccc ctgaacaaac 3120
acagcttccg gcccagggcc tcacctggac aacggtgctt ccccaacagc tgataccgcc 3180
gtcctgggga cttgggcttc ttgccttcat aaggcacaga gcagatggag atgggacagt 3240
ggagccagtt tggttttctc cctctgcact aggccaaagaa cttgctgcct tgccctgtgg 3300
gggtcccatc cggttccaga gagctctggc tggcattgac catgggggaa agggctggtt 3360
tcaggctgac atatggccgc aggtccagtt cagcccaggt ctctcatggt tatcttccaa 3420
cccactgtca cgctgacact atgctgccat gcctgggctg tggacctact gggcatttga 3480
ggaattggag aatggagatg gcaagagggc aggcctttaa gtttgggttg gagacaactt 3540
cctgtggccc ccacaagctg agtctggcct tctccagctg gccccaaaaa aggcctttgc 3600
tacatcctga ttatctctga aagtaatcaa tcaagtggct ccagtagctc tggattttct 3660
gccagggctg ggccattgtg gtgctgcccc agtatgacat gggaccaagg ccagcgcagg 3720
ttatccacct ctgcctggaa gtctatactc taccagggc atccctctgg tcagaggcag 3780
tgagtactgg gaactggagg ctgacctgtg cttagaagtc cttaactctg ggctggtaca 3840
ggcctcagcc ttgcccctca tgacgaaaag gtggcccagg agagaggatc aatgccatag 3900
gaggcagaag tctggcctct gtgcctctat ggagactatc ttccagttgc tgctcaacag 3960
agtgtgtggc tgagacctgc ttgggagtct ctgctggccc ttcactctgt caggaacaca 4020
cacacacaca cactcacaca cgcacacaca atcacaattt gctacagcaa caaaaaagac 4080
attgggctgt ggcattatta attaaagatg atatccagtc aaaaaaaaaa aaaaaaaaaa 4140
aaaa 4144

```

<210> 20

<211> 999

<212> PRT

<213> Homo sapiens

<400> 20

Met Thr Gln Trp Cys Glu Arg Glu Ile Ser Ser Ile Ala Pro Gly Glu

1

5

10

15

Leu Cys Cys Leu Leu Leu Ser Phe Leu Pro Gln Glu Glu Cys Gln Asn

<400> 18

Met Glu Leu Pro Ala Val Asn Leu Lys Val Ile Leu Leu Gly His Trp
 1 5 10 15

Leu Leu Thr Thr Trp Gly Cys Ile Val Phe Ser Gly Ser Tyr Ala Trp
 20 25 30

Ala Asn Phe Thr Ile Leu Ala Leu Gly Val Trp Ala Val Ala Gln Arg
 35 40 45

Asp Ser Ile Asp Ala Ile Ser Met Phe Leu Gly Gly Leu Leu Ala Thr
 50 55 60

Ile Phe Leu Asp Ile Val His Ile Ser Ile Phe Tyr Pro Arg Val Ser
 65 70 75 80

Leu Thr Asp Thr Gly Arg Phe Gly Val Gly Met Ala Ile Leu Ser Leu
 85 90 95

Leu Leu Lys Pro Leu Ser Cys Cys Phe Val Tyr His Met Tyr Arg Glu
 100 105 110

Arg Gly Gly Phe Leu Gly Ser Ser Gln Asp Arg Ser Ala Tyr Gln Thr
 115 120 125

Ile Asp Ser Ala Glu Ala Pro Ala Asp Pro Phe Ala Val Pro Glu Gly
 130 135 140

Arg Ser Gln Asp Ala Arg Gly Tyr
 145 150

<210> 19

<211> 4144

<212> DNA

<213> Homo sapiens

<400> 19

ctccttgggc aggtgaggat aacagccctg tggcgagctg gtccctgagca tctgagtgag 60
 cagtgatgcg gagaaatgac cttggtggga ggggacgtcc acagacgtga cccggacgtc 120
 gggacaggtg gatctggggt caaggggagt gtttagaata cttgttggca tccatgacgc 180
 agtgggtgtg gcgtgagata tccagcatcg caccctggaga gctgtgctgt ctgctccttt 240
 ccttcctgcc tcaggaggag tgtcagaact acgtgcgagt cctgatcgtc gccggccgga 300
 aggtgttcat gtgtggaacc aatgcctttt ccccatgtg caccagcaga cagggtggga 360
 acctcagccg gactattgag aagatcaatg gtgtggcccg ctgcccctat gaccacgcc 420
 acaactccac agctgtcatc tctcccagg gggagctcta tgcagccacg gtcattcgact 480
 tctcaggtcg ggacctgcc atctaccgca gcctgggagc tgggccaccg cttcgactg 540
 cccaatataa ctccaagtgg cttaatgagc caaacttcgt ggcagcctat gatattgggc 600
 tgtttgata cttcttctcg cgggagaacy cagtggagca cgactgtgga cgcacctgt 660
 actctcgcgt ggcccgcgtg tgcaagaatg acgtgggggg ccgattcctg ctggaggaca 720
 catggaccac attcatgaag gcccggtcca actgctcccg cccgggagag gtccctctct 780
 actataacga gctgcagagt gccttccact tgcggagca ggaacctcgc tatggagtgt 840
 tcacaaccaa cgtaaacagc attggggtt ctgctgtctg cgccttcaac ctgagtgc 900
 tctccaggc tttcaatggc ccatttcgct accaggagaa ccccagggt gcctggctcc 960
 ccatagccaa ccccatcccc aatttccagt gtggcaccct gcctgagacc ggtcccaacg 1020
 agaacctgac ggagcgcagc ctgcaggacg cgcagcgcct cttcctgatg agcgaggccg 1080
 tgcagccggt gacaccgag ccctgtgtca cccaggacag cgtgcgcttc tcacacctcg 1140
 tgggtggacct ggtgcaggct aaagacacgc tctaccatgt actctacatt ggcaccagat 1200
 cgggcacccat cctgaaggcg ctgtccacgg cgagccgcag cctccacggc tgctacctgg 1260

Trp Cys Ala Gly Val Pro Ser Val Thr Ser Asp Asn Ser His Thr Leu
 195 200 205
 Ser Gln Val Pro Ser Pro Leu Trp Ile Met Pro Pro Asp Glu Tyr Cys
 210 215 220
 Leu Met Trp Val Thr Ala Asp Leu Val Ser Phe Thr Leu Ile Val Gly
 225 230 235 240
 Ile Phe Val Leu Gln Lys Trp Arg Leu Gly Gly Ile Arg Ser Tyr Asn
 245 250 255
 Pro Glu Gln Ile Met Leu Ser Ala Ala Val Arg Arg Thr Ser Arg Asp
 260 265 270
 Val Ser Ile Met Lys Glu Lys Leu Ile Phe Ser Glu Ile Ser Asp Gly
 275 280 285
 Val Glu Val Ser Asp Val Leu Ser Val Cys Ser Asp Asn Ser Tyr Asp
 290 295 300
 Thr Tyr Ala Asn Ser Thr Ala Thr Pro Val Gly Pro Arg Gly Gly Gly
 305 310 315 320
 Ser His Thr Lys Thr Leu Ile Glu Arg Ser Gly Arg
 325 330

<210> 17
 <211> 1170
 <212> DNA
 <213> Homo sapiens

<400> 17
 aagtttgttc ccgagtttc gagcctagga gccccgcgc gctgcggcgc aggtgccctc 60
 ggcctgagtc gggatggagc tgcctgctgt gaacctgaag gtgattctcc taggtcactg 120
 gctgctgaca acctggggct gcattgtatt ctcaggctcc tatgcctggg ccaacttcac 180
 catcctggcc ttgggcgtgt gggctgtggc tcagcgggac tccatcgacg ccataagcat 240
 gtttctgggt ggcttgettg ccaccatctt cctggacatc gtgcacatca gcatcttcta 300
 cccgcgggtc agcctcacgg acacgggccc ctttggcgtg ggcattggcca tcttcagctt 360
 gctgctcaag ccgctctcct gctgcttctt ctaccacatg taccgggagc gcgggggttt 420
 ccttgggtct tctcaggacc gtagtgccta ccagacgatt gactcagcag aggcgcccgc 480
 agatcccttt gcagtcccag agggcaggag tcaagatgcc cgagggtact gaagccagcc 540
 acgtgcgcc cggccctgcc cggggccttc ctcgtgccg ggaggttgtt ctagggatgc 600
 tcttgacctc cgtctcttgg acctaaagatg gaatgtgtcc ccagctcagg gattgcctga 660
 accaagaggg caggagcccc catgggcgcg ccagtaccat gcacactcct gtcccgaact 720
 ccctgaggcc tccccctcct tcagggcacc cactgggttc caggctggaa ccagggtctc 780
 tctttacctc ctaccccatg gtggcaccac agaggccctc agccgagtc tgcctgagtg 840
 ttgcaagctc aggcctttta ggactgctga tgcctcccca ggcctccccc aagtttgctg 900
 ggctttgggt gaagccctga gagcttcagg tctgtctcag cccgaggagc agtctgacat 960
 gggagtggag ccctgtcctt ctactgcct ggtcacatgg tgcctaggga tgcagggtctg 1020
 gaggccagag gtgtcagcaa cactgtgacc caccacaacc tccagcctcc cttttcagag 1080
 cacagcatta aagtttgggg aattctgtaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1140
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1170

<210> 18
 <211> 152
 <212> PRT
 <213> Homo sapiens

```

caacagttat gacacatatg ccaacagcac cgccaccctt gtgggcccc gagggggtgg 1020
cagccacacc aagaccctca tagagcggag tgggcgttag ctgaagacat gtctgtccca 1080
cctgtacctg acacagaagc tggggagcct aggagagctg gtggaagtgt gtctgaactc 1140
ggagtgtctt gggagcgggc tccacagcct ccttgtgggc tccagccctt tgtcagccgc 1200
agcctctctt gagggggact ccctgtcccc tgaggcccgag ctgggccagg actccatcct 1260
ttcagatgcc cctgcaggcc tggggctcct tctgggaagt atggggccta gggcttggtc 1320
cccctcttct gagggcctct cctgtatccc gacctggaag ctttgatggg tcatgggcca 1380
tgccataccc cctgtggcaa tggagtgtgt ggatgtcac ctgtgccatc tgtcctcctg 1440
tctgtgccag gaggcacctg agttctctgc tgttatcctg ccccaagggc ctgggccgag 1500
cctctacctg aagcaactct gctcttctg tcagtctcaa agcacaagga gggtcagccc 1560
aggaggaagc cagctgcaat gtggagacac gtcctcctcc ccaaccacc tcatgccacc 1620
gccaaccccc tgccccagga gcgggcctga gccacgtccc ctaggagcag ctgggagatg 1680
ccaaaagagt gagctcaagg actactggga tcccaatgcc agtgtccagc agacctcaag 1740
gcagaagggc cacctaacc aggagtccac agactgatgt gacctcaggt tcccatca 1800
gtggccacag ggcagggccc acctggtaga agtgttctgg atatggccag ggtgggtgtg 1860
tggctaagtg ggcctgaaca gagggaacct agggcccttg gcccaatgtg attaaaggct 1920
gcatcttga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980
aaaaaaaaa aaaaaaaaaa

```

2000

<210> 16

<211> 332

<212> PRT

<213> Homo sapiens

<400> 16

```

Met His Asp Thr Thr Leu Arg Arg Thr Thr Asn Val Glu Glu Glu Phe
  1                      5                      10                      15

```

```

Pro Glu Leu Ala Arg Arg Pro Ala Ser Met Leu Asn Trp Thr Thr Leu
                20                      25                      30

```

```

Gln Arg Leu Asn Ala Gly Gln Trp Phe Leu Lys Thr Asp Pro Phe Trp
  35                      40                      45

```

```

Thr Ala Ser Ser Leu Ser Pro Ser Asp His Arg Glu Ala Gln Asn Gln
  50                      55                      60

```

```

Ser Ile Cys Ser Leu Ala Glu Leu Leu Glu Leu Ala Lys Gly Asn Ala
  65                      70                      75                      80

```

```

Thr Leu Leu Leu Asn Leu Arg Asp Pro Pro Arg Glu His Pro Tyr Arg
                85                      90                      95

```

```

Ser Ser Phe Ile Asn Val Thr Leu Glu Ala Val Leu His Ser Gly Phe
  100                      105                      110

```

```

Pro Gln His Gln Val Met Trp Leu Pro Ser Arg Gln Arg Pro Leu Val
  115                      120                      125

```

```

Arg Lys Val Ala Pro Gly Phe Gln Gln Thr Ser Gly Ser Lys Glu Ala
  130                      135                      140

```

```

Val Ala Ser Leu Arg Arg Gly His Ile Gln Arg Leu Asn Leu Arg Tyr
  145                      150                      155                      160

```

```

Thr Gln Val Ser Arg Gln Glu Leu Arg Asp Tyr Ala Ser Trp Asn Leu
                165                      170                      175

```

```

Ser Val Asn Leu Tyr Thr Val Asn Ala Pro Trp Leu Phe Ser Leu Leu
  180                      185                      190

```

<212> PRT

<213> Homo sapiens

<400> 14

Met Ile Val Val Ser Leu Ser Ala Ala Ala Val Ala Ala Ala Phe Met
 1 5 10 15

Ala Lys Cys Arg Met Val Leu Ser Ser Arg Tyr Phe Cys Ser His Phe
 20 25 30

Val Met Ser Ala Ser Arg Ala Arg Ile Arg Ser Ser Phe Ser Arg Thr
 35 40 45

Ser Ser Arg Arg Ala Gly Ala Leu Tyr Ser Gly Met Leu Ala Gly Trp
 50 55 60

Pro Phe Pro Cys Phe Cys Trp Val Leu Ser Ala Ser Ser Ser Leu Ser
 65 70 75 80

Ser Gln Val Arg Ser Leu Arg Ser Ile Cys Ser Arg Phe Ser His Ala
 85 90 95

Asp Cys Ser Trp Val Arg Ala Cys Cys Ser Phe Ser Thr Phe Ser Thr
 100 105 110

Tyr Ala Cys Phe Ser Arg Asn Ser Ser Ser Ser Leu Met Thr Leu Ala
 115 120 125

Trp Ala Leu Leu Lys Ala Trp Ser Arg Ile Ser Met Cys Leu Arg Trp
 130 135 140

Ser Ser Leu Ala Val Arg Thr Ala Ala Asn Ser Ile Ser Asn Phe Ser
 145 150 155 160

Phe Ser Phe Lys Asn Ser Leu Phe Trp Glu Ala
 165 170

<210> 15

<211> 2000

<212> DNA

<213> Homo sapiens

<400> 15

gcagaagctg tacgggctcc aggctgacat taccatcagc ctggacggcg tgccttctct 60
 catgcatgac accaccctgc ggcgaccac caacgtggag gaggagtctc cggagctggc 120
 ccgcaggcct gcttccatgc ttaactggac caccctgcag agactcaacg ctggccagtg 180
 gttcctgaag actgaccctt tctggacagc cagctccctg tcacctcccg accacagaga 240
 ggcccagaac cagtccatct gcagcctggc agagctcctg gagctggcca agggcaatgc 300
 cacactgctg ctcaacctgc gtgacctgcc ccgggagcac ccttaccgca gcagtcttat 360
 caacgtgact ctggaggccg tgcctgcactc cggcttcccc cagcaccagg tcatgtggct 420
 gcctagcagg cagaggcccc tgggtgcggaa ggtggctccc ggcttccaac agacatcagg 480
 ctccaaggag gcagtcgcca gcctgcggag aggccacatc cggcgctga acctgcgcta 540
 cactcagggtg tcccgccagg agctcaggga ctacgcgtcc tggaaacctga gtgtgaacct 600
 ctacacagtc aacgcaccgt ggctcttctc cctgctgtgg tgtguggggg tccatccgt 660
 caccctctgac aactcccaca cctgtccca ggtgcttccc cccctctgga tcatgcccc 720
 ggacgagtac tgtctcatgt gggtcactgc cgacctggtc tcttccacc ccatcgctgg 780
 catcttctgt ctccagaagt ggcgctggg tggcatacgg agctacaacc ctgagcagat 840
 catctgtagt gctgcggtgc gccggaccag ccgggacgtc agcatcatga aggagaagct 900
 tattttctca gagatcagcg atggtgtaga ggtctccgat gtgctctccg tatgttcaga 960

500

505

<210> 13
 <211> 2830
 <212> DNA
 <213> Homo sapiens

<400> 13

```

ggcagaggca tgcctcatggt gctccttccc cagcagcaat cctatgctcc ccttccagggt 60
cttctcttcc ttcttttccct cagccagctg gctgctggta agagagggtct ggcgagagtg 120
tgtcccagta gctgctgcta tggatggaac ggagcgggca ggacgtaggc tggaggagtc 180
tgtcttcccg gcattcttac gagatcgctg ctgcaggacc ttaatcatag catctttctc 240
tatgattttg qcatggagat ttttaatagt gtattccatg tcctgacacc ttctgttggc 300
ctgcaccacc tcttctctct cttgccagat gtgggcctcc agcgaactct cctcgtagct 360
gccattcctg gagggttga tgatcgtggt gtccctctca gctgctgcag tggctgcggc 420
attcatggca aagtgtcggg tgggtgctct cctcaggtag ttctgctccc actttgtcat 480
gtcggcctcc agggccagga tccgctcctc cttctcccgc acaagttcca ggagggtgg 540
ggcattgtat tccggcatgt tggctggctg gccatttcca tgtttctgct gggttctcag 600
tgcattcagg tctcttctca gccaaagtcc cagtctccgc tccatctgtt ctctgttctc 660
acatgcagac tgcagctggg tcagggcctg ctgcagcttc tcaactttct caacatatgc 720
ttgcttctct cgttaactct cttccagctt gatgacctg gctggggcgt tgcctaaagc 780
ctgggtccagg atctcgatgt gtctccgatg gtccctactt gcagtcggca ctgctgctaa 840
ctccatttct aatttctcct tttcttcaa gaattctttg ttctgggaag cataatgcc 900
ctctgcagct ttgtcttcat gcccttctga ttccctgctg gatagttgcc tgttagcagt 960
ctctagtcga tctcggagggt ctctgttgaa atcatgaagt cttctaactc cgccttccaa 1020
tttgtttctc atggccttgt ccagcgattc tcgcttggtg gtagacttga ccagactttc 1080
ataggcttcc gaaattctct gaagttcttt ttcaaacttg tggagcttgt cggcattgtc 1140
gtagtaaccc tgaagtctct ggtgaagcac ccggttctcc tctgttaata tctccaccat 1200
ttgctgggct cgtccacaa tcgcaaaggc atctggacca agctgctggc tgggggaggc 1260
ggcagggcgg ggctgtggag caccagggc catcgggagt ggaagcggca gggagacaga 1320
gtgcagtggc ccgctggcgg aagaggtctg ggaggacatg gggctgtgct gctgcaggt 1380
tgatgggaac ggaagtggc atgggcggct cgttacccca taatcagggg tgggtggta 1440
ccgcaggacg gccacatctg ttctcacagg ctgaggagca gggtagggct tgaccatctc 1500
gtggagcatc ccgggtgct ggtcaccata aaaaagtccg tgtctctggg tcttctgtgac 1560
tggggacatc atttgccttg tcttgaaggg gtactcaggt ggaggacccc gagggtccag 1620
cactttacct gcaggctggg caggggaggg cccctctctc actttgaagc ctttccatt 1680
ccccgagccg ggaagggtgt gcttggcccc attctctctc agggacagct gcattgtct 1740
ctcgtgagc gagcggagct ggccctgctt cagttccttc agcgcctcgt ccttatgcgc 1800
ctgtccactg ttggcaggtt tcacagtggg cctccctca gttcgggact tctgactggt 1860
gccccctgcc atgtagtaac catggcccac cgcctctgct gctgtgtgct gctgctgctg 1920
ccccctgaag aactgcgact gtgctttggc ctctctgtaa gtgggcagtt cctcgttgtt 1980
ctgctgaggc tgcgtggacc ggacctgtt ctccatcacc gtattgtcca cctgggtgtt 2040
ttgacctgc ggttcttggc gtgctgactg gtagaccatt tgtgggtctt cttgagttag 2100
gttttccgtg gaagaaaagt tgtttgtagg atgggctggt cctgcactcc ctgtggcctg 2160
gtgctgaatg gccagcaagt tcatgttctc ggttgggggt ccataccgca gttgttctg 2220
gatcagccgc tgcaalactg ttccagctgc cgcactctcg gaacctctca ttccaccctc 2280
tgagatcctc aggaagtgtt gggagtggaa gttacaaaga ggatcttcaa caacttttct 2340
cctgatgcta ctggttgctt ccaccgtcaa agcagatgtt tcatgcctcc cagaatagag 2400
ctgaaagtct ggggaaaagt aggtggagtc tctagaacc tggacaggac tactggggt 2460
ataaccaagca gaaggggacc ctaactcgtc tgggctgtag gatgcgggag aggtctccac 2520
aaactcactg tctgggggag aagaaaagca gaaaaaact cgaatcgtca ccattcagga 2580
cgaacccgcc aagcaccagc tcaagcgcag gtcccccggg aaagcggggg cttctctctc 2640
ccagcgtca gaatccctga gccggaggcc ccgcgggatt cagaccgcca gatccagg 2700
gagtgacaaa tgcgcgcaga aacttggggg acaactcggc cctggcaccg cgcgggttcc 2760
agggcgggtc aggcgcgcgc caactttccc cgcgtgccac ccgcgggtc ccccgccgg 2820
gcgctgggccc

```

2830

<210> 14
 <211> 171

180	185	190
Leu Ala Ala Arg Gly Ala His Val	Arg Gln Val	Pro Met Gly Arg Leu
195	200	205
Thr Arg Gly Val Leu His Ser Lys	Phe Trp Val	Val Asp Gly Arg His
210	215	220
Ile Tyr Met Gly Ser Ala Asn Met	Asp Trp Arg	Ser Leu Thr Gln Val
225	230	235
Lys Glu Leu Gly Ala Val Ile Tyr	Asn Cys Ser His	Leu Ala Gln Asp
245	250	255
Leu Glu Lys Thr Phe Gln Thr Tyr	Trp Val Leu Gly	Val Pro Lys Ala
260	265	270
Val Leu Pro Lys Thr Trp Pro Gln	Asn Phe Ser Ser	His Phe Asn Arg
275	280	285
Phe Gln Pro Phe His Gly Leu Phe	Asp Gly Val	Pro Thr Thr Ala Tyr
290	295	300
Phe Ser Ala Ser Pro Pro Ala Leu	Cys Pro Gln Gly	Arg Thr Arg Asp
305	310	315
Leu Glu Ala Leu Leu Ala Val Met	Gly Ser Ala Gln	Glu Phe Ile Tyr
325	330	335
Ala Ser Val Met Glu Tyr Phe Pro	Thr Thr Arg	Phe Ser His Pro Pro
340	345	350
Arg Tyr Trp Pro Val Leu Asp Asn	Ala Leu Arg	Ala Ala Phe Gly
355	360	365
Lys Gly Val Arg Val Arg Leu Leu	Val Gly Cys Gly	Leu Asn Thr Asp
370	375	380
Pro Thr Met Phe Pro Tyr Leu Arg	Ser Leu Gln Ala	Leu Ser Asn Pro
385	390	395
Ala Ala Asn Val Ser Val Asp Val	Lys Val Phe Ile	Val Pro Val Gly
405	410	415
Asn His Ser Asn Ile Pro Phe Ser	Arg Val Asn His	Ser Lys Phe Met
420	425	430
Val Thr Glu Lys Ala Ala Tyr Ile	Gly Thr Ser Asn	Trp Ser Glu Asp
435	440	445
Tyr Phe Ser Ser Thr Ala Gly Val	Gly Leu Val Val	Thr Gln Ser Pro
450	455	460
Gly Ala Gln Pro Ala Gly Ala Thr	Val Gln Glu Gln	Leu Arg Gln Leu
465	470	475
Phe Glu Arg Asp Trp Ser Ser Arg	Tyr Ala Val Gly	Leu Asp Gly Gln
485	490	495
Ala Pro Gly Gln Asp Cys Val	Trp Gln Gly	

```

accttccaga cctactgggt actgggggtg cccaaggctg tcctcccaa aacctggcct 960
cagaacttct catctcactt caaccgtttc cagcccttcc acggcctctt tgatgggggtg 1020
cccaccactg cctactttctc agcgtcgcca ccagcactct gtccccaggg ccgcaccogg 1080
gacctggagg cgctgctggc ggtgatgggg agcgcccagg agttcatcta tgcctccgtg 1140
atggagtatt tccccaccac gcgcttcagc cccccccga ggtactggcc ggtgctggac 1200
aacgcgctgc gggcggcagc cttcggcaag ggcgtgcgcg tgcgcctgct ggtcggctgc 1260
ggactcaaca cggacccac catgttcccc tacctgcggt ccctgcaggc gctcagcaac 1320
cccgcgcca acgtctctgt ggacgtgaaa gtcttcatcg tgccggtggg gaaccattcc 1380
aacatcccat tcagcagggt gaaccacagc aagttcatgg tcacggagaa ggcagcctac 1440
ataggcacct ccaactgggtc ggaggattac ttcagcagca cggcgggggt gggcttgggtg 1500
gtcaccaga gccctggcgc gcagcccgcg ggggccacgg tgcaggagca gctgcggcag 1560
ctctttgagc gggactggag ttcgcgctac gccgtcgcc tggacggaca ggctccgggc 1620
caggactgcg ttggcagggt ctgagggggg cctcttttcc tctcggcgac cccgccccgc 1680
acgcgccttc cctctgacc ccggcctggg cttcagccgc ttctcccgcc aagcagcccg 1740
ggtccgcact gcgccaggag ccgcctgcga ccgcccgggc gtgcgaacc gccgcctgc 1800
tctctgattt ccgagtcag cccccctga gccccacctc ctccagggag cctccaggga 1860
agcccccttc ctgactcctg gccacaggc caggcctaaa aaaaactcgt ggcttaaaaa 1920
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1980
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2010

```

<210> 12

<211> 506

<212> PRT

<213> Homo sapiens

<400> 12

```

Met Leu Lys Pro Leu Trp Lys Ala Ala Val Ala Pro Thr Trp Pro Cys
  1                      5                      10                      15

Ser Met Pro Pro Arg Arg Pro Trp Asp Arg Glu Ala Gly Thr Leu Gln
          20                      25                      30

Val Leu Gly Ala Leu Ala Val Leu Trp Leu Gly Ser Val Ala Leu Ile
  35                      40                      45

Cys Leu Leu Trp Gln Val Pro Arg Pro Pro Thr Trp Gly Gln Val Gln
  50                      55                      60

Pro Lys Asp Val Pro Arg Ser Trp Glu His Gly Ser Ser Pro Ala Trp
  65                      70                      75                      80

Glu Pro Leu Glu Ala Glu Ala Arg Gln Gln Arg Asp Ser Cys Gln Leu
          85                      90                      95

Val Leu Val Glu Ser Ile Pro Gln Asp Leu Pro Ser Ala Ala Gly Ser
  100                      105                      110

Pro Ser Ala Gln Pro Leu Gly Gln Ala Trp Leu Gln Leu Leu Asp Thr
  115                      120                      125

Ala Gln Glu Ser Val His Val Ala Ser Tyr Tyr Trp Ser Leu Thr Gly
  130                      135                      140

Pro Asp Ile Gly Val Asn Asp Ser Ser Ser Gln Leu Gly Glu Ala Leu
  145                      150                      155                      160

Leu Gln Lys Leu Gln Gln Leu Leu Gly Arg Asn Ile Ser Leu Ala Val
          165                      170                      175

Ala Thr Ser Ser Pro Thr Leu Ala Arg Thr Ser Thr Asp Leu Gln Val

```


aaaaaaaaa aaaaaaaaaa

1100

<210> 10

<211> 149

<212> PRT

<213> Homo sapiens

<400> 10

Met Ala Ala Ala Ala Leu Arg Arg Phe Trp Ser Arg Arg Arg Ala Glu
 1 5 10 15

Ala Gly Arg Ala Ala Val Tyr Val Gly Leu Leu Gly Gly Ala Ala Ala
 20 25 30

Cys Phe Thr Leu Ala Pro Ser Glu Gly Ala Phe Glu Glu Ala Leu Leu
 35 40 45

Glu Ala Ser Gly Thr Leu Leu Leu Leu Ala Pro Ala Thr Arg Asn Arg
 50 55 60

Gly Ser Trp Thr Trp Ala Ser Trp Val Ala Gly Gly Cys Trp Gly Pro
 65 70 75 80

Gly Cys Ala Thr Ala Thr Ser Thr Thr Thr Asn Ser Cys Thr Cys Arg
 85 90 95

Arg Ile Cys Gly Trp Ser Gly Pro Ser Ser Cys Ile Pro Arg Pro Thr
 100 105 110

Ser Gly Ser Ser Met Arg Ser Thr Ser Leu Ser Cys Ser Pro Thr Ile
 115 120 125

Arg Trp Thr Arg Arg Cys Gly Arg Ser Arg Ser Cys Arg Arg Arg Arg
 130 135 140

Arg Thr Gly Ser Pro
 145

<210> 11

<211> 2010

<212> DNA

<213> Homo sapiens

<400> 11

tggtgagctg cagagaagag gaggttggtc tggagcacag gcagcaccga gcctgccccg 60
 tgagctgagg gcctgcagtc tgcggctgga atcaggatag acaccaagga aggaccccc 120
 gagatgctga agcctctttg gaaagcagca gtggccccca catggccatg ctccatgccg 180
 ccccgccgcc cgtgggacag agaggctggc acgttgcagg tcttgggagc gctggctgtg 240
 ctgtggctgg gctccgtggc tcttatctgc ctctgtggc aagtgcctcg tcttccacc 300
 tggggccagg tgcagcccaa ggaagtgcgc aggtcctggg agcatggctc cagcccagct 360
 tgggagcccc tggaaagcaga ggccaggcag cagagggact cctgccagct tgccttgtg 420
 gaaagcatcc ccaggacct gccatctgca gccggcagcc cctctgcccc gccctgtggg 480
 caggcctggc tgcagctgct ggacactgcc caggagagcg tccactggc ttcatactac 540
 tggctccctca cagggcctga catcggggtc aacgactcgt ctccccagct gggagaggct 600
 cttctgcaga agctgcagca gctgctgggc aggaacattt cctggctgtt ggcaccagc 660
 agcccgacac tggccaggac atccaccgac ctgcagggtc tggctgcccc aggtgcccac 720
 gtacgacagg tgcctatggg ggggtcacc aggggtgttt tgcactccaa attctgggtt 780
 gtggatggac ggcacatata catgggcagt gccaacatgg actggcggc tctgacgcag 840
 gtgaaggagc ttggcgtgt catctataac tgcagccacc tggccaaga cctggagaag 900

```

tggtcatttc tgtcctttca ctggctgctg ccccaggaag actcctctag gctctccatc 240
tttcccttga gagctggctc cccaccccaa cctgctcagg caccaccgag gatctaggtc 300
tctgggtccc catacctgga cccacatggg tgggtgcctg ttgcatgttt aagagagagg 360
ggctgtgagg tgacagggca ctagggcctt cactcctttc tccccttcca tcttttcttt 420
accagtgcga cccatgtccc tagctcccggt gtattggggc tgaggctctg gggcctgtct 480
ccctgccagc gtgagggcaa gacccagag ccttagctga gcaagcccag aggggcagcg 540
tggccctccc ctcccctttt cctgcccgt cccatgcctc agcttgctgc ttgtgccagt 600
tgctgttttc gcttcagtgt ttgattctag cacttacatg tgtcctcccc accaagccct 660
ctatctcctt ctaatccttc aaccctggc cccctcccca taacagtgc ttttccaggg 720
aggaagaggc agcaggagct gttggccttg gtttgacag agcgggtagg gctgtaggga 780
aagcgggtga gctgtgtgc tgctgggctt cctttggcc ctgccttccc accctacgat 840
gtatgaaatg tatgtacaga ccagagatgt ttatacagcc gataaagatg gaaaaaaaaa 900
aaaaaaaaaa aaaaaa                                     915

```

<210> 8

<211> 71

<212> PRT

<213> Homo sapiens

<400> 8

```

Met Val Phe Leu Leu Glu Phe Leu Phe Leu Val Phe Phe Pro Gly Cys
  1             5             10             15

```

```

Val Asn Gln Leu Leu Leu Ser Tyr Pro Trp Gln Gly Gln Gly Thr Ser
      20             25             30

```

```

Leu Trp Ser Phe Leu Ser Phe His Trp Leu Leu Pro Gln Glu Asp Ser
      35             40             45

```

```

Ser Arg Leu Ser Ile Phe Pro Leu Arg Ala Gly Ser Pro Pro Gln Pro
      50             55             60

```

```

Ala Gln Ala Pro Pro Arg Ile
      65             70

```

<210> 9

<211> 1100

<212> DNA

<213> Homo sapiens

<400> 9

```

tgaccccaaa gacggaagag gatggccgcg gcggtcttga ggagattttg gtcccgggcg 60
cgcgagagag cggggcgcg cgtgtgtat gtgggtctgc tgggcggcg ggcggcctgc 120
ttcacgctgg cgccagcga ggtgacctc gaggagggcg tgctggaggc gtcggggacc 180
ctcctgctgc tggcgccggc caccgcgaac cgcggtctct ggacytgggc ttcgtgggtc 240
gctgggtgggt gctgggggccc tggatgcgag actgcgacat caacgacgac gaattcctgc 300
acctgccggc gcatttgccg gtggtcgggc cccagcagct gcattccgag accaagcagc 360
ggctcttcga tgagaagtac aagcctgtcg tgctcaccga cgatcagggt gaccaggcgc 420
tgtgggagga gcaggctctg cagaaggaga agaaaggacag gctcgccttg agccaggccc 480
actcgctggt gcaggcggag gcccgagat gaaacctga ggcctccgag tcttgccaaa 540
ctgcttgctt ggggtgtgag agttctgagt gtgcctcacc tgcagaacag ctgagacaga 600
tgatgtgcaa agtgttttct cactggattt gcacaagttt ggggagcctt tctgcccccc 660
gtctttgttc tttattagct gaagctaatt cagagccacc tgggtccggg agttggggac 720
agcagaacga cttgacacat gttcatcact ggcagagctg gtcatgagcc ttttatataa 780
gcctttttca tggggcctca gaggccctcc ttaaggaggt accacattgg tcagctgact 840
tgcaactct tctaaggcca cttagatttt ctttttcaag tttgggttgt ggcctggcat 900
ggtgatgtct gtaatcccag cagtttgcaa actgaggcaa gagaatcgct tgaggccagg 960
agtttgaggc cagctagagt gacatagcaa gactccgatg ctacaaaaaa gaataataat 1020
agtaattaac taaataaaat ttgagctgaa atgttaaaaa aaaaaaaaaa aaaaaaaaaa 1080

```

```

ccctgtcaga gtccccaga gcagagaggg tcagggttcc ctggaccttg gctcccagag 1020
caagccaaaa taaagactac actgttgccct tgggggcttg tcggggccagg gccaaagacgg 1080
tctgcgtgct gcagggccag gacagaaaata gccacacatg ccggtgagaa caaagagcct 1140
ctttctttct catgttgaca tcgactttct gtgccaagtc ctttgggtat aaggatgcta 1200
gggaattcct ataggcacca aacagaagga aagctagggg ctgggactac tgggtatagg 1260
acttgctcta gctctcaggt cctagcccaa gctcaatgca aacacagccc ctccgggctc 1320
tctgtttctg tgaggttctg gaatcccttc ctctgtgtcc gtgagtctga cagaatcgat 1380
gatgttccct tagagctggg aaatccatgt gtttattcac ggagggaact caccattacc 1440
tcccttgctt tctttgcttg ccttgagaaa atccagagtc ttcggaatgg caaaggcagc 1500
tcctggattt ccctggaggg gaggcactag ctgagggaag tagctccctt cattcatgat 1560
gcacagttaa cgcagcagac acacaactgc gcctactatt tgctcggtgc cctgcaaggc 1620
gtgctctaac ttgatttgt tatttcagct ctctccagga tagtgccaaa tgggtgcaatg 1680
ggaaacctgt ttgctgggg ggctctagat cactggctcc agaactcccc gctgccaggg 1740
tagcccttac cccagccccc ttgctcctgg acagcagtggt gtctcacctt tagcctctgc 1800
ccccagttct ggtctgacct aacagagggg ctctatgata ttaagaaggg gcccttccctg 1860
ctctgtgctt caacctatc tccataatag ggagtctaatt cctattcctt cctgctctga 1920
tgaggatggt gtgaggatga ggaggacggc atctcatttg gggctttttg gcagtggggc 1980
tcattttaat cctgcagggc tgcttgccag tggatctatc cagctgcttc cttgtagcca 2040
agaatgagtt caatgaattg tgattcactg attttattga ttttgtttta aaacagggag 2100
actggatttt ttgaagctgc tatcattttc tatttcttta ttaatttctt tgtaatcatc 2160
ttattaaagt tttcttattt agtggaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2220
aaaaaaaaa                                     2229

```

<210> 6
 <211> 111
 <212> PRT
 <213> Homo sapiens

```

<400> 6
Met Leu Gly Asn Ser Tyr Arg His Gln Thr Glu Gly Lys Leu Gly Ala
  1              5              10              15

Trp Thr Thr Gly Tyr Arg Thr Cys Ser Ser Ser Gln Val Leu Ala Gln
          20              25              30

Ala Gln Cys Lys His Ser Pro Ser Gly Leu Ser Val Ser Val Arg Phe
          35              40              45

Trp Asn Pro Phe Leu Cys Val Arg Glu Ser Asp Arg Ile Asp Asp Val
          50              55              60

Pro Leu Glu Leu Gly Asn Pro Cys Val Tyr Ser Arg Arg Glu Leu Thr
          65              70              75              80

Ile Thr Ser Leu Val Phe Phe Ala Cys Leu Gly Glu Ile Gln Ser Leu
          85              90              95

Arg Asn Gly Lys Gly Ser Ser Trp Ile Ser Leu Glu Gly Arg His
          100              105              110

```

<210> 7
 <211> 915
 <212> DNA
 <213> Homo sapiens

```

<400> 7
gcgtgagcac cctatctcag ctgctattcg ggcattgatgc tttgtagagg gtagagtaga 60
cagcccccct cctactcac catgggtatct ctcttgaat tctctttctt tgttttcttt 120
cctggttgtg tgaaccagtt gctgctgtca taccctctggc agggccaggg gacctctctt 180

```

cctccccggc catgtggaac tgagtcaatt aaacttcttg ttataaaagt aaaaaaaaaa 2100
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2160
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 2198

<210> 4
 <211> 140
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Pro Ser Ala Phe Ser Val Ser Ser Phe Pro Val Ser Ile Pro Ala
 1 5 10 15
 Val Leu Thr Gln Thr Asp Trp Thr Glu Pro Trp Leu Met Gly Leu Ala
 20 25 30
 Thr Phe His Ala Leu Cys Val Leu Leu Thr Cys Leu Ser Ser Arg Ser
 35 40 45
 Tyr Arg Leu Gln Ile Gly His Phe Leu Cys Leu Val Ile Leu Val Tyr
 50 55 60
 Cys Ala Glu Tyr Ile Asn Glu Ala Ala Ala Met Asn Trp Arg Leu Phe
 65 70 75 80
 Ser Lys Tyr Gln Tyr Phe Asp Ser Arg Gly Met Phe Ile Ser Ile Val
 85 90 95
 Phe Ser Ala Pro Leu Leu Val Asn Ala Met Ile Ile Val Val Met Trp
 100 105 110
 Val Trp Lys Thr Leu Asn Val Met Thr Asp Leu Lys Asn Ala Gln Glu
 115 120 125
 Arg Arg Lys Glu Lys Lys Arg Arg Arg Lys Glu Asp
 130 135 140

<210> 5
 <211> 2229
 <212> DNA
 <213> Homo sapiens

<400> 5
 ggagccgggc aaccagtgga aggagcctgg gagaggccag gcctccccgg actgctagcc 60
 tgcttttctt ggggtccctg gagccggagg aagaaccagg atgttgctgc ctgcagaagc 120
 tcagctcagg aagacttcca ggaacctgag gaggagctgc cactaacagc catatttccc 180
 aatggagact gtgatgacct tggaaggggg tcaaaagcct gtgatggagt cgtacacact 240
 cctgctgagc ccaccggaga ctcaagatga aggctggacc ctgctgctgt cctgggctct 300
 aacctacaga ctggggcctg gctcctctt actggccccc aggtctccat ggagactgca 360
 gaaacccccg cctgctggag gcctgccaca ctcacagtta ccagctagac agtgggggctt 420
 actaagacaa gcaggacctt aaacagtgtc tccctggga acctactccc caccagcat 480
 ttgctaagtc tgatcacagg gaggttattt tgtctctctg tctcggttct tctgagccac 540
 tgagacagat ggctgtccgc tttagaggctc tgcagagctg tggcacccca tgggtgtgtct 600
 gcagtgttct gggcacatgc atgggcaccc atcgttgaga gtgcagctgg gaagaactct 660
 gaaccagaag tcacagagc tgaggcatgg ccttgaacat gtcactcagt ctctggggct 720
 tctgtttcac aaatgcata gggggccacc agcccagtg ctttaaacca ggggcaggtt 780
 gtccctccag gcagcattgg aaatgtgtgt gtgttgaggg ggtcacagt actgtggggg 840
 cacccttggc atctagtggg catcccacaa tgtgcagaac agtctctgac agcaaagaat 900
 tgggtccattc aatgccaaat gtagtacctt tgagacattc tggctgagcc aatgccttct 960

<400> 2

Met Gln Arg Phe Leu Arg Gly Val Phe Ser Ile Pro Val Asp Met Lys
 1 5 10 15

Thr Leu Ala Phe His Leu Phe Phe Pro Phe Leu Phe Lys Gly Phe Asn
 20 25 30

Phe Gly Ile Phe Gln Arg Lys Phe Gly Gln Cys Gln Ile Pro Arg Asn
 35 40 45

Leu Gly Gly Phe Leu Ser Phe Gln Leu Lys Leu Tyr Leu Ile Pro Thr
 50 55 60

Val His Val Ser Asp His Leu Ile Thr Glu Pro Asn Thr Phe Leu Pro
 65 70 75 80

Cys Val Glu Lys

<210> 3

<211> 2198

<212> DNA

<213> Homo sapiens

<400> 3

gctctgtgga ttctggccag gccgggttcg gcggttgctg tgagagcggg cttcccaaca 60
 ccattgccgc cgccttctct gtcagctctt tccccgtcag catccacagc gtgctcacgc 120
 agacggactg gactgagccc tggctcatgg ggctggccac cttccacgcg ctctgcgtgc 180
 tcctcacctg cttgtcctcc cgaagctaca gactacagat cgggcacttt ctgtgtctag 240
 tcattctagt ctactgtgct gaatacatca atgaggcggc tgcgatgaac tggagattat 300
 tttcgaaata ccagtatttc gactccaggg ggatgttcat tttctatagta ttttcagccc 360
 cactgctggg gaatgccatg atcattgtgg ttatgtgggt atggaagact ttgaatgtga 420
 tgactgacct gaagaatgca caagagagaa gaaaggaaaa gaaaaggaga aggaagaag 480
 actgaggggc agcagctgct tggagtttgc gtccttcccg tcacccagc gcagctccca 540
 gtgctgcagt gtgcgtggcg tgggcatcct tccagctgac tcatggtttg aaaaaccgtt 600
 gttttattta aatatccaca gtggtagggc acacactgaa gttggccttt cagccagcac 660
 tgaatgtatc catcaggaca tgcgtcttca ggtgctgat cttttagtgc aggctgtggg 720
 aacggtctct gcagagcttc ataactggga atttgatttg aagaagtcca tgcataatgt 780
 gtaactagta ctaattataa atataaaaata cacaatataa aatatgaaac tcaataataa 840
 acagtgccac ctgtacatgg gcaccatgcc ctctcctcgt tgcgtgtgtt tctagtgcac 900
 gccacagttc gcagtagagg gtgttttcac ctccaagac atggggcaaa gtttggagac 960
 acctggttgt cactggaggg ggtggtgctc ctggtctctc ctgtggagcc cggggtgatg 1020
 cataaaatcc tgtgtgcctg ggtcagccgc atcacagaca atgacttgac atgaaatgtc 1080
 agctgtgctg gggcagagag accttggag gaagctcttg gaaaaacgt tgtatctcag 1140
 tttgatgaac caattcacia gaggttaggc cctctctagc aaagttagg gctgctttac 1200
 tgaaaaacaga atggaagccc tgaagtcaac actccatgga gaagcgtgtc tttcctaata 1260
 tccttggtgt ctgttgattt aggtgcttgg gaacacaatg ctcccagttc tgttaggaca 1320
 ggcatactgt tactttgcaa tatccacttt ataaaatagc tcctgcccag tggctcttgg 1380
 ttctgtcaa atgtggacct gtagtttaag aatgacaggt ggttagagac ccagatatat 1440
 aaaaataggt gttcaataag ggaatactga ttgtgcattg tatctggata gcatgcctaa 1500
 ttgtgcattt ctgaangtta ccaattcaaa atgtaattgg aacagttatc tttgattaga 1560
 caagcctggg aagagaatgt tgaggtgcag agctcacag ccaagtcat gccctctctg 1620
 ggcctttgtg gctgagaagt gggacagaaa gatgattaag gtaatgtgtc ctccctgtag 1680
 cattgtccag ggcgcttgtg tagatatttg acctcactga cagaaaagaa accagggagt 1740
 ttgtagagac tgtgcatttt tagtataaca tttccaccat ctgatattgt ttggctttgt 1800
 gtccccaccc aaattgcac tcaaattgca atccccatgt gtcaaggag ggacctgatg 1860
 ggaggtgatg ggatcatggg ggtggtttcc cctatgttgt tatcataata gagagggagt 1920
 tctcacaaga tctgctcgtt ttaaagacag cagtttcccc tgcgtgcact gtctctctcc 1980
 tgctgccttg tgaagaagt gcttgtttct cctctgcca tgaattgaag tttcccgagg 2040

SEQUENCE LISTING

<110> Valenzuela, Dario
 Yuan, Olive
 Hoffman, Heidi
 Hall, Jeff
 Rapiejko, Peter

<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

<130> GI 6908X

<140>

<141>

<160> 132

<170> PatentIn Ver. 2.0

<210> 1

<211> 1738

<212> DNA

<213> Homo sapiens

<400> 1

```

acttagtgta gcaccaggga gccctagagc tggaggatat cgaatagatt aaattttgct 60
cgtctcttcc acaagcccta accatgggtc ttaaaaacag cagattctgg gagecctcca 120
tgctctctct ctctctctct ttatctactt ccctcccaaa tgagagagtg acagagaatt 180
gtttttttat aaatcgaagt ttcttaatat tatcagggtt tgatacgtca gtggtctaaa 240
atgctatagt gcaattacta gcagttactg cacggagtgc caccgtgcca atagaggact 300
gttggtttta taagggaact cttagcccat ttctctctct cgcctatctc tacccttgct 360
caatgaaata tcatttaaatt ttcttttaaa aaaaatcagt ttaattctta ctgtgtgccc 420
aacacgaagg ctttttttga aagaaaaata gaatgttttg cctcaaagta gtccatataa 480
aatgtcttga atagaagaaa aaactaccaa accaaagggt actatttttg aaacatcgtg 540
tgttcattcc agcaaggcag aagactgcac cttctttcca gtgncatgct gtgtcatttt 600
ttttaagtcc tcttaatttt tagacacatt ttgtgtttat gttttaacaa tgtatgccta 660
accagtcac ttgtctgcac caatgcaaag gttctgaga ggagtattct ctatccctgt 720
ggatatgaag acactggcat ttcatctatt ttcccttctc ctttttaag gatttaactt 780
tggaatcttc caaagggaagt ttggccaatg ccagatcccc aggaatttgg ggggttttct 840
ttcttttcaa ctgaaattgt atctgattcc tactgttcat gttagtgtac atctaatac 900
agagccaaac actttttctc cctgtgtgga aaagtaggta tgccttaca taaaatctgt 960
cttttctggt agaaacctga gccactgaaa ataaaagaga caactagaag cacagtagag 1020
tcccagactg agatctacct ttgagaggct ttgaaagtaa tccctggggt ttggattatt 1080
ttcacaaggg ttatgccgtt ttattcaagt ttgttgctcc gttttgcacc tctgcaataa 1140
aagcaaaatg acaaccagta cataaggggt tagcttgaca aagttagact ccttgtgtta 1200
atttttaagt ttttttttcc ttaactatat ctgtctacag gcagatacag atagttgtat 1260
gaaaatctgc ttgcctgtaa aatttgcat tataaatgtg ttgccgatgg atcacttggg 1320
cctgtacaca taccaattag cgtgaccact tccatcttaa aaacaaacct aaaaaacaaa 1380
atattattata tatatatata tatatatata aaggactgtg gtttgtatac aaactattgc 1440
aaacacttgt gcaaacttgt cttgatataa aggaaaagca aaatcgtat aacattatta 1500
ctacttgaat gcctctgtga ctgatttttt ttttcatttt aaatataaac ttttttgtga 1560
aaagtatgct caatgttttt ttcccttttc cccattccct tgtaaatata ttttgttcta 1620
tgtgacttgg ttggaaata gttaactggg actgtaattu gcattaaata aaaagtaggt 1680
tagcctggaa atgaaattaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1728

```

<210> 2

<211> 84

<212> PRT

<213> Homo sapiens

Fig. 1B





Fig. 1A



(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:79.

89. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:80;

(b) a fragment of the amino acid sequence of SEQ ID NO:80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80; and

(c) the amino acid sequence encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;

the protein being substantially free from other mammalian proteins.

87. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:78;
 - (b) the amino acid sequence of SEQ ID NO:78 from amino acid 1 to amino acid 93;
 - (c) a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78; and
 - (d) the amino acid sequence encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;
- the protein being substantially free from other mammalian proteins.

88. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:79;
- (b) the nucleotide sequence of SEQ ID NO:79 from nucleotide 2 to nucleotide 1018;
- (c) the nucleotide sequence of SEQ ID NO:79 from nucleotide 53 to nucleotide 1018;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vp14_1 deposited with the ATCC under accession number 207011;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vp14_1 deposited with the ATCC under accession number 207011;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp14_1 deposited with the ATCC under accession number 207011;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:80;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:80, the fragment comprising eight contiguous amino acids of SEQ ID NO:80;

the protein being substantially free from other mammalian proteins.

86. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:77;
- (b) the nucleotide sequence of SEQ ID NO:77 from nucleotide 54 to nucleotide 368;
- (c) the nucleotide sequence of SEQ ID NO:77 from nucleotide 141 to nucleotide 368;
- (d) the nucleotide sequence of SEQ ID NO:77 from nucleotide 51 to nucleotide 332;
- (e) the nucleotide sequence of the full-length protein coding sequence of clone vq1_1 deposited with the ATCC under accession number 207012;
- (f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;
- (g) the nucleotide sequence of a mature protein coding sequence of clone vq1_1 deposited with the ATCC under accession number 207012;
- (h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vq1_1 deposited with the ATCC under accession number 207012;
- (i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:78;
- (j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:78, the fragment comprising eight contiguous amino acids of SEQ ID NO:78;
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h); and
- (l) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:77.

(c) the amino acid sequence encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012; the protein being substantially free from other mammalian proteins.

84. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:75;
- (b) the nucleotide sequence of SEQ ID NO:75 from nucleotide 144 to nucleotide 461;
- (c) the nucleotide sequence of the full-length protein coding sequence of clone vp19_1 deposited with the ATCC under accession number 207012;
- (d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp19_1 deposited with the ATCC under accession number 207012;
- (e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:76;
- (f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76;
- (g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d); and
- (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:75.

85. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:76;
- (b) a fragment of the amino acid sequence of SEQ ID NO:76, the fragment comprising eight contiguous amino acids of SEQ ID NO:76; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vp19_1 deposited with the ATCC under accession number 207012;

- (a) the nucleotide sequence of SEQ ID NO:73;
- (b) the nucleotide sequence of SEQ ID NO:73 from nucleotide 348 to nucleotide 743;
- (c) the nucleotide sequence of SEQ ID NO:73 from nucleotide 414 to nucleotide 743;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vp17_1 deposited with the ATCC under accession number 207012;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vp17_1 deposited with the ATCC under accession number 207012;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp17_1 deposited with the ATCC under accession number 207012;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:74;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:73.

83. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:74;
- (b) a fragment of the amino acid sequence of SEQ ID NO:74, the fragment comprising eight contiguous amino acids of SEQ ID NO:74; and

(f) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp15_1 deposited with the ATCC under accession number 207012;

(g) the nucleotide sequence of a mature protein coding sequence of clone vp15_1 deposited with the ATCC under accession number 207012;

(h) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp15_1 deposited with the ATCC under accession number 207012;

(i) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:72;

(j) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO:72;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h); and

(l) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(h), and that has a length that is at least 25% of the length of SEQ ID NO:71.

81. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:72;

(b) the amino acid sequence of SEQ ID NO:72 from amino acid 1 to amino acid 139;

(c) a fragment of the amino acid sequence of SEQ ID NO:72, the fragment comprising eight contiguous amino acids of SEQ ID NO:72; and

(d) the amino acid sequence encoded by the cDNA insert of clone vp15_1 deposited with the ATCC under accession number 207012;

the protein being substantially free from other mammalian proteins.

82. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:70;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO:70;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:69.

79. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:70;

(b) a fragment of the amino acid sequence of SEQ ID NO:70, the fragment comprising eight contiguous amino acids of SEQ ID NO:70; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012;

the protein being substantially free from other mammalian proteins.

80. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:71;

(b) the nucleotide sequence of SEQ ID NO:71 from nucleotide 44 to nucleotide 1513;

(c) the nucleotide sequence of SEQ ID NO:71 from nucleotide 92 to nucleotide 1513;

(d) the nucleotide sequence of SEQ ID NO:71 from nucleotide 1 to nucleotide 458;

(e) the nucleotide sequence of the full-length protein coding sequence of clone vp15_1 deposited with the ATCC under accession number 207012;

- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:67.

77. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:68;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:68, the fragment comprising eight contiguous amino acids of SEQ ID NO:68; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
- the protein being substantially free from other mammalian proteins.

78. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:69;
- (b) the nucleotide sequence of SEQ ID NO:69 from nucleotide 29 to nucleotide 1387;
- (c) the nucleotide sequence of SEQ ID NO:69 from nucleotide 113 to nucleotide 1387;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc61_1 deposited with the ATCC under accession number 207012;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc61_1 deposited with the ATCC under accession number 207012;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc61_1 deposited with the ATCC under accession number 207012;

C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:65.

75. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:66;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
- the protein being substantially free from other mammalian proteins.

76. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:67;
- (b) the nucleotide sequence of SEQ ID NO:67 from nucleotide 65 to nucleotide 457;
- (c) the nucleotide sequence of SEQ ID NO:67 from nucleotide 158 to nucleotide 457;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vp3_1 deposited with the ATCC under accession number 98933;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp3_1 deposited with the ATCC under accession number 98933;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:68;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68, the fragment comprising eight contiguous amino acids of SEQ ID NO:68;

- (a) the amino acid sequence of SEQ ID NO:64;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;
- the protein being substantially free from other mammalian proteins.

74. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:65;
- (b) the nucleotide sequence of SEQ ID NO:65 from nucleotide 134 to nucleotide 667;
- (c) the nucleotide sequence of SEQ ID NO:65 from nucleotide 191 to nucleotide 667;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc48_1 deposited with the ATCC under accession number 98933;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc48_1 deposited with the ATCC under accession number 98933;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:66;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66, the fragment comprising eight contiguous amino acids of SEQ ID NO:66;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees

71. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:62;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
- the protein being substantially free from other mammalian proteins.

72. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:63;
- (b) the nucleotide sequence of SEQ ID NO:63 from nucleotide 1048 to nucleotide 3726;
- (c) the nucleotide sequence of the full-length protein coding sequence of clone vb22_1 deposited with the ATCC under accession number 98933;
- (d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb22_1 deposited with the ATCC under accession number 98933;
- (e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:64;
- (f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64, the fragment comprising eight contiguous amino acids of SEQ ID NO:64;
- (g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d); and
- (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:63.

73. A protein comprising an amino acid sequence selected from the group consisting of:

(c) the amino acid sequence encoded by the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886; the protein being substantially free from other mammalian proteins.

70. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:61;
- (b) the nucleotide sequence of SEQ ID NO:61 from nucleotide 23 to nucleotide 757;
- (c) the nucleotide sequence of SEQ ID NO:61 from nucleotide 119 to nucleotide 757;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vp8_1 deposited with the ATCC under accession number 98886;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp8_1 deposited with the ATCC under accession number 98886;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:62;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:61.

- (a) the nucleotide sequence of SEQ ID NO:59;
- (b) the nucleotide sequence of SEQ ID NO:59 from nucleotide 30 to nucleotide 344;
- (c) the nucleotide sequence of SEQ ID NO:59 from nucleotide 84 to nucleotide 344;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vp7_1 deposited with the ATCC under accession number 98886;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vp7_1 deposited with the ATCC under accession number 98886;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vp7_1 deposited with the ATCC under accession number 98886;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:60;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:59.

69. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:60;
- (b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and

(d) the nucleotide sequence of the full-length protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;

(f) the nucleotide sequence of a mature protein coding sequence of clone vj2_1 deposited with the ATCC under accession number 98886;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:58;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:57.

67. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:58;

(b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and

(c) the amino acid sequence encoded by the cDNA insert of clone vj2_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins.

68. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(f) the nucleotide sequence of a mature protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:56;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:55.

65. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:56;

(b) a fragment of the amino acid sequence of SEQ ID NO:56, the fragment comprising eight contiguous amino acids of SEQ ID NO:56; and

(c) the amino acid sequence encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins.

66. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:57;

(b) the nucleotide sequence of SEQ ID NO:57 from nucleotide 542 to nucleotide 886;

(c) the nucleotide sequence of SEQ ID NO:57 from nucleotide 755 to nucleotide 886;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:54;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:55.

63. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:54;

(b) a fragment of the amino acid sequence of SEQ ID NO:54, the fragment comprising eight contiguous amino acids of SEQ ID NO:54; and

(c) the amino acid sequence encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins.

64. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:55;

(b) the nucleotide sequence of SEQ ID NO:55 from nucleotide 11 to nucleotide 1063;

(c) the nucleotide sequence of SEQ ID NO:55 from nucleotide 71 to nucleotide 1063;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vf3_1 deposited with the ATCC under accession number 98886;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vf3_1 deposited with the ATCC under accession number 98886;

- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:51.

61. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:52;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
- the protein being substantially free from other mammalian proteins.

62. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:53;
- (b) the nucleotide sequence of SEQ ID NO:53 from nucleotide 240 to nucleotide 503;
- (c) the nucleotide sequence of SEQ ID NO:53 from nucleotide 318 to nucleotide 503;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone ve16_1 deposited with the ATCC under accession number 98886;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;
- (f) the nucleotide sequence of a mature protein coding sequence of clone ve16_1 deposited with the ATCC under accession number 98886;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone ve16_1 deposited with the ATCC under accession number 98886;

C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:49.

59. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:50;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;
- the protein being substantially free from other mammalian proteins.

60. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:51;
- (b) the nucleotide sequence of SEQ ID NO:51 from nucleotide 15 to nucleotide 1934;
- (c) the nucleotide sequence of SEQ ID NO:51 from nucleotide 1704 to nucleotide 1934;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone ve13_1 deposited with the ATCC under accession number 98886;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
- (f) the nucleotide sequence of a mature protein coding sequence of clone ve13_1 deposited with the ATCC under accession number 98886;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone ve13_1 deposited with the ATCC under accession number 98886;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:52;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52;

- (a) the amino acid sequence of SEQ ID NO:48;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
- the protein being substantially free from other mammalian proteins.

58. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:49;
- (b) the nucleotide sequence of SEQ ID NO:49 from nucleotide 189 to nucleotide 1637;
- (c) the nucleotide sequence of SEQ ID NO:49 from nucleotide 270 to nucleotide 1637;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc57_1 deposited with the ATCC under accession number 98886;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc57_1 deposited with the ATCC under accession number 98886;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc57_1 deposited with the ATCC under accession number 98886;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:50;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50, the fragment comprising eight contiguous amino acids of SEQ ID NO:50;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees

the protein being substantially free from other mammalian proteins.

56. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:47;
- (b) the nucleotide sequence of SEQ ID NO:47 from nucleotide 111 to nucleotide 1337;
- (c) the nucleotide sequence of SEQ ID NO:47 from nucleotide 246 to nucleotide 1337;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc54_1 deposited with the ATCC under accession number 98886;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc54_1 deposited with the ATCC under accession number 98886;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:48;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48, the fragment comprising eight contiguous amino acids of SEQ ID NO:48;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:47.

57. A protein comprising an amino acid sequence selected from the group consisting of:

- (b) the nucleotide sequence of SEQ ID NO:45 from nucleotide 1922 to nucleotide 2350;
- (c) the nucleotide sequence of SEQ ID NO:45 from nucleotide 2237 to nucleotide 2350;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc47_1 deposited with the ATCC under accession number 98886;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc47_1 deposited with the ATCC under accession number 98886;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:46;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 55 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:45.

55. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:46;
- (b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vc47_1 deposited with the ATCC under accession number 98886;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:44;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:43.

53. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:44;

(b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc34_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins.

54. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:45;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:42;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:41.

51. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:42;

(b) a fragment of the amino acid sequence of SEQ ID NO:42, the fragment comprising eight contiguous amino acids of SEQ ID NO:42; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;

the protein being substantially free from other mammalian proteins.

52. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:43;

(b) the nucleotide sequence of SEQ ID NO:43 from nucleotide 232 to nucleotide 1461;

(c) the nucleotide sequence of SEQ ID NO:43 from nucleotide 280 to nucleotide 1461;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc34_1 deposited with the ATCC under accession number 98886;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:39.

49. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:40;

(b) a fragment of the amino acid sequence of SEQ ID NO:40, the fragment comprising eight contiguous amino acids of SEQ ID NO:40; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins.

50. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:41;

(b) the nucleotide sequence of SEQ ID NO:41 from nucleotide 13 to nucleotide 1416;

(c) the nucleotide sequence of SEQ ID NO:41 from nucleotide 346 to nucleotide 1416;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc33_1 deposited with the ATCC under accession number 98886;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc33_1 deposited with the ATCC under accession number 98886;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:37.

47. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:38;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
- the protein being substantially free from other mammalian proteins.

48. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:39;
- (b) the nucleotide sequence of SEQ ID NO:39 from nucleotide 21 to nucleotide 1142;
- (c) the nucleotide sequence of SEQ ID NO:39 from nucleotide 114 to nucleotide 1142;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc52_1 deposited with the ATCC under accession number 98862;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc52_1 deposited with the ATCC under accession number 98862;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:40;

45. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:36;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
- the protein being substantially free from other mammalian proteins.

46. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:37;
- (b) the nucleotide sequence of SEQ ID NO:37 from nucleotide 139 to nucleotide 1308;
- (c) the nucleotide sequence of SEQ ID NO:37 from nucleotide 211 to nucleotide 1308;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc51_1 deposited with the ATCC under accession number 98862;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc51_1 deposited with the ATCC under accession number 98862;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc51_1 deposited with the ATCC under accession number 98862;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:38;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(c) the amino acid sequence encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862; the protein being substantially free from other mammalian proteins.

44. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:35;
- (b) the nucleotide sequence of SEQ ID NO:35 from nucleotide 150 to nucleotide 776;
- (c) the nucleotide sequence of SEQ ID NO:35 from nucleotide 246 to nucleotide 776;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc50_1 deposited with the ATCC under accession number 98862;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc50_1 deposited with the ATCC under accession number 98862;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:36;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36, the fragment comprising eight contiguous amino acids of SEQ ID NO:36;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:35.

- (a) the nucleotide sequence of SEQ ID NO:33;
- (b) the nucleotide sequence of SEQ ID NO:33 from nucleotide 164 to nucleotide 2548;
- (c) the nucleotide sequence of SEQ ID NO:33 from nucleotide 242 to nucleotide 2548;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc49_1 deposited with the ATCC under accession number 98862;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc49_1 deposited with the ATCC under accession number 98862;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:34;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:33.

43. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:34;
- (b) a fragment of the amino acid sequence of SEQ ID NO:34, the fragment comprising eight contiguous amino acids of SEQ ID NO:34; and

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc46_1 deposited with the ATCC under accession number 98862;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:32;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:31.

41. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:32;

(b) a fragment of the amino acid sequence of SEQ ID NO:32, the fragment comprising eight contiguous amino acids of SEQ ID NO:32; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc46_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins.

42. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(f) the nucleotide sequence of a mature protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:30;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:29.

39. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:30;

(b) a fragment of the amino acid sequence of SEQ ID NO:30, the fragment comprising eight contiguous amino acids of SEQ ID NO:30; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins.

40. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:31;

(b) the nucleotide sequence of SEQ ID NO:31 from nucleotide 38 to nucleotide 553;

(c) the nucleotide sequence of SEQ ID NO:31 from nucleotide 104 to nucleotide 553;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:28;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:27.

37. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:28;

(b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins.

38. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:29;

(b) the nucleotide sequence of SEQ ID NO:29 from nucleotide 35 to nucleotide 1066;

(c) the nucleotide sequence of SEQ ID NO:29 from nucleotide 128 to nucleotide 1066;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc40_1 deposited with the ATCC under accession number 98862;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc40_1 deposited with the ATCC under accession number 98862;

(g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d); and

(h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:25.

35. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:26;

(b) a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins.

36. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:27;

(b) the nucleotide sequence of SEQ ID NO:27 from nucleotide 105 to nucleotide 365;

(c) the nucleotide sequence of SEQ ID NO:27 from nucleotide 147 to nucleotide 365;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;

(f) the nucleotide sequence of a mature protein coding sequence of clone vc39_1 deposited with the ATCC under accession number 98862;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc39_1 deposited with the ATCC under accession number 98862;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:23.

33. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:24;

(b) a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24; and

(c) the amino acid sequence encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;

the protein being substantially free from other mammalian proteins.

34. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:25;

(b) the nucleotide sequence of SEQ ID NO:25 from nucleotide 370 to nucleotide 1662;

(c) the nucleotide sequence of the full-length protein coding sequence of clone vc38_1 deposited with the ATCC under accession number 98862;

(d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc38_1 deposited with the ATCC under accession number 98862;

(e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:26;

(f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26, the fragment comprising eight contiguous amino acids of SEQ ID NO:26;

C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:21.

31. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:22;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
- the protein being substantially free from other mammalian proteins.

32. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:23;
- (b) the nucleotide sequence of SEQ ID NO:23 from nucleotide 135 to nucleotide 368;
- (c) the nucleotide sequence of SEQ ID NO:23 from nucleotide 243 to nucleotide 368;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc36_1 deposited with the ATCC under accession number 98862;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc36_1 deposited with the ATCC under accession number 98862;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:24;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24, the fragment comprising eight contiguous amino acids of SEQ ID NO:24;

- (a) the amino acid sequence of SEQ ID NO:20;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
- the protein being substantially free from other mammalian proteins.

30. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:21;
- (b) the nucleotide sequence of SEQ ID NO:21 from nucleotide 74 to nucleotide 1453;
- (c) the nucleotide sequence of SEQ ID NO:21 from nucleotide 224 to nucleotide 1453;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vc35_1 deposited with the ATCC under accession number 98862;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vc35_1 deposited with the ATCC under accession number 98862;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:22;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22, the fragment comprising eight contiguous amino acids of SEQ ID NO:22;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees

the protein being substantially free from other mammalian proteins.

28. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:19;
- (b) the nucleotide sequence of SEQ ID NO:19 from nucleotide 174 to nucleotide 3170;
- (c) the nucleotide sequence of SEQ ID NO:19 from nucleotide 1098 to nucleotide 3170;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vb21_1 deposited with the ATCC under accession number 98862;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vb21_1 deposited with the ATCC under accession number 98862;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb21_1 deposited with the ATCC under accession number 98862;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:19.

29. A protein comprising an amino acid sequence selected from the group consisting of:

- (b) the nucleotide sequence of SEQ ID NO:17 from nucleotide 74 to nucleotide 529;
- (c) the nucleotide sequence of SEQ ID NO:17 from nucleotide 140 to nucleotide 529;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vk2_1 deposited with the ATCC under accession number 98838;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:17.

27. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:18;
- (b) a fragment of the amino acid sequence of SEQ ID NO:18, the fragment comprising eight contiguous amino acids of SEQ ID NO:18; and
- (c) the amino acid sequence encoded by the cDNA insert of clone vk2_1 deposited with the ATCC under accession number 98838;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vl1_1 deposited with the ATCC under accession number 98846;

(f) the nucleotide sequence of a mature protein coding sequence of clone vl1_1 deposited with the ATCC under accession number 98846;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vl1_1 deposited with the ATCC under accession number 98846;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:16;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:15.

25. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:16;

(b) a fragment of the amino acid sequence of SEQ ID NO:16, the fragment comprising eight contiguous amino acids of SEQ ID NO:16; and

(c) the amino acid sequence encoded by the cDNA insert of clone vl1_1 deposited with the ATCC under accession number 98846;

the protein being substantially free from other mammalian proteins.

26. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:17;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:14;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:13.

23. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:14;

(b) a fragment of the amino acid sequence of SEQ ID NO:14, the fragment comprising eight contiguous amino acids of SEQ ID NO:14; and

(c) the amino acid sequence encoded by the cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;

the protein being substantially free from other mammalian proteins.

24. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:15;

(b) the nucleotide sequence of SEQ ID NO:15 from nucleotide 62 to nucleotide 1057;

(c) the nucleotide sequence of SEQ ID NO:15 from nucleotide 659 to nucleotide 1057;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vj1_1 deposited with the ATCC under accession number 98846;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:11.

21. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:12;

(b) a fragment of the amino acid sequence of SEQ ID NO:12, the fragment comprising eight contiguous amino acids of SEQ ID NO:12; and

(c) the amino acid sequence encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;

the protein being substantially free from other mammalian proteins.

22. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

(a) the nucleotide sequence of SEQ ID NO:13;

(b) the nucleotide sequence of SEQ ID NO:13 from nucleotide 380 to nucleotide 892;

(c) the nucleotide sequence of SEQ ID NO:13 from nucleotide 416 to nucleotide 892;

(d) the nucleotide sequence of the full-length protein coding sequence of clone vj1_1 deposited with the ATCC under accession number 98846;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vj1_1 deposited with the ATCC under accession number 98846;

(f) the nucleotide sequence of a mature protein coding sequence of clone vj1_1 deposited with the ATCC under accession number 98846;

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:9.

19. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
- the protein being substantially free from other mammalian proteins.

20. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:11;
- (b) the nucleotide sequence of SEQ ID NO:11 from nucleotide 124 to nucleotide 1641;
- (c) the nucleotide sequence of SEQ ID NO:11 from nucleotide 262 to nucleotide 1641;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vg2_1 deposited with the ATCC under accession number 98846;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vg2_1 deposited with the ATCC under accession number 98846;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:12;

17. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:8;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;
- the protein being substantially free from other mammalian proteins.

18. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:9;
- (b) the nucleotide sequence of SEQ ID NO:9 from nucleotide 22 to nucleotide 468;
- (c) the nucleotide sequence of SEQ ID NO:9 from nucleotide 118 to nucleotide 468;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vf2_1 deposited with the ATCC under accession number 98846;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vf2_1 deposited with the ATCC under accession number 98846;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10, the fragment comprising eight contiguous amino acids of SEQ ID NO:10;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(c) the amino acid sequence encoded by the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846; the protein being substantially free from other mammalian proteins.

16. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:7;
- (b) the nucleotide sequence of SEQ ID NO:7 from nucleotide 82 to nucleotide 294;
- (c) the nucleotide sequence of SEQ ID NO:7 from nucleotide 109 to nucleotide 294;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone ve11_1 deposited with the ATCC under accession number 98846;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;
- (f) the nucleotide sequence of a mature protein coding sequence of clone ve11_1 deposited with the ATCC under accession number 98846;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone ve11_1 deposited with the ATCC under accession number 98846;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:7.

- (a) the nucleotide sequence of SEQ ID NO:5;
- (b) the nucleotide sequence of SEQ ID NO:5 from nucleotide 1195 to nucleotide 1527;
- (c) the nucleotide sequence of SEQ ID NO:5 from nucleotide 1468 to nucleotide 1527;
- (d) the nucleotide sequence of the full-length protein coding sequence of clone vb14_1 deposited with the ATCC under accession number 98846;
- (e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;
- (f) the nucleotide sequence of a mature protein coding sequence of clone vb14_1 deposited with the ATCC under accession number 98846;
- (g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb14_1 deposited with the ATCC under accession number 98846;
- (h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
- (i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6;
- (j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and
- (k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:5.

15. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:6;
- (b) a fragment of the amino acid sequence of SEQ ID NO:6, the fragment comprising eight contiguous amino acids of SEQ ID NO:6; and

(d) the nucleotide sequence of the full-length protein coding sequence of clone vb12_1 deposited with the ATCC under accession number 98846;

(e) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;

(f) the nucleotide sequence of a mature protein coding sequence of clone vb12_1 deposited with the ATCC under accession number 98846;

(g) a nucleotide sequence encoding a mature protein encoded by the cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;

(h) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

(i) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4;

(j) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g); and

(k) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(g), and that has a length that is at least 25% of the length of SEQ ID NO:3.

13. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:4;

(b) a fragment of the amino acid sequence of SEQ ID NO:4, the fragment comprising eight contiguous amino acids of SEQ ID NO:4; and

(c) the amino acid sequence encoded by the cDNA insert of clone vb12_1 deposited with the ATCC under accession number 98846;

the protein being substantially free from other mammalian proteins.

14. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) growing a culture of a host cell in a suitable culture medium, wherein the host cell has been transformed with the polynucleotide of claim 2; and
 - (b) purifying said protein from the culture.
- 6. A protein produced according to the process of claim 5.
- 7. An isolated polynucleotide encoding the protein of claim 6.
- 8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846.
- 9. A protein comprising an amino acid sequence selected from the group consisting of:
 - (a) the amino acid sequence of SEQ ID NO:2;
 - (b) a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846;the protein being substantially free from other mammalian proteins.
- 10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.
- 11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.
- 12. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
 - (a) the nucleotide sequence of SEQ ID NO:3;
 - (b) the nucleotide sequence of SEQ ID NO:3 from nucleotide 63 to nucleotide 482;
 - (c) the nucleotide sequence of SEQ ID NO:3 from nucleotide 201 to nucleotide 482;

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

- (a) the nucleotide sequence of SEQ ID NO:1;
- (b) the nucleotide sequence of SEQ ID NO:1 from nucleotide 683 to nucleotide 934;
- (c) the nucleotide sequence of the full-length protein coding sequence of clone vb11_1 deposited with the ATCC under accession number 98846;
- (d) a nucleotide sequence encoding the full-length protein encoded by the cDNA insert of clone vb11_1 deposited with the ATCC under accession number 98846;
- (e) a nucleotide sequence encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- (f) a nucleotide sequence encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2, the fragment comprising eight contiguous amino acids of SEQ ID NO:2;
- (g) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 65 degrees C, or 4X SSC at 42 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d); and
- (h) the nucleotide sequence of a polynucleotide that hybridizes under conditions at least as stringent as 4X SSC at 50 degrees C, or 6X SSC at 40 degrees C with 50% formamide, to any one of the polynucleotides specified by (a)-(d), and that has a length that is at least 25% of the length of SEQ ID NO:1.

2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

3. A host cell transformed with the polynucleotide of claim 2.

4. The host cell of claim 3, wherein said cell is a mammalian cell.

5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:

the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such
5 polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present
10 invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

Patent and literature references cited herein are incorporated by reference as if fully set forth.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions
5 from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of
10 carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to
15 provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in
20 question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to
25 humans, are desired patients for such treatment with proteins of the present invention.

The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of
30 a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect

abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

5 For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably
10 be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the
15 methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical
20 applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium
25 sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other
30 ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Such term also includes any other species derived from an antibody or antibody sequence which is capable of binding the indicated protein.

Antibodies to a particular protein can be produced by methods well known to those skilled in the art. For example, monoclonal antibodies can be produced by generation of antibody-producing hybridomas in accordance with known methods (see for example, 5 Goding, 1983, *Monoclonal antibodies: principles and practice*, Academic Press Inc., New York; and Yokoyama, 1992, "Production of Monoclonal Antibodies" in *Current Protocols in Immunology*, Unit 2.5, Greene Publishing Assoc. and John Wiley & Sons). Polyclonal sera and antibodies can be produced by inoculation of a mammalian subject with the 10 relevant protein or fragments thereof in accordance with known methods. Fragments of antibodies, receptors, or other reactive peptides can be produced from the corresponding antibodies by cleavage of and collection of the desired fragments in accordance with known methods (see for example, Goding, *supra*; and Andrew et al., 1992, "Fragmentation of Immunoglobulins" in *Current Protocols in Immunology*, Unit 2.8, Greene Publishing 15 Assoc. and John Wiley & Sons). Chimeric antibodies and single chain antibodies can also be produced in accordance with known recombinant methods (see for example, 5,169,939, 5,194,594, and 5,576,184). Humanized antibodies can also be made from corresponding murine antibodies in accordance with well known methods (see for example, U.S. Patent Nos. 5,530,101, 5,585,089, and 5,693,762). Additionally, human antibodies may be 20 produced in non-human animals such as mice that have been genetically altered to express human antibody molecules (see for example Fishwild *et al.*, 1996, *Nature Biotechnology* 14: 845-851; Mendez *et al.*, 1997, *Nature Genetics* 15: 146-156 (erratum *Nature Genetics* 16: 410); and U.S. Patents 5,877,397 and 5,625,126). Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide 25 immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, J. Amer.Chem.Soc. 85, 2149-2154 (1963); J.L. Krstenansky, *et al.*, *FEBS Lett.* 211, 10 (1987).

Monoclonal antibodies binding to the protein of the invention may be useful 30 diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where

invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should
5 contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

10 The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician
15 will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 µg to about 100
20 mg (preferably about 0.1mg to about 10 mg, more preferably about 0.1 µg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is
25 contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain
30 polyclonal and monoclonal antibodies which specifically react with the protein. As used herein, the term "antibody" includes without limitation a polyclonal antibody, a monoclonal antibody, a chimeric antibody, a single-chain antibody, a CDR-grafted antibody, a humanized antibody, or fragments thereof which bind to the indicated protein.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in
5 combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If
10 administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical
15 composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is
20 administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention.
25 When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid
30 form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present

compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic
5 lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen
10 in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a
15 pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the
20 carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN, TNF0, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other
25 agents which either enhance the activity of the protein or complement its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor,
30 thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or circadian cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s);

extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this
5 recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells
10 become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas
15 to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed
20 in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the
25 inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block
30 the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static
5 conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

10 Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the
15 inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic
20 inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

25

Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to
30 tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/19351

SEQ ID NO:78 and fragments of the polypeptide of said polypeptide.

Group XL, claim(s)88-89, drawn to polynucleotide comprising SEQ ID NO:79, fragments thereof, polypeptide of SEQ ID NO:80 and fragments of the polypeptide of said polypeptide.

The inventions listed as Groups I-XL do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The main invention is Group I, which is first product, first method of making the product and first method of using the product. Pursuant to 37 CFR 1.474 (d), these claims are considered by the ISA/US to constitute the main invention. The products of Groups II-XL do not share the same or corresponding special technical feature with group I because they are drawn to products having materially different structures and functions, each defines a separate invention over the art. Therefore, the claims are not linked by a special technical feature within the meaning of PCT Rule 13.2 so as to form a single inventive concept.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/19351

Group XIX, claim(s)46-47, drawn to polynucleotide comprising SEQ ID NO:37, fragments thereof, polypeptide of SEQ ID NO:38 and fragments of the polypeptide of said polypeptide.

Group XX, claim(s)48-49, drawn to polynucleotide comprising SEQ ID NO:39, fragments thereof, polypeptide of SEQ ID NO:40 and fragments of the polypeptide of said polypeptide.

Group XXI, claim(s)50-51, drawn to polynucleotide comprising SEQ ID NO:41, fragments thereof, polypeptide of SEQ ID NO:42 and fragments of the polypeptide of said polypeptide.

Group XXII, claim(s)52-53, drawn to polynucleotide comprising SEQ ID NO:43, fragments thereof, polypeptide of SEQ ID NO:44 and fragments of the polypeptide of said polypeptide.

Group XXIII, claim(s)54-55, drawn to polynucleotide comprising SEQ ID NO:45, fragments thereof, polypeptide of SEQ ID NO:46 and fragments of the polypeptide of said polypeptide.

Group XXIV, claim(s)56-57, drawn to polynucleotide comprising SEQ ID NO:47, fragments thereof, polypeptide of SEQ ID NO:48 and fragments of the polypeptide of said polypeptide.

Group XXV, claim(s)58-59, drawn to polynucleotide comprising SEQ ID NO:49, fragments thereof, polypeptide of SEQ ID NO:50 and fragments of the polypeptide of said polypeptide.

Group XXVI, claim(s)60-61, drawn to polynucleotide comprising SEQ ID NO:51, fragments thereof, polypeptide of SEQ ID NO:52 and fragments of the polypeptide of said polypeptide.

Group XXVII, claim(s)62-63, drawn to polynucleotide comprising SEQ ID NO:53, fragments thereof, polypeptide of SEQ ID NO:54 and fragments of the polypeptide of said polypeptide.

Group XXVIII, claim(s)64-65, drawn to polynucleotide comprising SEQ ID NO:55, fragments thereof, polypeptide of SEQ ID NO:56 and fragments of the polypeptide of said polypeptide.

Group XXIX, claim(s)66-67, drawn to polynucleotide comprising SEQ ID NO:57, fragments thereof, polypeptide of SEQ ID NO:58 and fragments of the polypeptide of said polypeptide.

Group XXX, claim(s)68-69, drawn to polynucleotide comprising SEQ ID NO:59, fragments thereof, polypeptide of SEQ ID NO:60 and fragments of the polypeptide of said polypeptide.

Group XXXI, claim(s)70-71, drawn to polynucleotide comprising SEQ ID NO:61, fragments thereof, polypeptide of SEQ ID NO:62 and fragments of the polypeptide of said polypeptide.

Group XXXII, claim(s)72-73, drawn to polynucleotide comprising SEQ ID NO:63, fragments thereof, polypeptide of SEQ ID NO:64 and fragments of the polypeptide of said polypeptide.

Group XXXIII, claim(s)74-75, drawn to polynucleotide comprising SEQ ID NO:65, fragments thereof, polypeptide of SEQ ID NO:66 and fragments of the polypeptide of said polypeptide.

Group XXXIV, claim(s)76-77, drawn to polynucleotide comprising SEQ ID NO:67, fragments thereof, polypeptide of SEQ ID NO:68 and fragments of the polypeptide of said polypeptide.

Group XXXV, claim(s)78-79, drawn to polynucleotide comprising SEQ ID NO:69, fragments thereof, polypeptide of SEQ ID NO:70 and fragments of the polypeptide of said polypeptide.

Group XXXVI, claim(s)80-81, drawn to polynucleotide comprising SEQ ID NO:71, fragments thereof, polypeptide of SEQ ID NO:72 and fragments of the polypeptide of said polypeptide.

Group XXXVII, claim(s)82-83, drawn to polynucleotide comprising SEQ ID NO:73, fragments thereof, polypeptide of SEQ ID NO:74 and fragments of the polypeptide of said polypeptide.

Group XXXVIII, claim(s)84-85, drawn to polynucleotide comprising SEQ ID NO:75, fragments thereof, polypeptide of SEQ ID NO:76 and fragments of the polypeptide of said polypeptide.

Group XXXIX, claim(s)86-87, drawn to polynucleotide comprising SEQ ID NO:77, fragments thereof, polypeptide of

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/19351

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1-11, drawn to polynucleotide comprising SEQ ID NO:1, fragments thereof, expression vector containing said sequence, cell transformed with said vector, polypeptide of SEQ ID NO:2, fragments of the polypeptide of SEQ ID NO:2 and process for preparing said polypeptide.

Group II, claim(s)12-13, drawn to polynucleotide comprising SEQ ID NO:3, fragments thereof, polypeptide of SEQ ID NO:4 and fragments of the polypeptide of said polypeptide.

Group III, claim(s)14-15, drawn to polynucleotide comprising SEQ ID NO:5, fragments thereof, polypeptide of SEQ ID NO:6 and fragments of the polypeptide of said polypeptide.

Group IV, claim(s)16-17, drawn to polynucleotide comprising SEQ ID NO:7, fragments thereof, polypeptide of SEQ ID NO:8 and fragments of the polypeptide of said polypeptide.

Group V, claim(s)18-19, drawn to polynucleotide comprising SEQ ID NO:9, fragments thereof, polypeptide of SEQ ID NO:10 and fragments of the polypeptide of said polypeptide.

Group VI, claim(s)20-21, drawn to polynucleotide comprising SEQ ID NO:11, fragments thereof, polypeptide of SEQ ID NO:12 and fragments of the polypeptide of said polypeptide.

Group VII, claim(s)22-23, drawn to polynucleotide comprising SEQ ID NO:13, fragments thereof, polypeptide of SEQ ID NO:14 and fragments of the polypeptide of said polypeptide.

Group VIII, claim(s)24-25, drawn to polynucleotide comprising SEQ ID NO:15, fragments thereof, polypeptide of SEQ ID NO:16 and fragments of the polypeptide of said polypeptide.

Group IX, claim(s)26-27, drawn to polynucleotide comprising SEQ ID NO:17, fragments thereof, polypeptide of SEQ ID NO:18 and fragments of the polypeptide of said polypeptide.

Group X, claim(s)28-29, drawn to polynucleotide comprising SEQ ID NO:19, fragments thereof, polypeptide of SEQ ID NO:20 and fragments of the polypeptide of said polypeptide.

Group XI, claim(s)30-31, drawn to polynucleotide comprising SEQ ID NO:21, fragments thereof, polypeptide of SEQ ID NO:22 and fragments of the polypeptide of said polypeptide.

Group XII, claim(s)32-33, drawn to polynucleotide comprising SEQ ID NO:23, fragments thereof, polypeptide of SEQ ID NO:24 and fragments of the polypeptide of said polypeptide.

Group XIII, claim(s)34-35, drawn to polynucleotide comprising SEQ ID NO:25, fragments thereof, polypeptide of SEQ ID NO:26 and fragments of the polypeptide of said polypeptide.

Group XIV, claim(s)36-37, drawn to polynucleotide comprising SEQ ID NO:27, fragments thereof, polypeptide of SEQ ID NO:28 and fragments of the polypeptide of said polypeptide.

Group XV, claim(s)38-39, drawn to polynucleotide comprising SEQ ID NO:29, fragments thereof, polypeptide of SEQ ID NO:30 and fragments of the polypeptide of said polypeptide.

Group XVI, claim(s)40-41, drawn to polynucleotide comprising SEQ ID NO:31, fragments thereof, polypeptide of SEQ ID NO:32 and fragments of the polypeptide of said polypeptide.

Group XVII, claim(s)42-43, drawn to polynucleotide comprising SEQ ID NO:33, fragments thereof, polypeptide of SEQ ID NO:34 and fragments of the polypeptide of said polypeptide.

Group XVIII, claim(s)44-45, drawn to polynucleotide comprising SEQ ID NO:35, fragments thereof, polypeptide of SEQ ID NO:36 and fragments of the polypeptide of said polypeptide.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/19351

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-11 and 44-45
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/19351

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/04; C07K 14/705; C12N 15/09; 15/63; C12Q 1/68

US CL : 536/23.1, 24.3; 435/7.2, 69.1, 320.1; 530/350, 300

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 24.3; 435/7.2, 69.1, 320.1; 530/350, 300

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, JAPIO, BIOSIS, WPIDS, CAPLUS, EMBASE, N-GENESEQ35, N-ISSUED, EMBL-EST58, PIR60, SWISS-PROT37, SPTREMBL19, EMBL58

search terms: secreted proteins, 98862, 98846, VB11

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database EMBASE EST-58 , Accession No. AA458581, NID g2183488, HILLIER et al., 'aa12e01.rl Soares-NhHMPu-S1 Homo sapiens cDNA clone IMAGE:813048 5' similar to contains element PTR5 repetitive element; mRNA sequence, 9 June, 1997	1-11
O X	Database EMBASE EST 158, Accession No. Z99943, NID g2887308, PEARCE, A., 'Human DNA sequence from PAC 313L4 on chromosome 1q24. Contains ESTs.' 12 February 1998	44-45

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents.	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

16 NOVEMBER 1999

Date of mailing of the international search report

11 JAN 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

NIRMAL S. BASI

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

50 55 60

Phe Phe Ala Ala Ile Cys Leu Val Ser Leu Val Phe Thr Gly Cys Cys
65 70 75 80

Val Pro Glu Thr Lys Gly Arg Ser Leu Glu Gln Ile Glu Phe Leu Leu
85 90 95

Pro His Gly Glu Lys Val Leu Leu Ala Leu Gly Gln Gly Pro Arg Leu
100 105 110

Glu Gly Ala Lys Pro Pro Val Ala Gly Pro Leu Cys Trp Leu Cys Lys
115 120 125

Glu Asp Pro Ala Leu Pro Ser Gln Val Leu Trp Ala Pro Gln Gly Thr
130 135 140

Ser Trp Thr
145

Ser Lys Glu Val Ser Glu Lys Ala Lys Leu Tyr Ser
275 280

<210> 131
<211> 175
<212> PRT
<213> Homo sapiens

<400> 131
Met Arg Pro Ala Phe Ala Leu Cys Leu Leu Trp Gln Ala Leu Trp Pro
1 5 10 15

Gly Pro Gly Gly Gly Glu His Pro Thr Ala Asp Arg Ala Gly Cys Ser
20 25 30

Ala Ser Gly Ala Cys Tyr Ser Leu His His Ala Thr Met Lys Arg Gln
35 40 45

Ala Ala Glu Glu Ala Cys Ile Leu Arg Gly Gly Ala Leu Ser Thr Val
50 55 60

Arg Ala Gly Ala Glu Leu Arg Ala Val Leu Ala Leu Arg Ala Gly
65 70 75 80

Pro Gly Pro Gly Gly Gly Ser Lys Asp Leu Leu Phe Trp Val Ala Leu
85 90 95

Glu Arg Arg Arg Ser His Cys Thr Leu Glu Asn Glu Pro Leu Arg Gly
100 105 110

Phe Ser Trp Leu Ser Ser Asp Pro Gly Gly Leu Glu Ser Asp Thr Leu
115 120 125

Gln Trp Val Glu Glu Pro Gln Arg Ser Cys Thr Arg Ala Glu Met Arg
130 135 140

Gly Thr Pro Gly His Arg Trp Gly Arg Ala Arg Arg Leu Glu Gly Asp
145 150 155 160

Ala Met Pro Pro Ala Arg Gln Arg Leu Pro Val Gln Val Pro Val
165 170 175

<210> 132
<211> 147
<212> PRT
<213> Homo sapiens

<400> 132
Met Leu Phe Ile Met Gly Tyr Ala Val Gly Trp Gly Pro Ile Thr Trp
1 5 10 15

Leu Leu Met Ser Glu Val Leu Pro Leu Arg Ala Arg Gly Val Ala Ser
20 25 30

Gly Leu Cys Val Leu Ala Ser Trp Leu Thr Ala Phe Val Leu Thr Lys
35 40 45

Ser Phe Leu Pro Val Val Ser Thr Phe Gly Leu Gln Val Pro Phe Phe

130 135 140

<210> 130
 <211> 284
 <212> PRT
 <213> Homo sapiens

<400> 130
 Met Glu Asp Leu Asp Gln Ser Pro Leu Val Ser Ser Ser Asp Ser Pro
 1 5 10 15

Pro Arg Pro Gln Pro Ala Phe Lys Tyr Gln Phe Val Arg Glu Pro Glu
 20 25 30

Asp Glu Glu Glu Glu Glu Glu Glu Glu Glu Asp Glu Asp Glu Asp
 35 40 45

Leu Glu Glu Leu Glu Val Leu Glu Arg Lys Pro Ala Ala Gly Leu Ser
 50 55 60

Ala Ala Pro Val Pro Thr Ala Pro Ala Ala Gly Ala Pro Leu Met Asp
 65 70 75 80

Phe Gly Asn Asp Phe Val Pro Pro Ala Pro Arg Gly Pro Leu Pro Ala
 85 90 95

Ala Pro Pro Val Ala Pro Glu Arg Gln Pro Ser Trp Asp Pro Ser Pro
 100 105 110

Val Ser Ser Thr Val Pro Ala Pro Ser Pro Leu Ser Ala Ala Ala Val
 115 120 125

Ser Pro Ser Lys Leu Pro Glu Asp Asp Glu Pro Pro Ala Arg Pro Pro
 130 135 140

Pro Pro Pro Pro Ala Ser Val Ser Pro Gln Ala Glu Pro Val Trp Thr
 145 150 155 160

Pro Pro Ala Pro Ala Pro Ala Ala Pro Pro Ser Thr Pro Ala Ala Pro
 165 170 175

Lys Arg Arg Gly Ser Ser Gly Ser Val Asp Glu Thr Leu Phe Ala Leu
 180 185 190

Pro Ala Ala Ser Glu Pro Val Ile Arg Ser Ser Ala Glu Asn Met Asp
 195 200 205

Leu Lys Glu Gln Pro Gly Asn Thr Ile Ser Ala Gly Gln Glu Asp Phe
 210 215 220

Pro Ser Val Leu Leu Glu Thr Ala Ala Ser Leu Pro Ser Leu Ser Pro
 225 230 235 240

Leu Ser Ala Ala Ser Phe Lys Glu His Glu Tyr Leu Gly Asn Leu Ser
 245 250 255

Thr Val Leu Pro Thr Glu Gly Thr Leu Gln Glu Asn Val Ser Glu Ala
 260 265 270

<212> PRT

<213> Homo sapiens

<400> 128

Met Arg Ala Thr His Cys Gln Ala Ala Arg Met Phe Val Leu Phe Ser
 1 5 10 15

Arg Glu Gly Asn Pro Thr Gly Phe Cys Gly Asn Asn Gly Asn Leu Gln
 20 25 30

Met Pro Ala Trp Asp Asp Glu Ala His Ser Glu Gln Met Leu Phe Phe
 35 40 45

Phe Leu Arg Gln Ser Leu Ala Leu Thr Pro Arg Leu Glu Cys Ser Gly
 50 55 60

Ala Ile Ser Ala His Cys Lys Leu Cys Leu Pro Gly Ser Ser Asp Ser
 65 70 75 80

Pro Thr Ser Ala Ser Arg Val Ala Gly Ile Thr Pro Pro Cys Pro Ala
 85 90 95

Asn Phe Cys Val Phe Ser Arg Asp Gly Val Ser Pro Cys Trp Pro Gly
 100 105 110

Trp Ser Arg Thr Pro Asp Leu Arg
 115 120

<210> 129

<211> 143

<212> PRT

<213> Homo sapiens

<400> 129

Met Ala Glu Gly Glu Lys Asn Gln Asp Phe Thr Phe Lys Lys Glu Ser
 1 5 10 15

Pro Ser Asp Ser Ala Val Val Leu Pro Ser Thr Pro Gln Ala Ser Ala
 20 25 30

Asn Pro Ser Ser Pro Tyr Thr Asn Ser Ser Arg Lys Gln Pro Met Ser
 35 40 45

Ala Thr Leu Arg Glu Arg Leu Arg Lys Thr Arg Phe Ser Phe Asn Ser
 50 55 60

Ser Tyr Asn Val Val Lys Arg Leu Lys Val Glu Ser Glu Glu Asn Asp
 65 70 75 80

Gln Thr Phe Ser Glu Lys Pro Ala Ser Ser Thr Glu Glu Asn Cys Leu
 85 90 95

Glu Phe Gln Glu Ser Phe Lys His Ile Asp Ser Glu Phe Glu Glu Asn
 100 105 110

Thr Asn Leu Lys Asn Thr Leu Thr Ala Ile Ser Met Ser Val Asn Leu
 115 120 125

Ser His Leu Ile Leu Asp His Ala Val Leu Ser Lys Met Ser Leu

Glu Tyr Pro Trp Ser Thr Pro Cys Pro Pro Gly Thr Cys Pro Cys Gly
 100 105 110

Trp Arg Val Ser Arg Arg Lys Thr Leu Ala Pro Thr Ala Ala Pro
 115 120 125

<210> 126
 <211> 91
 <212> PRT
 <213> Homo sapiens

<400> 126
 Met Asn Gly Val Thr His His Val Ala Phe Cys Val Trp Phe Leu Pro
 1 5 10 15

Leu Ser Ile Met Ile Ser Ser Ser Cys Arg Ser Met His Leu Ser Phe
 20 25 30

Ile Pro Ser His Gly Ala Ile Ile Phe His Cys Val Tyr Lys Thr Thr
 35 40 45

Phe Cys Gln Ser Thr His Pro Trp Ile Thr Ser Ala Phe Leu Lys Gly
 50 55 60

Ala Phe Thr Ser Gln Thr Gln Phe Ser Val Gly Glu Gly Val Arg Gly
 65 70 75 80

Gln Tyr Arg Ser Asp Cys Lys Arg His Lys Leu
 85 90

<210> 127
 <211> 84
 <212> PRT
 <213> Homo sapiens

<400> 127
 Met Leu Phe Pro Ser Ser Ser Ser Lys Pro Phe Ser Leu Leu Ser Leu
 1 5 10 15

Thr Ile Trp Ala Arg Leu Val Gly Arg Leu Thr Asn Arg Ile Cys Pro
 20 25 30

Val Pro Pro Gly Ser Val Ala Ser Ser Met Ser Leu Gln Ala Gly Arg
 35 40 45

Cys Gly Asn Pro Val Val Leu Pro Gln Pro Met Pro Pro Gly Leu Leu
 50 55 60

Cys Met Asn Glu Cys Ser Leu Val Pro Gly Leu Gly Arg Gly Gln Val
 65 70 75 80

Asn Ser Arg Val

<210> 128
 <211> 120

Ser Leu Thr Asn Leu Ser Ser Ser Met Ala Gly Val Tyr Val Cys Lys
 145 150 155 160
 Ala His Asn Glu Val Gly Thr Ala Gln Cys Asn Val Thr Leu Glu Val
 165 170 175
 Ser Thr Gly Pro Gly Ala Ala Val Val Ala Gly Ala Val Val Gly Thr
 180 185 190
 Leu Val Gly Leu Gly Leu Leu Ala Gly Leu Val Leu Leu Tyr His Arg
 195 200 205
 Arg Gly Lys Ala Leu Glu Glu Pro Ala Asn Asp Ile Lys Glu Asp Ala
 210 215 220
 Ile Ala Pro Arg Thr Leu Pro Trp Pro Lys Ser Ser Asp Thr Ile Ser
 225 230 235 240
 Lys Asn Gly Thr Leu Ser Ser Val Thr Ser Ala Arg Ala Leu Arg Pro
 245 250 255
 Pro His Gly Pro Pro Arg Pro Gly Ala Leu Thr Pro Thr Pro Ser Leu
 260 265 270
 Ser Ser Gln Ala Leu Pro Ser Pro Arg Leu Pro Thr Thr Asp Gly Ala
 275 280 285
 His Pro Gln Pro Ile Ser Pro Ile Pro Gly Gly Val Ser Ser Ser Gly
 290 295 300
 Leu Ser Arg Met Gly Ala Val Pro Val Met Val Pro Ala Gln Ser Gln
 305 310 315 320
 Ala Gly Ser Leu Val
 325

<210> 125

<211> 127

<212> PRT

<213> Homo sapiens

<400> 125

Met Ile Ser Leu Pro Gly Pro Leu Val Thr Asn Leu Leu Arg Phe Leu
 1 5 10 15
 Phe Leu Gly Leu Ser Ala Leu Ala Pro Pro Ser Arg Ala Gln Leu Gln
 20 25 30
 Leu His Leu Pro Ala Asn Arg Leu Gln Ala Val Glu Gly Gly Glu Val
 35 40 45
 Val Leu Pro Ala Trp Tyr Thr Leu His Gly Glu Val Ser Ser Ser Gln
 50 55 60
 Pro Trp Glu Val Pro Phe Val Met Trp Phe Phe Lys Gln Lys Glu Lys
 65 70 75 80
 Glu Asp Gln Cys Cys Pro Thr Ser Met Gly Ser Gln Gln Ala Asn Leu
 85 90 95

<210> 123
 <211> 90
 <212> PRT
 <213> Homo sapiens

<400> 123
 Met Arg Leu Ser Thr Val Gly Thr Val His Ser Gly Pro Pro Leu Ser
 1 5 10 15
 Ser Gly Leu Leu Thr Gly Ala Pro Cys His Val Val Thr Met Ala His
 20 25 30
 Arg Pro Leu Leu Leu Leu Leu Leu Leu Pro Pro Glu Glu Leu Arg
 35 40 45
 Leu Cys Phe Gly Leu Leu Val Ser Gly Gln Phe Leu Val Val Leu Leu
 50 55 60
 Arg Leu Arg Gly Pro Asp Leu Phe Leu His His Arg Ile Val His Leu
 65 70 75 80
 Val Phe Leu Thr Leu Arg Phe Leu Ala Cys
 85 90

<210> 124
 <211> 325
 <212> PRT
 <213> Homo sapiens

<400> 124
 Met Gly Gly Ala Leu Cys Asp Val Val Leu Gln Thr Glu Arg Lys Gly
 1 5 10 15
 Gly Ser Val Leu Ser Tyr Ile Asn Gly Val Thr Thr Ser Lys Pro Gly
 20 25 30
 Val Ser Leu Val Tyr Ser Met Pro Ser Arg Asn Leu Ser Leu Arg Leu
 35 40 45
 Glu Gly Leu Gln Glu Lys Asp Ser Gly Pro Tyr Ser Cys Ser Val Asn
 50 55 60
 Val Gln Asp Lys Gln Gly Lys Ser Arg Gly His Ser Ile Lys Thr Leu
 65 70 75 80
 Glu Leu Asn Val Leu Val Pro Pro Ala Pro Pro Ser Cys Arg Leu Gln
 85 90 95
 Gly Val Pro His Val Gly Ala Asn Val Thr Leu Ser Cys Gln Ser Pro
 100 105 110
 Arg Ser Lys Pro Ala Val Gln Tyr Gln Trp Asp Arg Gln Leu Pro Ser
 115 120 125
 Phe Gln Thr Phe Phe Ala Pro Ala Leu Asp Val Ile Arg Gly Ser Leu
 130 135 140

<400> 119
cagacatgag cagccagg

18

<210> 120
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<221> oligonucleotide

<400> 120
tgcctcatat gatcgagag

19

<210> 121
<211> 51
<212> PRT
<213> Homo sapiens

<400> 121
Met Gly Leu Lys Asn Ser Arg Phe Trp Glu Pro Ser Met Leu Ser Leu
1 5 10 15

Ser Pro Leu Leu Ser Thr Ser Leu Pro Asn Glu Arg Val Thr Glu Asn
20 25 30

Cys Phe Phe Ile Asn Arg Ser Phe Leu Ile Val Ser Gly Phe Asp Thr
35 40 45

Ser Val Val
50

<210> 122
<211> 101
<212> PRT
<213> Homo sapiens

<400> 122
Met Glu Thr Val Met Thr Leu Glu Gly Gly Gln Lys Pro Val Met Glu
1 5 10 15

Ser Tyr Thr Leu Leu Leu Ser Pro Pro Glu Thr Gln Asp Glu Gly Trp
20 25 30

Thr Leu Ala Leu Ser Leu Ala Leu Thr Tyr Arg Leu Gly Pro Gly Ser
35 40 45

Val Leu Leu Ala Pro Arg Ser Pro Trp Arg Leu Gln Lys Pro Pro Pro
50 55 60

Ala Gly Gly Leu Pro His Ser Gln Leu Pro Ala Arg Gln Trp Gly Leu
65 70 75 80

Leu Arg Gln Ala Gly Pro Lys Thr Val Ser Pro Leu Gly Thr Tyr Ser
85 90 95

Pro Pro Ser Ile Cys
100

<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 114
accttgacac ctggctcc

18

<210> 115
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 115
actttcctct gcaattcatt c

21

<210> 116
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 116
tcacttctcc aaattctccg

20

<210> 117
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 117
tgggtctctg agatttcaac

20

<210> 118
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 118
tcactcactc ccagcatcc

19

<210> 119
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 108 tctgagggaa gaagggaatg	20
<210> 109 <211> 19 <212> DNA <213> Artificial Sequence	
<220> <223> oligonucleotide	
<400> 109 ttcaacagag ctgggcaag	19
<210> 110 <211> 18 <212> DNA <213> Artificial Sequence	
<220> <223> oligonucleotide	
<400> 110 tgtegtccgg tcactgtg	18
<210> 111 <211> 20 <212> DNA <213> Artificial Sequence	
<220> <223> oligonucleotide	
<400> 111 ctcataaagc aagagctggc	20
<210> 112 <211> 19 <212> DNA <213> Artificial Sequence	
<220> <223> oligonucleotide	
<400> 112 acggaagcac cagcactag	19
<210> 113 <211> 21 <212> DNA <213> Artificial Sequence	
<220> <223> oligonucleotide	
<400> 113 cccaaaagca gtattcaaaa c	21
<210> 114 <211> 18	

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 103

ttcaatgggt gaattgtatg g

21

<210> 104

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 104

tggaatagca tgactgggtg

20

<210> 105

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 105

tctcagaagc atcaccaact g

21

<210> 106

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 106

attctgtctt tctcttctct c

21

<210> 107

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 107

cctcactgag ggtgaactgc

20

<210> 108

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

ctgagttgat tagaatgctg

20

<210> 98

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 98

tgtacctcaa gcacagccc

19

<210> 99

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 99

cacatcacaa agggcacc

18

<210> 100

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 100

agacccttgg acctggcag

19

<210> 101

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 101

gaacctggag caaggacac

19

<210> 102

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 102

cccgtggaag tagagagcc

19

<210> 103

<211> 21

<212> DNA

<220>
<223> oligonucleotide

<400> 92
tgtgaaattg tctgtagaaa g 21

<210> 93
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 93
ctactctgga gtcagccgc 19

<210> 94
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 94
aacattgtgg aaacagtgac c 21

<210> 95
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 95
ggttggagag tcagcactcg 20

<210> 96
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 96
tgtgagagca cagactgcg 19

<210> 97
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 97

<210> 87
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 87
ggcaaccagt agcatcagg

19

<210> 88
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 88
tgaactcgga gtgctctgg

19

<210> 89
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 89
ctggcttcag taccctcg

18

<210> 90
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 90
acgccctggt ggaggacctc

20

<210> 91
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 91
aagagttcaa ctattggggc

20

<210> 92
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 81
tcagtcacag aggcattcaa g

<210> 82
<211> 21
<212> DNA
<213> Artificial Sequence

21

<220>
<223> oligonucleotide

<400> 82
ctgattgtgc attgtatctg g

<210> 83
<211> 19
<212> DNA
<213> Artificial Sequence

21

<220>
<223> oligonucleotide

<400> 83
tcacggacac agaggaagg

<210> 84
<211> 18
<212> DNA
<213> Artificial Sequence

19

<220>
<223> oligonucleotide

<400> 84
ccctagtgcc ctgtcacc

<210> 85
<211> 18
<212> DNA
<213> Artificial Sequence

18

<220>
<223> oligonucleotide

<400> 85
tcagggtttc atctcggg

<210> 86
<211> 20
<212> DNA
<213> Artificial Sequence

18

<220>
<223> oligonucleotide

<400> 86
ggagttcatc tatgcctccg

20

Ala Arg Arg Val His Glu Leu Glu Arg Val Lys Arg Arg Cys Leu Glu
85 90 95

Asn Gly Asn Leu Lys Glu Lys Asp Ile Leu Val Leu Pro Leu Asp Leu
100 105 110

Thr Asp Thr Gly Ser His Glu Ala Ala Thr Lys Ala Val Leu Gln Glu
115 120 125

Phe Gly Arg Ile Asp Ile Leu Val Asn Asn Gly Gly Met Ser Gln Arg
130 135 140

Ser Leu Cys Met Asp Thr Ser Leu Asp Val Tyr Arg Lys Leu Ile Glu
145 150 155 160

Leu Asn Tyr Leu Gly Thr Val Ser Leu Thr Lys Cys Val Leu Pro His
165 170 175

Met Ile Glu Arg Lys Gln Gly Lys Ile Val Thr Val Asn Ser Ile Leu
180 185 190

Gly Ile Ile Ser Val Pro Leu Ser Ile Gly Tyr Cys Ala Ser Lys His
195 200 205

Ala Leu Arg Gly Phe Phe Asn Gly Leu Arg Thr Glu Leu Ala Thr Tyr
210 215 220

Pro Gly Ile Ile Val Ser Asn Ile Cys Pro Gly Pro Val Gln Ser Asn
225 230 235 240

Ile Val Glu Asn Ser Leu Ala Gly Glu Val Thr Lys Thr Ile Gly Asn
245 250 255

Asn Gly Asp Gln Ser His Lys Met Thr Thr Ser Arg Cys Val Arg Leu
260 265 270

Met Leu Ile Ser Met Ala Asn Asp Leu Lys Glu Val Trp Ile Ser Glu
275 280 285

Gln Pro Phe Leu Leu Val Thr Tyr Leu Trp Gln Tyr Met Pro Thr Trp
290 295 300

Ala Trp Trp Ile Thr Asn Lys Met Gly Lys Lys Arg Ile Glu Asn Phe
305 310 315 320

Lys Ser Gly Val Asp Ala Asp Ser Ser Tyr Phe Lys Ile Phe Lys Thr
325 330 335

Lys His Asp

<210> 81
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

Phe Phe Ala Ala Ile Cys Leu Val Ser Leu Val Phe Thr Gly Cys Cys
65 70 75 80

Val Pro Glu Thr Lys Gly Arg Ser Leu Glu Gln Ile Glu Ser Phe Phe
85 90 95

Arg Thr Gly Arg Arg Ser Phe Leu Arg
100 105

<210> 79

<211> 1224

<212> DNA

<213> Homo sapiens

<400> 79

```

aatgaactgg gagctgctgc tgtggctgct ggtgctgtgc gcgctgctcc tgctcttggt 60
gcagctgctg cgcttctctga gggctgacgg cgacctgacg ctactatggg ccgagtgagg 120
gggacgacgc ccagaatggg agctgactga tatgggtggtg tgggtgactg gagcctcgag 180
tggaattggt gaggagctgg cttaccagtt gtctaaacta ggagtttctc ttgtgctgtc 240
agccagaaag gtgcatgagc tggaaaaggg gaaaagaaga tgcctagaga atggcaattt 300
aaaagaaaaa gatatacttg ttttgcccc tgacctgacc gacctgggt cccatgaagc 360
ggctaccaaa gctgttctcc aggagtttgg tagaatcgac attctgggtc acaatgggtg 420
aatgtccccc cgcttctctgt gcatggatac cagcttggtg gtctacagaa agctaataga 480
gcttaactac ttagggacgg tgtccttgac aaaatgtgt ctgcctcaca tgatcgagag 540
gaagcaagga aagattgtta ctgtgaatag catcctgggt atcatatctg tacctctttc 600
cattggatac tgtgctagca agcatgctct cgggggtttt ttaatggcc ttcgaacaga 660
acttgccaca taccaggtta taatagtctc taacatttgc caggacctg tgcaatcaaa 720
tattgtggag aattccctag ctggagaagt cacaaagact ataggcaata atggagacca 780
gtcccacaag atgacaacca gtctgtgtgt gcggctgatg ttaatcagca tggccaatga 840
tttgaaaagaa gtttggatct cagaacaacc ttcttgttta gtaacatatt tgtggcaata 900
catgccaacc tgggcctggt ggataacca caagatgggg aagaaaaagga ttgagaactt 960
taagagtgtg gtggatgcag actcttctta ttttaaaatc ttaagacaa aacatgactg 1020
aaaagagcac ctgtactttt caagccactg gagggagaaa tggaaaacat gaaaacagca 1080
atcttcttat gcttctgaat aatcaaagac taatttgtga ttttactttt taatagatat 1140
gactttgctt ccaacatgga atgaaataaa aaataaataa taaaagattg ccatgaatct 1200
tgcaaaaaaa aaaaaaaaaa aaaa 1224

```

<210> 80

<211> 339

<212> PRT

<213> Homo sapiens

<400> 80

Met Asn Trp Glu Leu Leu Leu Trp Leu Leu Val Leu Cys Ala Leu Leu
1 5 10 15

Leu Leu Leu Val Gln Leu Leu Arg Phe Leu Arg Ala Asp Gly Asp Leu
20 25 30

Thr Leu Leu Trp Ala Glu Trp Gln Gly Arg Arg Pro Glu Trp Glu Leu
35 40 45

Thr Asp Met Val Val Trp Val Thr Gly Ala Ser Ser Gly Ile Gly Glu
50 55 60

Glu Leu Ala Tyr Gln Leu Ser Lys Leu Gly Val Ser Leu Val Leu Ser
65 70 75 80

Met Gly Leu Cys Ile Pro Phe Ser Arg Pro Gln Pro Ala Ser Leu Leu
 1 5 10 15
 Pro Ala Trp Pro Thr Gly Leu Pro Leu Val Pro Val Pro Leu Val Val
 20 25 30
 Gly Asp Gly Ala Ala Ala Arg Gly Val Met Gly Leu Gly Ser Val Phe
 35 40 45
 Tyr Arg Pro Pro Arg Gly Pro Gln Trp Leu Pro Gly Glu Pro Asp Gly
 50 55 60
 Ala Pro Glu Gly Tyr Arg Leu Gly Gly Pro Ser Leu Arg Val Trp Gly
 65 70 75 80
 Gln Ala Leu Ala Ser Ala Ala Ser Gln Ser Pro Ser His Leu Pro Leu
 85 90 95
 Lys Ile Gln Ser Leu Leu Trp Met Ser Leu
 100 105

<210> 77
 <211> 823
 <212> DNA
 <213> Homo sapiens

<400> 77
 agcccccttgc agcacccgct ggctacctca ccctgggtgcc cctgctggcc accatgctct 60
 tcatcatggg ctacgcctg ggctggggtc ccatcacctg gctgctcatg tctgaggtcc 120
 tgccccctgcg tgcccggtggc gtggcctcag ggctctgcgt gctggccagc tggttcaccg 180
 ccttcgtcct caccaagtcc ttccctgccag tggtagcac cttcggcctc caggtgcctt 240
 tcttcttctt cgcggccatc tgcttggtga gcctgggtgtt cacaggctgc tgtgtgccc 300
 agaccaaggg acggtccctg gagcagatcg agtccttctt ccgcacgggg agaaggtcct 360
 tcttgcgcta ggtcaaggtc cccgcctgga gggggccaaa cccacagtgg ctgggcctct 420
 gtgttggtcg tgcaagggaag acccggtctt gccctcacia gtcttatggg caccacaggg 480
 aacatcctgg acttaaaaag ccagggcagg ccgggcacag tggttcacgc ctgtaatccc 540
 agcactttgg gagggccaaag caggtggatt acccaaggcc aggagtcaa gaccagcctg 600
 gccaacatgg tgaaccccg tctctactaa aaaatacaaa aaagctgggt gtgggtggcac 660
 acaccgtag ttccagctac ttgggaggt gaggcagcat tgcttgaacc cgggaggtgg 720
 aggtgcaat gagctgagat catgccattg cactccagcc tgggcaacga gagtgaaact 780
 ccgtcccccac cccctgcca aaaaaaaaaa aaaaaaaaaa aaa 823

<210> 78
 <211> 105
 <212> PRT
 <213> Homo sapiens

<400> 78
 Met Leu Phe Ile Met Gly Tyr Ala Val Gly Trp Gly Pro Ile Thr Trp
 1 5 10 15
 Leu Leu Met Ser Glu Val Leu Pro Leu Arg Ala Arg Gly Val Ala Ser
 20 25 30
 Gly Leu Cys Val Leu Ala Ser Trp Leu Thr Ala Phe Val Leu Thr Lys
 35 40 45
 Ser Phe Leu Pro Val Val Ser Thr Phe Gly Leu Glu Val Pro Phe Phe
 50 55 60

<213> Homo sapiens

<400> 74

Met Glu Ile Tyr Leu Ser Leu Gly Val Leu Ala Leu Gly Thr Leu Ser
 1 5 10 15

Leu Leu Ala Val Thr Ser Leu Pro Ser Ile Ala Asn Ser Leu Asn Trp
 20 25 30

Arg Glu Phe Ser Phe Val Gln Ser Ser Leu Gly Phe Val Ala Leu Val
 35 40 45

Leu Ser Thr Leu His Thr Leu Thr Tyr Gly Trp Thr Arg Ala Phe Glu
 50 55 60

Glu Ser Arg Tyr Lys Phe Tyr Leu Pro Pro Thr Phe Thr Leu Thr Leu
 65 70 75 80

Leu Val Pro Cys Val Val Ile Leu Ala Lys Ala Leu Phe Leu Leu Pro
 85 90 95

Cys Ile Ser Arg Arg Leu Ala Arg Ile Arg Arg Gly Trp Glu Arg Glu
 100 105 110

Ser Thr Ile Lys Phe Thr Leu Pro Thr Asp His Ala Leu Ala Glu Lys
 115 120 125

Thr Ser His Val
 130

<210> 75

<211> 922

<212> DNA

<213> Homo sapiens

<400> 75

gtgaaatgag aaaggcccag aacgtgcagg tctgcggagg ggaagtgtcc tgagtgaagg 60
 aggggacccc catcctgggg gatgctggga gtgagtgaat gagtgagatg gctgagtgaag 120
 gggtatgggg agcctgaggt tttatggggc tgtgtatccc cttctcccgg cccagcctg 180
 cctccctcct gcccgctgg ccacaggtc tccctctggt cccgtccct ctggtggtg 240
 gggatggagc ggcagcaagg ggtgtaatgg ggctgggttc tgtctttac aggccacccc 300
 gaggtcctca gtggttgcct ggggagccgg acggggctcc tgagggttac aggttgggtg 360
 ggccctccct gaggtctggt ggtcaggtt tgccctctgc tgcctctcag tcaccaagtc 420
 acctccctct gaaaatccag tccctctttt ggatgtcctt gtgagtcact ctgggcctgg 480
 ctgtcgtccc tccctcagctt cttgttctcg ggacaagggt caagccagga tgggcccagg 540
 cctgggatacc cccaccccag gacccccagg cccctcccc tgcctgcttg cggggggcag 600
 ggcagaaatg gactcctttt gggccccga ggtgggggtc cctcccagcc ctgcatactc 660
 cgtgccgtag acctgctccc cagaggaggg gccttgaccc acaggacgtg tgggtggcgcc 720
 tggcactcag ggacccccag ctgccccagc cctgggtctt ggcgcacctc ttccctcttg 780
 tcccgaagat ctgcgcctct agtgcctttt gaggggttcc catcatccct cctgatatt 840
 gtattgaaaa tattatgcac actgttctatg cttctactaa tcaataaacg ctttatttaa 900
 aaaaaaaaaa aaaaaaaaaa aa 922

<210> 76

<211> 106

<212> PRT

<213> Homo sapiens

<400> 76

<212> DNA

<213> Homo sapiens

<400> 73

```

aggaaaqcca gaacaagtgc ttcaagctgc cegtgtccgt ggtcaacacc acactgccgt 60
gcgtggccta cgtgctgctg tcaactcgtgt acttgcccgg cgtgctggcg gctgccctgc 120
agctgcggcg cggcaccaag taccagcgtt tccccgactg gctggaccac tggctacagc 180
accgcaagca gatcgggctg ctcagcttct tctgcgccgc cctgcacgcc ctctacagct 240
tctgcttgcc gctgcgccgc gccacccgct acgacctggg caacctggga gtcaagcagg 300
tcttggccaa caagagccac ctctgggtgg aggaggagg ctggcggatg gagatctacc 360
tctccctggg agtgetggcc ctcggcacgt tgtccctgct ggccgtgacc tcactgccgt 420
ccaatgcaaa ctgcgtcaac tggaggagg tcaacttctg tcagtcctca ctgggctttg 480
tggccctcgt gctgagcaca ctgcacacgc tcacctacgg ctggaccgcc gccttcaggg 540
agagcccgta caagtcttac ctgcctccca ccttcacgct cagctgctg gtgccctgcg 600
tcgtcaccct ggccaaagcc ctgtttctcc tgccctgcat cagccgcaga ctgccaggga 660
tccggagagg ctgggagagg gagagcacca tcaagttcac gctgccaca gaccacgccc 720
tggccagagg acgagccac gtatgagggt cctgcccagg gctctggacc ccgggcacac 780
gagggacggg gcccagagcc cgttaggttt tctttctctg gtgggtgcaaa gtggtataac 840
tgtgtgcaaa taggaggttt gaggtccaaa tctctgggac tcaaatgtat gcagtaatat 900
tcagaatgat atacacacat atgtgtatat gtatttacat atattccaca tatataacag 960
gatttgcatt tatacatagc tagctaaaaa gttgggtctc tgagatttca actttagtag 1020
ttaaaaaaaa gtgcctgacg ttaagagaag agcagatcat gctattgtga catttgacga 1080
gatatacaca cactttttgt acagaagagg cttgtgctgt ggtgggttcg atttatccct 1140
gcccacccca tccccacaac tccccctttg ctacttcccc aaggctcttg cagagctagg 1200
gctctgaagg ggagggaagg caacggctct gccagagacc atccctggag catgtgagca 1260
gcccgtgggc tcttccctcc acctggggca gcagcaggag gcccggggag gaggaaaatc 1320
aggcagtcgg cctggagtct gtgcctgggc ctttgcccgg tgggtggagg atggagggat 1380
tgggctgaag ctgctccacc tcatccttgc tgagtggggg agacatttcc cctgaaagtc 1440
agaagtcacc atagagcctg caaatggatc ctctgtgag agtgacgtca cctcctttcc 1500
agagccatta gtgagcctgg cttgggaaca agtgtaattt ccttccctcc tttaacctgg 1560
cgatgagcgt ccttttaaac actgtgcctt ctcacctttt ccactcttcag tttgaacgac 1620
tcccaggaag gcctagagca gaccttttag aaatcagccc aagggggaga gcaagagaaa 1680
acactctagg gagttaaagt ccccgggcgt cagagttgag cctgcctgg gctgaaggac 1740
tgtcttcacg aagtcagtcg tgaggaaaaa tattggggac tccaaatgtc ctctggcaga 1800
ggaccagaaa aaccacactg gctccaactt cctcctcatg gggcattaca cttcaaaaca 1860
gtggggagca acttttccac caaagctaca aaactaaaat gctgctgccc caaagcacaa 1920
gagggaagag caccgcccgg gccacaggac gtctgtcttc cagtcacagg ccactccttc 1980
tgctccctac tgactctagc ttacttcccc tgtgaagaaa cagggtgttct cggctgagcc 2040
cccaaccttc tgcagaacca ggttgatctg ccacagaaaa agcatctttg aagacaaaga 2100
gggtgagggt ttcattgagtc tctggggccc aaagccatct tctgatgga ggaagagagt 2160
agggccagtg aaggctgccc agagagaatg tcacagatga ggtgcccct gcccccctcc 2220
cgccagggag gtttcatgag ctcatgtcta tgcagcacat aagggttctt cagtgaagag 2280
caggagaaga gccactgca aggatagctc attaggcaca tgaccgatgc agggagggcc 2340
atgccgggga agctcttctt gcaggatatt tccatctgct gtgccaaagg tgagcggcag 2400
aaacttgtct cataaattgg cactgatgga gcatcagctg tggcccacag agagccttgc 2460
tgagaagggg gcaggtaaa gacagatctt agcattgcct tggcataaca agggccatc 2520
gattccctac taatgagagg caggagagac atgggcaatg gagaccacc aatgatcccc 2580
aaccgccgtg ggtactggct gcctgcctg ggccaggga tggctcctta taccaaagat 2640
gctggcacat agcagaaccc agtgcacgtc cccccctcc caccacctc tggctgaagg 2700
tgctcaagag ggaagcaatt ataagggtgg tggcaggagg gaacaggtg cactgtctg 2760
acaatcacac gaaaggcagg cgggctgtgt actgggccc gactgtgctt ccactgtctt 2820
cttccctacc tcaccaggct actggcagca gcatcccgag ajcacatcat ctccacagcc 2880
tggtaaatte catgtgcctc tgggtacaaa agtgccctca cgacatgctc tggaaatccc 2940
aaatgccaca gtctgagggt gatattctaa atctatgcct tcaaaagagt cctgtttttt 3000
ttttttttaa cctggtagac ggtataaaa cagtgcacaa aaacacctaa cttctgcaa 3060
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaa

```

3098

<210> 74

<211> 132

<212> PRT

Arg Ala Pro Phe Gln Leu His Ser Ala Ala Leu Asp Phe Ser Pro Pro
 195 200 205
 Gly Thr Glu Val Ser Ala Leu Cys Arg Gly Gln Leu Pro Ile Ser Val
 210 215 220
 Thr Cys Ile Ala Asp Glu Ile Gly Ala Arg Trp Asp Lys Leu Ser Gly
 225 230 235 240
 Asp Val Leu Cys Pro Cys Pro Gly Arg Tyr Leu Arg Ala Gly Lys Cys
 245 250 255
 Ala Glu Leu Pro Asn Cys Leu Asp Asp Leu Gly Gly Phe Ala Cys Glu
 260 265 270
 Cys Ala Thr Gly Phe Glu Leu Gly Lys Asp Gly Arg Ser Cys Val Thr
 275 280 285
 Ser Gly Glu Gly Gln Pro Thr Leu Gly Gly Thr Gly Val Pro Thr Arg
 290 295 300
 Arg Pro Pro Ala Thr Ala Thr Ser Pro Val Pro Gln Arg Thr Trp Pro
 305 310 315 320
 Ile Arg Val Asp Glu Lys Leu Gly Glu Thr Pro Leu Val Pro Glu Gln
 325 330 335
 Asp Asn Ser Val Thr Ser Ile Pro Glu Ile Pro Arg Trp Gly Ser Gln
 340 345 350
 Ser Thr Met Ser Thr Leu Gln Met Ser Leu Gln Ala Glu Ser Lys Ala
 355 360 365
 Thr Ile Thr Pro Ser Gly Ser Val Ile Ser Lys Phe Asn Ser Thr Thr
 370 375 380
 Ser Ser Ala Thr Pro Gln Ala Phe Asp Ser Ser Ser Ala Val Val Phe
 385 390 395 400
 Ile Phe Val Ser Thr Ala Val Val Val Leu Val Ile Leu Thr Met Thr
 405 410 415
 Val Leu Gly Leu Val Lys Leu Cys Phe His Glu Ser Pro Ser Ser Gln
 420 425 430
 Pro Arg Lys Glu Ser Met Gly Pro Pro Gly Leu Glu Ser Asp Pro Glu
 435 440 445
 Pro Ala Ala Leu Gly Ser Ser Ser Ala His Cys Thr Asn Asn Gly Val
 450 455 460
 Lys Val Gly Asp Cys Asp Leu Arg Asp Arg Ala Glu Gly Ala Leu Leu
 465 470 475 480
 Ala Glu Ser Pro Leu Gly Ser Ser Asp Ala
 485 490

<210> 73
 <211> 3098

```

gctgggagag acaccacttg tccctgaaca agacaattca gtaacatcta ttccctgagat 1080
tcctcgatgg ggatcacaga gcacgatgtc tacccttcaa atgtcccttc aagccgagtc 1140
aaagggccact atcaccocat cagggagcgt gatttccaag ttttaattcta cgacttcctc 1200
tgccactcct caggttttcg actcctcctc tgccgtgggc ttcataatttg tgagcacagc 1260
agtagtagtg ttggtgatct tgaccatgac agtactgggg cttgtcaagc tctgctttca 1320
cgaaagcccc tcttcccagc caaggaagga gtctatgggc ccgccgggccc tggagagtga 1380
tcctgagccc gctgcttttg gctccagttc tgcacattgc acaacaatg gggtgaaagt 1440
cggggactgt gatctgcggg acagagcaga ggggtgccttg ctggcggagt cccctcttgg 1500
ctctagtgat gcatagggaa acaggggaca tgggcactcc tgtgaacagt ttttcaacttt 1560
tgatgaaacg gggaaccaag aggaacttac ttgtgtaact gacaatttct gcagaaatcc 1620
cccttcctct aaattccctt tactccactg aggagctaaa tcagaactgc acactccttc 1680
cctgatgata gaggaagtgg aagtgccttt aggatgggtga tactggggga ccgggtagt 1740
ctggggagag atattttctt atgtttatc ggagaatttg gegaagtgat tgaacttttc 1800
aagacattgg aaacaaatag aacacaatat aatttacatt aaaaaataat ttctacaaa 1860
atggaaagga aatgttctat gttgttcagg ctaggagtat attggttcga aatcccagg 1920
aaaaaaataa aaataaaaaa ttaaaggatt gttgataaaa aaaaaaaaaa aaaaaaaaaa 1980
a
1981

```

<210> 72
 <211> 490
 <212> PRT
 <213> Homo sapiens

<400> 72
 Met Arg Pro Ala Phe Ala Leu Cys Leu Leu Trp Gln Ala Leu Trp Pro
 1 5 10 15
 Gly Pro Gly Gly Gly Glu His Pro Thr Ala Asp Arg Ala Gly Cys Ser
 20 25 30
 Ala Ser Gly Ala Cys Tyr Ser Leu His His Ala Thr Met Lys Arg Gln
 35 40 45
 Ala Ala Glu Glu Ala Cys Ile Leu Arg Gly Gly Ala Leu Ser Thr Val
 50 55 60
 Arg Ala Gly Ala Glu Leu Arg Ala Val Leu Ala Leu Leu Arg Ala Gly
 65 70 75 80
 Pro Gly Pro Gly Gly Gly Ser Lys Asp Leu Leu Phe Trp Val Ala Leu
 85 90 95
 Glu Arg Arg Arg Ser His Cys Thr Leu Glu Asn Glu Pro Leu Arg Gly
 100 105 110
 Phe Ser Trp Leu Ser Ser Asp Pro Gly Gly Leu Glu Ser Asp Thr Leu
 115 120 125
 Gln Trp Val Glu Glu Pro Gln Arg Ser Cys Thr Ala Arg Arg Cys Ala
 130 135 140
 Val Leu Gln Ala Thr Gly Gly Val Glu Pro Ala Gly Trp Lys Glu Met
 145 150 155 160
 Arg Cys His Leu Arg Ala Asn Gly Tyr Leu Cys Lys Tyr Gln Phe Glu
 165 170 175
 Val Leu Cys Pro Ala Pro Arg Pro Gly Ala Ala Ser Asn Leu Ser Tyr
 180 185 190

Tyr Leu Thr Trp Ser Ala Met Thr Asn Glu Pro Glu Thr Asn Cys Asn
275 280 285

Pro Ser Leu Leu Ser Ile Ile Gly Tyr Asn Thr Thr Ser Thr Val Pro
290 295 300

Lys Glu Gly Gln Ser Val Gln Trp Trp His Ala Gln Gly Ile Ile Gly
305 310 315 320

Leu Ile Leu Phe Leu Leu Cys Val Phe Tyr Ser Ser Ile Arg Thr Ser
325 330 335

Asn Asn Ser Gln Val Asn Lys Leu Thr Leu Thr Ser Asp Glu Ser Thr
340 345 350

Leu Ile Glu Asp Gly Gly Ala Arg Ser Asp Gly Ser Leu Glu Asp Gly
355 360 365

Asp Asp Val His Arg Ala Val Asp Asn Glu Arg Asp Gly Val Thr Tyr
370 375 380

Ser Tyr Ser Phe Phe His Phe Met Leu Phe Leu Ala Ser Leu Tyr Ile
385 390 395 400

Met Met Thr Leu Thr Asn Trp Tyr Arg Tyr Glu Pro Ser Arg Glu Met
405 410 415

Lys Ser Gln Trp Thr Ala Val Trp Val Lys Ile Ser Ser Ser Trp Ile
420 425 430

Gly Ile Val Leu Tyr Val Trp Thr Leu Val Ala Pro Leu Val Leu Thr
435 440 445

Asn Arg Asp Phe Asp
450

<210> 71
<211> 1981
<212> DNA
<213> Homo sapiens

<400> 71
gagatccaag ttgggagcag ctctgcgtgc ggggcctcag agaatgaggc cggcgttcgc 60
cctgtgectc ctctggcagg cgctctggcc cgggcagggc ggcggcgaac accccactgc 120
cgaccgtgct ggctgctcgg cctcgggggc ctgctacagc ctgcaccacy ctaccatgaa 180
ggcgagggcg gccgaggagg cctgcacccg gcgaggtggg gcgctcagca ccgtgcgtgc 240
gggcgcccag ctgcgcgctg tgctcgcgct cctgcgggca ggcccagggc ccggaggggg 300
ctccaaagac ctgctgttct gggtcgcact ggagcgcagg cgttcccact gcaccttga 360
gaacgagcct ttgcgggggt tctcctggct gtccctccgac cccggcggtc tcgaaagcga 420
cacgctgcag tgggtggagg agccccaaag ctccctgcacc gcgcggagat gcgcggtact 480
ccaggccacc ggtggggctg agcccgcagg ctggaagyag atgcgatgcc acctgcgcgc 540
caacggctac ctgtgcaagt accagtttga ggtcttgtgt cctgcgcgcg gccccggggc 600
cgctctaac ttgagctatc gcgcgccttt ctgctgcac agcgcgcgtc tggacttcag 660
tccacctggg accgaggtga gtgcgctctg ccggggacag ctcccgatct cagtactctg 720
catgcgggac gaaatcgggc ctgcgtggga caaactctg ggcgatgtgt tgtgtccctg 780
ccccgggagg tacctccgtg ctggcaaatg cgcagagctc cctaactgcc tagacgactt 840
gggaggcttt gcttcgcaat gtgctacggg cctcgagctg ggggaaggac gccgctcttg 900
tgtgaccagt ggggaaggac agccgacctt tggggggacc ggggtgccca ccaggcacc 960
gccggccact gcaaccagcc ccgtgcgcga gagaacatgg ccaatcaggg tcgacgagaa 1020

caaccttatt ctgtgtgtag acattgtatt ccacaatttt gaatggctgt gttttacctc 3060
 taaataaatg aattcagaga aaaaaaaaaa aaaaaaaaaa aaa 3103

<210> 70

<211> 453

<212> PRT

<213> Homo sapiens

<400> 70

Met Gly Ser Val Leu Gly Leu Cys Ser Met Ala Ser Trp Ile Pro Cys
 1 5 10 15

Leu Cys Gly Ser Ala Pro Cys Leu Leu Cys Arg Cys Cys Pro Ser Gly
 20 25 30

Asn Asn Ser Thr Val Thr Arg Leu Ile Tyr Ala Leu Phe Leu Leu Val
 35 40 45

Gly Val Cys Val Ala Cys Val Met Leu Ile Pro Gly Met Glu Glu Gln
 50 55 60

Leu Asn Lys Ile Pro Gly Phe Cys Glu Asn Glu Lys Gly Val Val Pro
 65 70 75 80

Cys Asn Ile Leu Val Gly Tyr Lys Ala Val Tyr Arg Leu Cys Phe Gly
 85 90 95

Leu Ala Met Phe Tyr Leu Leu Leu Ser Leu Leu Met Ile Lys Val Lys
 100 105 110

Ser Ser Ser Asp Pro Arg Ala Ala Val His Asn Gly Phe Trp Phe Phe
 115 120 125

Lys Phe Ala Ala Ala Ile Ala Ile Ile Ile Gly Ala Phe Phe Ile Pro
 130 135 140

Glu Gly Thr Phe Thr Thr Val Trp Phe Tyr Val Gly Met Ala Gly Ala
 145 150 155 160

Phe Cys Phe Ile Leu Ile Gln Leu Val Leu Leu Ile Asp Phe Ala His
 165 170 175

Ser Trp Asn Glu Ser Trp Val Glu Lys Met Glu Glu Gly Asn Ser Arg
 180 185 190

Cys Trp Tyr Ala Ala Leu Leu Ser Ala Thr Ala Leu Asn Tyr Leu Leu
 195 200 205

Ser Leu Val Ala Ile Val Leu Phe Phe Val Tyr Tyr Thr His Pro Ala
 210 215 220

Ser Cys Ser Glu Asn Lys Ala Phe Ile Ser Val Asn Met Leu Leu Cys
 225 230 235 240

Val Gly Ala Ser Val Met Ser Ile Leu Pro Lys Ile Gln Glu Ser Gln
 245 250 255

Pro Arg Ser Gly Leu Leu Gln Ser Ser Val Ile Thr Val Tyr Thr Met
 260 265 270

Ile Pro
130

<210> 69
<211> 3103
<212> DNA
<213> Homo sapiens

<400> 69

```

gatccgctgc tcttgtgacg ttgtggagat ggggagcgtc ctggggctgt gctccatggc 60
gagctggata ccatgtttgt gtggaagtgc cccgtgtttg ctatgccgat gctgtccatg 120
tggaacaac tccactgtaa ctgattgat ctatgcactt ttcttgcttg ttggagtatg 180
tgtagcttgt gtaatgttga taccaggaat ggaagaacaa ctgaataaga ttcctggatt 240
ttgtgagaat gagaaagggt ttgtcccttg taacattttg gttggctata aagctgtata 300
tcgtttgtgc ttgtgtttgg ctatgttcta tcttcttctc tctttactaa tgatcaaaagt 360
gaagagttagc agtgatccta gagctgcagt gcacaatgga ttttggttct ttaaatttgc 420
tgcagcaatt gcaattatta ttggggcatt cttcattcca gaaggaactt ttacaactgt 480
gtggttttat gtaggcattg caggtgcctt ttgtttcctc ctcatacaac tagtcttact 540
tattgatttt gcacattcat ggaatgaatc gtgggttgaa aaaaatggag aagggaactc 600
gagatgtttg tatgcagcct tgttatcagc tacagctctg aattatctgc tgtctttagt 660
tgctatcgtc ctgttctttg tctactcac tcatccagcc agttgttcag aaaacaaggc 720
gttcatcagt gtcaacatgc tctctctcgt tgggtgctct ctatgtcta tactgccaaa 780
aatccaagaa tcacaaccaa gatctggttt gttacagtct tcagtaatta cagtctacac 840
aatgtatttg acatggtcag ctatgaccaa tgaaccagaa acaaattgca acccaagctc 900
actaagcata attggctaca atacaacaag cactgtccca aaggaagggc agtcagtcga 960
gtgggtggcat gctcaaggaa ttataggact aattctcttt ttgttgtgtg tattttattc 1020
cagcatccgt acttcaacaa atagtcaggt taataaactg actctaacaa gtgatgaatc 1080
tacattaata gaagatgggt gagctagaag tgatggatca ctggaggatg gggacgatgt 1140
tcaccgagct gtagataatg aaagggatgg tgtcacttac agttattctt tctttcactt 1200
catgcttttc ctggtctcac tttatatcat gatgacctt accaactggt acaggataga 1260
acctctctgt gagatgaaaa gtcagtggac agctgtctgg gtgaaaaatc cttccagttg 1320
gattggcctc gtgctgtatg tttggacact cgtggcacca cttgttctta caaatcgtga 1380
ttttgactga gtgagacttc tagcatgaaa gtcccacttt gattattgct tatttgaaaa 1440
cagtattccc aacttttgta aagttgtgta tgtttttgct tcccattgaa cttctccagt 1500
gttctggcat gaattagatt ttactgcttg tcattttggt attttcttac caagtgcatt 1560
gatatgtgaa gtagaatgaa ttgcagagga aagttttatg aatatggtga tgagtttaga 1620
aaagtggcca ctattgggtt tattctctgc tctatagttg tgaaatgaag agtgaaaaca 1680
aatttgcttg actattttta aattatatta gaccttaagc tgttttagca agcattaaag 1740
caaatgtatg gctgcctttt gaaatatttg atgtgttgcc tggcaggata ctgcaaaaga 1800
catggtttat ttaaaaattt ataaacaagt cacttaaatg ccagttgtct gaaaaatctt 1860
ataaggtttt accttgata cggaaatttac acaggtaggg agtgtttagt ggacaatagt 1920
gtaggttatg gatggagggt tgggtactaa attgaataac gagtaataaa tcttacttgg 1980
gtagagatgg cctttgcca caaagtgaac tgttttggtt gttttaaact catgaagtat 2040
gggttcagtg gaaatgtttg gaactctgaa ggatttagac aaggttttga aaaggataat 2100
catgggttag aaggaagtgt ttgaaagtca ctttgaaagt tagttttggg ccagcacggc 2160
agctcaccct tgtaatccca gcactttggg aggtgaggtt gggtagatta cttgagccca 2220
ggaattcaag accagcctgg gcaacatggt gaaacctgtt ttctataaaa aataatctgg 2280
gctttgtagc atatgcctgt ggtcccagct actgaggagg ctgaggtggg aggattgctt 2340
gagcccagga ggtagaggtt gcagttagcc aaggtcacgt cactgcactc tagcctgggc 2400
aacagagtaa gacaaaaaaa tatatatata ttgaaatcaa aggaggcaaa attttgacag 2460
ggaagggaagt aactgcaaaa cactaggctt tagtaggtac ttatataaaa tctagtccag 2520
ttctctcatt taaaaaatg aagacactga agtacagact taaatagctc agatagctaa 2580
ttaggaaatt tcaagtgtgc caataatagc attctctctg acatttataa ataatttcta 2640
ttcaaaatac atgcataatt gattttacac ctctactctg gtggataatt tatgtgatgt 2700
ggattgctgg tgtccagcat gaccataaaa caggtcagaa gaatgatgga atgttttaga 2760
ataaactcct gcttatagta tactacacag ttcaaaagat gtttaaaatg cttttgtatt 2820
tactgccatg taattgaaat atatagatta ttgtaacctt tcaacctgaa aatcaagcag 2880
tatgagagtt tagttatttg tatgtgtcac tagtgtctaa tgaagctttt aaaaatctca 2940
attctctctt caaaaatatt tattaatgtg aatggaatat aacaattcag ctttaattccc 3000

```

Leu Val Met Cys Phe Leu Ser Tyr Phe Gly Thr Phe Ala Val Glu Phe
 130 135 140
 Arg His Tyr Arg Tyr Glu Ile Val Cys Ser Glu Tyr Gln Glu Asn Phe
 145 150 155 160
 Leu Ser Phe Ser Glu Ser Leu Ser Glu Ala Ser Glu Tyr Gln Thr Asp
 165 170 175
 Gln Val

<210> 67
 <211> 504
 <212> DNA
 <213> Homo sapiens

<400> 67
 aaaatccctg ctcccagctg ctttactaaa gagcaagttc ctgggcatct ctgtgtttct 60
 ctttatgggg ttcaaaacct ttcaaggacc tctctccatg cactgggttc ctgggacct 120
 atcactgggc tgccctcctga gccctcagc cctaccacag tctactgact ttcccatc 180
 agctgtgagc attcaacct gtcctctgga ccttgacacc tggctcccca accctgtccc 240
 aggaaaccca gattccacca gacacttcct tcttccccc gaggetatct ggctgagac 300
 aacaaatgct gcctcccacc ctgagtcctgg cactgggact ttcagaactc ctccctccct 360
 gactctttgc ccagaccgcg tcattcaatg gctagctttt tccatgggaa aaacacgagc 420
 accccaacc acaacggcca gttctctgat tccctaaatc cgcaccttt tcaaaacctc 480
 aaaaaaaaaa aaaaaaaaaa aaaa 504

<210> 68
 <211> 130
 <212> PRT
 <213> Homo sapiens

<400> 68
 Met Gly Phe Lys Thr Phe Gln Gly Pro Leu Ser Met Pro Leu Val Pro
 1 5 10 15
 Trp Thr Leu Ser Leu Gly Cys Leu Leu Ser Pro Ser Val Leu Pro Gln
 20 25 30
 Ser Thr Asp Phe Ser His Ser Ala Val Ser Ile Gln Pro Cys Pro Leu
 35 40 45
 Asp Leu Asp Thr Trp Leu Pro Asn Pro Val Pro Gly Asn Pro Asp Ser
 50 55 60
 Thr Arg His Phe Leu Leu Pro Pro Glu Ala Ile Trp Pro Glu Thr Thr
 65 70 75 80
 Asn Ala Ala Ser His Pro Glu Ser Gly Thr Gly Thr Phe Arg Thr Pro
 85 90 95
 Pro Ser Leu Thr Leu Cys Pro Arg Pro Val Ile Gln Trp Leu Ala Phe
 100 105 110
 Ser Met Gly Lys Thr Arg Ala Pro Pro Thr Thr Thr Ala Ser Ser Leu
 115 120 125

```

atatgccaca gactgtgaga gcaaagcccg ccgctgtgat ctggacttga tgcactgtga 1320
ctgagaatga tttccaaatg tgaatatgtg tagggacgtg gtctatcagg cctggaacaa 1380
gatgggggca gtgaagggtat ggttttagtgt ttgctttcat agtatgccat gtacaatgtt 1440
ttatatattca tagttttcttt taagtaacta ccatgagtct ctctaagcct catggacaaa 1500
gatgtagacc aaatgcaaga gctgagcttg ctttgggttc aaccatgac aaagaaaaac 1560
tgaggtcacc tgcaggctta cgtgggaagc taagaaaata tcacagaaaa atggaagaa 1620
atatggatgt gcagaggtaa taaaaagagc tgctgctgga cttttatcaa agataggcac 1680
cttacagtat cttgttgcaa gtccaaatca ggggagactt tggttaatatg tatcttttgc 1740
tcaaatttag tagggttttt tttttttttg gattaagggc ttttcaaatt tggaatttgt 1800
agaagccaat taaaagaata cccttcctaa aaaccaaatt gacacagctg gccccctgc 1860
tagccaaccc gcagttccca gttcccacct gctgagagtt cagaactcag accgtagggtg 1920
tggtgttatg agactgtgct tcataagaa aagcagaatt ccaaattcaa actgttgag 1980
tgagccaagt ggacagaccc tccatgagtg cactttcttc caagaaatcc ccagatttac 2040
cccatagagg tctgggatta cctggaatat aatatgaaaa acatttttta ggctgggtgt 2100
ggggctcaca cctgtaatcc cagcactttg ggaggtgag gcgggcggtat cacctgaggt 2160
tggtgagctg agaccagcct gaccaatgtg aagaaacccc gtcttacta aaaaaatac 2220
aaaattagcc tggtgtgtgt gcgcatgctt gtaatcccgg ctactcagga ggcgaggca 2280
ggagaatcac ttgaaccgg gaggcaggtt gcggtgagac gagatcacgc cattgcactc 2340
cagcctgggc aaaaagagct aaaaactcca tctcaaaaaa aaaaagaaaa aaagaaaaac 2400
gttttttaac tcaacccaaa gtctgaattt cttgaggaaa aggtcaatgt cttttcatct 2460
ctgtattgtt cccacctct taacacagt cctggcacat actaggtgct caataaatgt 2520
ctgttgaata gaattattaa taatttaaga gtaggaaaaa ggagtgtcag agagagactc 2580
aaagatgagt gagagagcat ggaagatggc tgtttcatgt gagacaggaa tggaagaagt 2640
tatgaatagg gatcagatgg gggagtgaga atccctgtta gtaaaatgtg aggaaaagaa 2700
caagctgaga acaagattct cctgtcaaaa aggcgtctta ctgtaaatag tccaaggtga 2760
catttgttag ttttgaatac tgcttttggg tttctttttt tcatttttat attttaaat 2820
ttttatcaaa gaacaaagac ttatgtagtt ttcttttatt ctacacaatc caaattaaac 2880
agcttttggg gatgcaattg tacactttct taagaatata tctaatacca catttttagca 2940
gaaccaagca atgactgaca ttattcattg ggatctggcc actaaataaa attcttttat 3000
gcataaaaaa aaaaaaaaaa aataaaaaaa aaa 3033

```

<210> 66

<211> 178

<212> PRT

<213> Homo sapiens

<400> 66

```

Met Asn Met Ala Ala Phe Leu Ala Leu Val Val Ala Val Leu Arg Phe
  1              5              10              15

Ile Gln Leu Lys Pro Lys Val Leu Asn Pro Trp Leu Asn Ile Ser Gly
      20              25              30

Leu Val Ala Leu Cys Leu Ala Ser Phe Gly Met Thr Leu Leu Gly Asn
      35              40              45

Phe Gln Leu Thr Asn Asp Glu Glu Ile His Asn Val Gly Thr Ser Leu
      50              55              60

Thr Phe Gly Phe Gly Thr Leu Thr Cys Trp Ile Gln Ala Ala Leu Thr
      65              70              75              80

Leu Lys Val Asn Ile Lys Asn Glu Gly Arg Arg Val Gly Ile Pro Arg
      85              90              95

Val Ile Leu Ser Ala Ser Ile Thr Leu Cys Val Val Leu Tyr Phe Ile
      100             105             110

Leu Met Ala Gln Ser Ile His Met Tyr Ala Ala Arg Val Gln Trp Gly
      115             120             125

```

725 730 735
 Ile Val Ser Val Thr Ala Tyr Ile Ala Leu Ala Leu Leu Ser Val Thr
 740 745 750
 Ile Ser Phe Arg Ile Tyr Lys Gly Val Ile Gln Ala Ile Gln Lys Ser
 755 760 765
 Asp Glu Gly His Pro Phe Arg Ala Tyr Leu Glu Ser Glu Val Ala Ile
 770 775 780
 Ser Glu Glu Leu Val Gln Lys Tyr Ser Asn Ser Ala Leu Gly His Val
 785 790 795 800
 Asn Cys Thr Ile Lys Glu Leu Arg Arg Leu Phe Leu Val Asp Asp Leu
 805 810 815
 Val Asp Ser Leu Lys Phe Ala Val Leu Met Trp Val Phe Thr Tyr Val
 820 825 830
 Gly Ala Leu Phe Asn Gly Leu Thr Leu Leu Ile Leu Ala Leu Ile Ser
 835 840 845
 Leu Phe Ser Val Pro Val Ile Tyr Glu Arg His Gln Ala Gln Ile Asp
 850 855 860
 His Tyr Leu Gly Leu Ala Asn Lys Asn Val Lys Asp Ala Met Ala Lys
 865 870 875 880
 Ile Gln Ala Lys Ile Pro Gly Leu Lys Arg Lys Ala Glu
 885 890

<210> 65
 <211> 3033
 <212> DNA
 <213> Homo sapiens

<400> 65
 atacttcata gctgtggaag atgacaaaat tttaccatta aattcagctg aaaggaaacc 60
 tgggtgtgaag catgcacat atataagcat tgcagggtgat gatectctctg caagctgtgt 120
 gtttagtcaa gttatgaaca tggcagcctt cctagccctt gtggtagctg ttctgcgctt 180
 catacaactg aaaccgaagg ttttaaaccg gtggctgaat attagtggat tgggtggctct 240
 gtgtctggct tccttcggaa tgaccttact tggtaatttt cagctcacaa atgatgaaga 300
 aatccataac gtcggaactt ccttgacctt tggatttggc acattgacct gctggatcca 360
 ggctgcgctg acactcaagg tcaacatcaa gaatgaagga cggagagttg gaattccacg 420
 ggttattctg tcggcatcta tcaactctctg tgtggctctc tacttcaccc tcatggccca 480
 aagcatccac atgtatgcag ccagggtcca gtggggcctg gtcattgtgt tcctgtctta 540
 ttttggcacc tttgccgtgg agttccggca ttaccgctat gagattgttt gctctgagta 600
 ccaggagaat ttctaagct tctcagaaag cctgtcagaa gcttctgaa atcagactga 660
 ccagggtgtaa accatcagtt tttccttgcg ggtgaggtgg gtgtgacagt gggggagggg 720
 ccagtaggac acactcacag gacttgacat agaacctcat ttcacacaca cacacacaca 780
 cacattcatg gccacatttg ccaaatgagc ttttcagggc gagttatttc tttaatgaaa 840
 aagcacaagc ccttatgtgt cgaatacac gctgttacac tganaatata tgcacgacag 900
 agcaagaagc ttgtgcatga tcacttctta tccgtccctt tcccagcact cctcctctt 960
 cccattctct ccacatgtct caagcaccct accgagtagg gcaggccaaa tgttctcttg 1020
 gagtaatgcc aactcccgac gttgccttca ggtccaaagg gcttggaaac agctcgtgag 1080
 gaagttctga atctggcact aatattcttg agtggataat agtgtatcat agaataggac 1140
 ggaaattgta ttgagatgtg accctgtgtc gcctgtggaa aggcatagtg agaagaactt 1200
 tcccacgaaa gcccccttca tcgttgttca gtggtcggtt gtttggatcc caggagagac 1260

405	410	415
Ser Asp Tyr Ser Glu Met Ala Lys Val Glu Gln Pro Val Pro Asp His 420 425 430		
Ser Glu Leu Val Glu Asp Ser Ser Pro Asp Ser Glu Pro Val Asp Leu 435 440 445		
Phe Ser Asp Asp Ser Ile Pro Asp Val Pro Gln Lys Gln Asp Glu Thr 450 455 460		
Val Met Leu Val Lys Glu Ser Leu Thr Glu Thr Ser Phe Glu Ser Met 465 470 475 480		
Ile Glu Tyr Glu Asn Lys Glu Lys Leu Ser Ala Leu Pro Pro Glu Gly 485 490 495		
Gly Lys Pro Tyr Leu Glu Ser Phe Lys Leu Ser Leu Asp Asn Thr Lys 500 505 510		
Asp Thr Leu Leu Pro Asp Glu Val Ser Thr Leu Ser Lys Lys Glu Lys 515 520 525		
Ile Pro Leu Gln Met Glu Glu Leu Ser Thr Ala Val Tyr Ser Asn Asp 530 535 540		
Asp Leu Phe Ile Ser Lys Glu Ala Gln Ile Arg Glu Thr Glu Thr Phe 545 550 555 560		
Ser Asp Ser Ser Pro Ile Glu Ile Ile Asp Glu Phe Pro Thr Leu Ile 565 570 575		
Ser Ser Lys Thr Asp Ser Phe Ser Lys Leu Ala Arg Glu Tyr Thr Asp 580 585 590		
Leu Glu Val Ser His Lys Ser Glu Ile Ala Asn Ala Pro Asp Gly Ala 595 600 605		
Gly Ser Leu Pro Cys Thr Glu Leu Pro His Asp Leu Ser Leu Lys Asn 610 615 620		
Ile Gln Pro Lys Val Glu Glu Lys Ile Ser Phe Ser Asp Asp Phe Ser 625 630 635 640		
Lys Asn Gly Ser Ala Thr Ser Lys Val Leu Leu Leu Pro Pro Asp Val 645 650 655		
Ser Ala Leu Ala Thr Gln Ala Glu Ile Glu Ser Ile Val Lys Pro Lys 660 665 670		
Val Leu Val Lys Glu Ala Glu Lys Lys Leu Pro Ser Asp Thr Glu Lys 675 680 685		
Glu Asp Arg Ser Pro Ser Ala Ile Phe Ser Ala Glu Leu Ser Lys Thr 690 695 700		
Ser Val Val Asp Leu Leu Tyr Trp Arg Asp Ile Lys Lys Thr Gly Val 705 710 715 720		
Val Phe Gly Ala Ser Leu Phe Leu Leu Leu Ser Leu Thr Val Phe Ser		

85	90	95
Val Lys Asp Ser Lys Glu Asp Ser Asp Met Leu Ala Ala Gly Gly Lys		
100	105	110
Ile Glu Ser Asn Leu Glu Ser Lys Val Asp Lys Lys Cys Phe Ala Asp		
115	120	125
Ser Leu Glu Gln Thr Asn His Glu Lys Asp Ser Glu Ser Ser Asn Asp		
130	135	140
Asp Thr Ser Phe Pro Ser Thr Pro Glu Gly Ile Lys Asp Arg Ser Gly		
145	150	155
Ala Tyr Ile Thr Cys Ala Pro Phe Asn Pro Ala Ala Thr Glu Ser Ile		
165	170	175
Ala Thr Asn Ile Phe Pro Leu Leu Gly Asp Pro Thr Ser Glu Asn Lys		
180	185	190
Thr Asp Glu Lys Lys Ile Glu Glu Lys Lys Ala Gln Ile Val Thr Glu		
195	200	205
Lys Asn Thr Ser Thr Lys Thr Ser Asn Pro Phe Leu Val Ala Ala Gln		
210	215	220
Asp Ser Glu Thr Asp Tyr Val Thr Thr Asp Asn Leu Thr Lys Val Thr		
225	230	235
Glu Glu Val Val Ala Asn Met Pro Glu Gly Leu Thr Pro Asp Leu Val		
245	250	255
Gln Glu Ala Cys Glu Ser Glu Leu Asn Glu Val Thr Gly Thr Lys Ile		
260	265	270
Ala Tyr Glu Thr Lys Met Asp Leu Val Gln Thr Ser Glu Val Met Gln		
275	280	285
Glu Ser Leu Tyr Pro Ala Ala Gln Leu Cys Pro Ser Phe Glu Glu Ser		
290	295	300
Glu Ala Thr Pro Ser Pro Val Leu Pro Asp Ile Val Met Glu Ala Pro		
305	310	315
Leu Asn Ser Ala Val Pro Ser Ala Gly Ala Ser Val Ile Gln Pro Ser		
325	330	335
Ser Ser Pro Leu Glu Ala Ser Ser Val Asn Tyr Glu Ser Ile Lys His		
340	345	350
Glu Pro Glu Asn Pro Pro Pro Tyr Glu Glu Ala Met Ser Val Ser Leu		
355	360	365
Lys Lys Val Ser Gly Ile Lys Glu Glu Ile Lys Glu Pro Glu Asn Ile		
370	375	380
Asn Ala Ala Leu Gln Glu Thr Glu Ala Pro Tyr Ile Ser Ile Ala Cys		
385	390	395
Asp Leu Ile Lys Glu Thr Lys Leu Ser Ala Glu Pro Ala Pro Asp Phe		400

```

tattctgcag cacagctttg cccatcattt gaagagtcag aagcttactcc ttcaccagtt 1980
ttgcctgaca ttgttatgga agcaccattg aattctgcag ttcctagtgc tgggtgcttcc 2040
gtgatacagc ccagctcatc accattagaa gcttcttcag ttaattatga aagcataaaa 2100
catgagcctg aaaaccccc accatatgaa gaggccatga gtgtatcact aaaaaaagta 2160
tcaggaataa aggaagaaat taaagagcct gaaaatatta atgcagctct tcaagaaaca 2220
gaagctcctt atatatctat tgcattgtat ttaattaaag aaacaaagct ttctgctgaa 2280
ccagctccgg atttctctga ttattcagaa atggcaaaag ttgaacagcc agtgctgat 2340
cattctgagc tagttgaaga ttcctcacct gattctgaac cagttgactt atttagtgat 2400
gattcaatac ctgacgttcc acaaaaaaca gatgaaactg tgatgcttgt gaaagaaagt 2460
ctcactgaga cttcatttga gtcaatgata gaatatgaaa ataaggaaaa actcagtgct 2520
ttgccacctg agggaggaaa gccatatttg gaatctttta agctcagttt agataacaca 2580
aaagataccc tgttacctga tgaagtttca acattgagca aaaaggagaa aattcctttg 2640
cagatggagg agctcagtac tgcagtttat tcaaatgatg acttatttat ttctaaggaa 2700
gcacagataa gagaaactga aacgttttca gattcatctc caattgaaat tatagatgag 2760
ttcctacat tgatcagttc taaaactgat tcattttcta aattagccag ggaatatact 2820
gacctagaag tatcccacaa aagtgaatgt gctaagccc cggatggagc tgggtcattg 2880
ccttgacagc aattgcccc tgacctttct ttgaagaaca tacaacccaa agttgaagag 2940
aaaatcagtt tctcagatga cttttctaaa aatgggtctg ctacatcaaa ggtgctctta 3000
ttgcctccag atgtttctgc ttgggacct caagcagaga tagagagcat agttaacccc 3060
aaagtctctg tgaaagaagc tgagaaaaaa ctctctccg atacagaaaa agaggacaga 3120
tcaccatctg ctatatcttc agcagagctg agtaaaactt cagttgttga cctcctgtac 3180
tggagagaca ttaagaagac tggagtgggtg ttgggtgcca gcttattcct gctgctttca 3240
ttgacagtat tcagcattgt gagcgttaaca gctacattg ccttggccct gctctctgtg 3300
accatcagct ttaggatata caagggtgtg atccaagcta tccagaaatc agatgaaggc 3360
caccatttca gggcatatct ggaatctgaa gttgctatat ctgaggagtt ggttcagaag 3420
tacagtaatt ctgctcttgg tcatgtgaac tgcacgataa aggaactcag gcgctcttc 3480
ttagtgtgat atttagttga ttctctgaag ttgagtggt tgatgtgggt atttacctat 3540
gttggtgcct tgtttaatgg tctgacacta ctgattttgg ctctcatttc actcttcagt 3600
gttcctgtta tttatgaacg gcatcaggca cagatagatc attatctagg acttgcaaat 3660
aagaatgtta aagatgctat ggctaaaatc caagcaaaaa tccctggatt gaagcgcaaa 3720
gctgaatgaa aacgccccaa ataattagta ggagtccatc tttaaagggg atattcattt 3780
gattatacgg gggagggtca gggagaacg aaccttgacg ttgcagtga gtttcacaga 3840
tcgttgtag atctttattt ttagccatgc actgttgta ggaataatta cctgtcttga 3900
ctgcatatgt ttcattcatc taagtattgt aagctgctat gtatggattt aaaccgtaat 3960
catatctttt tcttatctga ggcactgggt gaataaaaaa cctgtatatt ttactttgtt 4020
gcagatagtc ttgccgcac ttggcaagtt gcagagatgg tggagctaga aaaaaaaaaa 4080
aaaaaaaaaa aaa

```

<210> 64

<211> 893

<212> PRT

<213> Homo sapiens

<400> 64

```

Met Gly Ser Ser Phe Ser Val Ser Pro Lys Ala Glu Ser Ala Val Ile
  1                      5                      10                     15

```

```

Val Ala Asn Pro Arg Glu Glu Ile Ile Val Lys Asn Lys Asp Glu Glu
          20                      25                     30

```

```

Glu Lys Leu Val Ser Asn Asn Ile Leu His Asn Gln Gln Glu Leu Pro
  35                      40                     45

```

```

Thr Ala Leu Thr Lys Leu Val Lys Glu Asp Glu Val Val Ser Ser Glu
  50                      55                     60

```

```

Lys Ala Lys Asp Ser Phe Asn Glu Lys Arg Val Ala Val Glu Ala Pro
  65                      70                     75                     80

```

```

Met Arg Glu Glu Tyr Ala Asp Phe Lys Pro Phe Glu Arg Val Trp Glu

```

Glu Lys Leu Pro Lys Gln Arg Leu Asn Ala Glu Lys Ala Lys Leu Val
 145 150 155 160
 Lys Gln Val Gln Glu Lys Glu Asp Leu Leu Arg Arg Leu Lys Leu Val
 165 170 175
 Lys Met Tyr Arg Ser Lys Asn Asp Leu Ser Gln Leu Gln Leu Ile
 180 185 190
 Lys Lys Trp Arg Ser Cys Ser Gln Leu Leu Leu Tyr Glu Leu Gln Ser
 195 200 205
 Ala Val Ser Glu Glu Asn Lys Lys Leu Ser Leu Thr Gln Leu Ile Asp
 210 215 220
 His Tyr Gly Leu Asp Asp Lys Leu Leu His Tyr Asn Arg Ser Glu Glu
 225 230 235 240
 Glu Phe Ile Asp Val
 245

<210> 63
 <211> 4093
 <212> DNA
 <213> Homo sapiens

<400> 63
 ttgtttccgg gagccgtcac cacagtaggt ccttcggctc agtcggccca gcccctctca 60
 gtcttcccca acccccacaa ccgcccgcgg ctctgagacg cggccccggc ggccggcgga 120
 gcagctgcag catcatctcc accctccagc catggaagac ctggaccagt ctctcttggt 180
 ctcttctctg gacagccac cccggccgca gcccgcgttc aagtaccagt tctgtaggga 240
 gcccaggac gaggaggaag aagaggagga ggaagaggag gacgaggacg aagacctgga 300
 ggaagctggag gtgctggaga ggaagccgcg cgcgggctg tccgcggccc cagtgtccac 360
 cgcctctgcc gcccgcgcgc ccttgatgga cttcgaaat gacttctgtc cgcgcgcgc 420
 ccggggaccc ctgcgggcg ctccccctgt cgcgcgggag cggcagccgt cttgggaccc 480
 gagcccggtg tctcgaccg tgccgcgcgc atccccctgt tctgtgtccg cagtctgcgc 540
 ctccaagctc cctgaggacg acgagcctcc ggcccgccct cccctctctc ccccgccag 600
 cgtgagcccc caggcagagc ccgtgtggac cccgcagcc cccgctcccc cccgcgcgc 660
 ctccaccccg gccgcgcga agcgcagggg ctcttcgggc tcagtggatg agacctttt 720
 tgctcttctt gctgcatctg agcctgtgat acgctctct gcagaaaata tggacttgaa 780
 ggagcagcca ggtaacacta tttcggtctg tcaagaggat ttcccatctg tctgtctga 840
 aactgtctgt tctcttctct ctctgtctcc tctctcagcc gttcttttca aagaacatga 900
 ataccttggg aatttgtaaa cagtattacc cactgaagga acacttcaag aaaatgtcag 960
 tgaagcttct aaagaggtct cagagaaggc aaaactctac tcatagatag agatttaaca 1020
 gagttttcag aattagaata ctcaaaaatg ggatcatcgt tcagtgtctc tccaaaagca 1080
 gaatctgccg taatagtagc aaatcctagg gaagaaataa tctgaaaaaa taaagatgaa 1140
 gaagagaagt tagttagtaa taacatcctt cataatcaac aagagttacc tacagctctt 1200
 actaaattgg ttaaagagga tgaagttgtg tcttcagaaa aagcaaaaaga cagttttaat 1260
 gaaaagagag ttgcctgtga agctcctatg agggagggaat atgcagactt caaacattt 1320
 gagcgagtat gggaagtgaag agatagtaag gaagatagtg atatgttggc tgctggagggt 1380
 aaaatcgaga gcaacttgya aagtaaaagt gataaaaaat gttttgcaga tagccttgag 1440
 caaactaatc acgaaaaaga tagtgagagt agtaatgatg atacttcttt cccagtagc 1500
 ccagaaggta taaaggatcg ttcaggagca tatatcacat gtgtccctt taaccagca 1560
 gcaactgaga gcattgcaac aaacattttt cctttgttag gagatcctac ttcagaaaat 1620
 aagaccgatg aaaaaaaaat agaagaaaag aaggcccaaa tagtaacaga gaagaatact 1680
 agcaccaaaa catcaaaccc ttttcttgta gcagcacagg attctgagac agattatgtc 1740
 acaacagata atttaacaaa ggtgactgag gaagtcgtgg caaacatgcc tgaaggcctg 1800
 actccagatt tagracagga agcatgtgaa agtgaattga atgaagttac tggtaacaa 1860
 attgcttatg aaacaaaaat ggacttggtt caaacatcac aagttatgca agagtcaac 1920

<400> 61

```

tttttttttg ctctcgctgg gaatggcgga gggagagaaa aaccaagatt tcactttcaa 60
gatggaaagt ccgtcagact cagctgtggt tttacctagc actcctcagg cctctgcgaa 120
tccatcatct cctatacaa atagttcccg aaaacaacct atgagtgcga cacttagaga 180
aagattaagg aaaacaagat tttcatttaa ttctctttac aatgtggtga aacgtcttaa 240
agtagagagt gaagaaaatg atcagacctt ttcagagaaa ccagcatctt ccacagagga 300
aaactgtttg gaatttcaag aaagttttaa acatatagac agtgaatttg aagaaaatac 360
aaatttgaaa aatactttga agaactctaa tgtctgtgaa tctcagtcac ttgattctgg 420
atcatgcagt gctctccaaa atgagtttgt gagtgagaag ctctctaaac aaagattaaa 480
cgctgaaaaa gccaaattgg tgaagcaggc tcaggagaaa gaagaccttc ttcggagggt 540
aaaactagtc aaaatgtata gatcaaagaa tgatctgtct cagttacagt tgttaataaa 600
gaagtggaga agctgtagcc agctcttgct ttatgagttg cagtcagctg tgtctgaaga 660
gaacaagaaa ctaagcctta ctcaattgat agaccactat ggggttagatg ataaattact 720
acactataac agaagtgaag aagaatttat agatgtttta ttcttgattt ttgctccaga 780
atatcttttg gaatgacaac ttaattaaaa gatacttagg cacttttttt ttttttttga 840
gactgagttt cgctcttgct atcctggctg gagtgtgatg gtgcgatctt gactcactgc 900
aacctctgcc tctcgggttc cagcaattct cctgcctcag cctcccgagt agctgagatt 960
acaggcgccc gccaccatgc ccggctaatt tttgcatttt tagtagagac tgggtttcac 1020
cacgttgccc aggtgtgctt cgaactcctg acctcaggtg atccaccgcc taggctctcc 1080
aaaaccatta gggctcagag gaaggtatcc caatgaatat caattaaggg cactttaata 1140
tataaattat aaactaagtt ctaaaaggaa aattagtatt ttggatagat ttgtcaaac 1200
gacatttaag tcatgtttta aaagtcaatt gggcagttct ggaaactagt tttaatacat 1260
ttgtttttta tgacaaaaag ttttatctta aatgttaaaa attgtccaat ctggtyaatg 1320
tctaacccta aagtttaaaa atttctgcct cctaagttta tgtaccttgt ttccatccat 1380
ttaccacata ttccatctg atagtctagc aggttaattaa acttatatgt ccaaaaaaaaa 1440
aaaaaaaaaa aaaaaaa 1457

```

<210> 62

<211> 245

<212> PRT

<213> Homo sapiens

<400> 62

```

Met Ala Glu Gly Glu Lys Asn Gln Asp Phe Thr Phe Lys Met Glu Ser
  1                      5                      10                      15

Pro Ser Asp Ser Ala Val Val Leu Pro Ser Thr Pro Gln Ala Ser Ala
      20                      25                      30

Asn Pro Ser Ser Pro Tyr Thr Asn Ser Ser Arg Lys Gln Pro Met Ser
      35                      40                      45

Ala Thr Leu Arg Glu Arg Leu Arg Lys Thr Arg Phe Ser Phe Asn Ser
      50                      55                      60

Ser Tyr Asn Val Val Lys Arg Leu Lys Val Glu Ser Glu Glu Asn Asp
      65                      70                      75                      80

Gln Thr Phe Ser Glu Lys Pro Ala Ser Ser Thr Glu Glu Asn Cys Leu
      85                      90                      95

Glu Phe Gln Glu Ser Phe Lys His Ile Asp Ser Glu Phe Glu Glu Asn
      100                      105                      110

Thr Asn Leu Lys Asn Thr Leu Lys Asn Leu Asr Val Cys Glu Ser Gln
      115                      120                      125

Ser Leu Asp Ser Gly Ser Cys Ser Ala Leu Gln Asn Glu Phe Val Ser
      130                      135                      140

```

```

aaggctagtg acagcagatg tcatccagga acagccacac acggttctcc aggcgcgcgt 1140
cagcagctca aggtggggta tgagtggaaa gctgaggatc tcgcagcttg ttgctgagca 1200
aggtgcaacc gggctcatgc tgtcatcagc acaagacggg atggcaaggg ctttcagacg 1260
catttccaag agtccagcaa gccaggggga agatgatccc ttgcccgaag tgtaccctct 1320
agccaacttt tgggagcgct tctgtttgca aagcgctggg gatgtgcctg tctctgtgtg 1380
acccacgaac gggaagggag agcactggag taatgacact tctgtgtctg ctttgattct 1440
caaggctgat ctttaaaacc ctgccttg cgcaggtgc tttaaaggca gtctgcatct 1500
tttcttcctt tgggtgtggga gaggtaaaca ctttgatttg ctgaaagctg tatggagtat 1560
atttgaacag ctagtagtta gctttgaaag tggaagtgtg aacagacact acttgtgtcg 1620
ctttgggtcc ttcactttac cccacagaa gtctagaggc gtctgttata aagcgttacg 1680
gggctcctgc atgcaggagg aaggacctgt attagctgga aatcatcagg aaccagctt 1740
gcctccatct ctctgagatg tgctgggtac agcctgcccc tctagtctt gtccaccggg 1800
aagagccggc tggcggcaga tccccagggg cagagccctt gctggatcct gggagctcat 1860
ctttacctgt gccggagtgg gaactgtgat tccagccggg caggtcagag tggagcagt 1920
ctaagaggct gttgcaggag aactagacgg gcggggcctg ctgcatctgg atcatgtttc 1980
tgtgtctctg cccgcgctag ggactcaggg tctgggcttc tgccaggtga ggagcagaga 2040
gactgttccc ttgggtggag aggtgtgggc atgagagcca cccattgcca agcagcaaga 2100
atgttcgtgc tttttccag agaggggaac cccactgggt ttgtggaaa caatggaaac 2160
ttacagatgc ctgcctggga tgatgaggca cattcagaac aaatgctttt ttttttttg 2220
agacagagtc tcgctctgac gcccaggctg gactgcagtg gcgcgacttc ggctcactgc 2280
aaactttgcc tcccaggctt aagtgtattt cctacctcag cctcccgagt agctgggatt 2340
acaccaccat gcccagcaaa tttttgtgtt tttagttag agggagtttc accatgttgg 2400
ccaggttgtt ctgaactcc tgacctcagg tgatccatcc gccttggcct cccaaagtgc 2460
tgggattaca ggcgggagcc accatgcctg gccagaacaa atgccttttt aaacctttta 2520
agaacatttt taaaatgtct ttttctatgt caaatgtaac gtttattttt ttaaacaata 2580
aaattgattt gccaaaaaaa aaaaaaaaaa aaaaaaa 2617

```

<210> 60
 <211> 105
 <212> PRT
 <213> Homo sapiens

```

<400> 60
Met Gln Gly Ser Gly Ser Gln Phe Arg Ala Cys Leu Leu Cys Leu Cys
  1                      5                      10                     15

Phe Ser Cys Pro Cys Ser Pro Gly Gly Pro Arg Trp Asn Ser Arg Gln
  20                      25                     30

Gly Gly Arg Arg Phe Pro Lys Thr Cys Arg Ala Ile Ser Gln Asn Leu
  35                      40                     45

Val Phe Lys Tyr Lys Thr Phe Cys Pro Val Arg Tyr Met Gln Pro His
  50                      55                     60

Arg Ser Ser Leu Cys Leu His Phe Thr Ser Tyr Val Phe Ile Leu Ser
  65                      70                     75                     80

Thr Trp Gly Ser Leu Arg Thr Tyr Ser Thr Asp Leu Lys Lys Lys Lys
  85                      90                     95                     100

Leu Pro Gly Ser Ile Ser Val Ser Glu
  100                      105

```

<210> 61
 <211> 1457
 <212> DNA
 <213> Homo sapiens

```

tgaacccgat tctgggggagc atcttcccgc tccggcccca cgaacctccac aggggttacat 1560
tgtaatatat atgccccagc taacctgtct gatgggtggca tcttcttgca gacatttcaa 1620
acatgtaact tttatatgaa aaaaaataaa cacagatgaa agctgaaaaa aaaaaaaaaa 1680
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 1727

```

<210> 58
 <211> 115
 <212> PRT
 <213> Homo sapiens

```

<400> 58
Met Trp Ala Phe Ser Pro Leu Pro Cys Phe Val Cys Pro Val Asp Arg
  1                      5                      10                      15

Gly Arg Lys Ala Val Gln Trp Gln Ala Gly Pro Pro Leu Val Ala Gly
                20                      25                      30

Pro Pro Leu Ala Val Val Leu Arg Gly Gln Pro Gly Pro Val Thr Leu
                35                      40                      45

Leu Phe Lys Glu Cys Val Cys Arg Val Ala Gly Leu Leu Thr Val Leu
                50                      55                      60

Cys Val Gly Trp Val Phe Ser Leu Phe Leu Leu Phe Glu Val Pro Ser
                65                      70                      75                      80

Phe Gln Ser Leu Thr Leu Ser Pro Leu Pro Leu Pro Ser Ser Val Gly
                85                      90                      95

Cys Cys Cys Ala Arg Val Arg Ala Ala Leu His Thr Gly Pro Leu Gly
                100                      105                      110

Cys Val Asn
                115

```

<210> 59
 <211> 2617
 <212> DNA
 <213> Homo sapiens

```

<400> 59
tactgactcg aggggttccc ttccaaaata tgcagggttc aggcctccaa ttccgggect 60
gtctgctttg cttgtgtttc tctgttcctt gttctcccg agggcccagg tggaactcac 120
gacagggagg gagacgcttc ccaaaaacct gcagggttat ttcccagaat ttggttttca 180
agtacaaaac tttttgtcct gtaagatata tgcagcctca cagaagcagc ctctgcctcc 240
actttaccag ctacgttttt atcttaagca catggggctc ccttagaact tactccactg 300
atttaaaaaa aaaaaaactg cctggcagca tctcagtgtc agagtgcagc cggcacagga 360
aaggcccggt gtgacgaggg tgaggtggcc acagtgaccg gacgacaaat gagactctgc 420
aaatgagact ccagaggggtg aagatctgcg gtctccagac atcataggcc atgtgaccca 480
ctagggggccg cttaccctcg gccgtccgct ggctgaactg aacgcatttc ctctctccgc 540
aactctcccg tgaggctgca cccgtgtggg tagcactgga agcggcactg tttgcattgt 600
acataggaag gaaggaggtt cttccagcct caccagcacc tggcagcgag tcagagcctg 660
tgagggcatc cgaagcagtg atgcagtgtc aacctcccag ctggtgccac tctgccctcg 720
ggggctccaa gcattgtaac tcagtcattg gagctgcctc tttggaagtg cagatttatt 780
cctgtaataa tctgcctgc ttttacctct cgtccactga ccagcaagtg tgagtcctgg 840
tgtcagtcgg cacagtcag tgtccatctg catttgctca tgcagagggg gtgagttggg 900
cactccctgt tgttggtttt ccttttgcag cacactgggc agtctcccta taaaacaaaa 960
accccacctt ctgtgccttc tgccttagag cagagctccc cctcccattt cctcagtttt 1020
ccctgcaaaa tctgtccacc ggggaaggca gcaggaaccc tgggcagcgg gtgttctggg 1080

```

Asp Leu Lys Glu Gln Leu Ala Pro Leu Glu Lys Val Arg Ile Glu Ile
 210 215 220
 Ser Arg Lys Ala Glu Lys Arg Thr Thr Leu Val Leu Trp Gly Gly Leu
 225 230 235 240
 Ala Tyr Met Ala Thr Gln Phe Gly Ile Leu Ala Arg Leu Thr Trp Trp
 245 250 255
 Glu Tyr Ser Trp Asp Ile Met Glu Pro Val Thr Tyr Phe Ile Thr Tyr
 260 265 270
 Gly Ser Ala Met Ala Met Tyr Ala Tyr Phe Val Met Thr Arg Gln Glu
 275 280 285
 Tyr Val Tyr Pro Glu Ala Arg Asp Arg Gln Tyr Leu Leu Phe Phe His
 290 295 300
 Lys Gly Ala Lys Lys Ser Arg Phe Asp Leu Glu Lys Tyr Asn Gln Leu
 305 310 315 320
 Lys Asp Ala Ile Ala Gln Ala Glu Met Asp Leu Lys Arg Leu Arg Asp
 325 330 335
 Pro Leu Gln Val His Leu Pro Leu Arg Gln Ile Gly Glu Lys Asp
 340 345 350

<210> 57
 <211> 1727
 <212> DNA
 <213> Homo sapiens

<400> 57
 ggggaaggga tccttgaggc acccgaatgg tccctcaggg tgcagggagg cagaagcctg 60
 gccacagagg agcctcctaa ggcagcagct gcagcaagcg accctctccc ccactctccc 120
 cagccagag cggcttccag agcagatgct gtttccatcc tctcgtcaa aaccattctc 180
 gctgctgagc ttgacaatct gggcaaggct tgtggggcgc ttgacaaaaca gaatctgccc 240
 tgtgccgcct ggttccgtgg cctccagcat gagcctgcag gcagggcgct gcgggaaccc 300
 agttgtgtcg cccagccca tgcctccggg tctgtgtgac atgaatgagt gctcacttgt 360
 cccgggttta ggacgtggtc aagtgaacag caggggtctaa ctgtgtctac ttagccagc 420
 tcaaacagaa caaaggaaaa atatagaaag caacatctgt tgatcattta ggtttttttt 480
 taaaccacca tgtcactttg agtccttcat gggtttttga acagcattta tcaagaagaa 540
 aatgtgggct ttttccctc tcccgtgttt tgtttgtcct gtagatagag ggaggaaagc 600
 cgtgcagtgg caggcgggac cccctctggt ggcgggaccc cctcttgccg tggctctgcg 660
 gggccagccg ggacctgtca ctttattatt taaggagtgt gtgtgtagag tcgctggctt 720
 attaacagta ttgtgtgtgg gttgggtttt tagttgttcc cttctttttg aagtccttcc 780
 atttcaatcc ttgactctct ctcccttccc cttgcccagc tctgttgaat gcagctgtgc 840
 gcgtgtgagg gcgcgtctgc acacagggcc cttgggttgt gtgaactgaa attctccctg 900
 tattttgtgag actcgcagga gtccccatct gtagcacagg caatgccagt gccatgtctc 960
 agcctcagaa accaggcctc tccctccagc agcaggcaga accgtgtcgg tggctggggtg 1020
 ctgtccacag ctctgtctgc cttgtttctg ggcttgagct ggatagaggt ggggtctctt 1080
 caccttccc gaattcagaa cagacctgt gcctggcccc agtgtgcccc ggcaattccc 1140
 caggccctca ttgggagccc ttgtgttct gagcagcagg gccagggcag cacatgagca 1200
 gtgcccagg gctccctgcg tgaggacggc aaggtgcgat gtatgtctaa cttattgatg 1260
 gcaggcagcc ccctgtgccc cctaagcctg gccctgggta ttgtgtgagc ctgtgtccag 1320
 tgctgcggcc tggccgtggc tcgtctgttc ctttgggggg cccggggcgg ttgtgggaat 1380
 cagtcttcac agacagacgt gagccaggcg gaggactcgt tccctgcaga ggtcagtcct 1440
 cacctgcagg tgtcggggtg ggggggggca aggaggggca ggcacacacc atgtctgacc 1500

```

cacaacttca gttgtaaatc aagtgtgtgg atctcaaagg gtgcaattta tctttatata 2160
ggaatacatt tctagggctt ccttcaagcc cactctcttc accctatttt ttcttatctt 2220
aaattgagag aaagagaatt aatcttatac ttgtcaaaa cattttctac catatttcca 2280
gatgacatct gcgcttgaag agtcaaagga atctgtgtct aatatcctgt ttttaactgc 2340
ttagggggca ggatggaaag gatgatgggg gctgccacac cactgattgg ccttttcttt 2400
cacgtgattc atccttcttc attgtggcaa ggagttcttt ctctttttct tctctctttg 2460
ggatcattgt gtatgaaaag aaaaacttta aatgacaaac ccagactcca ggtgccttgc 2520
aaaggttgaa ggccagccag gattgtgtct gctgctgcta ctctgccaa cacccttttc 2580
attggcatga cggaatgaaa ggatgcatgt ctccacttcc tgacctccg cccacttctt 2640
tctccctcca ccaccccccag tcgtcagctc ctccctcat ttatttttct taagttgtgt 2700
gaattatttt taaccatttt atcctgtttg tgcataagggt ttttaagaag aaacagcaca 2760
gtgcaacgag caaatctttt tggggtgtgt gggaagcaag ggaggaggga catggagaaa 2820
agttctttta acaaatagca aactattgaa catgtgtaaa atcctgtatc atttatgaaa 2880
tatgtataaa aagcaatgta ccttctggaa caataaatac ttattcaatt tttgaaaaaa 2940
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2969

```

<210> 56

<211> 351

<212> PRT

<213> Homo sapiens

<400> 56

```

Met Ala Ala Ala Gly Arg Ser Leu Leu Leu Leu Ser Ser Arg
  1              5              10              15

Gly Gly Gly Gly Gly Gly Ala Gly Gly Cys Gly Ala Leu Thr Ala Gly
      20              25              30

Cys Phe Pro Gly Leu Gly Val Ser Arg His Arg Gln Gln His His
      35              40              45

Arg Thr Val His Gln Arg Ile Ala Ser Trp Gln Asn Leu Gly Ala Val
      50              55              60

Tyr Cys Ser Thr Val Val Pro Ser Asp Asp Val Thr Val Val Tyr Gln
      65              70              75              80

Asn Gly Leu Pro Val Ile Ser Val Arg Leu Pro Ser Arg Arg Glu Arg
      85              90              95

Cys Gln Phe Thr Leu Lys Pro Ile Ser Asp Ser Val Gly Val Phe Leu
      100             105             110

Arg Gln Leu Gln Glu Glu Asp Arg Gly Ile Asp Arg Val Ala Ile Tyr
      115             120             125

Ser Pro Asp Gly Val Arg Val Ala Ala Ser Thr Gly Ile Asp Leu Leu
      130             135             140

Leu Leu Asp Asp Phe Lys Leu Val Ile Asn Asp Leu Thr Tyr His Val
      145             150             155             160

Arg Pro Pro Lys Arg Asp Leu Leu Ser His Glu Asn Ala Ala Thr Leu
      165             170             175

Asn Asp Val Lys Thr Leu Val Gln Gln Leu Tyr Thr Thr Leu Cys Ile
      180             185             190

Glu Gln His Gln Leu Asn Lys Glu Arg Glu Leu Ile Glu Arg Leu Glu
      195             200             205

```

Met Phe Leu Leu Ala Lys Ser Leu Gly Phe Cys Leu Ala Ile Gly Tyr
 1 5 10 15

Cys Leu Cys His Leu Pro Arg Val Gly Ala Leu Asp Ile Lys Gly Arg
 20 25 30

Arg Arg Ser Val Leu Leu Leu Tyr Lys Ser Ser Met Gln Cys Ser Thr
 35 40 45

Arg Val Leu Gln Ala Ile Pro Gly Lys Arg Ala Cys Trp Thr Met Val
 50 55 60

Phe Asp Gly Thr Thr Gln Asp Ser Leu Val Thr Val Gln Phe Lys Gly
 65 70 75 80

Asn Val Thr Tyr Arg Arg Val Val
 85

<210> 55
 <211> 2969
 <212> DNA
 <213> Homo sapiens

<400> 55
 gagttgagag atggcgggccg ccgcaggttag atcgctcctg ctgctcctct cctctcgggg 60
 cggcggcgccg gggggcgccg gcggctgcgg ggcgctgact ggcggctgct tccctgggct 120
 gggcgctcagc cgccaccggc agcagcagca ccaccggacg gtaccaccaga ggatcgcttc 180
 ctggcagaat ttgggagctg tttattgcag cactgttggtg cctctctgatg atgttacagt 240
 ggtttatcaa aatgggttac ctgtgatatc tgtgaggcta ccacccggc gtgaacgctg 300
 tcagttcaca ctcaagccta tctctgactc tgttggtgta tttttacgac aactgcaaga 360
 agaggatcgg ggaattgaca gagttgctat ctattcacca gatgggtgttc gcgttgctgc 420
 ttcaacagga atagacctcc tctccttga tgactttaag ctgggtcatta atgacttaac 480
 ataccacgta cgaccaccaa aaagagacct cttaagtcat gaaaatgcag caacgctgaa 540
 tgatgtaaaag acattgggtcc agcaactata caccacactg tgcattgagc agcaccagtt 600
 aaacaaggaa agggagctta ttgaaagact agaggatctc aaagagcagc tggctccctc 660
 ggaaaaggta cgaattgaga ttagcagaaa agctgagaag aggaccactt tgggtgctatg 720
 ggggtggcctt gcctacatgg ccacacagtt tggcattttg gcccggtta cctgggtggga 780
 atattcctgg gacatcatgg agccagtaac atacttcac ctttatggaa gtgccatggc 840
 aatgtatgca tattttgtaa tgacacgcca ggaatatgtt tatccagaag ccagagacag 900
 acaatactta ctatttttcc ataaaggagc caaaaagtca cgttttgacc tagagaaata 960
 caatcaactc aaggatgcaa ttgctcaggc agaaatggac cttaagagac tgagagaccc 1020
 attacaagta catctgcctc tccgacaaat tggcgaaaaa gattgatctg caaaaagcct 1080
 ctgaatcctg gcagaaggaa cacctgtttg cctttttaat taaagcattg caggtggaag 1140
 ctgggagcca tgtggggggt agagcgtttt tacctttaat tataaaacaa aaacagaaaag 1200
 gatctgaggg aagaaggga ttgttaaacc tgaggatcag gcattgtgga atataagctc 1260
 aaagggctta gtgaatattg tcttaaccaa gtatctcagt ttctggatga aaatgatgca 1320
 gttatatagt tgagagattc ataaagagaa aacaatgctg ggggtgttcg tttcttgcat 1380
 ctctcttgca ggtcagcaa aagagtaaca caccagcacc ccactcgact ctatttgttt 1440
 ttaatttaac tgtccctatt ttgacatag gagtaataaa atatactaga aaagcaatt 1500
 ctcatgatat gctaaaatat cattagcatt tattttaaat tggaccagct cctgcagag 1560
 ttaccaggaa tcttctcttc cagcctccct ttactgacca cctacctgta cctcttggtt 1620
 acactttttt ttccatttga taattggaac caacttaaa ctgtttaata attgacactt 1680
 tagattatct cttaatacct tcttaaatgt ctatatatcc cagtgtcttg gatcagttgc 1740
 taaaaatcac tggcaacact gcatgaggtt gttggttttg tttgtttta ttaattgctc 1800
 ttccacagga ggaataattg cctcctttta tatacttata tattgataat cccctctccc 1860
 tccagaacac aaatcagagg gaaagggggt gttcagctgt actacnaaa caggaagatg 1920
 taaggtttac aaattggcta agaatcatgg ctctgtagcc atttcaacca gaataatttt 1980
 attgctaate tgccttgtgt gacagcattc cagccagcc agatgggact gccttgctc 2040
 gaggttttgt tcactctgaa ggacacacac ttcacactg tttgtgagcc ctcccacctc 2100

565	570	575
Phe Leu Leu Ser Ile Leu Ile Ala Trp Thr Val Gln Tyr Phe Gln Ser		
580	585	590
Val Ser Ala Ser Asp Pro Pro Pro Arg Pro Ser Gln Ala Ser Pro Asp		
595	600	605
Thr Ala Thr Ser Thr Ala Ser Pro Ala Val Thr Pro Ala Ala Asp Ala		
610	615	620
Ser Asp Gln Asp Gln Pro Thr Val Thr Asn Asn Pro Glu Pro Arg Gly		
625	630	635
		640

<210> 53

<211> 1908

<212> DNA

<213> Homo sapiens

<400> 53

```

gaactcaaga tggcggacga gactgagaca gcagtgaagc cgccggcacc tccgctgccg 60
cagatgatgg aagggaaacgg gaacggccat gacactgca gcgattgcga gaatgaggag 120
gacaacagct acaaccgggg gtaacgaaat cctcggagtc caattcccgt ccagcctccc 180
acaacctggg tctctggggg gcggggaagt caccgggagc ttagcttagc cccaccctca 240
tggtcttatt ggctaagtc aataggattct gcctggcgat tggttattgc ctttgtcatt 300
taccaagggt ggggtgctctg gatattaagg gccggagacg ttcagtacct ttattatata 360
aaagtcttat gcagtgttcc actcgtgtgc ttcaggccat tccgggaaa agagcatgtt 420
ggacgatggg ttctgatggg acaacacagg acagtctagt aacagtacag ttcaaaggga 480
acgttactta tagacgtgtt gtttgaacaa cgtgactagc aataaacgaa tcataaaaca 540
tttcgcagca gttcaccctc agtgaggaaa ctcacagac tatacaaact gtatgtataa 600
ttatatgtga aaatatcact accagagaat cccaaaatat aaactcacct tataaaccta 660
tgtaattaac ggtatggtaa tgctttgatt tacatagttt ccattgctcc aaataatcca 720
taagtatcct gaacgatata ttaataataa taagtcttcg aacatctttg ccttgttacc 780
tttgcagagc agccccaggc ttcaagaaat gagcgatgtt gtttcttggg gagtatttgg 840
aatcctcggg ctccatactg cctatcctgt actttagggt cttgccatta gttactattt 900
gttcttaggg atgaagaaac acaccaggca tttgaatgtt gaattctttt cccaaattag 960
tttttacttc tgtaagccac agcttattca tctttcttca catgggttagt gcctggcact 1020
ggcactcacg ctgtctctcc ccattctcct gtctatatat gtagatatat ttttaaactg 1080
aaagtcgtga gagatttttg ggtgtataac ttgctgagtc tgaggtagtc tgattttcgt 1140
agccagcttg ttattcgcag tattgggtggc agtgcagata taaaggata aagaccaagg 1200
actgcgtaga agagatgggc ccacaagatt atagtacata tttttattgt atcctttcta 1260
tgtttaggta tgcttagata cacaataact taccattgta ttatagttgc ctgcagtact 1320
cagtaacatg cagcagccta ttgctcctag gctacaaacc tgtatagcat gttactgtaa 1380
tgtacaccat atagcctagg catttagtag gttataccat ctgatttgtt gtaagtacac 1440
cctataatgt tggcaaggca aaaatcacct aacctgcat ttcccagcac atatgcctga 1500
cgttcagrga agcatgactg tatttaagtg gtttataatc tgcttgtggg aaatcttagg 1560
ttaaaagatc tagcttttat gttcttcagc cggcattaaa aatcacagga agggccgggc 1620
atggtgggtc atgcctgtaa tcccagtagc ttgggaggca gatcacgagg tcaggagatc 1680
gagaccatcc tggctaacac tgtgaaatcc catctctact aaaaatacaa aaaatttagc 1740
cgggcgtggg ggccggcgcc tgtagtccca actactcggg aggcctaaggc aggagaatgg 1800
cgtgaaccca ggaggcagag cttgcagtga gctgagatca cgccactgca ctccagcctg 1860
ggcgacagag cgagactcgg actcaaaaaa aaaaaaaaaa aaaaaaaaaa 1908

```

<210> 54

<211> 88

<212> PRT

<213> Homo sapiens

<400> 54

245	250	255
Leu Ala Leu Glu Leu Met Lys Lys Ala Ala Ser Lys Gly Leu His Gln 260 265 270		
Ala Val Asn Gly Leu Gly Trp Tyr Tyr His Lys Phe Lys Lys Asn Tyr 275 280 285		
Ala Lys Ala Ala Lys Tyr Trp Leu Lys Ala Glu Glu Met Gly Asn Pro 290 295 300		
Asp Ala Ser Tyr Asn Leu Gly Val Leu His Leu Asp Gly Ile Phe Pro 305 310 315 320		
Gly Val Pro Gly Arg Asn Gln Thr Leu Ala Gly Glu Tyr Phe His Lys 325 330 335		
Ala Ala Gln Gly Gly His Met Glu Gly Thr Leu Trp Cys Ser Leu Tyr 340 345 350		
Tyr Ile Thr Gly Asn Leu Glu Thr Phe Pro Arg Asp Pro Glu Lys Ala 355 360 365		
Val Val Trp Ala Lys His Val Ala Glu Lys Asn Gly Tyr Leu Gly His 370 375 380		
Val Ile Arg Lys Gly Leu Asn Ala Tyr Leu Glu Gly Ser Trp His Glu 385 390 395 400		
Ala Leu Leu Tyr Tyr Val Leu Ala Ala Glu Thr Gly Ile Glu Val Ser 405 410 415		
Gln Thr Asn Leu Ala His Ile Cys Glu Glu Arg Pro Asp Leu Ala Arg 420 425 430		
Arg Tyr Leu Gly Val Asn Cys Val Trp Arg Tyr Tyr Asn Phe Ser Val 435 440 445		
Phe Gln Ile Asp Ala Pro Ser Phe Ala Tyr Leu Lys Met Gly Asp Leu 450 455 460		
Tyr Tyr Tyr Gly His Gln Asn Gln Ser Gln Asp Leu Glu Leu Ser Val 465 470 475 480		
Gln Met Tyr Ala Gln Ala Ala Leu Asp Gly Asp Ser Gln Gly Phe Phe 485 490 495		
Asn Leu Ala Leu Leu Ile Glu Glu Gly Thr Ile Ile Pro His His Ile 500 505 510		
Leu Asp Phe Leu Glu Ile Asp Ser Thr Leu His Ser Asn Asn Ile Ser 515 520 525		
Ile Leu Gln Glu Leu Tyr Glu Arg Cys Trp Ser His Ser Asn Glu Glu 530 535 540		
Ser Phe Ser Pro Cys Ser Leu Ala Trp Leu Tyr Leu His Leu Arg Leu 545 550 555 560		
Leu Trp Gly Ala Ile Leu His Ser Ala Leu Ile Tyr Phe Leu Gly Thr		

tacatttcaa ttgcaatcca tgaaattaca tttagaagat tcttagtact taactgtagt 2640
 cttctccatg aattacacgt tagaatagac tggcagcaac ggaatatgca gcaagtaagc 2700
 ctctagctta tagtttcac cctaccctc atgcctgcgt gagtctgtac agggatatgt 2760
 gtgtgtgtgt gtgtgtgtgt gtgttagaga ggaagaggaa gagcagaatg tctgtatata 2820
 acatggctgc taaggtagtg aataaatcag taatgcaata ttgtgggtcc aaactactct 2880
 ttgcactact ttatttacag tagtaataa aattattttt atacaattga aaaaaaaaaa 2940
 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 2986

<210> 52

<211> 640

<212> PRT

<213> Homo sapiens

<400> 52

Met Cys Arg Ala Phe Pro Trp Glu Lys Glu Leu Lys Asp Lys His Pro
 1 5 10 15

Ser Leu Phe Gln Ala Leu Leu Glu Met Asp Leu Leu Thr Val Pro Arg
 20 25 30

Asn Gln Asn Glu Ser Val Ser Glu Ile Gly Gly Lys Ile Phe Glu Lys
 35 40 45

Ala Val Lys Arg Leu Ser Ser Ile Asp Gly Leu His Gln Ile Ser Ser
 50 55 60

Ile Val Pro Phe Leu Thr Asp Ser Ser Cys Cys Gly Tyr His Lys Ala
 65 70 75 80

Ser Tyr Tyr Leu Ala Val Phe Tyr Glu Thr Gly Leu Asn Val Pro Arg
 85 90 95

Asp Gln Leu Gln Gly Met Leu Tyr Ser Leu Val Gly Gly Gln Gly Ser
 100 105 110

Glu Arg Leu Ser Ser Met Asn Leu Gly Tyr Lys His Tyr Gln Gly Ile
 115 120 125

Asp Asn Tyr Pro Leu Asp Trp Glu Leu Ser Tyr Ala Tyr Tyr Ser Asn
 130 135 140

Ile Ala Thr Lys Thr Pro Leu Asp Gln His Thr Leu Gln Gly Asp Gln
 145 150 155 160

Ala Tyr Val Glu Thr Ile Arg Leu Lys Asp Asp Glu Ile Leu Lys Val
 165 170 175

Gln Thr Lys Glu Asp Gly Asp Val Phe Met Trp Leu Lys His Glu Ala
 180 185 190

Thr Arg Gly Asn Ala Ala Ala Gln Gln Arg Leu Ala Gln Met Leu Phe
 195 200 205

Trp Gly Gln Gln Gly Val Ala Lys Asn Pro Glu Ala Ala Ile Glu Trp
 210 215 220

Tyr Ala Lys Gly Ala Leu Glu Thr Glu Asp Pro Ala Leu Ile Tyr Asp
 225 230 235 240

Tyr Ala Ile Val Leu Phe Lys Gly Gln Gly Val Lys Lys Asn Arg Arg

Met Leu Glu Pro His Ser Cys Gln Tyr Ile Leu Gly Val Glu Ser Pro
 450 455 460

Val Ile Cys Lys Ile Leu Asp Thr Ala Asp Glu Asn Gly Leu Leu Ser
 465 470 475 480

Leu Pro Asn

<210> 51
 <211> 2986
 <212> DNA
 <213> Homo sapiens

<400> 51
 atgggagacc ctgatgtgc agagccttcc cctgggagaa ggagctgaaa gacaaacacc 60
 ccagcttggt ccaggcattg ctggagatgg atctgctgac cgtgccaagg aaccaaattg 120
 aatctgtatc agaaatcggg gggaagatat ttgagaaggc tgtaaagaga ctctctagca 180
 ttgatggctc tcaccaaatt agctctatcg tcccccttct gacggattcc agctgctgtg 240
 gataccataa agcatcctac taccttgcag tcttttatga gactggatta aatgttcctc 300
 gggactagct gcagggcatt ttgtatagtt tgggtggagg ccaggggagt gagaggctgt 360
 cttcaatgaa tcttgggtat aaacactacc agggatttga caactacccc ctggactggg 420
 aactgtcgtg tgcctactac agcaacattg ccaccaagac accccttgac cagcacacac 480
 tgcaaggaga tcaggcatat gttgaaacaa ttagactaaa agatgatgaa atactcaagg 540
 tacaacacaa agaagatgga gatgtcttta tgggttgaa gcatgaagct acccgaggca 600
 atgcagcagc tcagcaacga ttggcccaga tgctgttctg ggggcagcaa ggtgtggcca 660
 agaatcccga agcagcaatt gattgggtacg ccaagggcgc cctggagacg gaggatcctg 720
 cgtaaattca tgactatgcc attgtgctat tcaaggggtca aggagtaaaa aagaacagac 780
 ggcttgctct agagctgatg aagaaagcag cttccaaggg attgcatcag gcagtcaatg 840
 gcctgggatg gtattaccac aaattcaaga aaaattacgc caaagcagca aagtactggt 900
 taaaagcaga agaaatgggg aacccagatg cgtcatacaa tcttggagtc ctgcatttgg 960
 atggcatctt ccttggagtt cctggaagga atcaaacttt agctgggtgaa tatttccata 1020
 aggtctgcga aggtggacac atggaaggga ccttgtgtgt ttctctctac tatatcacag 1080
 gcaacctgga gacattccct agagatcctg agaaagctgt tgtatgggca aaacatgtag 1140
 ctgagaaaaa tggctacttg ggccatgtca tccgcaaagg cctcaatgcc tacctggaag 1200
 gttcatggca tgaagctttg ctgtattatg ttttagcagc agaaactgga attgaagtgt 1260
 cacagacaaa ttttagcacac atctgtgagg agaggccaga cctggccagg agatacttgg 1320
 gtgttaactg tgtttggaga tactataatt tctctgtttt tcaaatcgat gctccttctc 1380
 ttgcataatt gaagatggga gacctttact actatggcca ccaaaaccag tcacaagacc 1440
 tggagtgtgc tgtgcagatg tacgcccag ccgcccctga tggagactcc cagggatttt 1500
 ttaacctggc cctgttaatc gaggaaggta cgataatccc acaccatatt ttggatttct 1560
 tggaaaattg ctaactctc cattctaata acatctccat tctccaggaa ctgtacgaaa 1620
 ggtgtctggg ccacagtacc gaggaagcct tcagcccctg ctcttggcc tggctttacc 1680
 tgcacttgcg gcttctctgg ggtgctatcc tgcactcagc cctgatctac tttctgggaa 1740
 cctttctgct atccatattg atgcctgga ctgtgcagta ttccagctc gtctcagcaa 1800
 gcgatcccc tccaagacca tcccaggcct ccccagacac tgccacgtcc actgcaagtc 1860
 cagctgtgac tccagctgca gatgcctctg accaagacca gccacagta actaataacc 1920
 cggagccacg tgggtgaact gtcactcca gttctctcca gatgagagag aatcttttca 1980
 acagctggta ttgggaagct ggggccaggg catgatcctg ataaacacct taaatgtctt 2040
 gtcaactgga tgcaaatctt gcaattgggt tcatTTTTTT taaagtcaaa ttacaaggaa 2100
 gtacccagat caggcagtg taataccaaa ggtcatcaaa cacatcaaa gaacatcttg 2160
 atcatagggc atgtggggaa gtttactggg ccacacaga cttttgtct agtgattgta 2220
 tgtattagga gtcatagcac gccctacggc agatctggat tcttatacac taagatgtgt 2280
 cttaagaatc acagtgcgtg ctccatccct ttattgaaga acagaaaatt atgactactc 2340
 tacaagggtg ataataattt ggtacctgtg ctggccacag ccctgttctc caaagctgaa 2400
 ttgatagatt tctctttgac ttccaagacc tagcagttat aaggcacctt gaaataaatt 2460
 gtttgtgcct ggaaatgcag ggagggaat agctttgtaa attgttttac atttttctcc 2520
 ttgaattttt ctagggtcct agtgcctccg aaccatttaa tggcattgtc ggatatcttt 2580

Lys His Ile Arg Gln Tyr His Glu Glu Lys Glu Thr Gly Gln Lys Ile
 130 135 140
 Asn Ile His Glu Tyr Tyr Leu Gly Asn Met Leu Ala Lys Asn Leu Leu
 145 150 155 160
 Phe Glu Lys Glu Arg Glu Ala Glu Glu Lys Glu Lys Ser Asn Glu Ile
 165 170 175
 Pro Thr Lys Asn Ile Glu Gly Gln Met Thr Pro Tyr Tyr Pro Val Gly
 180 185 190
 Met Gly Asn Gly Thr Pro Cys Ser Leu Lys Gln Asn Arg Pro Arg Ser
 195 200 205
 Ser Thr Val Met Tyr Ile Cys His Pro Glu Ser Lys His Glu Ile Leu
 210 215 220
 Ser Val Ala Glu Val Thr Thr Cys Glu Tyr Glu Val Val Ile Leu Thr
 225 230 235 240
 Pro Leu Leu Cys Ser His Pro Lys Tyr Arg Phe Arg Ala Ser Pro Val
 245 250 255
 Asn Asp Ile Phe Cys Gln Ser Leu Pro Gly Ser Pro Phe Lys Pro Leu
 260 265 270
 Thr Leu Arg Gln Leu Glu Gln Gln Glu Glu Ile Leu Arg Val Pro Phe
 275 280 285
 Arg Arg Asn Lys Glu Glu Asp Leu Gln Ser Thr Lys Glu Glu Arg Phe
 290 295 300
 Pro Ala Ile His Lys Ser Ile Ala Ile Gly Ser Gln Pro Val Leu Thr
 305 310 315 320
 Val Gly Thr Thr His Ile Ser Lys Leu Thr Asp Asp Gln Leu Ile Lys
 325 330 335
 Glu Phe Leu Ser Gly Ser Tyr Cys Phe Arg Gly Gly Val Gly Trp Trp
 340 345 350
 Lys Tyr Glu Phe Cys Tyr Gly Lys His Val His Gln Tyr His Glu Asp
 355 360 365
 Lys Asp Ser Gly Lys Thr Ser Val Val Val Gly Thr Trp Asn Gln Glu
 370 375 380
 Glu His Ile Glu Trp Ala Lys Lys Asn Thr Ala Arg Ala Tyr His Leu
 385 390 395 400
 Gln Asp Asp Gly Thr Gln Thr Val Arg Met Val Ser His Phe Tyr Gly
 405 410 415
 Asn Gly Asp Ile Cys Asp Ile Thr Asp Lys Pro Arg Gln Val Thr Val
 420 425 430
 Lys Leu Lys Cys Lys Glu Ser Asp Ser Pro His Ala Val Thr Val Tyr
 435 440 445

ctaaaaatat cgaagggtcag atgacacccat actatcctgt gggaatggga aatgggtacac 780
 cttgtagttt gaaacagaac cggcccagat caagtactgt gatgtacata tgtcatcctg 840
 aatctaagca tgaattcttt tcagtagctg aagttacaac ttgtgaatat gaagttgtca 900
 ttttgacacc actcttctgc agtcaccta aatatagggt cagagcatct cctgtgaatg 960
 acatatcttg tcaatcactg ccaggatctc catttaagcc cctcacctcg aggcagctgg 1020
 agcagcagga agaaatacta aggggtgcctt ttaggagaaa taaagaggaa gatttgcaat 1080
 caactaaaga agagagattt ccagcgatcc acaagtcgat tgctattggc tctcagccag 1140
 tgtcactgt tgggacaacc cacatatcca aattgacaga tgaccaactc ataaaagagt 1200
 ttcttagtgg ttcttactgc tttcgtgggg gtgtcgggtg gtggaaaatat gaattctgct 1260
 atggcaaca tgtacatcaa taccatgagg acaaggatag tgggaaaacc tctgtggttg 1320
 tcgggacatg gaaccaagaa gagcatattg aatgggctaa gaagaatact gctagagctt 1380
 atcatcttca agacgatggt acccagacag tcaggatggt gtcacatttt tatggaaatg 1440
 gagatatttg tgatataact gacaaaccaa gacaggtgac tgtaaaacta aagtgcgaag 1500
 aatcagattc acctcatgct gttactgtat atatgctaga gcctcactcc tgtcaatata 1560
 ttcttggggg tgaatctcca gtgatctgta aaatcttaga tacagcagat gaaaatggac 1620
 ttctttctct ccccaactaa aggatattaa agttagggga aagaaaagat cattgaaagt 1680
 catgataaatt tctgtccac tgtgtctcat tatagagttc tcagccattg gacctcttct 1740
 aaaggatggt ataaaatgac tctcaaccac tttgtgaata catatgtgta tataagaggt 1800
 tattgataaa ctcttgaggc agacatttgt ctgcgttttt ttcatttttg ttgtgtctta 1860
 taaactgact gtttttcttt gcttggtatc tgtgattcca aaataaatct catccaagca 1920
 agttagagtc caacctaatc aaatgtcata attgtgttac ctattgaaag tttttaaata 1980
 ataatattat tatgtaaatt atagtatatg taagtagcta atgaagtaaa gatcatgaag 2040
 aaagaaattg ataggtgtaa atgagagacc atgtaaaata tgtaaattct agtacctgaa 2100
 atcttttcaa cagattttta tatagcaact gctctctgca agtagttaaa ctagaaactg 2160
 ggacacatgg aqaggctcac atgggagttg tcttcacctc tgttaacttc aagaaactct 2220
 tattttataa aggttctctc tctctcagaa cttttatcta ttactttttt cttcttatga 2280
 gtatgtttac tctcagagta tctatctgat gtagacagtt ggtgatgctt ctgagactca 2340
 gaatggttta ctctaacaaa acactgtgct gtctatccct tgtacttgcc tactgtaata 2400
 tggatttcac ttctgaacag ttacagcac aatatttatt ttaaagtga taaaatgtcc 2460
 acaagcagtg ttgtcatgta aaaaaaaaaa aaaaaaaaaa aaaaa 2505

<210> 50

<211> 483

<212> PRT

<213> Homo sapiens

<400> 50

Met Glu Gly Gly Gly Gly Val Arg Ser Leu Val Pro Gly Gly Pro
 1 5 10 15
 Val Leu Leu Val Leu Cys Gly Leu Leu Glu Ala Ser Gly Gly Gly Arg
 20 25 30
 Ala Leu Pro Gln Leu Ser Asp Asp Ile Pro Phe Arg Val Asn Trp Pro
 35 40 45
 Gly Thr Glu Phe Ser Leu Pro Thr Thr Gly Val Leu Tyr Lys Glu Asp
 50 55 60
 Asn Tyr Val Ile Met Thr Thr Ala His Lys Glu Lys Tyr Lys Cys Ile
 65 70 75 80
 Leu Pro Leu Val Thr Ser Gly Asp Glu Glu Glu Glu Lys Asp Tyr Lys
 85 90 95
 Gly Pro Asn Pro Arg Glu Leu Leu Glu Pro Leu Phe Lys Gln Ser Ser
 100 105 110
 Cys Ser Tyr Arg Ile Glu Ser Tyr Trp Thr Tyr Glu Val Cys His Gly
 115 120 125

195 200 205
 Tyr Pro Ser Ala Pro Phe Leu Ala Ala Gly Val Ser Met Gly Gly Met
 210 215 220
 Leu Leu Leu Asn Tyr Leu Gly Lys Ile Gly Ser Lys Thr Pro Leu Met
 225 230 235 240
 Ala Ala Ala Thr Phe Ser Val Gly Trp Asn Thr Phe Ala Cys Ser Glu
 245 250 255
 Ser Leu Glu Lys Pro Leu Asn Trp Leu Leu Phe Asn Tyr Tyr Leu Thr
 260 265 270
 Thr Cys Leu Gln Ser Ser Val Asn Lys His Arg His Met Phe Val Lys
 275 280 285
 Gln Val Asp Met Asp His Val Met Lys Ala Lys Ser Ile Arg Glu Phe
 290 295 300
 Asp Lys Arg Phe Thr Ser Val Met Phe Gly Tyr Gln Thr Ile Asp Asp
 305 310 315 320
 Tyr Tyr Thr Asp Ala Ser Pro Ser Pro Arg Leu Lys Ser Val Gly Ile
 325 330 335
 Pro Val Leu Cys Leu Asn Ser Val Asp Asp Val Phe Ser Pro Ser His
 340 345 350
 Ala Ile Pro Ile Glu Thr Ala Lys Gln Asn Pro Asn Val Ala Leu Val
 355 360 365
 Leu Thr Ser Tyr Gly Gly His Ile Gly Phe Leu Glu Gly Ile Trp Pro
 370 375 380
 Arg Gln Ser Thr Tyr Met Asp Arg Val Phe Lys Gln Phe Val Gln Ala
 385 390 395 400
 Met Val Glu His Gly His Glu Leu Ser
 405

<210> 49
 <211> 2505
 <212> DNA
 <213> Homo sapiens

<400> 49
 ggacaggagg ctcaaggggg cggaggcggc gttgccgggc tctccggaag gagacgtggc 60
 ggcgggttggg cgggtgatac cggggcgctt tatagtcccg ccgcctcttc ctcacctctc 120
 tctctctctc cctctctctc tggagcagag gaggttgttg cgggtggcttg agaaagcggc 180
 ggcggaggat ggaggaagga ggcggcggcg tacggagtct ggtcccgggc gggccgggtg 240
 tactggctct ctgcggcctc ctggaggcgt ccggcggcgg ccgagccctt cctcaactca 300
 gcgatgacat ccttttccga gtcaactggc ccggcaccca gttctctctg cccacaactg 360
 gagttttata taaagaagat aattatgtca tcatgacaac tgcacataaa gaaaaatata 420
 aatgcatact tccccttgtg acaagtgggg atgagggaaga agaaaaggat tataaaggcc 480
 ctaatccaag agagcttttg gagccactat ttaaacaag cagttgttcc tacagaattg 540
 agtcttattg gacttacgaa gtatgtcatg gaaaacacat tcggcagtac catgaagaga 600
 aagaaactgg tcagaaaata aatattcacg agtactacct tgggaatatg ttggccaaga 660
 accttctatt tgaaaaagaa cgagaagcag aagaaaagga aaaatcaaat gagattccca 720

```

tggatgatgt tttctcacc agtcacgcta ttccaataga aactgctaag caaaatccta 1200
atgttgcttt ggtccttact tcttatggag gccatattgg tttcttgagg ggaatctggc 1260
caagacagtc cacttacatg gatcgtgtct tcaagcaatt tgtgcaagcc atggttgagc 1320
atggacatga actctcttaa catgtagttc tttgggtgca ttttgtctga accacaattg 1380
tgaaggcagc tcagcttagt gcacaaattt taactgttgt atataaagca aataagccag 1440
cagatgggtg aagaggtcca gaatgatatg caaaaactac ttttttagaga aacaaaacaa 1500
ctttgtagca acaaattaaa tatagtatta gattgttact tacgtagatt ttatttttac 1560
tatgccttac caagtacatc cttaaacaaa gtagtatgta catgaaattg cacttaacca 1620
aaactattgt gtaaaacaaa ttttaattcc tcagggtttt aatttaaact agtatttttt 1680
tagattattt gttttagggt atttaatggt actttaataa ctactaagaa atattggcta 1740
tttcaatgta agttataagg tggtagattc ctaagggtat ttatagttga tgataacatg 1800
aaaactgaaa taagataaaa tacaacgtgc taaatctttt atgtattcta actttaaaag 1860
acaagtgcac caaagttaga ctgacttcta tatgtgctct tttactctga taatattaaa 1920
ttaggactaa cttatgtttt ataagtatta taatttacat gcttattttt aaaatagtat 1980
atgtggacac atatatatca ttatattaaa ataaattcta ccatttttaa aaaaaaaaaa 2040
aaaaaaaaaa aa
2052

```

<210> 48

<211> 409

<212> PRT

<213> Homo sapiens

<400> 48

```

Met Gln Arg Leu Ala Met Asp Leu Arg Met Leu Ser Arg Glu Leu Ser
  1              5              10              15

Leu Tyr Leu Glu His Gln Val Arg Val Gly Phe Phe Gly Ser Gly Val
      20              25              30

Gly Leu Ser Leu Ile Leu Gly Phe Ser Val Ala Tyr Ala Phe Tyr Tyr
      35              40              45

Leu Ser Ser Ile Ala Lys Lys Pro Gln Leu Val Thr Gly Gly Glu Ser
      50              55              60

Phe Ser Arg Phe Leu Gln Asp His Cys Pro Val Val Thr Glu Thr Tyr
      65              70              75              80

Tyr Pro Thr Val Trp Cys Trp Glu Gly Arg Gly Gln Thr Leu Leu Arg
      85              90              95

Pro Phe Ile Thr Ser Lys Pro Pro Val Gln Tyr Arg Asn Glu Leu Ile
      100             105             110

Lys Thr Ala Asp Gly Gly Gln Ile Ser Leu Asp Trp Phe Asp Asn Asp
      115             120             125

Asn Ser Thr Cys Tyr Met Asp Ala Ser Thr Arg Pro Thr Ile Leu Leu
      130             135             140

Leu Pro Gly Leu Thr Gly Thr Ser Lys Glu Ser Tyr Ile Leu His Met
      145             150             155             160

Ile His Leu Ser Glu Glu Leu Gly Tyr Arg Cys Val Val Phe Asn Asn
      165             170             175

Arg Gly Val Ala Gly Glu Asn Leu Leu Thr Pro Arg Thr Tyr Cys Cys
      180             185             190

Ala Asn Thr Glu Asp Leu Glu Thr Val Ile His His Val His Ser Leu

```

<210> 46
 <211> 143
 <212> PRT
 <213> Homo sapiens

<400> 46
 Met Val Pro Asp Trp Ser Pro Phe Ile Lys Ile Asn Cys Pro Ala Gln
 1 5 10 15
 Leu Ser Ala Gly Pro Pro Gln Ser Gln Ser Leu Val Leu Gly Pro Lys
 20 25 30
 Ala Gly Pro Arg Gly Cys Arg Lys Gln Ser Val Ala Ser Lys Trp Gly
 35 40 45
 Leu Ser Tyr Pro Leu Gln Cys Val Gly Ala Glu Arg Ser Leu Gly Asp
 50 55 60
 Phe Ser Ala Gly Pro Pro Tyr Ser Arg Asp Pro Ser Val Phe Lys Thr
 65 70 75 80
 Lys Gln Glu Gly Lys Glu Glu Trp Arg Asn Ser Ser Val Leu Thr Leu
 85 90 95
 Phe Pro Leu Val Ser Ala Val Leu Gly Pro Leu Cys Thr Ser Tyr His
 100 105 110
 Phe Pro Leu Glu Ser Ala Pro Gln Gly Arg Val Arg Asp Glu Asp Ser
 115 120 125
 Gly Cys Lys Glu Val Ser Gln Leu Gly Asn Gly Ser Gly Gln Leu
 130 135 140

<210> 47
 <211> 2052
 <212> DNA
 <213> Homo sapiens

<400> 47
 gactgtggtc gggagtaggc agcggcgccg cgtccgctct cgcgccctct cgcgccctcg 60
 ccagccggct ctccctccgc cgcaggaccc gcgcgcgcgc ctggggggcc atgcagcgcc 120
 tggccatgga cctgcggatg ttgtcccggg agctctccct ctacctggaa caccaagtcc 180
 ggggtggggtt ctccggctcg ggggtgggct tatcccttat cctgggcttc agcgctcgctt 240
 atgccttcta ctacctgagc agcattgcc aaaaacccca gttagtgacc gggggtgaga 300
 gtttcagccg ctcccttcaa gaccactgtc ccgtgggttac agaaaacgtac taccgcacgg 360
 tctggtgctg ggagggtcga ggacagaccc tgcttagacc ttctcatcact tcgaagcccc 420
 cgggtgcagta caggaatgaa cttattaaaa ctgcagatgg aggacagatt tcaactggact 480
 ggtttgataa tgataacagt acgtgttata tggatgccag caccagacct actatcttat 540
 tgttgcctgg cctcacggga acaagcaagg agtcatatat ccttcatatg atccatctta 600
 gtgaagaatt aggatacaga tgtgtggttt ttaacaacag agggagtggcg ggggagaatc 660
 tcttgacgcc aaggacttat tgtgtgcta acactgaaga cttggagaca gttattcacc 720
 atgtacacag cctgtacct tctgtcctt tccctggcagc aggggtttca atgggaggaa 780
 tgctgcttct aaattacttg ggcaaaattg ggtccaaaac gcctttgatg gcagctgcaa 840
 ctttttccgt tgggttgaa accttcgctt gctcagagtc attggaaaaa ccaactgaact 900
 ggctactttt taattactat ttgacaacct gccttcagtc ttcagttaat aagcaccgac 960
 atatgtttgt aaaacaagtt gatatggatc atgtcatgaa ggctaaatcc atcagagagt 1020
 ttgataagcg attcacttca gtcatgtttg gataccaaac aattgatgat tattatactg 1080
 atgccagtc gagtcctaga ctgaagtcag taggaattcc agtatltgtg ctaaattctg 1140

```

tgccccctaa ccaggccttt ctcacagcca catagcatcc ccaggcctgc tgcactgggc 180
cagccgcagc ctcagagccc agcctgaggg gcctctcact gggatcccca gctttgtccc 240
tgagatgagg gggctgatcc taagagtgtg ggtgggagtg cctctgcccc gggggttctg 300
gtggtgttgg gctctggccc aggcctcctg gctctgtgtc cttccataga ctccagggtt 360
ctcacagtca ttcacaaacc aactgaatgt tgggtgtctt tggcttcttg tctcagggtt 420
ggaggtatta aagccatgga agagcagctt ctcctgggct gcaacagcct gtcttctgtg 480
gcctctagct ccacctcag agtttgggat aggggctgaa tcctttgctt gttctccctc 540
ccagggtgtg cccccagagt cagtacttca ggttgagggg agtgggaggt tggctctgga 600
ggggctgccc agtggcagga ggaaggggct caggagcagg ggggtggctc actgcagcgg 660
ccagactgtg ttgattacag atgattatct caaggtgtgt gtgtgtgtgc gcgtgtgtg 720
gtgtgcgtgt gtgtattttt aaataacagc tctattgaga tatagttcac ataccataca 780
attcaccat tgaaagtgt caattcaatg gtttctagta tgttcacaga gttgtataat 840
gaacaccaca gttaatttta gaacattttt ttctattctc ttacaatgtg taaaaataaa 900
taagggtttt tttaaaaaaa cattttcatc acacaaaaaa tgagctctc gatggatgtt 960
atccctcatt tgtcccaaaa cccccagcct ctggcaacca ctaatctact ttctatctct 1020
ggatttgctt atcatggaca ttcttatga acggagtgc acaccatgtg gcattttgtg 1080
tctggtttct tccactgagc atcatgatt caagttcatg taggagcag catctgagct 1140
tcattccttc tcatggtgca atcatcttc actgtgtgta taagaccaca ttttgtcaat 1200
ccacacatcc atggatcaca agtgcatttt taaaggtgtc tttacatct caaacacagt 1260
tctcagttgg cgaggggggc agaggacaat acagaagtga ctgtaagcgg cataaactgt 1320
agcttcccag aggggctcca ggggctcggg ggagaggtcg aggtaggag gcaatgtcct 1380
tcctttgagc agccactgag agggagaagg agttgcagag atcaggaagg agaggattta 1440
ttccagttt tctggcagtt ttctctcact ctttcggaga cctaggatgg gttaggagag 1500
ggcatggcaa aggcagaggt ggctctgcta gaggaggcgg caggtccgca ggccgaacct 1560
ggggagccag ccatgtctgg cctgagggcc tgccttgagg agaagataaa gcttgagga 1620
gccttttggg ccgatctggg aaccagcaa gactagatta gcctgactga tgacagacct 1680
gggatgagga tgagggcagt taagtatttg tttaatcttg ctttgtcttt tcaaacagcg 1740
atttagtaat cctgtttgag gctgcagtgt ggcaatgctt tccagaggat ggagtcctt 1800
ttgtttgttt tgaaaaata gagataaggt ttactatgt tgcctaggct ggtctcctac 1860
tcggcctcaa gccatcctcc tgcctgggccc tcccaaagtg ttgggattac aggcgtgagc 1920
catggtgcca gactggagtc cttttattaa aattaactgc cctgctcagc tttctgtcgg 1980
gccaccccag agccaatcct tggttcttgg gcccaaggct ggaccagggt gttgcaggaa 2040
acagtctgta gcattcaagt ggggcctgtc gtaccacttc cagtgtgtag gtgcagaacg 2100
ctctttgggg gattttctct ctgggcccacc ttactccagg gatccctcag ttttcaaac 2160
aaagcaagag ggcaaggaa aatggagaaa cagctcagtg ttgactctct tccccctggt 2220
gagtgtgtg ctggggcctc tgtgcacatc ataccacttc ccccttgaat cagccccaca 2280
aggcagggtg agagatgagg actcagggtg caaggaggtc tcacagcttg gaaattgagc 2340
aggacagctc tgattctcca aggccaaagt cttctctata tcatgaggca gcccaaaaat 2400
gtgtttctac acatatctgt tgtagaaact caggccaggc tcctatatgc tctgggtgac 2460
agcgggaagg tgccttccag tgtgtatcag tgtggcccat ctgggagtc taatgtcatt 2520
gcctcttcca aaatatcagc aaagctgacc ctagtgttg tagtgctcaa atgcacctct 2580
ctgcctttgt gccataggga aatggatttg gtccctgggg tgggtgatac aacttctgtc 2640
tcaattccat gaccctcact cagcaccctc acccagggc tgtgcagagg aggaataacc 2700
gtccttgaga accatccagc cctagggtga gaaattagat ttatggaact aatcagttct 2760
tcttccctgt cagtgtgtgt gagaatgaaa tgggggaaat tgataagcct cagtcatgtt 2820
ttctgtcgag acaaggcagc tttggtagct ggtgggactg acgcctctct cacctgtgtc 2880
ctctgcctct gagtgactat aaattgcgaa ccccatgagg tggcacctgc agccacagat 2940
cgcttaggca ccttcacag gggccacctt atgaactggc tgcaggacgg caatcctgcc 3000
gtgaagccag gcacctcggg aggggcaagg tggcagaacc gagagagcag atgctccttg 3060
ctgtttctgt aaggccacca gtggctgggt ggctggccc tggtagcaag gtggtaacgg 3120
tgtgagtggc tgaatcctgc accacttttc ctgagcctcc ttcctcctgg attcctgcaa 3180
ctatattctc actacatggc tcaccaccaa ttcttctctc ctgccccaaag gaggctggag 3240
aagaggctca ggtcagtcg ggtacgcagg aacctatgtc tgtaaaatga aaatgcctgc 3300
cttcaagggtc tgtcttgagg ttgaaaggag atggtctaca tcaagggtta ggaagaccac 3360
aatgtggctg tgcggccac ctccaggctg gcttcagctc cccatcccc tagtcatacc 3420
cctgtgaagt ccttcccat actgaatcgg gctacctgtg tatcttatag ggtgttgaa 3480
atgacagatt gtgaattcca aggccccata aaagacagcg tgggctgggc gtggtggctc 3540
acgcctgtaa tcccagcact ttgggaggcc gagccaagtg gatcacttga ggtcaggagt 3600
tctagaccag cctggcagc atggtgaaaa cctatctcta ctaaaaaaa aaaaaaaaaa 3666
aaaaaa

```


Glu Asp Arg Tyr Ser Leu Gly Ser Ser Leu Asp Ser Gly Met Arg Thr
 145 150 155 160
 Pro Leu Cys Arg Ile Cys Phe Gln Gly Pro Glu Gln Gly Glu Leu Leu
 165 170 175
 Ser Pro Cys Arg Cys Asp Gly Ser Val Lys Cys Thr His Gln Pro Cys
 180 185 190
 Leu Ile Lys Trp Ile Ser Glu Arg Gly Cys Trp Ser Cys Glu Leu Cys
 195 200 205
 Tyr Tyr Lys Tyr His Val Ile Ala Ile Ser Thr Lys Asn Pro Leu Gln
 210 215 220
 Trp Gln Ala Ile Ser Leu Thr Val Ile Glu Lys Val Gln Val Ala Ala
 225 230 235 240
 Ala Ile Leu Gly Ser Leu Phe Leu Ile Ala Ser Ile Ser Trp Leu Ile
 245 250 255
 Trp Ser Thr Phe Ser Pro Ser Ala Arg Trp Gln Arg Gln Asp Leu Leu
 260 265 270
 Phe Gln Ile Cys Tyr Gly Met Tyr Gly Phe Met Asp Val Val Cys Ile
 275 280 285
 Gly Leu Ile Ile His Glu Gly Pro Ser Val Tyr Arg Ile Phe Lys Arg
 290 295 300
 Trp Gln Ala Val Asn Gln Gln Trp Lys Val Leu Asn Tyr Asp Lys Thr
 305 310 315 320
 Lys Asp Leu Glu Asp Gln Lys Ala Gly Gly Arg Thr Asn Pro Arg Thr
 325 330 335
 Ser Ser Ser Thr Gln Ala Asn Ile Pro Ser Ser Glu Glu Glu Thr Ala
 340 345 350
 Gly Thr Pro Ala Pro Glu Gln Gly Pro Ala Gln Ala Ala Gly His Pro
 355 360 365
 Ser Gly Pro Leu Ser His His His Cys Ala Tyr Thr Ile Leu His Ile
 370 375 380
 Leu Ser His Leu Arg Pro His Glu Gln Arg Ser Pro Pro Gly Ser Ser
 385 390 395 400
 Arg Glu Leu Val Met Arg Val Thr Thr Val
 405 410

<210> 45

<211> 3666

<212> DNA

<213> Homo sapiens

<400> 45

aagacaagta ttcttgaaat gtgtcacctg gctctgttgg ccaagccagc agtgccacaa 60
 gagaagcagc tgccatggcc cagtgcacc tggagtgttt gacgatgctt tgtgtccatg 120

```

gtcatgagag tcacgacagt gtgagagcag agggcccgaa ggaaggccat gaccaccact 1500
gagggcccg agcagggtgg ggaggtgcag tggcaccccc ggagccaaca gagggagcag 1560
gcagaggggtg ggggacctgg cgggagccct ggggtagtgt cagagcgga gtgaggctgg 1620
tgcaggagca gttctgctat ttccaatcag tcaatgccac tctccacaac aacaatgaaa 1680
accaacacca actcaacaac aaagtgaat acaggctgaa cctggcccaa cagaaaaacc 1740
ctgccccaat gcacctgcag gcaagggtacc cgaagaagca gaggtgagg gcaggcaaag 1800
cctgtgtgac tgtggcagt cgggaggcca agggggccaa gaggaagaag atctgtgttc 1860
tgccctgctc tcacctgtt tggttttgtt tctcctggg ctgtgttctg caggcagcca 1920
gaaaaggagg aggcacgggt gagctggcag ggacacactg cctttggggc tcctgggctc 1980
atttggatgg gcaagattcg ctgacaaatg gctgtgggga tgggtgggtg gatggtcagg 2040
gagggaggtc caggggaggga tatgctgggt tgagcagcca gagggagagt gtgtctcctt 2100
cctgaaggaa cttccaaatg gaactcccga ttccaggtgg gctaaaagag ggcttaggtt 2160
tgaaaagggt tgccttctg tgcccttgtt aatttatttt atagtattt gggtcaaaga 2220
tgtttacagg acacacacac acacacacac acacacacac acacacacac ccctagagaa 2280
aagtacagat ttccagtggg tatttcaagc acagtcttgc tgcgtggtc tcagcttgg 2340
aagctgtcaa tcccggagca actttcccaa ctaccacaac ccaccatggc caggacatgt 2400
gcaatgccag ccccttctt tcttggcaca tgcacagacc cagtccctc acggtagggtc 2460
accctgacc tacgggcttc caagagagca gctgcagtgg ttgggaggag cttgaccagt 2520
gtgccccaa gagtggagta gagcccaatc taagtattcc ttgctgcttg gaaccctccc 2580
tgtttgaac cctcccaaaa gaggcagtca ggctgatgct cagtgccttg tgcctcctgc 2640
tccttccgc gtagccaggt gggcccaagg gtgctggca gggagcacta cccctggacc 2700
cctcctgctc gctctgggga ccctgccagg gaaggccact ggtgtttcac ctgcaaagt 2760
tctggttgc actgcacagt ggtcgcgtca tccatgggta taaaaggac actgtcaagt 2820
acttttttaa actagtttt agggttttt aaaactctct gttgtttgta atattctctt 2880
aaaagcttga aaataaaact tctttcccta ccaaaaaaaa aaaaaaaa 2940
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2980

```

<210> 44
 <211> 410
 <212> PRT
 <213> Homo sapiens

```

<400> 44
Met Leu Met Pro Leu Cys Gly Leu Leu Trp Trp Trp Trp Cys Cys Cys
  1             5             10             15

Ser Gly Trp Tyr Cys Tyr Gly Leu Cys Ala Pro Ala Pro Gln Met Leu
  20             25             30

Arg His Gln Gly Leu Leu Lys Cys Arg Cys Arg Met Leu Phe Asn Asp
  35             40             45

Leu Lys Val Phe Leu Leu Arg Arg Pro Pro Gln Ala Pro Leu Pro Met
  50             55             60

His Gly Asp Pro Gln Pro Pro Gly Leu Ala Ala Asn Asn Thr Leu Pro
  65             70             75             80

Ala Leu Gly Ala Gly Gly Trp Ala Gly Trp Arg Gly Pro Arg Glu Val
  85             90             95

Val Gly Arg Glu Pro Pro Pro Val Pro Pro Pro Pro Pro Leu Pro Pro
 100             105             110

Ser Ser Val Glu Asp Asp Trp Gly Gly Pro Ala Thr Glu Pro Pro Ala
 115             120             125

Ser Leu Leu Ser Ser Ala Ser Ser Asp Asp Phe Cys Lys Glu Lys Thr
 130             135             140

```